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Osteoarthritis (OA) is very common and is the main cause of chronic joint pain and disability 
in older people. According to this systematic review nearly 67% of people with OA had 
comorbidity. There is little information available on how the incidence and prevalence of OA 
has changed over the past 20 years in the UK, and what is the likelihood of having other 
chronic conditions,  their progression, and associated outcomes. 
Objectives 
This research aimed to answer five questions: 1) how common is osteoarthritis in the UK 
and what are the trends over the past twenty years; 2) are people with osteoarthritis more 
likely to have other chronic conditions and multimorbidity (two or more conditions in an 
individual) than people without osteoarthritis; 3) in people with OA how do these long-term 
conditions coexist; 4) how does the group of long-term conditions progress with time; and 5) 
does the presence of long-term conditions in osteoarthritis add to the burden both to patients 
and to health services.  
Methods 
A large nationally representative UK primary care database known as the Clinical Practice 
Research Datalink (CPRD) GOLD was used for the study. Six different studies were 
performed in this thesis in people aged 20 years or more with OA and age, sex, and practice 
matched controls. These are: 1) epidemiology of osteoarthritis in the UK (chapter 3); 2) risk 
of comorbidities occurring before and after the diagnosis of osteoarthritis using both case-
control and cohort design (chapter 4); 3) clusters of multimorbidity in people with OA and 
controls using latent class analysis (chapter 5); 4) illness pathways (transition and 
trajectories) of multimorbidity clusters in people with OA and controls using latent transition 
analysis and latent class growth analysis, respectively (chapter 6 and 7); 5) outcomes such 
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as all-cause mortality, outpatient visits, inpatient admission and disability adjusted life years 
(DALYs) associated with OA and their comorbidities (chapter 8). 
Results 
The prevalence of OA in the UK primary care in 2017 was 10.7% and the incidence was 6.8 
per 1000 person-years in people aged 20 and over. OA was more common in women 
compared to men and increased with age, especially after age  40 years. The prevalence 
has increased at a rate of 1.4% per year since 1998, whereas the incidence is declining at a 
rate of -1.6% per year. The burden of joint pain defined as OA is quite high, constituting 
nearly one third of primary care adult patients. 
People with OA are more likely to have multimorbidity prior to (aOR 1.71, 95%CI 1.69-1.74) 
and after the diagnosis of OA (aHR 1.29, 95%CI 1.28-1.30) than people without OA. 
Musculoskeletal (MSK), gastrointestinal (GI), cardiovascular (CV) and psychological 
conditions were associated with OA before and after the diagnosis of OA, whereas dementia 
and systemic lupus erythematous (SLE) were only associated with OA after its diagnosis. 
Other conditions that showed significant associations with OA both before and after 
diagnosis, were  anaemia, inflammatory bowel disease (IBD), benign prostatic hypertrophy 
(BPH), gall stones, liver diseases, cancer, and hearing impairment. 
Five multimorbidity clusters were identified in OA. These clusters were led by both pain and 
hypertension, hypertension only, depression, back pain only, and relative healthy group 
(lowest number of any conditions). 
Over time, comorbidity clusters changed after the diagnosis of OA. About 30% of people 
changed from the cluster driven by either back pain or hypertension to the cluster driven by 
both back pain and hypertension. The accumulation of multimorbidity in people with OA 
happens in five different ways, and  17.5% of people develop multimorbidity quicker 
compared to relative healthy group. Obesity, smoking and alcohol use during the diagnosis 
of OA are strongly associated with the faster development of multimorbidity. 
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People with OA were 1.2 times more likely to consult with general practitioners (GP), 1.1 
times more likely to be  hospitalised, 3.25 times likely to get higher DALYs and 1.9 times 
more likely to die. Within OA, people with  multimorbidity had higher mortality, burden, and 
health utilisations.  
Conclusions  
OA affects one in ten people aged 20 years or more in the UK. The burden of both GP 
diagnosed OA and joint pain in primary care is consistently high and increasing further. 
People with OA are more likely to develop other  chronic conditions. Five different 
comorbidity clusters  have been  identified. While younger people are likely to have  pain and 
depression, the elderly are likely to have CV-MSK comorbidities. The growth of 
multimorbidity in people with OA differs with 17.5% developing it faster than others. People 
with OA and CV-MSK and CV comorbidity have worse health outcomes. This information 
from this study can be used to develop personalised care in primary care. Further research 
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1 Chapter 1. Introduction 
1.1 Osteoarthritis  
 
1.1.1 Definition  
Osteoarthritis (OA) is the most common arthritis and a major cause of chronic pain and 
disability in developing as well as developed countries (Vos et al., 2012). Despite being 
the most common arthritis in the middle-aged and elderly population, the definition of the 
condition is still under active research (Zhang and Jordan, 2010; Kraus et al., 2015).  
According to the National Institute for Health and Care Excellence UK, (NICE, UK) 
“Osteoarthritis is characterized pathologically by localized loss of cartilage, remodelling 
of adjacent bone and associated inflammation. Osteoarthritis includes a slow but 
efficient repair process that often compensates for the initial trauma, resulting in a 
structurally altered but symptom-free joint (Osteoarthritis - NICE CKS, n.d.).” 
Achieving consensus on globally accepted definitions of disease and standards for 
classifying OA would help in better understanding across both the clinical and research 
domains. Also, from public health perspectives, a uniform epidemiological definition is 
essential for better estimation and comparison of disease burden and associated risk 
factors, and for designing effective interventions (Martel-Pelletier et al., 2016).  
The site specificity of OA shows higher inclination toward certain synovial joints 
(Doherty, 2001). One of the interesting hypotheses to explain this is linked to human 
evolution. Joints that have undergone major changes in orientation and function to adapt 
to bipedal gait and altered fore-leg (arm) usage may not be fully adapted and are 
relatively under-designed, so more commonly fail to compensate for adverse mechanical 




1.1.2 Classification criteria 
Diagnosis and classification of OA can be done in several ways, for example, according 
to  pathological features, radiographic features, or physical signs and symptoms 
(Abhishek A and Doherty M, 2013). One common problem in finding a single definition 
for OA is the involvement of different joints such as hips, knees, hands, or foot joints.  
In general, clinical, and radiographic OA diagnostic criteria are the most accepted and 
efficient in clinical settings. Radiographs are the most common method of classification 
because of widespread availability, low cost, good standardisation and reasonable 
reproducibility (Kinds et al., 2011). The Kellgren and Lawrence (K-L) system was the first 
suggested, globally adopted method which measures OA through an ordinal scale (0 to 
4), being used over the past half century. K-L depends on the presence of osteophytes, 
narrowing of joint space, subchondral sclerosis, cysts and deformity (Schiphof, Boers 
and Bierma-Zeinstra, 2008). Details of K-L are given in Table 1.1-1.   
Table 1.1-1. K-L grading system for classification of OA 





1957)   



























Reprinted with permission from Wright RW. Osteoarthritis classification scales: interobserver reliability and 
arthroscopic correlation. J Bone Joint Surg Am.2014;96:1145–1151; * JSN = joint space narrowing 
 
1.1.3 Clinical diagnosis 
OA can be diagnosed alternatively using clinical signs and symptoms.  
The commonest algorithm for clinical diagnosis is the American College of 
Rheumatology (ACR) criteria (Altman et al., 1986), specifically: 
- Aged 40 years or more 
- Crepitus or bony swelling 
- Pain most of the days of the month 
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- Morning stiffness of less than half an hour 
- Plain radiographic changes  
- Negative Rheumatoid Factor 
Not always, the presence of radiographic changes in joint are manifested as 
symptomatic (Bedson and Croft, 2008; Neogi et al., 2009). The sign and symptoms 
reported by a person is influenced by individual factors such as disease status, presence 
of other chronic conditions, perceived severity, socio-economic factors and altered pain 
physiology (Wise et al., 2010; Luong et al., 2012; Neogi, 2013). So, identifying people 
with symptomatic OA is more useful than radiographic screening only, where the latter 
categorises a non-symptomatic individual with OA and is relatively insensitive at 
showing milder early OA.
1.2 Epidemiology of Osteoarthritis  
 
1.2.1 Prevalence of Osteoarthritis  
OA can develop in any synovial joint, but the most frequently affected joints are knees, 
hips, hands, spinal facet joints and feet. Prevalence and incidence data largely vary 
according to  the site, study area, definition of OA (symptomatic versus radiographic), 
age group and gender (Abhishek A and Doherty M, 2013). Table 1.2-1 describes the 
prevalence of OA reported in different studies. In the year 2005, 26 million people in the 
United States had OA.(Lawrence et al., 2008) According to Versus Arthritis one third of 
people in the United Kingdom aged 45 years and over have sought treatment for OA 
(Versus Arthritis, 2019). In total, 8.75 million people in the UK have visited any health 
facility for treatment and by 2035, 8.3 million people in the UK aged 45 years or over 
could have  knee OA (“Osteoarthritis in General Practice; Data and perspectives,” 2013). 
(Table 1.2-1) Studies from different countries report the overall prevalence of OA among 
those aged 45 years to vary between 20% to 35%. The Framingham community cohort 
study reported a higher prevalence of radiographic hip OA among men (Kim et al., 
2014). In Sweden, among people aged  56–84 years the prevalence of radiographic and 
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symptomatic knee OA were 25.4% and 15.4%, respectively (Turkiewicz et al., 2015). In 
England, among 26,000 adults aged 50 years or more, 50% reported having OA in at 
least one of four joints (hand, hip, foot, knee) (Thomas, Peat and Croft, 2014). 
Table 1.2-1 Prevalence of OA from different studies 
 
 Sample characteristics Prevalence (%) 








Overall  Hip Knee Hand 
(Plotnikoff et 
al., 2015) 
Canada M&F >18  Community 
survey 
Self-reported 4733 14.8 10.5 8.5  
Framingham 
(Kim et al., 
2014) 
USA M&F >45  Cohort 
database 






(J. M. Jordan et 
al., 2007) 
USA M&F >45   Radiographic 
and 
symptomatic 
3018 27.8 36 43  
NHANES III 
(Dillon et al., 
2006) 
USA M&F >60 Community 
survey 
Radiographic 6913   37 8 













M&F 18-49 Community 
survey 















Australia M&F >18  Community  Self-reported  19000 20.4    
Korean 
NANHES  




M&F >50  Radiographic  9512 34.10    
Zoetermeer 
(van Saase et 
al., 1989) 
 
Netherlands M&F >19  Community Radiographic 6585    27-
80 
 M- Men; W-Women 
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1.2.2 Incidence of Osteoarthritis  
 
Few studies have used large databases to describe OA incidence. The crude incidence 
rate of OA in Canadian adults was 14.6 per 1000 person-years in 2000/2001(Rahman et 
al., 2014). Primary care records of more than 3 million patients in Spain reported the 
incidence rates (per 1000 person-years) for knee, hip, and hand osteoarthritis as 6.5, 2.1, 
and 2.4, respectively (Prieto-Alhambra et al., 2014).(Figure 1.2-1) Ascertaining OA 
through administrative records has limitations, still it supports the potential of large 
databases for estimation of population burden and trends. 
Figure 1.2-1 Incidence of joint specific OA 
 
Age and sex-specific incidence rates (/1000 person-years) of knee osteoarthritis (black), hip osteoarthritis 
(red), and hand osteoarthritis (green). Solid, all population; short dash line, women; long dash line, men. 
(Prieto-Alhambra et al., 2014) Produced with permission (copyright number 4897681007765) 
In the UK during the year 2013, the age-sex standardized incidence rate of clinical OA 
(symptomatic) was 40.5 per 1000 person-years and was higher in women than men. Joint 
specific rates were higher for the knee (19.7) followed by the hip (10.4) and the hand (4.3) 
with progressive increases with age (Yu et al., 2017). 
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1.2.3 Trends in incidence of OA  
Very few countries have explored the trends in incidence of OA. According to a UK CPRD 
data analysis, the trends for any clinical OA are increasing gradually over the last 15 years 
(1998-2013), as illustrated in Figure 1.2-2. In Sweden, age-standardized hospitalization 
rates due to OA have increased from 1998 to 2014 for the hip and knee (Kiadaliri et al., 
2018). In Canada, during 2000-01 to 2008-09, crude incidence rates changed from 11.8 to 
14.2 per 1000 person-years for men, and from 15.7 to 18.5 per 1000 person-years for 
women (Rahman et al., 2014). The increase in crude rates per annum was about 2.5-
3.3% for both men and women (Rahman et al., 2014). 
Figure 1.2-2 Trends of clinical OA incidence in UK 
 
 
Red: women; Blue: men; Black: men and women combined. Solid lines represent incidence estimation; dash 








1.3 Burden of Osteoarthritis  
1.3.1 Disability Adjusted Life Years (DALYs) in OA 
According to one estimate, 27.6% of the older population (>60 years) in the world have 
OA (Symmons, Mathers and Pfleger, 2003) (Figure 1.3-1). Global burden of disease 
(GBD 2010) ranked hip and knee OA as the 11th highest contributor to global disability 
and the 38th highest in disability adjusted life years (DALYs). Increasing life expectancy 
and ageing populations are expected to make OA the fourth leading cause of disability by 
the year 2020 (Woolf and Pfleger, 2003). Years of life with disability (YLDs) for hip and 
knee OA increased by 6.6 million over the period 1990-2010 (10.5 million in 1990 to 17.1 
million in 2010). The United Nations estimates that by 2050 more than 20% of the world’s 
population will be aged 60 years or more (‘World Population Prospects: The 2017 
Revision’, 2017). By 2050, it is estimated that 130 million people worldwide will suffer from 
OA, 40 million of whom will be severely disabled by the condition (WHO Scientific Group 
on the Burden of Musculoskeletal Conditions at the Start of the New Millennium, 2003). 
Figure 1.3-1  Prevalence of OA in the world 
  
A region= Developed countries in North America, Western Europe, Japan, Australia and New Zealand, AF= 
Countries in sub-Sharan Africa, AM BD- Developing countries in Americas, EM- Eastern Mediterranean and 
North African regions, EU BC- Developing Countries in Europe, SEA- South East Asia, WP B- Western Pacific 




1.3.2 Economic burden of OA 
 As for economic considerations, the direct costs for topical and oral NSAIDs used for 
management of OA in UK were estimated at £19.2 million and £25.65 million, respectively 
(Chen et al., 2012). Higher costs were incurred for hip and knee replacement surgery 
(costing more than £850 million) and arthroscopic surgery for OA was about £1.34 million. 
Similarly, the loss of economic production (indirect cost) was over £3.2 billion. OA results 
in increasing economic burden for all countries, both from direct and indirect costs.  
1.4 Risk factors for Osteoarthritis 
OA is a common complex disorder with multiple genetic, constitutional, and environmental 
risk factors.   
1.4.1 Individual level risk factors  
1.4.1.1 Ageing  
Studies have documented that OA increases with age (Figure 1.2-1). OA is uncommon in 
people aged less than 40 years , although  recent studies have started to document knee 
pain symptoms and/or symptomatic OA in quite a number of younger adults (Plotnikoff et 
al., 2015). Age influences risk of OA differently according to joint site. For example, the 
Fallon Community Health Plan reports higher incidence of hand OA in both men and 
women with increasing age (Oliveria et al., 1995) whereas, in the Spanish population 
higher incidence of knee and hip clinical OA with age was reported compared to hand OA 
(Prieto-Alhambra et al., 2014).  
1.4.1.2 Gender  
Gender has a strong relationship with OA mostly towards the latter half of life. Prevalence 
of OA is higher among women (Felson, 2000). Not only OA diagnosis, also the severity 
and involvement of multiple joints become more common after the age of 50 years. In 
women the interphalangeal joints, first carpometacarpal joints and knees are most 
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commonly affected, whereas, men are more likely to have OA at metacarpophalangeal 
joints and hips (Moskowitz, 2007). There are theoretical explanations to describe the role 
of oestrogen, and the reduced levels following the menopause, in influencing and 
mediating the risk factors for OA (Spector and Campion, 1989). 
1.4.1.3 Obesity and metabolic syndrome 
Worldwide the prevalence of obesity has nearly tripled since 1975 (WHO report, 2019). In 
2016, more than 1.9 billion adults aged 18 years and more, were overweight, of which 650 
million were obese(WHO report, 2019). A strong association of obesity with OA has been 
established and reported in various systematic reviews (Zhou et al., 2014; Zheng and 
Chen, 2015). However, most of the studies reported associations with knee OA and hip 
OA. This association is explained through higher/altered loading of weight-bearing joints 
and possible systemic low-grade inflammation (Runhaar et al., 2011). Higher BMI also 
associates with OA of non-weight bearing joints, such as in the hand, suggesting a role for 
biomechanical, metabolic, or inflammatory aspects of obesity.  
Figure 1.4-1 Potential obesity related pathways that contribute to OA  
 
Produced with permission (copyright number 4897690041039). (Vincent et al., 2012) 
8 
 
The exact metabolic relationship between obesity and OA is not clear.  It is thought that 
adipokines released into the systemic circulation from excess fat cells deteriorates the 
health of chondrocytes and other joint tissues through degradative enzymes (Gómez et 
al., 2011). Local intra-capsular fat (e.g. retro-patellar fat in the knee) has also been 
implicated in releasing local cytokines that may damage cartilage (Simopoulou et al., 
2007). (Figure 1.4-1) 
1.4.1.4 Nutritional factors 
Amongst, nutritional factors, vitamin D has been studied most extensively. Lower intake of 
vitamin D and increased risk of OA has been suggested because of impairment in 
cartilage metabolism (Garfinkel, Dilisio and Agrawal, 2017). However, the findings remain 
conflicting for vitamin D and other nutrients/vitamins (E, K and C). An inconsistent 
protective effect of vitamin C and E with osteoarthritis risk has been suggested 
(McAlindon et al., 1996; Wluka et al., 2002). Similarly, low vitamin K has been reported  in 
people with OA aged 50 years or more (Neogi et al., 2006).  
1.4.1.5 Bone density and bone mass 
High bone density has been recognised as a risk factor for incident OA (Nevitt et al., 
2010), although a causal relationship and mechanism remain unclear. High bone mass is 
linked with subchondral bone sclerosis rather than with joint space narrowing. This might 
be an indication of a hypertrophic OA phenotype. 
1.4.1.6 Smoking 
Smoking, a major risk factor for cardio-vascular disease, does not have a significant  
association with OA (Hui, Doherty and Zhang, 2011). Another systematic review by the 
same group found similar findings on smoking having no significant role in incidence and 
progression of OA (Pearce et al., 2013). 
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1.4.1.7 Low birth weight 
Low birth weight and pre-term birth have been associated with higher risk of hip 
arthroplasty as an adult (Hussain et al., 2018). Even hip osteophytes in later life is linked 
with lower birth weight (Clynes et al., 2014).  
1.4.1.8 Sports and physical activity 
Individuals engaged in heavy activities or high contact sports are at increased risk of 
developing OA. Reviews have reported conflicting evidence on physical activities and OA, 
mostly because of non-uniformity of measuring physical activities (Tran et al., 2016; 
Timmins et al., 2017).  It is not merely the activities, but joint loading, injury, physical 
strength, and other factors that determine the risk of OA. Moderate levels of physical 
activity do not cause OA through improving the muscle balance and controlling overweight 
and obesity. Overall a moderate level of physical activity is necessary to maintain joint and 
overall health.  
1.4.1.9 Occupational factors 
There is a strong evidence of association of OA with occupation. McWilliams et al 
reported in a systematic review the risk of knee OA was 1.6 times high with occupational 
activities. The weight bearing joints of lower limbs are exposed to excessive load, stress, 
trauma due to different activities in occupation such as weightlifting, prolong standing and 
lift walking (Klussmann et al., 2010; Schram et al., 2020). A genetic study among co-twins 
supported the mentioned occupational activities relation with knee OA (Skousgaard et al., 
2018). Not only the weight bearing joints, but small joints in hand have reported to develop 
OA due to occupation exposure (Fontana et al., 2007).  
1.4.1.10 Genetic  
OA has a genetic component which may vary by joint site. More than 20 gene 
polymorphisms are known to be associated with OA (Bravatà et al., 2015; Ren et al., 
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2017). According to Twin and family studies, the heritable component of OA varies 
between 50 and 65%. It has greater genetic influences for hand and hip OA compared to 
knee OA (Spector et al., 1996). However, having familial clustering of OA could be 
because of sharing similar living environment and lifestyles, which needs to be excluded. 
In addition, differences in the pattern of OA also exist, such as hip OA being more 
common in the Western countries, whereas knee OA is more common in the Asian and 
Chinese population (Allen, 2010).  
1.4.2 Joint-Level Risk Factors 
1.4.2.1 Bone/joint shape 
Constitutional joint shape and risk of OA is gaining interest among researchers. A 
significant difference in femoral head shape and incident hip OA was reported among men 
in the Johnston County osteoarthritis project (J. M. Jordan et al., 2007). The Nottingham 
musculoskeletal research group also found the pistol-grip deformity of the hip is 
associated with hip OA (Doherty et al., 2008). Neogi et al predicted knee OA using joint 
shape (full joint) rather than individual bones (Neogi et al., 2009). Bone/joint shapes alter 
the biomechanics of the joint which then predispose to OA.  
1.4.2.2 Injury 
Joint injury includes meniscal damage, ligament rupture, or direct articular cartilage injury. 
Patients with anterior cruciate ligament (ACL) deficiency and reconstructed knees had 
altered synovial fluid biomarker levels indicative of OA (Riccardo, Fabio and Pietro, 2017). 
Apart from overt injuries, repetitive micro-trauma may also compromise joint tissues. 
1.4.2.3 Muscle strength and mass 
Muscle weakness predisposes to an increased risk of knee OA (Dell’isola et al., 2018). 
Especially, in weight bearing joints, stronger muscles afford stability and protect the joint 
from undue loading, minimising the trauma to cartilage and joint tissues. However, the role 
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of muscle strength and mass in OA development and progression is still somewhat 
unclear for other joint sites. 
1.4.2.4 Other joint-level risk factors 
Limb length can be another joint level factor associated with OA. Unequal limb length 
causes more loading in the longer leg and increases the risk of knee OA. Similarly, bony 
malalignment such as varus or valgus changes the biomechanics of joint loading and 
predisposes to knee OA.  
1.5 Clinical manifestation of Osteoarthritis 
People with OA may present with pain, stiffness, reduced function, and participation 
restriction which all may cause reduced quality of life.  
1.5.1 Pain  
Pain reported in OA is multidimensional and can be influenced by both peripheral (local 
joint tissue) factors and central (nervous system) factors. Pain is typically usage-related, 
relieved by rest, and worsens towards the end of the day (Hawker et al., 2008). Pain in 
OA cannot originate from cartilage as it is not innervated, but there are nociceptors in the 
joint synovium, capsule, subchondral bone, and periosteum. Stimulation of peripheral 
nociceptor sensory nerves can be via soluble inflammatory mediators such as cytokines 
and prostaglandins and by biomechanical trauma, and  the ascending signals are 
frequently modified in OA at the spinal cord and brain level (Lluch et al., 2014). Central 
sensitization is described as sensitization of nociceptive stimuli by active neurons which 
becomes hyperresponsive to subsequent stimuli to the neuron’s receptor fields (O’Neill 
and Felson, 2018). So, even in the presence of low intensity nociceptive stimuli from the 
OA joint, higher perceived pain can be because of sensitization of the pain centres from 
chronic input and from other sources of pain. This suggests the possible presence of other 
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painful conditions such as; fibromyalgia or chronic fatigue syndrome in an individual, 
which alters the pain sensitivity (Woolf and Salter, 2000).  
1.5.2 Stiffness  
In contrast to inflammatory arthritis, morning stiffness on arising is a minor feature of OA 
and is generally short-lived (less than 30 minutes) and rapidly wears off with movement. 
Similarly, stiffness after inactivity is short-lived and minor. 
1.5.3 Functional impairment 
Both pain and reduced range of joint movement result in impairment of joint function. Such 
impairments can cause disability with difficulty undertaking activities of daily living, and 
restriction in participation in social and work activities. Disability and participation 
restriction often have a negative impact on quality of life.  
1.6 Pathology of OA 
 
OA has a long history parallel to the evolution of man. As evidenced by osteoarthritic 
changes seen in a Comanchean dinosaur fossil, it appears to have remained 
pathologically unchanged for 100 million years (Dequeker and Luyten, 2008). The 
changes in osteoarthritic joints are relatively well recognised, although the causes for 
these changes are not. A variety of hypotheses aimed at explaining the changes have 
been voiced, including chronic mechanical overloading, matrix proteolysis, pro-
inflammatory cytokine production, activation of cellular inflammatory signalling pathways, 
premature ageing of chondrocytes and cartilage matrix, and damage to the chondrocyte’s 
deoxyribonucleic acid (DNA) (Hochberg et al., 2015). The most robust hypothesis is the 
role of adverse biomechanical factors in the pathogenesis of OA (Hochberg et al., 2015), 
however, it is by no means likely to be the only driving factor for OA. Most likely, a large 
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variety of factors contribute to the pathogenesis of OA and are responsible for the 
pathological changes witnessed.  
1.6.1 Pathophysiology  
The understanding towards the pathophysiology of OA is evolving. Though it was 
previously thought to be a consequence of normal ageing and damage due to mechanical 
factors, this theory is now thought to be inaccurate. Although much remains to be known 
regarding the causes of OA, different reasons apart from the ‘wear and tear’ have been 
postulated (Doherty et al., 2016). OA causes biochemical changes to the cartilage, bone, 
and synovium altogether (Hochberg et al., 2015). The metabolic dynamic process of OA 
involves both attrition and synthesis of tissues responsible for pathogenesis  (Doherty et 
al., 2016). Figure 1.6-1 shows the possible changes in joints during OA. 
Figure 1.6-1 Changes in joints in OA 
 
Different tissues like cartilage, synovial tissue, and subchondral bone, osteophytes involved in the clinical and 
structural changes of the disease shown on left. right hand side shows the bi-directional interplay between 




1.6.1.1 Non-vascular pathology  
The production of new tissue in synovial joints with OA with increased metabolic activity at 
many joint sites are evident. These suggest  a potentially regenerative process, that is a 
repair/modelling phase after the ‘wear and tear’. In many cases this slow repair process 
may be successful, thus leaving a structurally abnormal joint without pain. This may 
explain the evolutionary advantage and preservation of OA in species with synovial joints. 
However, with overwhelming insult and/or a poor repair process, the joint may continue to 
remodel to try to keep pace with the insults and progress towards joint failure with 
associated symptoms and functional impairment.  
Normal articular hyaline cartilage forms a smooth covering for the joint surfaces and is 
responsible for the biomechanical properties of joints (Hochberg et al., 2015). Articular 
cartilage undergoes a variety of changes in OA. Initially, disruption to the type II collagen 
scaffolding causes the cartilage volume to increase as the water content increases and 
proteoglycan swelling occurs (Hochberg et al., 2015). This is later followed by cartilage 
loss secondary to the formation of superficial cracks (fibrillation) and continued protein-
degrading activity (Hochberg et al., 2015). Deep to these changes in the non-calcified 
cartilage, the calcified zone becomes thicker. In addition, blood vessels and nerves break 
through the tidemark separating the calcified and non-calcified cartilage, leading to 
neovascularisation and neo-innervation of the cartilage (Hochberg et al., 2015). As 
articular cartilage is aneural, these changes do not produce any pain until innervated 
tissue gets involved (Bijlsma et al., 2011). 
Deeper within the joint, at the junction between cartilage and bone, periosteal and 
synovial mesenchymal stem cells are induced to proliferate and form fibrocartilage which 
then undergoes endochondral ossification to form bone (Doherty et al., 2016). The bony 
spurs appear on the marginal aspects of joints and are known as osteophytes. Some 
changes are seen directly within the subchondral bone in OA, although it’s cause is 
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unclear (Hochberg et al., 2015). Subchondral sclerosis, cysts, and bone marrow lesions 
(BMLs) are the morphological changes in subchondral bone (Hochberg et al., 2015). 
Recent evidence suggests low-grade inflammation of the synovial membrane (synovitis) in 
OA (Doherty et al., 2016). Cartilage debris is released from the damaged cartilage 
surface, causing pathological synovial changes and the release of cytokines, growth 
factors, and enzymes that can further disrupt articular cartilage homeostasis (Hochberg et 
al., 2015). Finally, the pathological changes in synovium, cartilage, and bone are often 
accompanied by changes in the menisci, joint capsule, intra-articular ligaments, extra-
articular connective tissues, and peri-articular muscle (Doherty et al., 2016). 
The role of inflammation in the pathogenesis of OA is widely debated. The presence of 
inflammation in OA is generally accepted, as evidenced by the presence of synovitis, 
effusion, and stiffness (Robinson et al., 2016). Changes indicative of inflammation, such 
as effusion, synovial hypertrophy , and Power Doppler signals, can be visualised using 
ultrasound examination. Ultrasound markers of inflammation are raised in those with knee 
pain compared to those without knee pain (Sarmanova et al., 2017). In addition, the 
intensity of ultrasound inflammation increases with worsening structural changes 
(Sarmanova et al., 2017). Others believe inflammation to be a primary driver of OA 
(Berenbaum, 2013; Robinson et al., 2016). Low-grade local and systemic inflammation 
are thought to cause OA through a multitude of mechanisms, including innate and 
adaptive immune mechanisms and inflammatory mediators (Robinson et al., 2016). Post-
traumatic OA is thought to cause OA through local inflammation which causes synovitis 
and activates mechanoreceptors (Berenbaum et al., 2013). Similarly, OA is thought to be 
driven by low-grade systemic inflammation in metabolic syndrome, by a secretory 
inflammatory phenotype in increased age, and by innate immunity in crystal OA 
(Berenbaum et al., 2013).  
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The vicious cycle of mechanical factors leading to OA has been recently emphasized 
(Felson, 2013). Abnormal mechanical loading may result from various insults such as 
malalignment, congenital dysplasia, meniscal tears, or chronic excessive loading (Felson, 
2013). The affected cartilage is damaged, and the underlying bone may also undergo 
remodelling, further driving the abnormal loading (Felson, 2013). Consequently, cartilage 
debris may cause a secondary inflammatory response in the synovium, evidenced by 
synovitis and excess fluid secretion (Felson, 2013). The basis for the hypothesis is 
grounded primarily in studies that have found associations between risk factors that cause 
abnormal mechanical forces in the joint, such as obesity, injury, and occupational 
overuse, and the development of OA (Felson, 2013).  
1.6.1.2 Vascular pathology 
In the context of increasing reporting of metabolic syndromes and cardiovascular diseases 
in OA, vascular pathology has gained recent attention. Even though cartilage itself is 
avascular, the vascular pathologies in subchondral regions drive the possible hypothesis 
(Imhof et al., 2000). Bone remodelling is accomplished by the co-ordinated action of 
osteoclasts and osteoblasts. The initiating event for sites of bone remodelling is not 
known, but it seems likely that these sites are targeted and the basis of this targeting may 
be regions of loss of osteocyte viability (Noble, 2003). 
These osteocytes are prone to apoptosis due to reduced blood flow around them, 
triggering the osteoclast activities and excavation of non-viable bones. Bone marrow 
oedema, a consequence of bone trauma is known to be responsible for reduced blood 
flow (Mandalia et al., 2005). It is also found to be associated with structural deterioration in 
knee OA (Hunter et al., 2013). The reasons for bone marrow oedema are not well 
understood, but probably it is related to local trauma and injury. 
Another vascular mechanism for OA is subchondral bone ischaemia, which leads to 
reduced nutrients and oxygen supply to the cartilage. The increased turnover of the 
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subchondral bone in OA could be secondary to episodic ischaemia, in turn due to vascular 
pathology in the subchondral bone. A detailed mechanism of subchondral bone 
vascularisation role is provided in Figure 1.6-2.  
Figure 1.6-2 Subchondral vascular pathology of OA 
 
Role of the subchondral vasculature in the initiation and/or progression of OA.  
The left panel shows a representation of healthy articular cartilage overlying the subchondral trabecular bone. 
In addition to structural support and absorption of shock offered by the subchondral bone, its small vessels 
and probably the interstitial bone fluid in osteocyte canaliculi, provide important nutrition to the cartilage. The 
right panel shows some cartilage erosion, as seen in OA. Typically, the subchondral bone would also be 
altered in OA, with areas of bone marrow oedema (BMO), increased bone turnover, and sclerosis. BMO may 
be due to episodes of ischaemia, perhaps due to occlusion of the supply vessels by atherosclerosis, or 
venous stasis due to loading and/or increased intra-articular pressure, or to embolus formation in the small 
vessels of the subchondral bone. The latter could be due to trauma, obesity, or increased propensity to clot, 
perhaps exacerbated by reperfusion injury, at sites where blood flow has been lost and then recovers into 
hypoxic tissues. One result of local ischaemia in the bone may be to deny the overlying cartilage of nutrition, 
causing catabolic and reparative events in the cartilage. Osteocyte death in areas of bone affected by hypoxia 
will also be targeted for resorption and replacement, increasing subchondral bone turnover. The support to the 
articular cartilage and the shock absorption provided by the subchondral bone may be compromised during 
episodes of bone repair, leading to articular cartilage damage. (Findlay, 2007) Produced with permission 
(copyright no 4897680137150).  
It is not only the inflow of  blood, but also obstruction to the outflow that  may decrease the 
cellular nutrient and oxygen supply (Wang C. -C et al., 2011). Episodes of venous stasis 
in OA may lead to loss of osteocyte viability in regions of the bone. This is likely to occur 
especially in the highly vascular subchondral region of long bones. In vascular conditions 
such as hypertension, there is evidence of impaired capacity of vascular growth and 
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angiogenesis, which in turn may lead to endothelial cell damage or dysfunction. The 
factors responsible for such changes in hypertension are seen in OA too, though this is in 
a preliminary research stage (Enomoto et al., 2003). The reduced microcirculation in 
diabetes and other peripheral vascular diseases might be explained also under the above 
mechanisms.  
Listing the pathophysiological changes and the factors responsible is not complete without 
the multifactorial explanation. There is complex interaction between adverse mechanics, 
inflammation, and the systemic vascular changes, as potentially other factors. For large 
joints, the adverse mechanical loading of the joint may be the preliminary and primary 
driver of OA, proceeding to secondary inflammation. However, in smaller joints with 
greater inflammatory features, such as in erosive hand OA, there may be more extreme  
inflammation that may be an important driver of tissue damage. Also, the commonality of 
the vascular changing factors seen at subchondral regions could make the pathogenesis 
process proceed faster. 
1.7 Management of Osteoarthritis  
Management of OA has always been challenging because of the diversity of joints 
involved and symptoms reported. An individual’s pain severity and illness perception 
towards the condition varies because of individual and health system factors. Thus, 
assessment and management of people with OA is recommended to be individualised 
‘person-care’ rather than just ‘disease-specific’.  There is no single specific “cure” for 
symptomatic OA and the management aims to improve symptoms and reduce further joint 
insult in order to halt or retard the progression of OA (Anandacoomarasamy and March, 
2010). Major guidelines support a package of care that comprises  core non-
pharmacological and adjunctive pharmacological modalities with an emphasis on  
individualised management and patient engagement (Doherty and Dougados, 2001; 
Zhang et al., 2008). (Figure 1.7-1) 
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Figure 1.7-1 NICE guideline for management of OA (Conaghan et al., 2008) 
 
The core and options approach emphasised by NICE recommended treatments. Treatment option that are to 
be considered for everyone are in the centre, ‘First line’ analgesic to try in the second ring and other 
interventions are in the outer ring. From NATIONAL INSTITUTE OF CARE AND EXCELLENCE (NICE) GUIDELINES 
(COPYRIGHT NUMBER 4897690227029) 
1.7.1 Core treatment 
The core treatments of the NICE guideline include, education and information, exercise, 
and reduction of adverse mechanical factors (e.g. weight loss if overweight or obese) 
(NICE, 2014). 
It is a primary responsibility of the healthcare professionals to provide tailored information 
and education to the patients about the nature of condition, the causes, prognosis, 
diagnostic options, and the available treatments, including their possible advantages and 
disadvantages. Enquiry should be made about the individual’s illness perceptions of OA 
and incorrect perspectives should be discussed and changed. All information should be 
given in terms that can be understood by the individual patient. Such education underpins 
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the success of any treatment especially for patients with hip, knee, or multiple joint OA 
(Mazzuca et al., 1997). 
Continuing physical activity in people with OA, whilst pacing activities and avoiding undue 
mechanical stress, is important to maintain joint health. Although many perceive activity 
as a damaging factor for the joints, lack of activity is deleterious and regular appropriate 
activity and exercise (both local strengthening exercises, and aerobic exercise) is 
essential for effective management of OA(Doherty et al., 2016). It is recommended that, 
people with OA should continue with neuro-muscular training, strengthening, and aerobic 
exercise within optimal limits to improve general fitness, muscle strength and maintain 
joint range of motion (Hunter and Eckstein, 2009). It is evident that both local 
strengthening and aerobic exercises reduce pain in OA (Ettinger et al., 1997). Also 
physiotherapy and exercise used as therapeutic purpose is more effective in OA 
management (Fransen et al., 2015). 
Another important core treatment option is reduction of modifiable mechanical risk factors 
such as obesity. Reduction and maintenance of weight in overweight and obese people  
has been shown to significantly improve function and prevent OA (Miller et al., 2006; 
Schlenk et al., 2011) and is strongly recommended. Other mechanisms to reduce joint 
loading are the use of walking aids, splints, environmental modification (e.g. raised toilet 
seats, walk-in showers instead of a bath etc.), modification of footwear (e.g. thick 
compressible sole), local heat or cold applications, and transcutaneous nerve stimulation.  
1.7.2 Pharmacological  
Present pharmacological therapy in OA aims solely to improve the symptoms, mostly joint 
pain, and stiffness. Currently there is no drug that is licensed as a disease-modifying OA 




Figure 1.7-2 Treatment algorithm for symptomatic OA  
 
COX-2, Cyclo-oxygenase-2; NSAID, Nonsteroidal anti-inflammatory drug; PGE2, prostaglandin E2; PPI, 
proton pump inhibitor; PO, oral; SNRI, selective norepinephrine reuptake inhibitors; SSRI, selective serotonin 
reuptake inhibitor. (Argoff and Gloth, 2011) Produced with permission 
Topical non-steroidal anti-inflammatory drugs (NSAIDS) can be considered as first-line 
treatment for readily accessible joints such as hands, knees, feet (but not deep joints such 
as hips). These drugs have better efficacy and minimum side-effects compared to oral  
NSAIDs and paracetamol (Derry et al., 2016).  A recent systematic review reports the 
good efficacy and excellent safety of topical capsaicin and topical NSAIDS used in 
licensed dosage in OA (Persson et al., 2018). 
The second preferred drug of choice is oral paracetamol. This has long been considered 
as the safest systemic analgesic and older trials confirmed its efficacy in reducing pain in 
OA (Zhang, Jones and Doherty, 2004; Towheed et al., 2006). More recent trials, however, 
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show little or no benefit compared to placebo, and there are growing concerns over its 
side-effect profile (Roberts et al., 2016). 
Oral NSAIDs have analgesic, anti-inflammatory, and anti-pyretic effects and are effective 
for OA when used with safe dosage (da Costa et al., 2017). Oral opioid analgesics are 
reserved for marked pain resistant to other analgesics. Oral NSAIDS and specific COX-2 
inhibitors, particularly in older people, have several potentially serious gastrointestinal, 
renal, and cardiac side-effects in long term use. They should always be prescribed with a 
PPI, and there are numerous absolute or relative contraindications to their use in patients 
with comorbidity and on other medications (which apply to many people with OA).   
According to a Cochrane meta-analysis, glucosamine, chondroitin, and their combination 
show slight pain reduction compared to placebo in hip and knee OA patients (Effect size   
-0.5, 95% confidence interval -0.9 to 0.0) (Wandel et al., 2010). However, this effect is 
considered not clinically significant and, although popular as over-the-counter self-
medications, they are not recommended by NICE (NICE, 2014).  
A meta-analysis of 27 trials concluded that intra-articular corticosteroids helps in pain 
reduction (Jüni et al., 2015) and they are recommended for consideration in people with 
pain resistant to other simple analgesics. The recommendation of hyaluronic acid use in 
OA is still debatable because of great heterogeneity of evidence (Fernández López and 
Ruano-Ravina, 2006) and NICE recommends to not use it within the NHS (NICE, 2014).  
1.7.3 Surgical  
If conservative management fails to give enough improvement, surgical treatment may 
need to be considered. Of the surgical options available, joint replacement for knee or hip 
OA are the most successful. Total joint replacement (TJR) is one of the preferred options 
for end-stage OA (Choong and Dowsey, 2014). However, although post-surgical 
improvement in pain and function has been reported by many observational studies, up to 
23 
 
20-30% of people still experience pain following TJR (Wylde et al., 2017). The trend of 
TJR in UK is seen to be consistent decline over the past 20 years (Yu, Jordan and Peat, 
2018). (Figure 1.7-3 and Figure 1.7-4) 
Figure 1.7-3 Trends of primary hip replacement in UK among clinical and diagnosed OA 
(% of total diagnosed cases) 
 
Figure 1.7-4 Trends of primary knee replacement in UK 
 
Notes: Square, diamond, and circle line represents proportion of clinical OA, diagnosed OA (any joint), and 
diagnosed OA (joint-specific), respectively. Black and grey lines indicate the proportion with diagnosis in 10 
years and 3 years prior to the index joint replacement, respectively. (Yu, Jordan, and Peat, 2018), produced 
with permission  
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1.8 Comorbidities or Multimorbidity 
 
1.8.1 Definitions and difference 
The presence of multiple diseases in any given individual is becoming increasingly 
frequent. It can be termed as comorbidity or multimorbidity. Comorbidity is defined as 
“existence or occurrence of any distinct additional entity during the clinical course of a 
patient who has the index disease under study”(Feinstein, 1970), while multimorbidity 
denotes “the  coexistence of two or more chronic diseases in one individual” (Akker, 
Buntinx and Knottnerus, 1996). A diagram showing the difference between the two is 
given in Figure 1.8-1.  
Figure 1.8-1 Comorbidity and Multimorbidity 
Comorbidity      Multimorbidity  
      
Comorbidity has been defined broadly in two ways: 
1. Two or more medical conditions existing simultaneously but independent of each other.  
2. Two or more medical conditions existing simultaneously and linked with each other. 
Throughout this thesis, I used ‘comorbidity’ to OA irrespective of a causal relationship 
between the conditions. I also used the term multimorbidity when there were 2 or more 












1.8.2 Measuring comorbidity 
Apart from inconsistencies in definition of OA, the measurement of comorbidity has been 
challenging. Authors have developed and validated various tools for comorbidity 
measurement as listed in Table 1.8-1. Of these, commonly used tools are the Charlson 
comorbidity index (Charlson et al., 1987) and the cumulative illness rating scale (Linn, 
Linn and Gurel, 1968). These tools differ in methods of capturing information on disease 
and very few tools have been designed to measure the burden and severity of the 
disease.  
Table 1.8-1 Measuring comorbidity and multimorbidity  
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1.8.3 Types of comorbidity 
The extensive list of possible comorbidities makes it difficult to group the conditions. Still, 
attempts have been made to classify comorbidities as per their relationship and 
aetiopathogenesis.  
1.8.3.1 Primary vs Secondary (Feinstein, 1970) 
According to Feinstein, comorbidities can be grouped as primary or secondary based on 
chronological sequence and causal inference. Chronological comorbidity (Figure 1.8-2) is 
time dependent and develops in sequence. For example, in a person having chronic 
condition A, B develops in later life and C develops even later in life. There could be a 
linkage between the conditions, but this need not be so. In this case B is the primary 
comorbidity of A and C is the secondary comorbidity of A and can also be the primary 
comorbidity of B. 
 Figure 1.8-2 Chronological comorbidity model 
 
In causal inference, condition B developed later than A but occurs because of A. Similarly, 
C can develop in late life which is induced by A or B or both. The causal link could be 
direct because of the disease, associated medication uses or other factors. Similarly, B is 











1.8.3.2 Concordant and discordant comorbidity (Piette and Kerr, 2006) 
Conditions of similar pathophysiologic risk profile and which are more likely to share a 
common management plan are grouped as concordant comorbidity. For example, 
diabetes and cardio-vascular diseases (CVDs) follow similar management programs and 
are classified as concordant comorbidity. Discordant conditions do not share similar 
pathophysiology or management plan. For example, osteoarthritis and asthma have 
different management plans but can exist together.  
1.8.4 Comorbidity in OA 
Abundant studies have been done on comorbidity in cardio-vascular diseases and 
psychiatric and cancer conditions, but there is a paucity of data on comorbidities in OA. 
This appears surprising, given that OA is one of the leading chronic conditions in older 
people, in whom multiple conditions are common. Two reasons could be that OA is not 
perceived to have a higher fatality index as does CVD, and it is considered an inevitable 
accompaniment of ageing. Other possible reasons could be the underexamined and 
perception of the unshared risk factors and no association with other conditions. However, 
recent research on comorbidity in OA is increasing, especially with respect to pain severity 
in OA which might be linked to central sensitisation mechanisms and coexistence of other 
painful conditions. Recently some reviews have examined the existing literature on 
individual comorbidities in OA, though on a separate individual basis.  
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1.8.4.1 OA and Cardio-Vascular Diseases (CVD) 
A systematic review reported, among 358,944 participants, that the risk of CVD was 
significantly increased by 24% in patients with OA (n=80,911) compared with the general 
population (H. Wang et al., 2016). Another review published in the same year by Hall et al 
reported a pooled prevalence of overall CVDs of 38.4% in people with OA and the risk of 
having heart failure was three times higher in OA compared to non-OA (Hall et al., 2016). 
Similar findings have been documented by Parkinson et al (Parkinson, Waters and 
Franck, 2017). 
1.8.4.2 OA and Diabetes 
Louati et al, included 49 studies in a meta-analysis of the association of diabetes with OA. 
The prevalence of diabetes in people with OA was 14.4% and the risk of diabetes was 1.4 
times higher compared to non-OA controls (Louati et al., 2015). In  2016, Williams  et al 
did another review of the  association of OA with diabetes and reported in people with 
diabetes an odds ratio of 1.2 of developing OA (Williams et al., 2016). One hospital based 
study reported the odds of having hand or knee OA was higher in female diabetics 
compared to males (Nieves-Plaza et al., 2013). 
1.8.4.3 OA and depression 
Evidence for an association between OA and depression is inconclusive. A recently 
published review found a prevalence of depressive episodes in OA of 19.9%, and the 
prevalence of anxiety was 21.3%. However, the risk of having depression and anxiety in 
people with OA compared to non-OA population was not statistically significant (Stubbs et 
al., 2016a). 
1.8.4.4 OA and Chronic Obstructive Pulmonary Diseases (COPD) 
The only review  on OA with COPD  reported a prevalence of OA in COPD of 35.5% 
(Wshah et al., 2018). 
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1.8.4.5 OA with Fatigue and sleep disturbances 
Fatigue is defined as weakness and tiredness. Fatigue in OA is not well researched 
compared to rheumatoid arthritis (RA) and other inflammatory diseases. People with OA 
often report tiredness, irritability and low mood and depression (Snijders et al., 2011). 
More frequent in older age, it is associated with disturbances in sleep, early morning 
wakening and difficulty in falling asleep (Parmelee, Tighe and Dautovich, 2015). These 
disturbances could be due to OA pain and deprived sleep could amplify the pain and 
cause fatigue and can have fibromyalgia syndrome. 
1.8.4.6 OA and musculoskeletal disorders  
 
Joint pain and other musculoskeletal comorbidities in OA is well documented, especially, 
the relationship of back pain with OA (Suri et al., 2010; Bollegala, Perruccio and Badley, 
2011). Another primary care database study in UK reported positive associations of OA 
with other arthropathies, upper limb sprain, synovial and tendon disorders and other joint 
disorders (Kadam, Jordan and Croft, 2004). 
1.8.4.7 OA and multiple comorbidities 
Versus arthritis has published a report on multimorbidity in OA (Loftis, Ellis and Margham, 
2014). According to this, one in five people with OA in the UK have at least one other 
chronic condition. Three of ten people aged 45 years or more with multimorbidity have 
musculoskeletal problems (Versus Arthritis, 2016). Even though musculoskeletal 
conditions are extremely common and cause impaired quality of life, their associations 





1.8.5 Systematic review of OA and comorbidities 
I did a systematic review and metanalysis of the comorbidities in OA in the beginning of 
my PhD (Swain et al. 2019). 
Four databases for observational studies on comorbidities in individuals with OA were 
searched. Studies of OA only or in comparison with non‐OA controls were included. The 
risk of bias and study quality were assessed using the Newcastle‐Ottawa Scale. The 
prevalence of comorbidities in the OA group and the prevalence ratio (PR) and 95% 
confidence interval (95% CI) between OA and non‐OA groups were calculated. 
In all, 42 studies from 16 countries (27 case‐only and 15 comparative studies) met the 
inclusion criteria. The mean age of participants varied from 51 to 76 years. The pooled 
prevalence of any comorbidity was 67% (95% CI 57–74) in individuals with OA versus 
56% (95% CI 44–68) in individuals without OA. The pooled prevalence ratio (PR) for any 
comorbidity was 1.21 (95% CI 1.02–1.45). The PR increased from 0.73 (95% CI 0.43–
1.25) for 1 comorbidity to 1.58 (95% CI 1.03–2.42) for 2, and to 1.94 (95% CI 1.45–2.59) 
for ≥3 comorbidities. The key comorbidities associated with OA were stroke (PR 2.61 
[95% CI 2.13–3.21]), peptic ulcer (PR 2.36 [95% CI 1.71–3.27]), and metabolic syndrome 
(PR 1.94 [95% CI 1.21–3.12]). 
Heterogeneity in the prevalence estimates observed in this review, stemming from 
diversity of methodologies, may have caused uncertainty of the results. There was 
ambiguity in disease definitions, for example over whether peptic ulcer, gastritis, and 
acidity should be considered separate entities. Suboptimal information about OA reported 
in studies made it difficult to differentiate between structural OA and symptomatic OA and 
to determine whether associations were linked primarily with structural OA or with pain 
experience. Similarly, the count of chronic conditions and the definition used varied 
considerably between studies and may have influenced the estimates. The comparative 
32 
 
groups included any non‐OA cases, so the comorbidity pattern might have been different 
because of the selection of comparative/control groups, which needs to be interpreted 
with caution. Furthermore, the unavailability of joint‐specific OA within comparative studies 
limited the estimation of joint‐specific comorbidities. The study also compiles data from 
different study designs and thus has limitations for understanding the time sequences of 
OA with comorbidities. Unfortunately, there were not enough studies in each subgroup 
(only 1 in the cohort design) in comparative studies to perform subgroup analysis as per 
the study design. 
Individuals with OA are more likely to have other chronic conditions. The association is 
dose‐dependent in terms of the number of comorbidities, suggesting multimorbidity. 
Further studies on the causality of this association and clinical implications are needed. 












1.9 Aim and objectives  
 
1.9.1 Rationale  
OA is a common chronic condition with subsequent significant detrimental impact on daily 
activities and quality of life (Szoeke et al., 2006; Litwic et al., 2013). Four out of five people 
with OA have at least one other long-term condition such as hypertension, CVD or 
depression (Breedveld, 2004). A few studies have reported the association of OA with 
multiple chronic diseases such as long-term widespread pain, CVD and diabetes, but the 
pattern and distribution of these have not been fully explored (Kadam, Jordan and Croft, 
2004; Hoogeboom, Broeder, et al., 2012; Zambon et al., 2015a).  
However, most research on comorbidity in OA has focused on CVD and metabolic 
syndrome. Musculoskeletal conditions such as OA, despite being one of the leading chronic 
conditions, have often been neglected in comorbidity/multimorbidity research. Because of 
a lack of clear understanding of the distribution and causal relationship between OA and its 
comorbidities, optimal management of the disease and its comorbidities remains undefined 
(de Rooij et al., 2014). For example, although the association between OA pain and 
widespread pain has been investigated, the temporal direction of the causal association 
between these two conditions is unknown. 
Aim: The overall aim of the thesis is to understand and explore the comorbidities 
occurrence in people with OA. 
1.9.2 Objectives 
The specific objectives are:  
• To examine the trends in prevalence and incidence of OA in the UK population over 
the last 20 years 
• To examine the temporal association between OA and comorbidities  
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• To identify the common clusters of comorbidities in OA and controls  
• To understand the transition of people from one cluster to another with time in both 
OA and controls 
• To explore the trajectory of the growth of multimorbidity and associated factors in 
people with OA and controls 







2 Chapter 2 Materials and methods 
 
2.1 Population based studies using the Clinical Practice Data-Link (CPRD) 
GOLD database 
 
A series of observational studies were carried out using the CPRD database to investigate the 
incidence and prevalence of OA, to identify the most common comorbidities associated with OA, 
their temporal associations with OA, and resultant healthcare utilization and mortality rates in 
people with OA compared to those with OA alone. 
2.1.1 Definition of the Study population 
 I used data contained within the CPRD database (Nada F Khan, Harrison and Rose, 2010; 
Herrett, Arlene M. Gallagher, et al., 2015). For this study CPRD GOLD was used. CPRD GOLD 
contains prospective healthcare data on around 17 million people from over 736 general 
practices throughout the UK and is a nationwide primary care database. For this study, data 
available for registered people from 1st January 1997 to 31st December 2017 were used. 
General inclusion criteria: 
• aged 20 years or more during the study year, 
• have had minimum active registration for at least 12 months with the up-to-standard 
practice prior to the study, 
• acceptable quality (decided by the CPRD based on certain parameters to select data 
suitable for research purpose) 
2.1.2 Clinical Practice Research Datalink 
 
The CPRD is one of the largest general practice based electronic databases created for health 
research. Started in 1987 in London, initially it was named as Value Added Medical Products 
(VAMP) research databank (Kousoulis, Rafi and de Lusignan, 2015). Later in 1993 it was 
renamed as the general practice research database (GPRD) and since  2012 it has been known 
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as the CPRD (Williams et al., 2012). The database depends on the large general practices 
network in the UK. General practitioners in the UK are the gatekeepers of care of the National 
Health Service (NHS). The NHS covers  around 98% of the UK population and patient data are 
routinely recorded on computers at each health centre (National Health Services, UK, no date). 
The anonymised electronic health record data of participating practices are routinely collated by 
the CPRD (Clinical Practice Research Datalink | CPRD, no date). CPRD has linkage to other 
health databases such as office of the national statistics (ONS) death registration, CPRD 
mother baby link, hospital episode statistics (HES) inpatient and outpatient data, national cancer 
registration and analysis service (NCRAS) cancer registration data, and data for index of 
multiple deprivation  which enables access to multi‐linked longitudinal data, thus enhancing the 
data available for health care research. 
2.1.2.1 Contents of CPRD 
 
Currently, CPRD data are available in two forms namely, CPRD GOLD and CPRD Aurum 
based on the software used at practice level. CPRD GOLD includes data from practices using 
Vision software, whereas CPRD Aurum includes data from practices which use EMIS-Web 
electronic patient record software. The basic differences in two databases are because of the 
different structure and coding system in use. The details of CPRD GOLD are explained later 
(next page).  
Vision software is an electronic system for GPs to manage patients, which records information 
primarily as "events". The records of patient information exist from their first until their last 
contact with the participating practice. Practice level data are uploaded to CPRD monthly. The 
collected data are processed through the quality check to ensure internal consistency of patient 
data, complete longitudinal records, complete practice level data and compliance with CPRD 
recording guidelines. As of December 2017, the CPRD contained data on 17,480,766 patients 
of which 12.80% were considered as ‘non-acceptable’ for research after the quality check. With 
such a large amount of patient data and good representation of the UK population, the CPRD 
provides an excellent opportunity for research in areas such as health service research, drug 
37 
 
utilisation, clinical epidemiology, disease management, outcomes research, drug safety, health 
outcomes and pharmaco‐economics. 
2.1.2.2 Structure of CPRD 
 
The CPRD collates data broadly in two categories, namely practice data and patient data 
against masked identifiers. In practice data, the geographical regions are recorded according to 
the 13 regions in the UK with ten from England and one each for Wales, Scotland, and Northern 
Ireland.  
The database is further separated into clinical, referral, immunisation, test, and therapy data. It 
contains information on demographics, medical staff and practices, and clinical data, which 
records extensive clinical information on consultation, diagnoses, laboratory test/examination 
data, referral details, immunisation, and therapy. Descriptions of the CPRD structure are shown 
in the following Table 2.1-1. 
 Table 2.1-1. Details of the CPRD dataset 
Data files  Demographic/clinical details Registration details 
Patient  Gender, birth year, birth month,  
marital status, family number,  
child health surveillance registration 
details, prescription exemption 
Patient identifiers, VAMP identifier, first 
registration date, current registration date, 
registration status, registration gaps, 
internal transfer, transfer out date, transfer 
out reason, death date, acceptable 
 
Practice  Practice identifier, region. Last collection 
date, up to standard date 
 
Staff Gender and role Staff ID, 
 
Consultation consultation type,  Patient identifier, event date, system date, 
consultation identifier, staff identifier, 
duration 
 
Clinical  Event date, consultation type,  
medical code, episode, additional 
details 
Patient identifier, consultation identifier, 
staff identifier, entity type 
 
Referral Event date, medical code,  
NHS speciality, FHSA speciality, 
inpatient, attendance type, urgency 
Patient identifier, consultation identifier, 
staff identifier, system date, source  
 
Immunisation Immunisation details Patient identifier, consultation identifier, 
staff identifier, system date, source 
 
Test Medical code, consultation type, 
event date 
Patient identifier, consultation identifier, 
staff identifier, entity type 
 
Therapy Details of the prescription  Patient identifier, consultation identifier, 
staff identifier, event date, system date 
38 
 
(product code, dosage, BNF, 
quantity, duration) 
FHSA- Family Health Services Appeal Authority; BNF- British National Formulary; VAMP- Value Added Medical 
Services; ID- Identification number 
2.1.2.3 External linkage  
 
Leading external databases are the Hospital Episode Statistic (HES), Office for National 
Statistics (ONS) mortality data, Cancer Registry, Myocardial Ischaemia National, Audit Project 
(MINAP), mother‐baby link, national joint registry, and socioeconomic deprivation. Not all the 
practices are linked to external data source. ONS mortality data and HES are only available for 
English practices. Researchers must request these external linkages if needed with appropriate 
justification. 
2.1.2.4 Diagnostic codes and validation 
 
During the initial period of the CPRD, diagnoses were based on the Oxford Medical Information 
system (OXMIS), which was later replaced by Read codes in 1995. A substantial amount of 
research has been done to examine the validity and completeness of the CPRD, which provides 
satisfactory results. HES records data regarding hospital admissions, but uses  ICD‐10 for 
diagnosis, rather than the Read coding system.  
2.1.2.5 CPRD Coverage  
 
The CPRD GOLD had information for nearly 17 million patients by December 2017,  
representing 12% of the UK population. Of these, nearly 5 million were active registered 
patients. The database covers nearly 735 practices from 13 regions of the UK. However, the 
participation of practices across the regions is not uniform and  some regions contribute more 
than others. According to a publication in 2013, the contribution of patients to the total database 
was highest from London (13%) and lowest from  the East Midlands (0.7%) (Herrett, Arlene M 
Gallagher, et al., 2015). This was validated later in 2016. According to Kontopontelis E. et al  the 
Vision clinical computer system is used by less than 10% of practices and is heavily 
concentrated in three major conurbations and the Southern region (Kontopantelis et al., 2018).  
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Table 2.1-2. Number of participating practices and CPRD GOLD-registered patients in 13 areas 
in the UK in 2017 
 Practices 
(LCD) 











North East 3(0.96%) 3120(0.7%) 2493(0.7%) 2297(0.83%) 884(0.4%) 
North West 23(7.4%) 33895(7.7%) 25717(7.2%) 15511(5.6%) 13690(6.0%) 
Yorkshire and 
The Humber 
2(0.64%) 2879(0.65%) 2408(0.7%) 1779(0.6%) 2315(1.0%) 
East Midlands 0(0%) 271(0.06%) 0(0%) 0(0%) 293(0.1%) 
West Midlands 21(6.7%) 39795(9.0%) 32683(9.1%) 22293(8.1%) 19357(8.5%) 
East of 
England 
9(2.9%) 26858(6.1%) 20363(5.7%) 12937(4.7%) 10582(4.6%) 
South West 13(4.2%) 42418(9.6%) 26425(7.4%) 15821(5.7%) 9436(4.1%) 
South Central 13(4.2%) 57954(13.1%) 43435(12.2%) 22663(8.2%) 14306(6.3%) 
London 38(12.2%) 66860(15.1%) 44699(12.5%) 34029(12.3%) 29200(12.8%) 
South East 
Coast 
35(11.2%) 57098(12.9%) 50052(14.0%) 43212(15.6%) 28779(12.6%) 
Northern 
Ireland 
20(6.4%) 9230(2.1%) 9297(2.6%) 8730(3.1%) 7979(3.5%) 
Scotland 68(21.8%) 46282(10.5%) 45812(12.8%) 43941(15.8%) 39468(17.3%) 
Wales 67(21.5%) 55519(12.6%) 53801(15.1%) 53743(19.4%) 52163(22.8%) 








LCD: Last Collection Date from practices; CRD: Current Registration Date of the patient. Dates for each year interval 
include 1st January of the year till 31st December of that year.  
 
During  2017, data was collected from 312 practices. Table 2.1-2 describes the contribution of 
practices to 2017 data. Nearly 43% of the data are from practices in Scotland and Wales, 
whereas no practices were contributing from the East Midlands region. Similarly, from 2014 
onwards, the number of current registered patients for each year in the East Midlands region 
was nearly zero. This validates the findings of other authors describing non-uniform distribution 
of the CPRD data in the UK. 
2.1.2.6 Strengths and limitations of the CPRD  
 
The CPRD is one of the largest primary care datasets, which includes information on morbidity 
and lifestyle factors with linkage to secondary care and mortality data.  
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A major strength of the database is the large number of patients and the longitudinal data, which 
allows researchers to investigate disease associations and outcomes. The CPRD is broadly 
representative of the general population of UK and makes population-based studies feasible. 
However, the representativeness at the practice level is debatable. The quality of the data is 
maintained by the Quality and Outcomes Framework (QOF), which was introduced in 2004. 
QOF has certain indicators for measuring the quality of services provided at practice level. 
Internal audits that exclude patients with non‐continuous follow-up or poor recording that 
questions the validity of the patient’s record, maintains data quality. With approval, investigators 
can obtain access to original medical records and contact GPs for additional questionnaire 
surveys of enrolled individuals. Other strengths include the availability of laboratory and 
examination results data, multiple external linkage, and high recording rate of secondary care 
events in GP records. 
One of the key limitations of the CPRD is completeness of the data on every patient with 
missing values for BMI and other lifestyle factors. Also, information on socio‐economic data, 
such as occupation and employment, are generally limited. However, recent external linkage to 
the Townsend score, an index of deprivation, helps to compensate for this. However, some of 
the indicators are available for England only. Missingness of lifestyle factors is important from 
the epidemiological research perspective. The CPRD records events within General Practice 
but information on hospital events may not be so complete. The addition of HES helps, though 
this is limited to data from England and Wales. There is no consistent definition for each 
disease, which needs to be developed and validated by the researchers. The size and 
complexity of the CPRD requires technical expertise.  
2.1.3 Population structure of UK (1997, 2017) 
Being that OA predominates  in older people, understanding the population structure  is 
important in interpreting the findings. Because OA is strongly related with ageing, the trends of 
the incidence and prevalence are dependent on the changes in population structure of the 
country. Therefore, it is essential to understand the changes in the UK, which is depicted below. 
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Figure 2.1-1 Population structure of UK in 1997 and 2017  
 




Source: Office For National Statistics, National Records Of Scotland and Northern Ireland Statistics And Research 
Agency, 2016 
 
Over the twenty years from 1997 to 2017, there has been a change in population structure. In  
2017 the percentage of the population aged 60-64 years and above is higher than in 1997. In 
1997, there was a higher contribution from young adults (25 -40 years), which shifted higher in 
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the pyramid during  2017 (Office For National Statistics, National Records Of Scotland, and 
Northern Ireland Statistics And Research Agency, 2016). (Figure 2.1-1) 
2.1.4 Study Design 
• A repeated cross-sectional study design was used to estimate the annual prevalence of 
OA and a cohort study to estimate the annual incidence and prevalence of OA.   
• A combined case-control and cohort study design was used to examine the temporal 
associations between OA and comorbidities. 
• Latent class analysis was undertaken to identify common clusters of comorbidities ever 
diagnosed in OA and controls  
• Latent transition analysis was performed to identify the movement of people within 
clusters after the index date (first recording of OA diagnosis) 
• Latent trajectory analysis was used to estimate the trajectory of multimorbidity in OA and 
controls after the index date 
• A cohort study was undertaken to examine the association of OA and the identified 
clusters with mortality and other health utilisation  
 
2.1.5 Case definition 
In this study OA is broadly identified in two categories; (1) physician-diagnosed; and (2) OA-
related joint pain.  
Read codes (clinical terminology used in general practice in the UK) was used to identify people 
with a diagnosis of incident OA and joint pain from the CPRD between 1st January 1997 and 
31st December 2017. The available Read code list for these diagnoses (www.keele.ac.uk/mrr ) 
was updated and adapted according to inclusion and exclusion criteria (e.g., physician-
diagnosed OA and patients having total knee/hip replacement). For joint specific OA, separate 
codes for each of hip, knee, ankle/foot, wrist/hand, unspecified and generalised were extracted 
and used in further analysis. 
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2.1.5.1 Physician-diagnosed OA  
 
o at least one recorded physician diagnosis of OA for hip, knee, ankle/foot, 
wrist/hand, elbow, shoulder joints, or recorded as ‘generalised’ and ‘unspecified’  
o any recording of joint replacement 
2.1.5.2 OA related joint pain 
 
OA related joint pain was identified as a minimum of one consultation record of peripheral joint 
pain symptom of any of the joints (knee, hip, hand/wrist, and ankle/foot). 
2.1.6 Exposures and outcomes 
• For the case control study, the exposure was previous comorbidity, and the outcome is 
OA. 
• For the cohort study, incident OA cases within 1st January 1997 until 31st December 
2017 were considered as the exposed group, and  matched control group of non-OA 
participants as a non-exposed group, the outcome of interest being subsequent 
comorbidity and mortality. 
• For latent class analysis all the comorbidities were included as exposures and the 
clusters identified were the outcomes 
• For outcomes of OA and the comorbidity clusters, both OA and clusters were included 
as the exposures, and mortality and other health utilisations were the outcomes 
2.1.7 Extraction of comorbidity list 
 
2.1.7.1 Comorbidity definition and extraction 
 
Comorbidity was defined as the presence of any chronic conditions other than OA in individuals 
of both OA and non-OA control. An extensive list of 49 chronic conditions was prepared from 
the chronic diseases included in the Quality Outcome Framework (QOF) (Quality and Outcome 
Framework (QOF), no date), chronic conditions listed in the US Department of Health and 
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Human Services Initiative on Multiple Chronic Conditions (Medicare, Baltimore and Usa, 2017) 
and the Charlson comorbidity index (Charlson et al., 1987). The list was updated with findings 
from the systematic review and a previous community-based knee pain study (Sarmanova et 
al., 2018; Swain et al., 2019). Multimorbidity was measured as the presence of two or more 
chronic conditions in an individual, for further analysis (Akker, Buntinx and Knottnerus, 1996). 
The 49 comorbidities in this study were further categorised into eight groups namely, 
musculoskeletal, respiratory, genitourinary, neuropsychiatric, cancer, circulatory, 
metabolic/endocrine, and digestive. In addition, a list of six conditions were grouped as ‘other’ 
category. The definition of all these conditions was based on physician diagnoses recorded as 
Read codes. 
Comorbidity was defined as the presence of any chronic conditions (in OA group, any additional 
diseases other than OA) in individuals of both groups. An extensive list of 49 chronic conditions 
was prepared from the chronic diseases included in the Quality Outcome Framework (QOF) 
(Quality and Outcome Framework (QOF), no date), chronic conditions listed in the US 
Department of Health and Human Services Initiative on Multiple Chronic Conditions (Medicare, 
Baltimore and Usa, 2017) and the Charlson comorbidity index (Charlson et al., 1987). The list 
was updated with findings from the systematic review and a previous community-based knee 
pain study(Sarmanova et al., 2018; Swain et al., 2019). I preferred this approach over the 
commonly used Charlson comorbidity index alone  (Charlson et al., 1994; Quan et al., 2011) 
because, although it is a useful predictor of mortality, the Charlson index summarises only 17 
diagnostic categories to represent health status (specifically, myocardial infarction, congestive 
heart failure, peripheral vascular disease, cerebrovascular disease, dementia, chronic 
pulmonary disease, rheumatological disease, peptic ulcer disease, mild liver disease, moderate 
or severe liver disease, diabetes mellitus (DM), DM with chronic complications, renal diseases, 
any malignancy (including leukaemia and lymphoma), metastatic solid tumour and HIV 
infection). The Charlson index does not consider conditions like fibromyalgia, chronic fatigue 
syndrome, depression or back pain which are relevant to my study interests. Polymyalgia 
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included in the study was recorded as polymyalgia only not ‘polymyalgia rheumatica’. 
Multimorbidity was defined as the presence of two or more chronic conditions in an individual 
excluding OA, for further analysis (Akker, Buntinx and Knottnerus, 1996). 
2.1.8 Data/ Statistical Analysis 
All data analysis was done using R (version 3.5) and STATA (version 15 and 16) software. 
Details of the methods are given in respective chapters. 
2.1.9 Study approval 
 This study was approved by the independent scientific advisory committee for CPRD research 
(protocol reference: 19_030 R).
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3 Chapter 3 Incidence and prevalence of OA in the UK 




To date, very few studies are available on the trends of OA incidence and prevalence using 
national representative cohort data. The lack of such information creates challenges in 
reliable estimation of the burden of OA. Worldwide the incidence of OA has varied from 14.6 
per 1000 person-years in Canada (Rahman et al., 2014) to 40.5 per 1000 person-years in 
the UK (Yu et al., 2017). Only three countries have reported increasing trends of the 
incidence of OA, whereas none have published prevalence trend data.  In Sweden age-
standardized hospitalisation rates due to OA increased from 1998 to 2014 for the hip and 
knee (Kiadaliri et al., 2018). In Canada, during January 2000 to September 2008, crude OA 
incidence rates increased from 11.8 to 14.2 per 1000 person-years for men, and from 15.7 to 
18.5 person-years for women (Rahman et al., 2014). However, one recent UK study using 
the CPRD reported no change in the  incidence of physician-diagnosed OA between 1992 
to2013 (Yu et al., 2017). According to Versus Arthritis  UK, one third of people in the UK 
aged 45 years and over have sought treatment for OA (Versus Arthritis, 2019). In total, 8.75 
million people in the UK have visited any health facility for OA treatment, and by 2035 it is 
estimated that 8.3 million people in the UK aged 45 years or over could have knee OA 
(Versus Arthritis, 2013).  
Most available studies have used incidence to describe the burden of OA, but prevalence of 
any chronic disease is thought to be a better measure of the disease burden explaining the 
potential health resource users. This study aimed to explore the trends in both incidence and 
prevalence of OA (overall and joint specific) in the UK during the period 1997-2017 using this 





3.2.1 Source of data 
CPRD GOLD data was used for registered people from the start of the database (1994) until 
31st December 2017 for this study. Details of the selection of study participants is given in a 
flow diagram at  Appendix Figure 1 (page 302).  
3.2.1.1 Case Definition of OA  
 
Read codes were used to identify people with a diagnosis of incident OA and/or joint pain 
from the CPRD between 1st January 1997 and 31st December 2017. The available Read 
code list (www.keele.ac.uk/mrr ) was updated and adapted according to inclusion and 
exclusion criteria (e.g., physician-diagnosed OA or patients having total knee/hip 
replacement). Using the Read code list,  the possible codes for OA diagnosis and OA-related 
joint pain were extracted separately. The extracted codes were matched with the obtained 
Read codes from the repository of Keele University (www.keele.ac.uk/mrr). After removing 
any duplication, a comprehensive list of the codes was prepared separately for both OA 
diagnosis and joint pain. Both lists were shared with the researchers (having expertise with 
Read codes), clinical experts and a general practitioner for their comment. After receiving 
inputs from all experts, the final list was prepared and used for the study. For joint-specific 
OA, separate codes for each of hip, knee, ankle/foot, wrist/hand, unspecified joint and 
generalised OA were extracted and used in further analysis. The codes are provided in 
Appendix Table 1 and Table 2 (pages 298-299).  
OA was defined according to two definitions: (1) General Practitioner (GP) diagnosed; and 
(2) OA-related joint pain.  
GP-diagnosed OA was defined as either: 
• at least one recorded physician-diagnosis of OA for hip, knee, ankle/foot, wrist/hand, 
elbow, shoulder joints, or recorded as ‘generalised’ or ‘unspecified’, or 
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• any recording (in clinical file) of joint replacement in the absence of recording of GP-
diagnosed OA during the study year 
OA related joint pain was defined as: 
• a minimum of one consultation record of peripheral joint pain of any of the joints 
(knee, hip, hand/wrist, and ankle/foot) without any record of OA before the date of 
joint pain diagnosis 
For diagnosed OA and joint pain, the index date was defined as the first date of diagnosis 
recorded in the database.  
3.2.1.2 Study population  
 
General criteria for inclusion were: 
• patients aged 20 years or more during each study year of 1997 to 2017 
• patients who had active registration for at least 12 months with the up-to-standard 
(UTS) practice prior to the study start date (determined by CPRD database 
standards), 
• flagged as ‘Acceptable’ in the database following the quality check 
Different exclusion criteria were used for calculating incidence and prevalence. The exclusion 
criteria were used to avoid misclassification. 
Exclusion criteria for incidence: 
Patients meeting the following criteria were excluded from incidence estimation:  
• For the ‘GP-diagnosed’ OA definition, any previous history of diagnosis of OA or any 
listed joint diseases (rheumatoid arthritis, psoriatic arthritis, systemic lupus 
erythematosus, ankylosing spondylitis, septic arthritis, spondyloarthropathy, crystal 
disease and human parvovirus B19 infection in the same joint recorded with joint 
pain/OA) before or within three years of the index date  
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• For the joint pain definition, any previous history of diagnosis of rheumatoid arthritis, 
psoriatic arthritis, systemic lupus erythematosus, ankylosing spondylitis, septic 
arthritis, and human parvovirus B19 infection in recorded joint pain consultation 
before the index date  
• Any record of specific non-OA diagnosis (soft-tissue disorders, other bone/cartilage 
diseases) at the same joint within +/- 12 months the recorded OA/joint pain 
consultation.  
• Any history of severe joint injury within one year prior to the index date 
 
3.2.1.3 Estimation of incidence and prevalence 
 
Annual prevalence of OA was calculated by dividing the number of people ever diagnosed 
with OA between 30th June previous year to 1st July of each calendar year, by the total 
number of eligible people in the population at the same time point of the calendar year.   
Annual incidence rate for OA was calculated by dividing the number of incident (new) cases 
between 1st January to 31st December of each year, by the number of person-years at risk 
during that calendar year. Person-years of follow-up were calculated for eligible  people at 
risk (i.e., no previous diagnosis of OA) from the latest of 1st January  to the first diagnosis of 
OA, date of transfer-out, death, last data collection or 31st December of the study year 
whichever came first. Inclusion of study participants using the dates is depicted in detail in 
Appendix Fig-2 (page 303) and Appendix Table 3 (page 303). 
3.2.1.4 Statistical analysis 
 
The incidence and prevalence for each year from 1997 to 2017 were standardised according 
to age (5 years band), sex and length of data contribution (observation period) using the 
CPRD population structure in the year 2017 as reference. This method of adjustment for the 
observation period has been used previously (Kuo et al., 2014b). The length of data 
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contribution of each patient was defined as the period from the UTS date for each participant 
to 1st July of each calendar year for prevalence and 1st January of each calendar year for 
incidence. The UTS date is always later than the registration date. The length of data 
contribution was then categorised in four groups 0-3 years, 4-6 years, 7-9 years and >=10 
years. Standardization by length of data contribution was done because higher estimates 
were observed for longer lengths of data contribution. (Appendix Fig-3, page 304) For 1997, 
no data contribution was seen for >=10 years. (Appendix Fig 3 and 4, pages 304-305) 
Because, even though the first registration date with the database was traced back before 
1987, the UTS practice data started recording in 1988, which is acceptable as a quality data, 
as per CPRD. For sex specific estimation, only age and length of data contribution 
standardisation was done. Age-sex standardized incidence and prevalence were calculated 
for 13 regions of the UK. Choropleth maps were used to represent the geographical 
variations of OA in the UK using QGIS (QGIS Geographic Information System. Open Source 
Geospatial Foundation Project., 2016).  
Age, sex, and length of data standardised trends (overall and sex specific) of the incidence 
and prevalence of OA were calculated for any-OA, joint specific and unspecified OA for 
1998-2017. Unspecified OA cases are coded as ‘unspecified’ in the database without any 
mentioning of the site involved. The incidence and prevalence were estimated across each 
age group for both sexes only for the year 2017. The 95% CIs were derived based on the 
assumption of a Poisson distribution for the observed cases. The trends were tested using 
Joinpoint regression analysis (Kim et al., 2000) and Joinpoint software (Joinpoint Regression 
Program, 2018). Bayesian Information Criterion (BIC) values were used to provide ‘join 
points’, which describe the significant change across the trend line and best-fit data series. 
Using BIC, a maximum of three joinpoints were selected. Annual percentage changes (APC) 
for each segment and average annual percentage changes (AAPC) for the entire study 
period were calculated at the significance level of 0.05.  
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Both incidence and prevalence trends were modelled as a function of age at diagnosis, 
period (year of diagnosis) and birth (year of birth) cohort. To assess the cohort effect, age-
period-cohort (A-P-C) analysis was undertaken (Keyes et al., 2010). For visual clarity 
incidence and prevalence were aggregated in five-year age groups for period and birth 
cohort graphs.  The A-P-C analysis was performed in R using the package ‘Epi’ and ‘APC’ 
(Carstensen, 2005; Nielsen, 2015; Carstensen et al., 2019). Statistical analyses were 
performed using STATA ( SE v 15, STATA corp, Texas) and R(V 5.2, R software, Austria) 
(R: A language and  evironment for  statistical computing., no date; ‘StataCorp. 2011. Stata 
Statistical Software: Release 12. College Station, TX: StataCorp LP.’, no date). 
3.3 Results  
 
3.3.1 GP diagnosed OA 
3.3.1.1 Prevalence in 2017 
 
Of 1,690,618 eligible individuals in 2017, 181,464 had a recorded diagnosis of OA at any 
site. The prevalence in 2017 was 10.78% (95% CI: 10.73%-10.83%). It was higher in women 
(12.79%; 95% CI 12.71%-12.86%) than in men (8.58%; 95%CI 8.52%-8.65%) across all age 
groups. The prevalence in younger age groups (less than 30 years) was very low, but it 
increased sharply at age 40-44 years in women and 45-49 years in men. In both men and 
women, the increasing trend continued until the age group of 80-84 years, reaching a peak of 
47% for women and 35% for men. After ages 80-84, it plateaued and then started to decline 








Figure 3.3-1 Prevalence of GP diagnosed OA by age and sex in 2017 
 
Joint specific distribution of OA shows that the overall standardised prevalence estimates in 
descending order were as unspecified site (7.62%, 95%CI 7.58-7.65%), knee (2.86%, 95% CI 
2.83-2.89%), hip (1.47%, 95%CI 1.45-1.49%), wrist or hand (0.52%, 95%CI 0.51-0.53%) and 
ankle or foot (0.29%, 95% CI 0.28-0.30%). 
Joint specific OA prevalence across age in both men and women is shown in Figure 3.3-2. 
Among men, unspecified OA (6%) was the leading form of recorded OA followed by knee (2%), 
hip (1%), wrist and hand (0.7%), and ankle/foot (0.4%) OA. A similar pattern was seen in 
women, unspecified OA (8%) being the most recorded, followed by knee (2.5%), hip (1.2%), 
wrist and hand (1.1%), and ankle/foot (0.5%) OA. Across the age groups, the prevalence of all 
joint specific OA was seen to rise until age group 85-89 in both men and women, and then fall. 
In younger women, the prevalence of hand and wrist OA was higher than hip OA until the age 
group 70-74 years, after which hip OA became more common than hand and wrist OA.  
53 
 
Figure 3.3-2 Joint specific prevalence of GP diagnosed OA by age and sex in 2017 
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3.3.1.2 Trends of the prevalence (1997-2017)  
 
Table 3.3-1 shows the temporal trend of any GP-diagnosed OA. Both the crude and 
standardised prevalence increased from 1997 to 2017. The standardized estimates were 
slightly higher than the crude estimates until 2014 after which they were slightly less for years 
2016 and 2017. (Table 3.3-1) The age standardised rates were seen to rise in both men and 
women across the years. 




Eligible population Cases Crude [95% CI] 
Age-sex  
Standardized [95% CI] 
Age-sex-LOD 
standardized [95% CI] 
1997 5711501 195362 3.42 [3.40-3.44] 6.15 [6.11-6.19]  
1998 5781677 215113 3.72 [3.70-3.74] 7.20 [7.16-7.24] 8.23 [8.06-8.40] 
1999 5848216 234835 4.01 [3.98-4.03] 7.41 [7.37-7.45] 8.47 [8.39-8.55] 
2000 5896329 255264 4.32 [4.30-4.35] 7.41 [7.37-7.44] 8.94 [8.88-9.00] 
2001 5900383 276091 4.77 [4.74-4.80] 7.87 [7.83-7.90] 9.08 [9.03-9.13] 
2002 5862771 296445 5.05 [5.02-5.08] 7.98 [7.95-8.01] 9.27 [9.22-9.32] 
2003 5788957 317611 5.48 [5.45-5.51] 8.19 [8.16-8.22] 9.47 [9.42-9.52] 
2004 5705620 339718 5.95 [5.92-5.98] 8.55 [8.52-8.58] 9.77 [9.73-9.82] 
2005 5615033 363534 6.47 [6.43-6.52] 9.06 [9.03-9.09] 10.21 [10.16-10.26] 
2006 5467107 378799 6.92 [6.90-6.94] 9.44 [9.42-9.47] 10.62 [10.57-10.66] 
2007 5294313 388708 7.34 [7.30-7.38] 9.73 [9.71-9.76] 10.64 [10.60-10.68] 
2008 5112496 398003 7.78 [7.74-7.82] 10.07 [10.04-10.10] 10.91 [10.87-10.95] 
2009 4924529 405402 8.23 [8.20-8.26] 10.35 [10.32-10.38] 10.91 [10.88-10.95] 
2010 4689058 403343 8.60 [8.56-8.64] 10.54 [10.51-10.57] 10.93 [10.90-10.96] 
2011 4421201 398434 9.01 [8.96-9.06] 10.69 [10.66-10.72] 10.94 [10.91-10.97] 
2012 4165371 391691 9.40 [9.36-9.44] 10.76 [10.73-10.79] 10.87 [10.84-10.90] 
2013 3812788 374298 9.82 [9.78-9.86] 10.87 [10.84-10.90] 10.90 [10.87-10.93] 
2014 3314992 337168 10.17 [10.14-10.20] 10.96 [10.93-10.99] 10.95 [10.92-10.98] 
2015 2761702 290020 10.50 [10.47-10.53] 10.94 [10.90-10.97] 10.93 [10.90-10.96] 
2016 2100061 223948 10.66 [10.63-10.69] 10.96 [10.93-11.00] 10.95 [10.92-10.99] 
2017 1690618 181464 10.77 [10.72-10.82] 10.77 [10.72-10.82] 10.77 [10.72-10.82] 
Age-sex and length of data contribution (LOD) standardization was done using 2017 CPRD population as standard 
population. For 1997, LOD standardisation was not calculated because of absence of data for >=10 years. (See 
Appendix Figure 3 and 4, page 304-305) 
 
 
The overall standardized prevalence of people with any OA in 2017 was found to increase to 












The temporal trends of prevalence for men and women are not parallel across the study period. 
(Figure 3.3-3) In 1998 the difference in prevalence between men and women was 2.5% which 
increased to nearly 5% in 2017. The average annual percentage change was 1.4% (95% CI 
1.3-1.6%) overall, being 1.6% (95% CI 1.4-2.8%) in women and 1.3% (95% CI 1.1-1.4%) in 
men. The joinpoint trend analysis showed a statistically significant increase in prevalence 









Figure 3.3-4 Joinpoint trend analysis 
 
The trend in prevalence has increased for all the joint specific OA sites since 1998 (Figure 
3.3-5). The prevalence of unspecified site OA increased from 5.2% in 1998 to 7.8% in 2017. 

















As Table 3.3-2 and Table 3.3-3 show, the temporal trends were higher in women compared to 
men. In men, the trend of wrist and hand OA was seen to be parallel with hip OA, whereas, in 
women, the gap started to narrow from 2005. The highest increase was seen for unspecified 
OA (APC 1.9%; 95%CI 1.6-2.2%), followed by hip OA (APC 1.7%; 95%CI 1.3-2.0%) in both 
sexes. Details of sex differences are given in Table 3.3-2 and Table 3.3-3. 
Table 3.3-2 Trend in prevalence of GP diagnosed OA by joints in men 
 
Standardised Prevalence (%) [95% CI] 
Years Hip  Knee Wrist/Hand Ankle/Foot Unspecified 
1998 0.95 [0.92-0.98] 2.19 [1.15-2.24] 0.30 [0.27-0.33] 0.28 [0.24-0.32] 4.18 [4.15-4.21] 
1999 0.86 [0.83-0.89] 2.14 [2.11-2.15] 0.28 [0.24-0.31] 0.31 [0.29-0.33] 4.48 [4.45-4.51] 
2000 0.90 [0.87-0.93] 2.11 [2.06-2.16] 0.27 [0.26-0.29] 0.27 [0.25-0.29] 4.82 [4.75-4.89] 
2001 0.92 [0.89-0.95] 2.13 [2.09-2.18] 0.27 [0.26-0.29] 0.27 [0.25-0.29] 4.92 [4.86-4.98] 
2002 0.93 [0.91-0.96] 2.14 [2.10-2.18] 0.27 [0.25-0.28] 0.27 [0.25-0.28] 5.08 [5.02-5.14] 
2003 0.96 [0.93-0.98] 2.21 [2.18-2.25] 0.27 [0.26-0.29] 0.27 [0.26-0.28] 5.17 [5.12-5.23] 
2004 0.98 [0.95-1.01] 2.26 [2.22-2.30] 0.28 [0.26-0.29] 0.27 [0.26-0.29] 5.37 [5.31-5.43] 
2005 1.04 [1.01-1.06] 2.32 [2.28-2.36] 0.28 [0.27-0.30] 0.28 [0.26-0.29] 5.70 [5.65-5.76] 
2006 1.05 [1.03-1.08] 2.39 [2.35-2.42] 0.29 [0.28-0.31] 0.28 [0.27-0.30] 5.97 [5.92-6.02] 
2007 1.05 [1.03-1.07] 2.36 [2.33-2.39] 0.28 [0.27-0.30] 0.27 [0.26-0.29] 6.03 [5.98-6.08] 
2008 1.10 [1.08-1.12] 2.46 [2.43-2.49] 0.30 [0.28-0.31] 0.29 [0.28-0.30] 6.13 [6.09-6.18] 
2009 1.09 [1.07-1.11] 2.42 [2.40-2.45] 0.29 [0.28-0.30] 0.28 [0.28-0.29] 6.11 [6.07-6.15] 
2010 1.10 [1.08-1.12] 2.44[2.41-2.47] 0.29 [0.28-0.30] 0.29 [0.28-0.30] 6.12 [6.08-6.16] 
2011 1.12 [1.11-1.14] 2.50 [2.48-2.52] 0.30 [0.29-0.31] 0.29 [0.28-0.30] 6.03 [5.99-6.06] 
2012 1.11 [1.09-1.12] 2.46 [2.43-2.48] 0.29 [0.29-0.30] 0.28 [0.27-0.29] 5.99 [5.96-6.03] 
2013 1.12 [1.11-1.14] 2.49 [2.46-2.51] 0.29 [0.28-0.30] 0.28 [0.27-0.29] 5.97 [5.93-6.00] 
2014 1.16 [1.14-1.18] 2.56 [2.53-2.58] 0.30 [0.30-0.31] 0.29 [0.28-0.30] 5.92 [5.88-5.95] 
2015 1.20 [1.18-1.22] 2.60 [2.58-2.63] 0.32 [0.31-0.32] 0.30 [0.29-0.31] 5.79 [5.76-5.83] 
2016 1.19 [1.17-1.21] 2.55 [2.53-2.58] 0.30 [0.29-0.31] 0.28 [0.27-0.29] 5.91 [5.87-5.95] 
2017 1.20 [1.18-1.22] 2.51 [2.48-2.54] 0.29 [0.28-0.31] 0.27 [0.26-0.28] 5.77 [5.73-5.82] 
 
AAPC 1.5 [0.9 to 1.9] * 0.9 [0.4 to 1.4] * 0.2 [-0.4 to 0.9] 0.1 [-0.2 to 0.4] 1.7 [1.3 to 2.1] * 
  
AAPC: Average annual percentage change; CI- Confidence interval; Age and length of data standardized using 








Table 3.3-3 Trend in prevalence of GP diagnosed OA by joint in women 
 
AAPC: Average annual percentage change; CI- Confidence interval; Age and length of data standardized using 

















 Standardised Prevalence (%) [95% CI] 
Years  Hip  Knee  Wrist/Hand Ankle/Foot  Unspecified 
1998 1.24 [1.21-1.27] 2.51 [2.48-2.54] 0.60 [0.56-0.64] 0.41 [0.38-0.44] 6.27 [6.24-6.30] 
1999 1.18 [1.15-1.21] 2.56 [2.52-2.60] 0.62[0.59-0.65] 0.43 [0.40-0.47] 6.75 [6.71-6.79] 
2000 1.25 [1.22-1.29] 2.63 [2.58-2.68] 0.61 [0.58-0.63] 0.35 [0.33-0.36] 7.51 [7.43-7.59] 
2001 1.28 [1.25-1.31] 2.67 [2.63-2.72] 0.63 [0.60-0.65] 0.34 [0.32-0.36] 7.64 [7.57-7.72] 
2002 1.30 [1.27-1.33] 2.69 [2.65-2.73] 0.61 [0.59-0.63] 0.33 [0.32-0.35] 7.92 [7.85-7.99] 
2003 1.33 [1.30-1.36] 2.76 [2.72-2.80] 0.62 [0.60-0.64] 0.33 [0.31-0.34] 8.08 [8.02-8.15] 
2004 1.36 [1.33-1.39] 2.81 [2.77-2.85] 0.64 [0.62-0.66] 0.34 [0.32-0.35] 8.46 [8.40-8.53] 
2005 1.43 [1.40-1.46] 2.89 [2.85-2.93] 0.66 [0.64-0.68] 0.34 [0.33-0.35] 8.97 [8.90-9.03] 
2006 1.48 [1.45-1.51] 2.98 [2.94-3.01] 0.68 [0.67-0.70] 0.35 [0.34-0.36] 9.36 [9.30-9.42] 
2007 1.48 [1.45-1.50] 2.96 [2.92-2.99] 0.67 [0.65-0.68] 0.33 [0.32-0.34] 9.47 [9.41-9.53] 
2008 1.55 [1.52-1.57] 3.09 [3.06-3.13] 0.69 [0.68-0.71] 0.35 [0.33-0.36] 9.62 [9.57-9.67] 
2009 1.55 [1.53-1.57] 3.10 [3.07-3.13] 0.71 [0.69-0.72] 0.34 [0.33-0.35] 9.68 [9.64-9.73] 
2010 1.56 [1.54-1.58] 3.13 [3.11-3.16] 0.71 [0.70-0.72] 0.34 [0.33-0.35] 9.66 [9.62-9.71] 
2011 1.59 [1.57-1.61] 3.22 [3.19-3.24] 0.73 [0.71-0.74] 0.35 [0.34-0.36] 9.58 [9.54-9.62] 
2012 1.57 [1.55-1.59] 3.16 [3.13-3.19] 0.71 [0.70-0.73] 0.33 [0.32-0.33] 9.57 [9.52-9.61] 
2013 1.58 [1.57-1.60] 3.20 [3.17-3.23 0.72 [0.70-0.73] 0.33 [0.32-0.34] 9.56 [9.52-9.60] 
2014 1.63 [1.61-1.65] 3.29 [3.26-3.31] 0.74 [0.73-0.76] 0.34 [0.33-0.35] 9.50 [9.46-9.54] 
2015 1.68 [1.66-1.70] 3.36 [3.33-3.39] 0.77 [0.76-0.79] 0.35 [0.34-0.36] 9.38 [9.34-9.42] 
2016 1.65 [1.63-1.68] 3.26 [3.23-3.29] 0.74 [0.73-0.76] 0.33 [0.32-0.34] 9.49 [9.44-9.54] 
2017 1.68 [1.65-1.70] 3.23 [3.19-3.26] 0.74 [0.72-0.75] 0.32 [0.31-0.34] 9.35 [9.30-9.41] 
 
AAPC 1.8 [1.5 to 2.1] * 1.3 [1.0 to 1.7] * 1.3 [1.1 to 1.5] * 
-1.2 [-2.0 to -0.3] 
* 2.2 [1.9 to 2.5] * 
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3.3.1.3 Prevalence of GP diagnosed multiple joint OA 
 
The prevalence of multiple joint OA, i.e., OA affecting more than one joint in the same individual 
was examined. Five types of OA reported in different joints (hip, knee, ankle/foot, wrist/hand 
and unspecified) were included for this count. The trend was calculated at five year intervals 
starting from 1997. In 2017 nearly 21% of people with OA had it reported in more than one 
joint, this prevalence having increased by 10% from 1997. (Figure 3.3-6) While the prevalence 
of single joint OA declined, the crude prevalence of multiple joint OA increased. 




Further analysis of pattern of joint involved among people having OA diagnosed at any-two 
joint revealed knee, hip, and wrist/hand in combination with unspecified OA contributing more 
than 70% of the total pattern. (Figure 3.3-7) 
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The contribution from East Midlands to the CPRD-GOLD was nearly zero, which did not allow to have whole 
country representation for 2017. 
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3.3.1.4 Incidence of GP diagnosed OA in the UK 
 
In 2017 the total person-years of follow up for any OA was 1,495,497 with 10147 incident 
cases, and the incidence was 6.8 per 1000 person-years [95% CI 6.7-6.9 person-years]. The 
incidence was higher in women (8.1; 95% CI 7.9 to 8.3) than in men (5.5; 95% CI 5.3 to 5.7 
per 1000 person-years). Age specific incidence in 2017 shows that, at the younger age (30-34 
years) the incidence was 0.08 per 1000 person-years in both sexes but this became 
increasingly higher in women than in men after 40 years of age. The incidence peaked at the 
age of 75-79 years to 27.0 [95% CI 23.5-29.8] per 1000 person-years in women and 18.0 [95% 
CI 15.4-20.6] per 1000 person-years in men. (Figure 3.3-9) 




The joint-specific incidence rate (per 1000 person-years) in 2017 was highest for unspecified 
OA (5.20; 95% CI 5.06-5.30), then knee OA (2.30; 95% CI 2.22-2.37), hip OA (1.15; 95% CI 
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1.10-1.20), wrist and hand OA (0.65; 95% CI 0.62-0.73) and ankle and foot OA (0.19; 95% CI 
0.17-0.21). All the joint specific incidence rates were higher in women than in men. In men, 
incidence rates increased until the age group 70-74 years and in women the rate increased 
until 75-79 years after which it declined. Ankle and foot, and knee OA rates increased until 70-












3.3.1.5 Trends in incidence of GP diagnosed OA in the UK (1997-2017) 
 
Table 3.3-4 shows the temporal trends in incidence of any OA from 1997 to 2017. The 
standardised rates were slightly higher than crude rates.  
Table 3.3-4 Incidence of GP diagnosed OA in the UK 
Incidence (1000 person-years) 







1997 1321487 12296 9.30 [9.14-9.47] 9.17 [9.00-9.34]  
1998 1509159 14817 9.81 [9.66-9.97] 9.05 [8.89-9.20] 9.50 [9.40-9.70] 
1999 1831971 17216 9.39 [9.26-9.54] 8.87 [8.73-9.01] 9.69 [9.00-10.37] 
2000 2262732 20599 9.10 [8.98-9.22] 8.97 [8.84-9.11] 9.61 [9.31-9.92] 
2001 2534401 23615 9.31 [9.19-9.43] 9.20 [9.07-9.32] 9.36 [9.15-9.57] 
2002 2858237 26597 9.30 [9.19-9.41] 9.37 [9.25-9.49] 9.64 [9.44-9.84] 
2003 3046692 29358 9.63 [9.52-9.74] 9.63 [9.51-9.74] 10.00 [9.81-10.19] 
2004 3247175 32543 10.02 [9.91-10.13] 10.06 [9.95-10.17] 10.42 [10.23-10.61] 
2005 3317484 33093 9.97 [9.86-10.08] 10.15 [10.04-10.26] 10.33 [10.15-10.52] 
2006 3346598 30840 9.21 [9.11-9.31] 9.39 [9.29-9.50] 9.55 [9.37-9.72] 
2007 3374993 30236 8.95 [8.88-9.06] 9.15 [9.04-9.25] 9.49 [9.32-9.65] 
2008 3381824 30261 8.94 [8.84-9.05] 9.20 [9.10-9.30] 9.59 [9.44-9.74] 
2009 3362701 29387 8.73 [8.63-8.83] 8.99 [8.89-9.10] 9.36 [9.22-9.50] 
2010 3314620 27133 8.18 [8.09-8.28] 8.42 [8.32-8.52] 8.74 [8.62-8.87] 
2011 3235505 26100 8.06 [7.96-8.16] 8.30 [8.20-8.40] 8.48 [8.36-8.59] 
2012 3196392 24727 7.73 [7.64-7.83] 7.95 [7.85-8.05] 8.10 [7.90-8.30] 
2013 3030317 23409 7.72 [7.62-7.82] 7.87 [7.77-7.97] 7.94 [7.84-8.05] 
2014 2758065 21113 7.65 [7.55-7.75] 7.74 [7.64-7.85] 7.75 [7.65-7.86] 
2015 2360852 17690 7.49 [7.38-7.60] 7.52 [7.41-7.63] 7.51 [7.40-7.62] 
2016 1889587 13540 7.16 [7.04-7.28] 7.18 [7.06-7.30] 7.17 [7.05-7.29] 
2017 1495497 10146 6.78 [6.67-6.93] 6.78 [6.67-6.93] 6.78 [6.67-6.93] 
Age-sex and length of data contribution (LOD) standardization was done using 2017 CPRD population as standard 
population. For 1997, LOD standardisation was not calculated because of absence of data for >=10 years. 
 
In general, both crude and standardised estimates decreased over time during this period, 
changing from 9.5 per 1000 person-years [95% CI 9.4-9.7] to 6.8 per 1000 person-years [95% 
CI 6.7-6.9]. A similar trend was seen in both men and women. Figure 3.3-11 shows age and 
LOD standardised rates in men and women. The incidence of OA in men declined from 8.0 
per 1000 person-years (95% CI 7.8 to 8.3 per 1000 person-years) in 1997 to 5.5 per 1000 
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person-years (95% CI 5.3 to 5.7 per 1000 person-years) in 2017, whereas in women the 
incidence reduced from 11.5 per 1000 person-years (95% CI 11.2 to 11.7 per 1000 person-
years) to 8.1 per 1000 person-years (95%CI 7.9 to 8.3 per 1000 person-years) 









Joinpoint analysis identified two points of changes in overall trend in 2002 and 2005. The AAPC 
was -1.6% (95% CI -2.0 to -1.1%), indicating a slight decline in the incidence since 1998. 
Women (-1.9%; 95% CI -2.2 to -1.6%) had a higher decline in rates compared to men (-1.5%; 
-1.1 to -1.9%).  (Figure 3.3-12) 
Figure 3.3-12 Joinpoint analysis of trend in incidence of GP diagnosed OA 
 
 
Trends in joint specific OA incidence are shown in Figure 3.3-13. No change in trend was 
observed for ankle and foot and wrist and hand sites. Unspecified OA showed a declining 
trend, whereas OA at the knee and hip showed slightly increasing trends. The incidence of 
unspecified OA reduced from 9.0 per 1000 person-years [95% CI 8.8 - 9.1 per 1000 person-
years] in 1998 to 5.2 per 1000 person -years [95% CI 5.1-5.3 per 1000 person-years] in 2017. 










Table 3.3-5 Trends in incidence GP diagnosed OA by joint in men 
 Standardised Incidence (per 1000 person-years) [95% CI] 
Years Hip Knee Wrist/Hand Ankle/Foot Unspecified 
1998 0.86 [0.74-0.98] 1.69 [1.26-2.02] 0.44 [0.34-0.54] 0.25 [0.19-0.28] 6.72 [3.73-9.71] 
1999 0.74 [0.48-0.99] 1.70 [1.31-2.09] 0.35 [0.29-0.41] 0.29 [0.12-0.45] 7.22 [6.42-8.03] 
2000 0.71 [0.60-0.83] 1.94 [1.74-2.13] 0.34 [0.27-0.42] 0.23 [0.16-0.29] 6.29 [5.94-6.65] 
2001 0.96 [0.86-1.06] 2.00 [1.87-2.14] 0.32 [0.22-0.42] 0.15 [0.11-0.19] 5.64 [5.41-5.88] 
2002 1.03 [0.93-1.12] 2.12 [1.98-2.25] 0.36 [0.30-0.42] 0.17 [0.13-0.21] 5.77 [5.55-5.99] 
2003 0.98 [0.89-1.07] 2.26 [2.13-2.39] 0.36 [0.30-0.42] 0.19 [0.15-0.23] 5.91 [5.7-6.12] 
2004 1.12 [1.04-1.21] 2.44 [2.31-2.57] 0.40 [0.32-0.49] 0.18 [0.15-0.22] 6.02 [5.82-6.23] 
2005 1.00 [0.92-1.08] 2.21 [2.09-2.33] 0.40 [0.31-0.49] 0.16 [0.12-0.20] 6.18 [5.98-6.38] 
2006 0.98 [0.90-1.06] 2.34 [2.22-2.47] 0.43 [0.39-0.46] 0.19 [0.15-0.24] 5.53 [5.33-5.73] 
2007 1.02 [0.96-1.08] 2.30 [2.19-2.42] 0.41 [0.37-0.44] 0.24 [0.20-0.28] 5.43 [5.33-5.53] 
2008 1.05 [1.00-1.10] 2.36 [2.25-2.46] 0.41 [0.38-0.45] 0.21 [0.17-0.25] 5.42 [5.33-5.51] 
2009 1.0 [0.93-1.07] 2.42 [2.32-2.52] 0.44 [0.40-0.47] 0.24 [0.20-0.28] 5.41 [5.30-5.52] 
2010 0.96 [0.90-1.02] 2.31 [2.22-2.40] 0.49 [0.46-0.54] 0.21 [0.18-0.24] 4.93 [4.85-5.02] 
2011 0.97 [0.91-1.03] 2.24 [2.16-2.32] 0.48 [0.45-0.52] 0.22 [0.19-0.25] 4.62 [4.56-4.68] 
2012 0.92 [0.87-0.97] 2.17 [2.09-2.25] 0.47 [0.43-0.51] 0.19 [0.16-0.22] 4.37 [4.29-4.45] 
2013 0.94 [0.89-0.99] 2.04 [1.97-2.12] 0.46 [0.42-0.50] 0.18 [0.15-0.21] 4.33 [4.20-4.46] 
2014 0.98 [0.91-1.05] 2.17 [2.09-2.25] 0.46 [0.42-0.50] 0.20 [0.14-0.26] 4.02 [3.92-4.12] 
2015 0.97 [0.91-1.04] 2.19 [2.10-2.27] 0.49 [0.45-0.54] 0.19 [0.13-0.25] 3.94 [3.83-4.05] 
2016 0.96 [0.90-1.02] 1.98 [1.89-2.06] 0.50 [0.45-0.55] 0.19 [0.13-0.25] 3.77 [3.63-3.90] 
2017 0.93 [0.86-0.99] 1.93 [1.83-2.02] 0.42 [0.37-0.47] 0.17 [0.14-0.20] 3.71 [3.57-3.84] 
AAPC 1.2 [0.0 to 2.3]* 1.1 [0.3 to 1.8]* 0.4 [-1.6 to 2.3] -2.5 [-5.1 to 0.1] -3.2 [-4.0 to -2.4]* 
AAPC: Average annual percentage change; CI- Confidence interval; Age and length of data standardized using 
2017 CPRD population; *P-value <0.05 
















Table 3.3-6 Trend in incidence of GP diagnosed OA by joint in women 
 Standardised Incidence (1000 person-years) [95% CI] 
Years Hip Knee Wrist/Hand Ankle/Foot Unspecified 
1998 1.20[1.12-1.27] 2.00 [1.89-2.11] 0.89 [0.80-0.98] 0.18 [0.02-0.99] 10.76 [6.91-14.62] 
1999 1.08 [0.79-1.38] 2.12 [1.70-2.53] 0.85 [0.77-0.93] 0.15 [0.041-0.26] 12.12 [11.11-13.12] 
2000 1.15 [1.01-1.30] 2.19 [1.98-2.40] 0.73 [0.67-0.79] 0.22 [0.16-0.29] 9.93 [9.49-10.37] 
2001 1.24 [1.13-1.34] 2.77 [2.61-2.92] 0.61 [0.55-0.67] 0.23 [0.19-0.28] 9.02 [8.73-9.31] 
2002 1.38 [1.28-1.48] 2.70 [2.55-2.84] 0.78 [0.71-0.85] 0.24 [0.19-0.28] 9.22 [8.95-9.49] 
2003 1.32 [1.23-1.41] 2.95 [2.81-3.09] 0.74 [0.68-0.80] 0.21 [0.17-0.24] 9.72 [9.46-9.98] 
2004 1.47 [1.37-1.57] 3.04 [2.90-3.19] 0.86 [0.80-0.92] 0.24 [0.20-0.28] 10.33 [10.07-10.59] 
2005 1.44 [1.34-1.53] 3.00 [2.86-3.14] 0.94 [0.89-0.99] 0.25 [0.21-0.29] 10.42 [10.15-10.69] 
2006 1.32 [1.24-1.41] 2.99 [2.85-3.12] 0.89 [0.85-0.94] 0.22 [0.18-0.26] 9.31 [9.07-9.55] 
2007 1.41 [1.33-1.49] 3.01 [2.89-3.14] 0.92 [0.87-0.97] 0.24 [0.21-0.28] 8.96 [8.74-9.18] 
2008 1.39 [1.31-1.47] 3.01 [2.90-3.13] 0.94 [0.88-0.97] 0.27 [0.23-0.30] 9.14 [8.93-9.35] 
2009 1.43 [1.36-1.51] 3.14 [3.03-3.25] 1.06 [1.01-1.11] 0.28 [0.24-0.31] 8.68 [8.49-8.87] 
2010 1.33 [1.27-1.40] 3.02 [2.92-3.12] 1.08 [1.02-1.13] 0.22 [0.19-0.25] 8.11 [7.94-8.28] 
2011 1.39 [1.32-1.45] 2.98 [2.88-3.07] 1.09 [1.04-1.15] 0.23 [0.21-0.26] 7.71 [7.55-7.86] 
2012 1.31 [1.25-1.38] 2.90 [2.81-2.99] 1.07 [1.01-1.12] 0.22 [0.20-0.25] 7.44 [7.29-7.6] 
2013 1.30 [1.25-1.36] 2.80 [2.71-2.88] 1.07 [1.01-1.12] 0.20 [0.18-0.22] 7.26 [7.12-7.40] 
2014 1.37 [1.31-1.43] 2.87 [2.78-2.96] 1.04 [0.97-1.10] 0.23 [0.20-0.25] 6.83 [6.7-6.97] 
2015 1.31 [1.24-1.37] 2.75 [2.66-2.84] 1.09 [1.02-1.16] 0.22 [0.19-0.24] 6.65 [6.51-6.80] 
2016 1.37 [1.30-1.44] 2.51 [2.42-2.61] 1.04 [0.97-1.11] 0.21 [0.19-0.24] 6.44 [6.27-6.60] 
2017 1.37 [1.29-1.45] 2.63 [2.52-2.74] 1.04 [0.96-1.12] 0.21 [0.18-0.25] 6.02 [5.84-6.19] 
 
AAPC 1.0 [0.2 to 1.7]* 1.6 [0.8 to 2.3]* 0.8 [-0.5 to 2.0] 3.6 [1.0 to 6.2]* -3.3 [-5.4 to -1.2]* 
AAPC: Average annual percentage change; CI- Confidence interval; Age and length of data standardized using 
2017 CPRD population; *P-value <0.05 
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Standardised incidence rates decreased in all regions of the UK since 1997. In 2014 
Yorkshire and Humber and the North East had the highest incidence rates of 14-15 per 1000 
person-years and 12-13 per 1000 person-years, respectively. Lowest incidence rates were 
seen in Northern Ireland and South East England.  (Figure 3.3-14) 
3.3.1.6 Age period cohort analysis 
 
Cohort effects 
The incidence was found to decline according to birth cohorts. For people with the same age, 
those born later were less likely to have OA than those born earlier. (Figure 3.3-15)  The 
reduction speeded up gradually after 1960, particularly for people aged 20-40 years, 
suggesting a potential aetiological change after 1960 that has made people less likely to 
develop OA.  In contrast, prevalence increased and speeded up gradually by age, but 
remained almost unchanged for people born after 1960. The plot of distribution of incidence 
and prevalence across the age group for different periods is provided in Figure 3.3-16. 
Figure 3.3-15. Age-period-cohort analysis of trend of OA (1997-2017) incidence (A) and 






Figure 3.3-16. Incidence and prevalence by age and calendar years 
A) Incidence        B) Prevalence 
         
Each line represents the distribution of OA across age in the period as stated. The lower incidence in the year 2017 
compared to other years in same age group explains possible cohort effects.  
 
Prevalence of any GP diagnosed OA varied between geographic regions.  In 2017 the age-
sex standardised prevalence in Scotland, West Midlands and Northern Ireland was between 
7%-9%. The regions in the South of England had prevalence ranging from 3%-5%. Spatial-
temporal maps of the prevalence show a decline in prevalence since 1997 in all UK regions 
except for Scotland and the West Midlands. The prevalence for East Midlands could not be 










3.3.2 Joint pain definition of OA 
 
3.3.2.1 Prevalence of joint pain defined OA in 2017 
 
In 2017 out of 1,600,036 eligible patients 544,763 cases of joint pain were recorded. The age-
sex-LOD standardised prevalence in 2017 was 34.04% [95% CI 33.98%-34.11%]. (Table 
3.3-7)  Women (37.7%; 95% CI 37.5%-37.9%) had a greater prevalence of joint pain than men 
(29.9%; 95% CI 29.8%-30.0%).  
Age specific distribution of prevalence for 2017 is given in Figure 3.3-17. In the youngest age 
group (20 to 24 years), the prevalence of joint pain was about 4% and was the same in men 
and women. The prevalence increased with age until the age group of 80 to 84 years, where 
it attained the peak of 57.4% [95% CI 56.6%-58.1%].  The gap between men and women 
widened after the age of 35-39 years which again became narrower in those over 85 years.  
Site specific joint pain prevalence according to age group is shown in Figure 3.3-18. The 
prevalence increased with age at all joints. In 2017, knee joint pain had the highest prevalence 
(18.6%; 95%CI 18.5%-18.7%) followed by ankle and foot (10.7%; 95%CI 10.6%-10.7%), hip, 
(7.9%; 95% CI 7.8%-7.9%) wrist and hand (7.1%; 95% CI 7.0%-7.1%) and unspecified (6.5%; 















In the younger age group of 25-29 years the leading sites  for prevalence were knee (6.4%; 
95% CI 6.3%-6.6%), ankle and foot (3.9%; 95% CI 3.7%-3.9%), and wrist and hand (2.8%; 
95%CI 2.7%-2.9%). In the older age group of 80-84 years, the order was knee (33.5%; 95%CI 
32.9%-34.1%), hip (22.3%, 95%CI 21.9%-22.8%), ankle and foot (19.7%; 19.2%-20.1%), and 












3.3.2.2 Trends of prevalence of joint pain defined OA 
 
Table 3.3-7 Prevalence of joint pain defined OA in the UK 
 




Cases Crude  Age-sex 
standardised   
Age-sex and LOD 
standardised  
1997 5255368 278466 5.29[5.22-5.35] 6.79[6.71-6.86] 8.99[8.91-9.06] 
1998 5329284 313405 5.88[5.82-5.94] 7.46[7.32-7.52] 9.66[9.52-9.72] 
1999 5400350 347664 6.43[6.40-6.46] 8.10[8.00-8.12] 10.3[10.2-10.32] 
2000 5454259 383134 7.02[6.98-7.06] 8.93[8.91-8.96] 11.43[11.41-11.46] 
2001 5465735 421949 7.71[7.65-7.77] 9.74[9.71-9.77] 12.04[12.01-12.07] 
2002 5437891 467109 8.58[8.50-8.66] 10.72[10.69-10.75] 13.02[12.99-13.05] 
2003 5374918 528317 9.82[9.78-9.86] 12.12[12.09-12.15] 14.32[14.29-14.35] 
2004 5303535 599496 11.30[11.22-11.38] 13.76[13.73-13.80] 15.86[15.83-15.9] 
2005 5225335 677041 12.95[12.90-13.00] 15.58[15.55-15.62] 17.58[17.55-17.62] 
2006 5093687 745604 14.63[14.59-14.67] 17.36[17.32-17.39] 19.16[19.12-19.19] 
2007 4938346 809153 16.38[16.32-16.44] 19.11[19.12-19.19] 20.61[20.62-20.69] 
2008 4774617 875077 18.32[18.27-18.37] 21.09[21.06-21.13] 22.49[22.46-22.53] 
2009 4604954 938701 20.38[20.32-20.44] 23.06[23.02-23.10] 24.36[24.32-24.4] 
2010 4391276 980286 22.32[22.28-22.36] 24.87[24.83-24.91] 25.77[25.73-25.81] 
2011 4145387 1010886 24.38[24.31-24.45] 26.69[26.64-26.73] 27.49[27.44-27.53] 
2012 3909979 1029322 26.32[26.26-26.38] 28.33[28.29-28.38] 29.03[28.99-29.08] 
2013 3582506 1011137 28.22[28.15-28.29] 29.85[29.80-29.89] 30.25[30.2-30.29] 
2014 3118698 938341 30.08[30.00-30.16] 31.28[31.23-31.33] 31.48[31.43-31.53] 
2015 2600729 823024 31.64[31.56-31.72] 32.41[32.35-32.46] 32.51[32.45-32.56] 
2016 1980645 646372 32.63[32.57-32.69] 32.99[32.92-33.05] 33.04[32.97-33.1] 
2017 1600036 544763 34.04[33.97-34.11] 34.04[33.98-34.11] 34.04[33.98-34.11] 
Age-sex standardized rates are standardized with mid-2017 UK population as standard population.  
 
The temporal crude and standardised prevalence values have increased since 1997. The 
standardised prevalence increased nearly 3.8 times from 9.0% in 1997 to 34% in 2017.  A 
similar trend was seen in both men (from 8.1% in 1997 to 30.4% in 2017) and women (from 
9.8% in 1997 to 37.7% in 2017). The difference in prevalence between men and women in 
1997 was 1.7%, which increased to 7.3% in 2017. (Figure 3.3-19) 
The joinpoint model shows three change points in prevalence trend at years 2000, 2007 and 
2012. The rate of change during 2002-2007 was highest followed by that in 1997-2002. The 















Joint specific analysis (Figure 3.3-21) shows an increasing trend for all sites, except for 
unspecified. The trend for knee pain grew most rapidly followed by ankle/foot, hip and wrist 
and hand pain. The prevalence of knee pain increased by 16% from 2.8% [95% CI 2.7-2.8%] 
in 1997 to 18.6% [95% CI 18.5%-18.7%] in 2017. Similarly, hip pain prevalence changed from 
1.5% in 1997 to 7.9% in 2017 and ankle/foot pain increased from 1.3% to 10.7% in 2017. The 
trend shows an increase in APC for all regions. The highest increase was observed for 
wrist/hand pain (11.4%; 95% CI 11.0-11.9) and the lowest was reported for unspecified pain 
(7.9%; 95% CI 7.5-8.4). Details for region specific pain in men and women are given in Table 
3.3-8 and Table 3.3-9. 







Table 3.3-8 Trend in prevalence of joint-pain defined OA for different sites in men 
 













 Standardised Prevalence (%) [95% CI] 
Year Hip Knee  Wrist/Hand Ankle/Foot  Unspecified 
1997 1.06[1.04-1.08] 2.87[2.85-2.89] 0.56[0.54-0.58] 1.09[1.06-1.12] 0.95[0.93-0.97] 
1998 1.17[1.15-1.19] 3.15[3.12-3.18] 0.63[0.60-0.66] 1.24[1.22-1.26] 1.08[1.06-1.10] 
1999 1.27[1.25-1.29] 3.42[3.40-3.44] 0.71[0.68-0.74] 1.36[1.34-1.38] 1.19[1.17-1.21] 
2000 1.40[1.38-1.42] 3.72[3.70-3.75] 0.80[0.79-0.81] 1.52[1.50-1.53] 1.33[1.31-1.35] 
2001 1.52[1.51-1.54] 4.04[4.02-4.07] 0.90[0.89-0.92] 1.68[1.66-1.70] 1.49[1.47-1.51] 
2002 1.66[1.65-1.68] 4.43[4.40-4.46] 1.02[1.01-1.04] 1.88[1.86-1.90] 1.70[1.68-1.71] 
2003 1.84[1.82-1.86] 5.13[5.10-5.16] 1.18[1.16-1.19] 2.16[2.14-2.18] 1.90[1.88-1.92] 
2004 2.05[2.03-2.08] 5.98[5.94-6.01] 1.37[1.35-1.38] 2.49[2.46-2.51] 2.10[2.08-2.12] 
2005 2.30[2.28-2.32] 6.95[6.91-6.98] 1.60[1.58-1.62] 2.88[2.85-2.90] 2.33[2.31-2.35] 
2006 2.55[2.53-2.58] 7.91[7.88-7.95] 1.84[1.82-1.86] 3.30[3.27-3.32] 2.52[2.50-2.54] 
2007 2.80[2.78-2.83] 8.91[8.87-8.95] 2.10[2.08-2.12] 3.76[3.74-3.79] 2.72[2.69-2.74] 
2008 3.08[3.05-3.10] 10.01[9.97-10.05] 2.39[2.37-2.42] 4.29[4.27-4.32] 2.91[2.88-2.93] 
2009 3.38[3.35-3.40] 11.16[11.12-11.20] 2.71[2.69-2.74] 4.86[4.83-4.89] 3.13[3.10-3.15] 
2010 3.64[3.62-3.67] 12.28[12.24-12.33] 3.06[3.03-3.08] 5.41[5.38-5.44] 3.32[3.29-3.34] 
2011 3.94[3.91-3.97] 13.41[13.37-13.46] 3.46[3.44-3.49] 5.99[5.95-6.02] 3.51[3.49-3.54] 
2012 4.19[4.16-4.22] 14.43[14.38-14.48] 3.85[3.82-3.88] 6.53[6.50-6.57] 3.66[3.64-3.69] 
2013 4.44[4.40-4.47] 15.39[15.34-15.44] 4.22[4.19-4.25] 7.05[7.01-7.09] 3.81[3.78-3.84] 
2014 4.68[4.64-4.71] 16.29[16.24-16.35] 4.63[4.60-4.67] 7.57[7.53-7.61] 3.95[3.92-3.98] 
2015 4.89[4.85-4.93] 16.98[16.92-17.05] 4.96[4.92-5.00] 8.03[7.98-8.07] 4.13[4.09-4.16] 
2016 5.02[4.97-5.06] 17.37[17.29-17.44] 5.14[5.10-5.19] 8.33[8.27-8.38] 4.19[4.15-4.23] 
2017 5.21[5.17-5.26] 18.00[17.91-18.08] 5.47[5.42-5.52] 8.78[8.72-8.85] 4.21[4.17-4.26] 
 
AAPC 8.3[8.0-8.6]* 9.7[9.3-10.0]* 12.1[11.9-12.3]* 11.0[10.7-11.3]* 7.8[7.5-8.0] * 
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Table 3.3-9 Trend in prevalence of joint-pain defined OA for different sites in women 
 
 Standardised Prevalence (%) [95% CI] 
Year  Hip Knee  Wrist/Hand Ankle/Foot  Unspecified 
1997 1.94[1.92-1.96] 2.68[2.65-2.71] 0.95[0.91-0.99] 1.56[1.52-1.60] 1.91[1.88-1.94] 
1998 2.14[2.11-2.17] 2.96[2.94-2.98] 1.07[1.05-1.09] 1.77[1.74-1.80] 2.15[2.12-2.18] 
1999 2.35[2.32-2.38] 3.24[3.21-3.26] 1.20[1.00-1.40] 1.96[1.92-2.00] 2.38[2.35-2.41] 
2000 2.67[2.64-2.69] 3.61[3.59-3.64] 1.35[1.34-1.37] 2.23[2.21-2.25] 2.65[2.62-2.67] 
2001 2.92[2.90-2.94] 3.96[3.93-3.99] 1.51[1.49-1.53] 2.47[2.44-2.49] 2.93[2.90-2.95] 
2002 3.22[3.20-3.25] 4.38[4.35-4.40] 1.70[1.68-1.72] 2.76[2.74-2.79] 3.28[3.25-3.30] 
2003 3.58[3.55-3.61] 5.15[5.12-5.18] 1.95[1.93-1.97] 3.18[3.15-3.20] 3.67[3.64-3.69] 
2004 4.01[3.99-4.04] 6.13[6.10-6.16] 2.26[2.24-2.28] 3.68[3.66-3.71] 4.08[4.05-4.10] 
2005 4.50[4.47-4.53] 7.19[7.16-7.23] 2.63[2.61-2.65] 4.24[4.21-4.26] 4.54[4.51-4.57] 
2006 4.99[4.96-5.02] 8.28[8.24-8.32] 3.01[2.99-3.04] 4.85[4.82-4.88] 4.94[4.91-4.97] 
2007 5.49[5.46-5.52] 9.35[9.31-9.39] 3.42[3.40-3.45] 5.53[5.50-5.56] 5.32[5.29-5.35] 
2008 6.03[6.00-6.06] 10.57[10.53-10.61] 3.89[3.86-3.92] 6.31[6.27-6.34] 5.74[5.70-5.77] 
2009 6.60[6.56-6.63] 11.80[11.75-11.84] 4.40[4.37-4.43] 7.10[7.06-7.14] 6.17[6.14-6.21] 
2010 7.13[7.09-7.17] 12.95[12.91-13.00] 4.91[4.88-4.94] 7.86[7.82-7.90] 6.55[6.52-6.59] 
2011 7.71[7.67-7.74] 14.12[14.07-14.16] 5.50[5.47-5.54] 8.62[8.58-8.66] 6.92[6.88-6.96] 
2012 8.23[8.19-8.27] 15.24[15.19-15.29] 6.07[6.04-6.11] 9.40[9.35-9.44] 7.26[7.22-7.30] 
2013 8.74[8.70-8.78] 16.28[16.23-16.34] 6.66[6.62-6.70] 10.12[10.07-10.16] 7.60[7.56-7.64] 
2014 9.26[9.21-9.30] 17.26[17.20-17.31] 7.28[7.24-7.32] 10.85[10.80-10.90] 7.91[7.86-7.95] 
2015 9.71[9.66-9.76] 17.95[17.89-18.02] 7.75[7.71-7.80] 11.49[11.43-11.54] 8.23[8.18-8.28] 
2016 9.96[9.9-10.02] 18.37[18.29-18.44] 8.06[8.01-8.11] 11.86[11.79-11.92] 8.40[8.34-8.45] 
2017 10.41[10.35-10.48] 19.17[19.09-19.26] 8.60[8.54-8.66] 12.50[12.43-12.57] 8.67[8.61-8.73] 
 
AAPC 8.8[8.3-9.3]* 10.4[9.9-10.8]* 11.7[11.4-11.9]* 10.9[10.6-11.2]* 7.9[7.6-8.1]* 
AAPC: Annual average percentage change; P value <0.05 
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3.3.2.3 Prevalence of multiple joint-pain defined OA in 2017 
 
According to the joint pain definition, in the year 2017 nearly 34% of the reported cases had 
at least two joints involved. The prevalence of joint pain at two or more sites in 2017 had 
increased from the 12% reported in 1997. There was an increasing trend of multiple joints 
involvement from 1997-2017 in the UK. (Figure 3.3-22) 



































1997 2002 2007 2012 2017
One Two Three Four or more
84 
 
Figure 3.3-23. Pattern of sites involved in any two joint pain defined OA in 2017 
  
 
AF: Ankle/Foot; WH: Wrist/Hand; US: Unspecified 
Exploring the pattern among people having two or more sites involved showed the leading 
pattern of joint pain was knee pain in combination with ankle/foot, hip, wrist/hand in 




























There has been an increase in joint pain prevalence in all regions of the UK. In 2014 
the highest prevalence was seen in the East Midlands and North-East regions of 
England. The prevalence is seen to be more uniform across the geographic regions 
within the range of 30%-45% (Figure 3.3-24). 
3.3.2.4 Incidence of joint pain defined OA in 2017 
 
During the 814,595 person-years of follow-up in 2017, 25,130 patients were newly 
diagnosed with joint pain. The age-sex and LOD standardised incidence was 30.85 per 
1000 person-years (95% CI 30.47-31.22 per 1000 person-years). (Table 3.3-10) The 
incidence was higher in women (39.6 per 1000 person-years; 95% CI 38.9-40.2) than in 
men (31.3 per 1000 person-years; 95% CI 30.8-31.8).  
Table 3.3-10 Incidence of joint-pain defined OA 
                                                  Incidence (per 1000 person-years) 95%CI 







1997 1076611 25153 23.36[23.01-23.61] 21.37[21.10-21.64] 22.27[22.04-22.54] 
1998 1233658 27944 22.65[22.35-22.95] 20.80[20.55-21.05] 21.59[21.35-21.85] 
1999 1502017 31445 20.93[20.71-21.15] 19.20[18.99-19.42] 19.90[19.69-20.12] 
2000 1842864 36857 20.00[19.72-20.28] 18.33[18.14-18.52] 19.03[18.84-19.22] 
2001 1999954 41891 20.94[20.74-21.14] 19.28[19.09-19.47] 19.98[19.79-20.17] 
2002 2289680 55593 24.28[24.06-24.40] 22.27[22.08-22.46] 22.97[22.78-23.16] 
2003 2426284 69062 28.46[28.23-28.69] 26.18[25.98-26.38] 26.68[26.48-26.88] 
2004 2520108 78154 31.01[30.71-31.29] 28.71[28.51-28.91] 29.21[29.01-29.43] 
2005 2438636 78963 32.38[32.12-32.64] 31.16[30.76-31.57] 31.67[31.26-32.07] 
2006 2447866 82525 33.71[33.41-33.91] 32.21[31.89-32.52] 32.71[32.39-33.02] 
2007 2428912 87288 35.93[35.63-36.13] 34.26[33.98-34.54] 34.66[34.39-34.94] 
2008 2342811 86841 37.06[36.82-37.30] 35.89[35.60-36.18] 36.29[36.00-36.58] 
2009 2189674 83468 38.11[37.88-38.34] 37.23[36.93-37.53] 37.63[37.33-37.93] 
2010 2146039 80878 37.68[37.45-37.91] 36.82[36.52-37.12] 37.02[36.72-37.32] 
2011 2058909 78329 38.04[37.72-38.36] 37.15[36.86-37.43] 37.35[37.06-37.63] 
2012 1968436 72291 36.72[36.42-36.92] 36.36[36.06-36.66] 36.56[36.26-36.86] 
2013 1760340 65004 36.92[36.68-37.20] 36.63[36.32-36.94] 36.83[36.52-37.13] 
2014 1603263 57952 36.14[35.84-36.44] 35.60[35.28-35.91] 35.70[35.38-36.01] 
2015 1363172 46664 34.23[33.92-34.54] 33.69[33.37-34.02] 33.74[33.42-34.06] 
2016 1079817 35304 32.69[32.33-33.05] 32.36[32.01-32.73] 32.41[32.06-32.78] 
2017 814595 25130 30.85[30.40-31.20] 30.85[30.47-31.22] 30.85[30.47-31.22] 
Age-sex standardized rates are standardized with CPRD 2017 UK population as standard population.  
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The incidence (per 1000 person-years) of joint pain defined OA in 2017, in decreasing 
order, was knee (14.96; 95% CI 14.70-15.22), ankle or foot (9.24; 95% CI 9.04-9.44), 
hip (7.29; 95%CI 7.10-7.49), wrist or hand (6.29, 95%CI 6.14-6.45) and unspecified 
(2.38, 95%CI 2.24-2.51). 
Age specific distribution for 2017 showed an incidence in the younger age group (20-24 
years) of 19.6 per 1000 person-years [95% CI 18.7-20.6], which increased and peaked 
at 70-74 years of age (51.9 per 1000 person-years; 95% CI 48.3-55.7) followed by a 
decline with age. Women had higher incidence rates compared to men in all age groups.  
The difference in incidence rates between men and women was lowest (6 per 1000 
person -years) in the younger age (25-29 years) but increased to 17 per 1000 person-
years in the middle age group (50-54 years) and then narrowed in the elderly population 
(80-84 years). (Figure 3.3-25) 




The joint specific incidence of joint pain is depicted in Figure 3.3-26. The descending 
order of incidence rates are knee (14.9 per 1000 person-years; 95% CI 14.7-15.2), 
ankle/foot (9.2 per 1000 person-years; 95% CI 9.1-9.4), hip (7.3 per 1000 person-years; 
95% CI 7.1-7.4), wrist/hand (6.3 per 1000 person-years; 6.1-6.4) and unspecified (3.8 
per 1000 person-years; 95% CI 3.7-3.9). At each site, the incidence increased with age 
but then declined after age 70 years. A sharper rise in the incidence rate with age group 
was seen at the knee and hip compared to other sites.  Up until age 50 years, the sites 
with the highest incidence rates were knee, ankle/foot, wrist/hand, and hip, but this order 
changed after 70 years of age to knee, hip, ankle/foot, wrist/hand and unspecified. A 
similar order was maintained with age in men, whereas in women older than 70 the 




















3.3.2.5 Trends of joint pain defined OA incidence in the UK (1997-2017) 
 
The trend of joint pain incidence showed a decline in earlier years which then increased 
after 2004. The standardised rate changed from 22.3 per 1000 person-years [95% CI 
22.0-22.5 person-years] in 1997 to 30.8 per 1000 person-years [95% CI 30.5-31.22 
person-years] in 2017. Both men and women showed a similar trend and remained in 
parallel throughout the study years. In men the incidence rate increased from 18.9 per 
1000 person-years [95% CI 18.5-19.2] in 1997 to 26.9 per 1000 person-years [95% CI 
26.5-27.4 person-years] in 2017. In women the incidence rate changed from 26.0 per 
1000 person-years [95% CI 25.6-26.5 person-years] in 1997 to 35.2 per 1000 person-
years [95% CI 34.6-35.7 person-years] in 2017. (Figure 3.3-27) 






The joinpoint analysis demonstrates the annual percentage change of the trend. It 
divides the trend line into four periods, specifically: declining (1997-2000); rapid increase 
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(2000-2005); slow increase (2005-2011); and declining (2011-2017). The APC between 
the years 2000-2005 was 11.65% and the average annual percentage change from 1997 
to 2017 was 1.9% [95% CI 1.0-2.7]. (Figure 3.3-28) The AAPC in men (2.1%; 95% CI (-
1.3% to 2.9%) was higher compared to women (1.7%; 95% CI 0.6%-2.8%), which was 
statistically significant. (Figure 3.3-28) 
Figure 3.3-28. Joinpoint analysis of the trend of any joint pain defined OA incidence 
 
The site-specific trends are shown in Figure 3.3-29. The increase in trend for joint pain 
was highest for knee pain followed by ankle/foot, hip, and wrist/hand pain, whereas the 
trend for unspecified joint pain showed a decline. The incidence rate of knee pain 
increased from 8.5 per 1000 person-years [95% CI 8.4 to 8.7] in 1997 to 14.9 per 1000 
person-years [95% CI 14.7 to 15.2] in 2017. The wrist/hand region pain incidence 
increased from 2.7 per 1000 person-years [95% CI 2.6 to 2.8] in 1997 to 6.3 per 1000 
person-years [95% CI 6.1 to 6.4] in 2017. Men and women showed similar trends over 
the study period. There was an increase in AAPC for all regions except for unspecified 
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(-1.1; 95% CI -2.6 to -0.4). The highest increase was seen for wrist/hand pain (4.4; 95% 
CI 3.2 to 5.7) followed by ankle/foot pain (3.1; 1.7 to 4.6). Details of the distribution and 
AAPC are given in Table 3.3-11 and Table 3.3-12.  












Table 3.3-11 Trends in incidence of joint-pain defined OA by joint in men    
 
 Standardised Incidence (per 1000 person years) [95% CI] 
 
 Hip  Knee  Wrist/Hand  Ankle/Foot  Unspecified  
1997 3.65[3.60-3.70] 8.25[8.20-8.30] 1.93[1.86-2.00] 4.24[4.18-4.30] 2.97[2.91-3.06] 
1998 3.71[3.65-3.77] 7.21[7.14-7.28] 1.98[1.91-2.05] 3.73[3.67-3.79] 3.00[2.91-3.09] 
1999 3.33[3.28-3.38] 6.54[6.44-6.64] 1.78[1.72-1.84] 3.32[3.22-3.42] 2.64[2.57-2.71] 
2000 3.32[3.25-3.39] 6.30[6.21-6.39] 1.94[1.88-2.00] 3.34[3.24-3.14] 2.85[2.75-2.95] 
2001 3.29[3.21-3.37] 6.52[6.42-6.62] 2.72[2.64-2.80] 3.71[3.63-3.79] 3.16[3.06-3.26] 
2002 3.50[3.41-3.59] 8.76[8.71-8.81] 2.63[2.53-2.73] 4.29[4.21-4.37] 3.22[3.12-3.32] 
2003 3.69[3.62-3.76] 11.62[11.58-11.66] 2.65[2.60-2.70] 4.72[4.65-4.77] 3.18[3.12-3.24] 
2004 4.18[4.10-4.26] 12.96[12.90-13.02] 3.00[2.92-3.08] 5.38[5.32-5.44] 3.19[3.12-3.26] 
2005 4.66[4.48-4.85] 14.57[14.33-14.80] 3.50[3.39-3.61] 6.16[6.00-6.33] 3.56[3.45-3.68] 
2006 4.71[4.57-4.86] 14.71[14.48-14.93] 3.73[3.62-3.84] 6.94[6.79-7.09] 3.21[3.12-3.31] 
2007 4.87[4.73-5.01] 15.71[15.49-15.93] 3.94[3.84-4.05] 7.35[7.20-7.50] 3.29[3.20-3.39] 
2008 5.26[5.11-5.40] 16.41[16.18-16.64] 3.95[3.85-4.06] 7.96[7.80-8.13] 3.34[3.24-3.44] 
2009 5.61[5.45-5.76] 18.07[17.82-18.32] 4.64[4.52-4.76] 8.60[8.43-8.78] 3.53[3.42-3.64] 
2010 5.48[5.32-5.63] 17.28[17.03-17.52] 5.04[4.91-5.16] 8.55[8.39-8.72] 3.21[3.11-3.31] 
2011 5.39[5.23-5.54] 16.94[16.70-17.19] 5.40[5.27-5.53] 8.44[8.27-8.60] 3.06[2.96-3.16] 
2012 5.32[5.17-5.47] 16.56[16.31-16.81] 5.41[5.28-5.54] 8.30[8.12-8.47] 2.99[2.89-3.09] 
2013 5.59[5.42-5.76] 16.88[16.62-17.15] 5.60[5.46-5.74] 8.67[8.49-8.86] 3.11[3.00-3.22] 
2014 5.44[5.27-5.61] 15.99[15.73-16.26] 5.53[5.39-5.68] 8.23[8.05-8.41] 2.84[2.74-2.94] 
2015 5.43[5.25-5.62] 14.73[14.46-15.00] 5.18[5.03-5.32] 7.53[7.35-7.72] 2.55[2.45-2.66] 
2016 5.20[5.00-5.39] 13.56[13.27-13.85] 4.73[4.57-4.88] 7.29[7.08-7.49] 2.39[2.28-2.51] 




1.1[-0.4 to 2.5] 2.6[1.3 to 3.8]* 5.2[3.8 to 6.8]* 3.1[1.6 to 4.7]* -0.9[-1.7 to -0.1]* 












Table 3.3-12. Trends in incidence of joint pain defined OA by joint in women 
 
 Standardised Incidence (per 1000 person years) [95% CI] 
 
Year  
         Hip  Knee  Wrist/Hand  Ankle/Foot  Unspecified  
1997 7.49[7.41-7.57] 8.80[8.60-9.00] 3.52[2.92-4.12] 5.75[4.75-6.75] 6.10[5.10-7.10] 
1998 7.43[7.38-7.48] 7.74[7.54-7.94] 3.30[2.50-4.10] 5.30[4.30-6.30] 6.16[5.76-6.56] 
1999 6.84[6.77-6.91] 7.19[6.90-7.39] 3.01[2.00-4.00] 5.05[4.05-6.05] 5.10[4.10-6.10] 
2000 6.70[6.61-6.79] 6.80[6.65-6.95] 3.01[2.01-4.01] 4.91[4.00-5.82] 5.10[4.10-6.10] 
2001 6.92[6.82-7.02] 7.28[7.16-7.40] 4.21[4.04-4.36] 5.29[4.59-5.99] 5.70[5.00-6.40] 
2002 6.95[6.90-7.00] 9.67[9.56-9.78] 4.21[4.05-4.37] 6.06[5.06-7.06] 6.15[5.25-6.85] 
2003 7.42[7.32-7.52] 12.88[12.78-12.98] 4.19[4.00-4.38] 6.94[6.76-7.12] 6.08[5.08-7.08] 
2004 8.08[8.00-8.16] 14.69[14.59-14.79] 4.84[4.71-4.97] 7.75[7.55-7.95] 6.57[6.38-6.77] 
2005 8.71[8.53-8.88] 16.36[16.14-16.59] 5.63[5.51-5.76] 8.72[8.56-8.89] 6.98[6.84-7.12] 
2006 9.17[9.00-9.35] 16.33[16.11-16.55] 5.84[5.72-5.97] 9.74[9.58-9.91] 6.24[6.12-6.37] 
2007 9.65[9.47-9.83] 17.60[17.37-17.84] 6.18[6.05-6.31] 10.55[10.38-10.73] 6.44[6.31-6.57] 
2008 10.06[9.87-10.25] 18.55[18.30-18.79] 6.63[6.50-6.77] 11.21[11.03-11.40] 6.68[6.55-6.82] 
2009 10.9[10.69-11.10] 19.72[19.45-19.98] 7.14[7.00-7.29] 11.97[11.78-12.17] 6.72[6.57-6.86] 
2010 10.64[10.44-10.84] 18.91[18.65-19.16] 7.82[7.67-7.97] 11.87[11.68-12.07] 6.17[6.03-6.30] 
2011 11.08[10.87-11.29] 19.54[19.27-19.80] 8.21[8.06-8.37] 11.83[11.63-12.02] 6.12[5.98-6.25] 
2012 10.70[10.49-10.91] 18.44[18.17-18.71] 8.21[8.05-8.38] 11.54[11.34-11.74] 6.00[5.86-6.14] 
2013 11.12[10.89-11.34] 19.21[18.92-19.50] 8.76[8.58-8.94] 12.28[12.07-12.50] 6.25[6.11-6.40] 
2014 11.16[10.93-11.40] 18.35[18.06-18.64] 8.43[8.25-8.60] 11.79[11.58-12.01] 5.64[5.50-5.79] 
2015 10.78[10.53-11.03] 17.06[16.76-17.35] 7.88[7.69-8.06] 10.80[10.58-11.03] 5.36[5.21-5.50] 
2016 10.81[10.52-11.09] 16.17[15.84-16.50] 7.41[7.21-7.61] 10.22[9.98-10.46] 5.17[5.00-5.33] 
2017 10.17[9.85-10.49] 16.38[15.99-16.77] 7.63[7.40-7.87] 10.52[10.23-10.81] 5.11[4.92-5.31] 
  
AAPC 1.6[0.8 to 2.4]* 3.2[1.9 to 4.6]* 4.2[2.9 to 5.4]* 2.9 [1.9 to 3.9]* -0.8[-2.3 to 0.7] 
AAPC: Annual average percentage change; *P value <0.05 
 
Geographic distribution of joint pain incidence showed an increase since 1997 in all 
regions except Yorkshire and The Humber. In 2017 the highest incidence was seen in 
Northern Ireland and the West Midlands, followed by the Southern England region. 











3.4 Discussion  
 
This is the first study to describe trends in both incidence and prevalence of GP-
diagnosed OA and the alternative definition of OA (joint pain defined OA) in the UK. To 
date the available literature has not been able to provide clear epidemiological 
information. This study describes the higher burden of OA in the UK with a prevalence 
of 10.7% and incidence 6.8 per 1000 person-years in people aged 20 and over in 2017. 
The prevalence of site-specific OA in descending order is unspecified (7.6%), knee 
(2.9%), hip (1.5%), wrist/hand (0.5%) and ankle/foot (0.3%). Furthermore, the OA 
prevalence is increasing at a rate of 1.4% per year since 1998, whereas its incidence is 
declining at a rate of -1.6% per year. Geographically, the prevalence of OA is not 
uniformly distributed. Scotland, Northern Ireland, and the West Midlands had higher 
prevalence compared to the rest of the country. The incidence was highest in the East 
Midlands and North-East regions. 
3.4.1 Prevalence and incidence of GP-diagnosed OA 
 
Earlier studies from different countries have reported the overall prevalence among 
those aged 45 years and over to vary between 20% to 35% (Dillon et al., 2006; Brennan-
Olsen et al., 2017). The prevalence in the USA was  28% (J. M. Jordan et al., 2007) and 
in Australia, the prevalence of any OA in adults aged 18 years or more was 20.4%. In 
this study, the estimated prevalence among people aged 20 years or more using a 
primary care database and the findings is lower than others. The estimated prevalence 
from this study among people aged 45 years or more using the entire CPRD database 
was nearly 23%. Jordan et al, compared the prevalence of OA determined in four 
different databases and reported a prevalence of OA of 1.6% in those aged 15 years or 
more in the GPRD database, currently known as CPRD (K. Jordan et al., 2007). A similar 
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finding was reported later in 2014 in the CPRD database of North Staffordshire (Jordan 
et al., 2014).  
Very few studies have examined the incidence of OA, especially in the UK. Using CPRD 
data, one study reported the standardised incidence of OA in 2014 to be 6.3 per 1000 
person-years (Yu et al., 2017) compared to 6.8 per 1000 person-years seen in this study 
in 2017. The estimates are lower than that reported in the Canadian study (Rahman et 
al., 2014) and higher than those reported in Spain (Prieto-Alhambra et al., 2014). 
However, the patterns in age and gender stratified rates are similar irrespective of the 
definition of OA. Use of different definitions makes comparison between studies very 
difficult. However, it should not affect the comparison within the study for different groups 
such as incidence by age and gender. Although ‘physician-diagnosed’ definition of OA 
was used, the findings are quite comparable to other administrative database studies. 
Another published report from GPRD found the annual incidence of OA was nearly 15 
per 1000 person-years among those aged 40 years or more (Parsons et al., 2011). An 
extra analysis was performed to calculate the incidence in 2017 among people aged 40 
years or more. The standardized incidence of any-OA in 2017 among people aged 40 
years or more to be 16.2 per 1000 person-years in this study. Yu et al reported the 
standardised incidence rate of any joint OA to be 8.6 per 1000 person-years among 
persons aged 15 years or more in a regional administrative database (Yu et al., 2015) 
and suggesting a similar burden found in this study.  
The increasing prevalence and incidence with age and in women in this study supports 
the existing epidemiological findings for OA. The sudden rise of both prevalence and 
incidence at the age group of 40 years has been biologically explained and reported 
uniformly in previous studies (Zhang and Jordan, 2010). Similarly, the decline of 
prevalence and incidence that was observed in later old age (85 years or more) is a 
common phenomenon for almost all chronic conditions. This may be because of two 
reasons: [1] the smaller sample size available for those aged more than 85 years; and 
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[2] people with OA are likely to have cardiovascular and other comorbidities hence die 
sooner that those without OA, resulting in relatively healthier people surviving into this 
age band (“healthy survivor” bias). The incidence pattern with age group accords with 
previous findings from the UK and other countries (Parsons et al., 2011; Yu et al., 2017). 
Also, there is enough scientific consensus regarding the biological relationship of sex 
and age with OA (Doherty, 2001). The association of OA with gender, along with other 
particular risk factors (e.g. increased weight and bone mass) and the increasing 
prevalence of OA in women following the menopause, has signalled the role of 
oestrogen as an influence (Spector and Campion, 1989; Spector et al., 1996). 
In both sexes, the prevalence and incidence of ‘unspecified’ site OA was high compared 
to other joint OA. A similar finding was reported by Yu et al (Yu et al., 2015). The 
‘unspecified’ reporting of the OA site explains the recording pattern in primary care. 
However, whether the ‘unspecified’ term used in the database is a substitute to record 
multiple joint involvement, remains unclear. Without proper radiographic evidence, 
physicians might record it as unspecified, which needs further exploration. This suggests 
that the GP coding for OA needs to be improved. In addition, care must be taken when 
interpreting the prevalence of OA by different body sites.  
Many  people with OA may never consult their GP about their OA (Yu, Jordan and Peat, 
2018), so the prevalence from CPRD is generally lower than in studies that examine 
samples of the general population specifically for OA. For example, in this study, the 
prevalence of knee OA was nearly 3% whereas, a community-based study of adults in 
Canada reported the prevalence to be 8.5% (Plotnikoff et al., 2015). Similarly, the 
prevalence of hip OA in this study was nearly 1.2%, whereas in the same Canadian 
study the prevalence was reported to be 10.5% (Plotnikoff et al., 2015). However, studies 
have reported the prevalence of knee OA to be higher followed by hip and wrist/hand, 
similar to findings from this study (Kingsbury et al., 2014).  
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The incidence rates of hip and knee OA are quite comparable to the incidence calculated 
using the Consultations in Primary Care Archive (CiPCA) database from the UK (Yu et 
al., 2015). The hand/wrist OA incidence (0.65 per 1000) is slightly lower than the 
published rate (1.1 per 1000 person-years)(Yu et al., 2015). The incidence rates for 
hand/wrist OA reported in those aged 40 years or more are 1.2 per 1000 person-years, 
close to the findings in the same age group in the CiPCA database. This could be 
because of the quality of the database, as CPRD GOLD database used for this study 
represents the whole country and wider heterogeneity in diagnosis and recording, while 
the published literature had a better supervised uniform recording of OA diagnosis in 
primary care database. Other factors could be because of the different health seeking 
behaviour of people in different parts of the country, for example a preference to see a 
physician for large joint problems compared to small joints.  
Both the incidence and prevalence of ankle/foot OA in this study was much less 
compared to the previously reported research (Menz et al., 2010; Roddy and Menz, 
2018). This could be due to the difference in study population, diagnosis and recording 
of the ankle/foot OA by the GPs. McCarthy et al reported the inconsistency and 
incomplete recording of the musculoskeletal recording in primary care, especially the 
examination of the joints (McCarthy, Sheane and Cunnane, 2009). Other possible 
reasons could be the reporting of the symptoms by the people in primary care and 
diagnostic facilities available to identify specific causes. 
Other factors for differences in results could be because of the broader age band used 
(20 years and more). This study included those aged 20 years or more, so lower 
estimates compared to other studies are justified in the context of a larger proportion of 
younger people in the denominator (eligible population). However, the standardised 




3.4.2 Trends of prevalence and incidence 
 
In the year 2017 an increase in standardized prevalence from 1997 was observed. The 
annual percentage increase was 3.9%. So far, no literature is available on trends of OA 
prevalence. OA is a chronic condition without a specific cure, thus, once a person has 
consulted for OA the record remains in the database until the person dies or leaves the 
practice. This suggests increased healthcare utilization for OA in primary care. OA is a 
common complex disorder with variation in phenotypic expression and sometimes OA 
may be difficult to differentiate from other joint and regional pain conditions. No 
significant change in rate for joint-specific prevalence was found, but the ‘unspecified’ 
OA rate was declining, indicating possible improvement in clinical coding. Perhaps the 
increase in trend of ‘joint-pain’ after the year 2005 partially explains the gap if physicians 
became more prone to report symptoms rather than a specific diagnosis.  The third 
reason for this increase may be related to a change in some risk factors for development 
of OA, such as the increase in obesity in recent decades, which is nearly parallel to the 
prevalence rise of OA. 
Surprisingly, an overall slow decline in incidence rates for any-OA since 1997 was seen. 
The annual percentage change is on a downward trend at the rate of -1.7% per 1000 
person-years. However, detailed joinpoint analysis reveals a slight rise in incidence from 
2000-2004 followed by a slow decline. The decline might be because of the introduction 
of the Quality of Framework (QoF) introduced by the NHS for quality recording of cases 
which included OA, which could have increased the accuracy in recoding the OA in the 
data base. A similar trend was seen in a ‘GP diagnosed’ diabetes analysis in the CPRD 
(Tate et al., 2017), which explains the change in pattern of coding after the year 2004. 
However, the insignificant change in rate for site specific incidence except for 
‘unspecified’ which is declining at an annual rate of 2.3 per 1000 person-years, indicates 
improvement in coding. It may be that the increase in incidence of ‘joint-pain’ after the 
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year 2005 partially explains the gap, which is discussed later. (Appendix Fig 5, page 
306) Physicians might be increasingly reporting the symptoms rather than the diagnosis, 
which can be a problem in large databases.  
Age-period-cohort effects, length of data contribution and the participation of practices 
in the CPRD database influence the incidence estimates (K. Jordan et al., 2007; Kuo et 
al., 2014b).  Age-period-cohort analysis shows a strong cohort effect in incidence among 
people born after the 1960s. It suggests that people born after this period may be 
exposed less to physically very demanding occupations such as coal-mining, farming 
and certain heavy industrial work because of changing patterns of occupation in the UK 
since the 1960s, including the decline in mining activities (Long-term trends in UK 
employment: 1861 to 2018 - Office for National Statistics, 2019). The maximum available 
length of data run-period was used to eliminate the problem of prevalent cases for OA 
for robust incidence estimates. In contrast, prevalence remained almost unchanged in 
people born after the 1960s.   
3.4.3 Geographical distribution of the prevalence and incidence 
 
There is clear evidence for regional variations in OA. OA is more prevalent in Scotland, 
the West Midlands and Northern Ireland compared to the rest of the UK.  The prevalence 
for all the regions was estimated until 2014, but because of lack of data from the East 
Midland regions after 2014 comprehensive comparison could no longer made. However, 
the geographical distribution of the prevalence up until that time may represent 
consultation behaviour changes rather than a change in OA per se. Other reasons for a 
higher prevalence in certain regions could be because of different socio-economic 
conditions, lifestyles, and variations in health seeking behaviours in the population. 
Interestingly findings from this study largely match the obesity distribution mapping of 
UK undertaken by the Health Survey for England, Scotland and Northern Ireland 
(‘Statistics on Obesity, Physical Activity and Diet, England 2018’, 2018) in that the 
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prevalence of obesity is higher in the Northern region of the UK compared to the South, 
and obesity is recognised as an important risk factor for OA (Appendix-3). However, 
further research is required to explain the underlying factors for OA. The spatial 
distribution of the disease prevalence needs careful interpretation.  
As seen for prevalence, geographical non-uniformity in incidence is clearly observed in 
this study. The middle regions of the UK had higher incidence rates in the year 2014 
compared to the rest of the country. The given map aligns with the mapping done by Yu 
et al for the year 2013 (Yu et al., 2017). This variation might be because the rates are 
sensitive to the practice areas involved, definitions, coding, incentives, and length of run-
in period for practices. This supports the missing information from the East Midlands 
after the year 2014.  
3.4.4 Prevalence and Incidence of joint-pain defined OA 
 
Even though the information for OA related joint-pain was analysed, the primary purpose 
was to explore the comprehensive inclusion of the definition of OA i.e., both GP-
diagnosed and OA related joint pain. In most general practices recording OA as joint 
pain may be common because of the absence of more definite (e.g., radiographic) 
confirmation of the diagnosis. The standardized prevalence of joint pain in this study was 
34% and was higher among women compared to men. Jordan et al reported a similar 
prevalence using UK and Swedish primary care databases. Nearly 30% of people aged 
18 years or more had any joint pain. Major injuries and other possible causes of joint 
pain  that happened within 1 year before the index date were excluded from the analysis. 
However, the increased prevalence of OA related joint pain needs further exploration. 
Although, there are few studies available on joint pain in the UK, the findings are quite 
comparable to previous literature (Finney et al., 2017).  
The age distribution of joint pain follows a similar pattern to GP diagnosed OA, i.e., a 
linear increase with age until 80-85 years followed by a decline. However, nearly 10% of 
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people in the age group 20-29 years in 2017 consulted for joint pain. This suggests that 
the problem could be related to injuries, since diagnosis of OA at younger ages is rare 
or not diagnosed properly or could be an issue with coding. Possibly the absence of 
recording of injury history (unavailable) for the joint pain might have escaped the 
exclusion criteria.  Jordan et al, documented the prevalence of arthralgia in the age group 
of 15-24 years to be 19.2%, which is much higher than findings from this study (Jordan 
et al., 2010).  
Interestingly, in younger ages the prevalence for knee pain was highest followed by 
ankle/foot and wrist/hand pain, whereas in elderly people, this was highest for knee pain, 
followed by hip and ankle/foot. This supports the above-mentioned explanation about 
the recording of the conditions, especially the missing injury records. Joint injuries in 
younger age especially knee and ankle/foot are quite common because of sport or 
physical activities. However, in the elderly population, joint pain of knee and hip are more 
likely to be linked with structural changes because of OA. Another study done by Finney 
et al also reported knee pain as the commonest site in the UK (Finney et al., 2017). The 
age stratified findings indicate that careful use of the joint-pain definition for OA is needed 
in younger people in large primary care databases.  
The definition of OA used in this study based on recording of joint pain found the 
standardized incidence rate to be 31 per 1000 person-years in 2017, which is less than 
the 40.5 per 1000 person-years for ‘clinical-OA’ reported by Yu et al for the year 2013 
(Yu et al., 2015). This could be because of the different age criteria used in these studies 
as explained before. Thus, the incidence of joint pain is less in the younger population 
lowering the overall estimates compared to that calculated for 45 years or more. The 
pattern of estimates across age groups is consistent with other findings, i.e. an increase 
with age and subsequent  decline after the age of 70 years (Yu et al., 2015). However, 
high consultations in the younger age group needs further exploration since identifying 
the reasons for joint pain in younger people is difficult in administrative database. The 
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finding of higher incidence among women from this study agrees with other studies. By 
the age of 70 years, nearly 60% of the population have consulted for joint pain, which 
supports the current evidence (Parsons et al., 2011). This indicates the consultation 
burden of ‘joint-pain’ which might guide future planning of the care process. 
The significant increase in the prevalence of joint-pain over twenty years highlight the 
rising burden. There has been a steep rise in the trend after the year 2004 with incidence 
trend. However, the rate of change subsequently slowed down after 2013. The possible 
reasons discussed for increasing prevalence of GP-diagnosed OA may best explain this. 
The rate of change was higher for knee, ankle/foot, and hip. This could be because of 
the clear recording of the body site based on symptoms. The lowest trend seen was for 
‘unspecified’ joint pain which complements the ‘GP-diagnosed’ OA trend, where an exact 
diagnosis could not be ascertained. (Appendix Figure  5, page no 306) The rate of 
change for the wrist/hand was highest followed by ankle/foot and knee. The higher 
ankle/foot pain trend echoes the recent findings from Murray et al (Murray et al., 2018). 
It is possible that joint pain may be attributable to other pathologies occurring at the joint 
site or in surrounding structures, for example ligamentous or tendon injury, ankle sprain, 
or referred pain from other areas. The cause of the increasing prevalence of joint pain 
needs further study. Since 1997, the trend of joint pain defined OA incidence has not 
been consistent. The rise in the incidence rate from 2003 could be because of the 
introduction of the QOF into the NHS (NHS, 2016), which might have reduced 
misclassification bias. This trend complements the trends of ‘GP diagnosed’ OA 
incidence, which is seen to fall after 2003. However, there is a downward trend seen 
after 2009. Similar trends were observed by Yu et al, who studied up until 2013 (Yu et 
al., 2015).  
An increase in trend of knee pain was observed compared to other studies. In one of the 
population-based studies of changes in the prevalence of knee OA symptoms and 
radiographic changes in the USA, Nguyen et al. found substantial increases in self-
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reported knee pain but not radiographic OA between 1974 and 1994 after adjusting for 
the changing distribution of BMI (Nguyen et al., 2011). However, the annual percentage 
change for wrist/hand was highest compared to other sites (van Saase et al., 1989). 
These joint pain estimates can be a proxy indicator of future OA severity and burden in 
the country. The burden of joint pain is more common in Northern Ireland and Southern 
parts of the UK. This could be because of the more representation of GP practices from 
those areas to the CPRD GOLD database. However, such unequal distribution needs 
further research. 
3.4.5 Study limitations  
 
There are several limitations to this study. Firstly, this study based the OA case definition 
on diagnosis by the general practitioners rather than presence of structural OA on 
imaging. However, concordance between symptoms and radiographic OA (the usual 
way to assess structural OA) is variable and often poor, depending on the joint site being 
assessed (Hunter et al., 2013). Furthermore, patient-centred outcomes rather than 
imaging changes are key determinants of disability and burden of disease, and NICE 
recommend that a purely clinical diagnosis is sufficient and that imaging should be 
reserved for specific situations such as atypical clinical features or rapid progression of 
symptoms (NICE, 2014). Site specific estimates could be biased because of coding used 
by the practitioners (e.g., OA or ‘Unspecified’). A stand-alone primary care database was 
used for this study and the use of alternative ‘joint pain’ definition reflects the primary 
care burden through the broader selection criteria. 
Secondly, the analysis the temporal trend of BMI using CPRD GOLD data was difficult 
owing to its incompleteness. Therefor the national health survey data was used to 
explain the findings. This comparison has helped to explain high BMI trend as one of the 
risk factors for the prevalence and incidence.  
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Thirdly, the index date reflects the date of allocation of Read codes for OA and does not 
reflect actual disease onset. However, the date of allocation of a Read code for OA would 
be expected to be within a few months of the date of diagnosis. Sensitivity analysis was 
not performed to examine the effects of changes in Read codes on the results. However, 
the codes were verified in this study as explained in the methods and do not suggest a 
change in the Read code list will alter the findings on temporal trends in the epidemiology 
of OA. Exclusion criteria used in this study might have led to underestimation of the 
burden.  
Another limitation is the geographical presentation of the estimates, which needs 
cautious interpretation because of the non-uniform distribution of the practices involved 
in the database. 
3.4.6 Conclusion 
 
The standardised incidence of GP-diagnosed OA has been declining from 2010, 
however the prevalence is rising gradually. An increase in the trends of both 
standardised incidence and prevalence of joint pain related to OA was observed.   Nearly 
one in every 10 adults aged 20 years or more has OA and the knee is the leading site 
reported to be involved in both sexes. The increasing rate of ‘joint pain’ incidence and 
prevalence is a matter for concern. The results from this study suggest that the changing 
burden of OA and joint-pain in primary care necessitates an appropriate policy and 









Summary of Chapter 3 
 
Chapter 3  the burden of OA in the primary care settings in the UK. Key findings 
are  
• The prevalence of OA in the primary care is nearly 10% and annual 
incidence was 7 per 1000 person years 
• Women  contributed to the burden more compared to men 
• There was an increase in burden of OA after the age of 40 years in both 
men and women 
• Knee OA is the most reported joint specific OA followed by hip, wrist/hand, 
and ankle/foot 
• The trend of prevalence is increasing  while the incidence is declining. 
As the burden of the OA in the primary care is evident, it would be interesting to 
understand the burden of the other different chronic conditions present with OA. 
Thus, in the next chapter (chapter 4) the association of OA with various 
comorbidities will be explored.
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4 Chapter 4  
Comorbidities in OA 
 
4.1 Introduction  
 
Presence of two or more chronic conditions in an individual has become a norm rather 
than an exception (Fortin et al., 2010). Multiple chronic conditions in an individual could 
be explained through shared pathogenesis, shared aetiology or ageing in which the 
risk of developing other chronic conditions becomes high (Piette and Kerr, 2006). 
There has been a growing interest in researching the comorbidities that may associate 
with OA. However, to date the list of comorbidities studied are primarily limited to CVD, 
diabetes, depression and chronic obstructive pulmonary diseases (Nieves-Plaza et al., 
2013; Stubbs et al., 2016b; H. Wang et al., 2016; Parkinson, Waters and Franck, 
2017). According to Versus Arthritis, three in ten people with OA have more than one 
long term condition (Loftis, Ellis and Margham, 2014). 
The systematic review shows that on average 67% of people with OA had one or more 
other chronic conditions, and the risk of having comorbidity was 20% greater than in 
those without OA (Swain et al., 2019).  Other systematic reviews on comorbidities in 
OA report significant associations with cardio-vascular conditions and diabetes 
(Nieves-Plaza et al., 2013; H. Wang et al., 2016). The presence of additional 
comorbidities escalates the disease severity and healthcare utilization, and demands 
complex management guidelines (Bähler et al., 2015). The temporal and causal 
association between these conditions has yet to be established as most studies are 
cross-sectional. Current evidence is restricted to a few comorbidities and the ‘time-to-
event’ i.e. occurrence of comorbidities after diagnosis of OA has not been studied.  
Except for shared risk factors such as ageing and obesity, little is known about 
biological plausibility to explain concurrence of OA and associated comorbidities. 
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Furthermore, whether comorbidities in OA occur because of OA itself, or because of 
the medication used to treat OA remains unclear. Lack of evidence on causality, 
pattern and distribution of comorbidities in OA makes the management of OA with 
comorbidities less clearly defined (de Rooij et al., 2014). To date, no large database 
studies are available on the reported associations, and many possible associations 
have not been investigated. Therefore, using data representative of the general 
population of UK from the CPRD, this study aimed to examine the burden of 
comorbidity at the time of first diagnosis of OA (i.e., newly diagnosed, or incident OA) 
compared with matched controls. I further followed patients with incident OA and their 




4.2.1 Source of data 
CPRD GOLD data was used for this study.  
4.2.2 Study population 
For this analysis, data available for registered people since inception of CPRD (1st Jan 
1985) to 31st December 2017 was used.  
General criteria for inclusion were that participants should: 
• be aged 20 years or more at study entry 
• have had active registration for at least 36 months with the UTS practice prior 
to the study, 
• be flagged as acceptable data (determined by CPRD database standards) 
4.2.3 Case definition of OA 
For this study only GP-diagnosed OA was used, because of the ambiguity in using a 
‘joint-pain’ definition to define the OA population (please see Chapter 3 discussion 
section for OA and joint pain). 
GP-diagnosed OA was defined as: 
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• at least one recorded physician diagnosis of OA for hip, knee, ankle/foot, 
wrist/hand, or recorded as ‘unspecified’  
• any recording of knee or hip replacement in the absence of recording of GP-
diagnosed OA during the study period 
4.2.4 Eligible study population for retrospective and prospective 
analysis 
For the analysis, controls were participants registered with the UTS practices who had 
no record of diagnosed OA, OA related joint pain or total joint replacement. One control 
was selected per OA case and was matched in a 1:1 ratio by age (+2 years), gender, 
year of first registration and practice and having at least one consultation recording in 
the database. The same index date as their matched case was used (date of first OA 
diagnosis). The matched controls were selected using the ‘sttocc’ command in Stata. 
Details of the method of patient selection are given in Appendix Figure 6 (page 307). 
4.2.5 Comorbidity definition and extraction 
 
Details of the comorbidity selection is provided in chapter 2, section 2.1.7.1. Forty nine 
chronic conditions excluding OA were extracted for the study. The comorbidities in this 
study were further categorised into eight groups namely, musculoskeletal, respiratory, 
genitourinary, neuropsychiatric, cancer, circulatory, metabolic/endocrine, and digestive. 
In addition, a list of six conditions were grouped as ‘other’ category. The definition of all 
these conditions was based on physician diagnoses recorded as Read codes. A 
summary of the disease list with primary codes is given in the Appendix Table 4 (page 
309).  
In the CPRD, the code list for important comorbidities was obtained using the medical 
browser provided by the CPRD interface. Wherever required, this was further refined 
after comparing with codes used by other researchers in the department. A final list of 
the codes was shared with the general practitioner collaborator (CM) for input and 
verification. Finally, the corrected codes were read and agreed by all the research 
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team. Most of the code lists for comorbidities listed are externally validated (Deyo, 
1992; Nada F. Khan, Harrison and Rose, 2010).  
4.2.6 Covariates 
 
Because of the longitudinal nature of the data, the health behaviour of participants was 
subject to vary over time. For example, BMI status, alcohol use and smoking habits 
can change multiple times during 20 years of follow-up. Studies have confirmed  that 
such health risk behaviours largely influence the incidence of comorbidities (Bhaskaran 
et al., 2013). The whole study period was divided into five follow-up intervals (0-1 year, 
0-5 years, 0-10 years, 0-15 years, and 0-20 years) after and before the index date. The  
status of each covariate (BMI, alcohol use and smoking status) at the end of each 
follow-up interval was extracted from an additional file provided by the CPRD. The 
purpose of restricting to five follow-up intervals was to prevent the large expansion of 
the database to save the data memory and time for running time varying covariate 
(TVC) analysis. Such an approach is suggested in the Stata manual for TVC analysis. 
In case of missing information for one follow-up time, it was imputed using last 
observation carried forward, assuming the status remained unchanged. BMI was 
categorised into four groups based on the values (Kg/m2) such as underweight 
(<18.50), normal (18.50-24.99), overweight (25.00-29.99) and obese (30.00 and 
above) (NHS, 2018). Smoking status was divided into ex-smokers, current smokers, 
and non-smokers. Alcohol use was grouped into non-user, ex-user, current user 1-9 
units/week, current users >10 units/week and current users (unknown quantity). As 
missing data information was less than 10%, the whole dataset was used for analysis 
for which complete information on covariates was available.  
4.2.7 Statistical methods  
Both case-control and cohort designs were used to explore the temporal association 
with comorbidities. The case-control design assessed comorbidities that were present 
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on or before the first diagnosis of OA (up to a maximum of 20 years before the index 
date), whereas the cohort design assessed the occurrence of comorbidities after the 
diagnosis of OA. 
For the case-control analysis, the prevalence of a specific comorbidity in cases and 
controls was estimated by calculating the proportions of people diagnosed with any 
comorbidities during the past 1, 5, 10, 15 and 20 years before the index date. This 
method was used primarily to examine whether the longer observational period would 
give greater prevalence - to assess the observational bias (Kuo et al., 2014a). The 
denominator for prevalence calculation was the total number of cases or matched 
controls during each study period. The ORs of having two or more comorbidities (other 
than OA) during the retrospective time points was calculated. During the retrospective 
analysis, the association of multiple chronic conditions with OA was examined. The 
study population was divided into five groups (none, single, two, three and four or more 
comorbidities) based on their total count of comorbidities. ORs and 95% CIs were used 
to estimate the association between OA and each coexisting medical condition. 
Conditional logistic regression was used to adjust for age, gender, BMI, smoking, 
alcohol use and index date. Even though controls were matched for age and gender, 
for the retrospective study the outcome of interest was OA. So, these factors were 
adjusted in the model.  
In the prospective cohort study, the incident comorbidity was assessed as the earliest 
date of diagnosis after the index date. The study period was until the incident date of 
comorbidity, death date, transfer out or end of the study (31st Dec 2017), whichever 
came first. Only people at risk for a given comorbidity (not having such comorbidity at 
index date) were considered to estimate HRs of a specific comorbidity. For calculation 
of cumulative probabilities, at baseline the percentage of the specific comorbidity was 
zero and the subsequent risk was calculated among the at-risk population. The 
Nelson-Aalen method was used to display the cumulative probability of each 
113 
 
comorbidity in people with incident OA and matched controls. Along with that, HRs with 
95% CIs were calculated for each comorbidity separately using Cox proportional 
hazards model adjusting for age, smoking, alcohol use, BMI, and index date. 
Proportionality assumption for each comorbidity was tested looking at Kaplan-Meir 
curves and use of the Schoenfeld residual test. The Schoenfeld test was done for both 
global and individual covariates and OA. The Cox model incorporated a time varying 
covariate analysis which accounted for the change in age, BMI, alcohol use and 
smoking status over time, and time invariable factors such as sex and the index year.  
The association and risk of 49 comorbidities with OA was tested. This simultaneous 
testing of several hypothesis creates the risk of higher false discovery rate which is 
known as ‘multiple testing’ (Greenland, 2008). To explain further, even though the 
significance level was fixed at 0.05, not considering the multiplicity of tests would 
increase the probability that some of the true null hypotheses were being rejected by 
chance alone. To address the problem of multiple testing p values  were adjusted to 
identify significant associations. The false discovery rate method proposed by 
Benjamini and Hochberg was used to calculate adjusted p values for both retrospective 
and prospective analyses (Benjamini and Yekutieli, 2001). Details of the method are 
given in Appendix Method 1 (page 352). R software was used to calculate adjusted p 
values using ‘fisheries stock assessment’ (FSA) package using the ‘False discovery 
method’ (Ogle, & dunnTest, 2019). For sensitivity analysis various other methods were 
proposed for calculating adjusted p values. (Appendix Method1, page 344) 
Comorbidity association with joint specific OA was also explored using the above-
mentioned methods. The analysis was restricted to hip, knee, wrist/hand, and 
ankle/foot because of the higher incidence rate for having enough statistical power. 
The statistical analyses were performed using STATA statistical software V.15 and R 
software V3.5.  
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4.2.8 Sensitivity analysis 
For sensitivity analysis, the matched cases and control were who had none of the 
studied comorbidities on or before the index date. (Appendix Fig 7, page 308) This 
analysis was performed to study the temporal association of OA only with specific 
comorbidities. This was because in the main analysis, HR was calculated among 
people ‘at-risk’ for that comorbidity only. This makes it difficult to explain the direct 
association of each comorbidity with OA, which could have been influenced by 
presence of other conditions. Whereas the sensitivity analysis looked at people without 
any comorbidities at the index date i.e., OA-only population may provide better 
interpretation. However, this population might not be true representative of the OA 
phenotypes. 
4.3 Results  
 
4.3.1 Retrospective case-control study 
 
4.3.1.1 Characteristics of the study population  
 
During the period 1997 to 2017, 221,807 incident OA patients were identified with a 
median age of 61 years at diagnosis (IQR: 52.18-70.43 years) and nearly 58% being 
women. Individuals with same sex, age (+2 years) and from the same practice but 
without OA were selected as matched controls for the 221,807 OA cases. Table 4.3-1 
shows characteristics of cases and matched controls. Both unadjusted and adjusted 
associations of BMI, smoking and alcohol use with OA were significant. Being obese 
was associated with 2.15 times (95% CI 2.11-2.18) higher risk of developing OA 
compared to normal weight people. Ex-smokers and current smokers had 10-15% 
higher risk of developing OA compared to non-smokers. The odd ratio of having OA 
was 1.15 (95% CI 1.14-1.17) among ex-smokers compared to non-smokers. Details of 




Table 4.3-1 Characteristics of incident OA patients and controls from 1997- 2017 at 
index date 












Age (years)     
<40 years 12701(6.07) 13501(5.71) NA  NA  
40-49 years 30813(14.24) 31673(13.86) NA  NA  
50-59 years 60300(27.12) 59606(26.81) NA  NA  
60-69 years 60462(27.19) 59924(26.95) NA  NA  
70-79 years 40891(18.39) 40418(18.18) NA  NA  
80-89 years 15932(7.16) 15815(7.11) NA  NA  
>90 years 1191(0.53) 1353(0.60) NA  NA  
Gender     
Men 94067(42.31) 94067(42.31) NA  NA  
Women 128223(57.69) 128223(57.69) NA  NA  
BMI (kg/m2)     
<18.5 
(Underweight) 
4866(1.39) 3091(2.19) 0.85 (0.82-0.90)* 0.86 (0.82-0.89)* 
18.5- 24.9 
(Normal) 
86872(28.69) 63674(30.09) Reference  Reference  
25.0-29.9 
(Overweight) 
83188(37.29) 82870(37.42) 1.38 (1.36-1.40)* 1.38 (1.36 -1.40)* 




    
Never  41534(19.90) 44328(18.68) Reference  Reference  
Ex-drinker 5425(2.75) 6099(2.42) 1.04 (1.00-1.08) 1.05 (1.01-1.09)* 
Current 1-9 80506(34.96) 77699(36.22) 0.89 (0.88-0.91)* 0.90 (0.88-0.91)* 
Current >=10 43282(19.45) 43233(19.47) 0.92 (0.91-0.95)* 0.93 (0.92-0.95)* 
Current Unknown 51560(22.95) 51004(23.20) 0.92 (0.91-0.94)* 0.92 (0.91-0.94)* 
Smoking Status     
Never smoked 124190(55.87) 117839(53.01) Reference  Reference  
Ex-smoker 40366(18.16) 41812(18.81) 1.15 (1.14-1.17)* 1.15 (1.14-1.17)* 
Current smoker 57723(15.97) 62679(28.18) 1.10 (1.08-1.12)* 1.10 (1.08-1.12)* 
 
Mean age (SD) 61.14(13.03) 60.98(13.15)   
Mean BMI (SD) 28.28(5.62) 26.62(4.98)   
#Adjusted by index date and age; *P value < 0.05; NA- not applicable; BMI- body mass index 
Mean age (Overall: 60.96 years, SD 13.24 years; Men-60.71 sd-12.78; Women-61.21years SD 13.31 ).  
 
4.3.1.2 Association of comorbidities 
 
Comorbidities diagnosed prior to the diagnosis of any OA and present before the index 
date in both case and control groups are shown in Table 4.3-2. Comorbidities 
diagnosed within 1 year, 5 years, 10 years, 15 years, and 20 years before the index 
date were analysed. Within the one-year observation period prior to the index date, the 
prevalence of two or more chronic conditions among cases was 2.69% compared to 
1.59% in the control group. This increased to 53.05% and 41.78%, respectively, for 
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diagnoses recorded during the 20 years before the index date. The longer the 
observation period, the more prevalent cases were identified. In both groups, leading 
comorbidities recorded within the 1 year before the index date were back pain (OA 
3.44%, non-OA 2.02%), hypertension (OA 2.16%, non-OA 1.77%), high cholesterol 
(OA 1.37%, non-OA 1.02%), depression (OA 1.34%, non-OA 0.82%) and hearing 
problems (OA 1.06%, non-OA 0.75%). Within the twenty years before the index date, 
leading comorbidities recorded were back pain (OA 40.12%, non-OA 29.61%), 
hypertension (OA 25.60%, non-OA 22.03%), depression (OA 18.32%, non-OA 
13.10%), high cholesterol (OA 12.67%, non-OA 10.47%) and hearing problems (OA 
9.21%, non-OA 7.46%). (Table 4.3-2) 
Table 4.3-3 provides information on the association of comorbidities with incident OA 
over different time periods (1 year to 20 years). Out of 49 comorbidities studied, within 
the 1-year time, a significant association was seen with 33, which increased to 39 
comorbidities in the 10 years period and 43 comorbidities in the 20 years period. The 
comorbidities reported within 1 year before the index date with the strongest 
associations with OA were rheumatoid arthritis (aOR: 3.69; 95% CI 2.90-4.68), 
fibromyalgia (aOR: 2.77; 95% CI 2.21-3.46), Sjogren’s syndrome (aOR: 2.60; 95% CI 
1.44-4.69), epilepsy (aOR: 1.89; 95% CI 1.40-2.54),  psychosis (aOR: 1.89; 95% CI 
1.06- 3.39), and Parkinson’s disease (aOR: 1.75; 95% CI 1.33-2.31). Whereas, within 
20 years before the index date, the strongest associations were seen with rheumatoid 
arthritis (aOR: 1.95; 95% CI 1.80-2.11), fibromyalgia (aOR: 1.89; 95% CI 1.75-2.04), 
polymyalgia (aOR: 1.74; 95% CI 1.62-1.87), back pain (aOR: 1.67; 95% CI 1.64-1.69),  
Sjogren’s syndrome (aOR 1.67; 95% CI 1.39-2.00), systemic lupus erythematous 
(SLE) (aOR: 1.54; 95% CI 1.15-2.07), ankylosing spondylitis (aOR: 1.53; 95% CI 1.44-
1.62), gout (aOR: 1.52; 95% CI 1.46-1.57) and heart failure (aOR: 1.52; 95% CI 1.43-
1.62). (Table 4.3-3) 
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The association of OA with multimorbidity before the index date is depicted in Figure 
4.3-1. One year before the index date, the adjusted odds ratio of OA among people 
with two or more chronic conditions was 1.52 (95% 1.45-1.59) compared to those who 
had less than 2 comorbidities. The odds ratio for OA in the same groups for the past 20 
years prior to the index date was 1.71 (95% CI 1.69-1.74). (Figure 4.3-1) 
Associations of comorbidities with joint specific incident OA are shown in Table 4.3-4.  
For hip joint OA, within 20 years before the index date leading comorbidities having a 
positive association with hip OA were back pain (aOR 1.66; 95% CI 1.59-1.73), 
ankylosing spondylitis (aOR 1.62; 95% CI 1.39-1.90), fibromyalgia (aOR 1.51; 95% CI 
1.17-1.92), gastro-intestinal bleeding (aOR 1.49; 95% CI 1.23-1.80), polymyalgia (aOR 
1.39; 95% CI 1.14-1.69) and depression (aOR 1.32; 95% CI 1.25-1.39).  
Leading comorbidities associated with knee OA within 20 years before the index date 
were musculoskeletal conditions such as fibromyalgia (aOR 1.75; 95% CI 1.49-2.05), 
polymyalgia (aOR 1.56; 95% CI 1.32-1.77), ankylosing spondylitis (aOR 1.55; 95% CI 
1.37-1.73), back pain (aOR 1.51; 95% CI 1.47-1.56), and gout (aOR 1.49; 95% CI 
1.39-1.61), as well as depression (aOR 1.46; 95% CI 1.43-1.49) and sleep disorder 
(aOR 1.44; 95% CI 1.26-1.53).  
For wrist and hand OA, leading associations were seen with gout (aOR 1.70; 95% CI 
1.39-2.08), back pain (aOR 1.58; 95% CI 1.49-1.69), ankylosing spondylitis (aOR 1.57; 
95% CI 1.24-1.96), benign prostate hypertrophy (aOR 1.56; 95% CI 1.29-1.89), 
hypertension (aOR 1.50; 95% CI 1.22-1.86), depression (aOR 1.48; 95% CI 1.34-1.57)  
and migraine (aOR 1.47; 95% CI 1.30-1.67).  
Comorbidities associated with ankle/foot OA within 20 years before the index date 
were gout (aOR 2.56; 95% CI 2.01-3.14), inflammatory bowel disease (aOR 1.63; 95% 
CI 1.29-2.06), back pain (aOR 1.59; 95% CI 1.45-1.23), gastritis (aOR 1.45; 95% CI 
1.18-1.78), gall bladder stone (aOR 1.45; 95% CI 1.14-1.83), hearing problems (aOR 
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1.41; 95% CI 1.23-1.67) and benign prostate hypertrophy (aOR 1.40; 95% CI 1.10-
1.22). 
Details of associations with comorbidities at each 5 years observation period interval 
are provided in Appendix Table 6 (page 311). 
Figure 4.3-1. Association with two or more comorbidities before the index date 
 
 

























               Table 4.3-2. Comorbidities in the 1 and 20 years prior to the diagnosis of OA at any joint 
  Within 1 year  Within 20 years  
 Controls OA cases Controls OA cases 
  n % n % n % n % 
Musculoskeletal         
Ankylosing spondylitis 132 0.06 215 0.09 2158 1.03 3258 1.55 
Back pain 4452 2.02 7632 3.44 61835 29.61 84092 40.12 
Gout 493 0.22 749 0.34 4829 2.31 8013 3.82 
Osteoporosis  632 0.28 1166 0.52 4896 2.34 6260 2.98 
Polymyalgia  170 0.08 323 0.14 1243 0.59 2226 1.06 
Rheumatoid arthritis 91 0.04 367 0.16 972 0.46 1956 0.93 
Sjogren’s syndrome 18 0.01 48 0.02 202 0.09 340 0.16 
Systemic lupus erythematosus 5 0.00 11 0.00 81 0.04 122 0.05 
Fibromyalgia 115 0.05 404 0.18 1073 0.51 2162 1.03 
Fatigue 218 0.09 360 0.16 1739 0.83 2453 1.17 
Respiratory         
Asthma 691 0.31 1081 0.48 12320 5.90 17029 8.12 
COPD 602 0.27 927 0.42 9296 4.45 12642 6.05 
Genito-Urinary         
Chronic kidney disease 1566 0.71 2002 0.90 7527 3.60 8965 4.27 
Benign prostatic hypertrophy^  639 0.29 989 0.45 6365 3.05 8436 4.02 
Renal stone 114 0.05 158 0.07 1567 0.75 1923 0.91 
Neuro/Psychiatric         
Stroke  1354 0.61 1773 0.80 14200 6.80 16158 7.70 
Dementia  235 0.11 355 0.16 990 0.47 1068 0.51 
Epilepsy 72 0.03 144 0.06 1125 0.54 1376 0.65 
Multiple sclerosis 22 0.01 35 0.01 433 0.20 348 0.17 
Parkinson’s disease 80 0.03 161 0.07 502 0.24 696 0.33 
Migraine 500 0.23 745 0.33 8489 4.06 11359 5.41 
Depression 1799 0.82 2978 1.34 27362 13.10 38417 18.32 
Psychosis  18 0.001 41 0.01 419 0.20 398 0.19 
Schizophrenia 51 0.02 84 0.04 1034 0.49 1073 0.51 
Cancer 874 0.39 902 0.41 7984 3.80 8972 4.28 
Circulatory          
Coronary heart disease 967 0.44 1257 0.56 14262 6.83 18302 8.73 
Arterial/Venous 116 0.05 176 0.08 1062 0.51 1429 0.68 
Heart failure 289 0.13 444 0.20 1847 0.88 3113 1.48 
Hypertension 3906 1.77 4805 2.16 46012 22.03 53659 25.60 
Peripheral vascular disease 413 0.18 753 0.34 3906 1.87 5539 2.64 
Metabolic         
High cholesterol 2239 1.02 3053 1.37 21865 10.47 26558 12.67 
Diabetes mellitus  1397 0.63 1948 0.88 12656 6.06 16147 7.70 
Hyperthyroid  137 0.06 142 0.06 1843 0.88 2047 0.97 
Hypothyroidism  895 0.40 1203 0.54 9793 4.69 12276 5.85 
Digestive         
Gastritis  610 0.28 997 0.45 7551 3.61 10527 5.02 
Gastrointestinal bleed 155 0.07 270 0.12 1570 0.75 2253 1.07 
Gall stones 533 0.24 660 0.30 6461 3.09 9189 4.38 
Inflammatory bowel disease 578 0.26 805 0.36 6409 3.06 8704 4.15 
Liver disease 73 0.03 135 0.06 689 0.32 1029 0.49 
Irritable bowel syndrome 986 0.44 1421 0.63 10015 4.79 14335 6.83 
Others          
Hearing  1666 0.75 2357 1.06 15587 7.46 19315 9.21 
Vision problem 130 0.06 136 0.06 1136 0.54 1313 0.62 
Psoriasis  277 0.12 439 0.19 3655 1.75 4602 2.19 
Scleroderma 2  12  54 0.02 55 0.02 
Sleep disorder 481 0.22 724 0.32 3820 1.82 5148 2.45 
Tuberculosis 16 0.01 32 0.01 342 0.16 417 0.19 
Anaemia 588 0.26 920 0.41 5406 2.59 6732 3.21 
Comorbidities (count)         
No comorbidity 195859 88.10 184311 82.91 77845 35.01 59752 26.88 
Single comorbidity 22891 10.29 31971 14.38 51546 23.18 44541 20.03 
Any two comorbidities 3058 1.37 5042 2.26 38897 17.49 41327 18.59 
Any three comorbidities 415 0.19 787 0.35 25282 11.37 31429 14.14 
Four or more  67 0.03 179 0.08 28720 12.92 45241 20.35 
COPD- Chronic Obstructive Pulmonary Disease;  ^only for men Expanded version of this table is available at Appendix Table 5 (page 304). 
120 
 
 Table 4.3-3. Association between any OA and comorbidities in different time periods prior to the index date 
 20 years  10 years 5 years  1 year  
 Adjusted OR# Adjusted OR# Adjusted OR# Adjusted OR# 
>= 2 comorbidities  1.71 (1.69-1.74)* 1.58 (1.56-1.60)* 1.53 (1.49-1.55)* 1.52(1.45-1.59)* 
Musculoskeletal     
Ankylosing spondylitis 1.53 (1.44-1.62)* 1.63 (1.52-1.75)* 1.63 (1.47-1.79)* 1.49 (1.19-1.86)* 
Back pain 1.67 (1.64-1.69)* 1.51 (1.48-1.53)* 1.45 (1.43-1.48)* 1.60 (1.54-1.69)* 
Gout 1.52 (1.46-1.57)* 1.52 (1.45-1.59)* 1.49 (1.41-1.58)* 1.26 (1.11-1.42)* 
Osteoporosis  1.41 (1.35-1.47)* 1.42 (1.36-1.49)* 1.49 (1.42-1.58)* 1.74 (1.57-1.93)* 
Polymyalgia  1.74 (1.62-1.87)* 1.86 (1.72-2.01)* 1.86 (1.69-2.05)* 1.71 (1.41-2.08)* 
Rheumatoid arthritis 1.95 (1.80-2.11)* 2.17 (1.98-2.38)* 2.50 (2.21-2.82)* 3.69 (2.90-4.68)* 
Sjogren’s syndrome 1.67 (1.39-2.00)* 1.94 (1.56-2.40)* 2.47 (1.85-3.30)* 2.60 (1.44-4.69) 
Systemic lupus erythematosus 1.54 (1.15-2.07) 1.59 (1.09-2.29) 1.72 (1.05-2.82) 2.31 (0.76-7.05) 
Fibromyalgia 1.89 (1.75-2.04)* 2.07 (1.89-2.25)* 2.19 (1.96-2.45)* 2.77 (2.21-3.46)* 
Fatigue 1.42 (1.32-1.51)* 1.46 (1.36-1.57)* 1.48 (1.36-1.62)* 1.56 (1.30-1.86)* 
Respiratory     
Asthma 1.33 (1.30-1.37)* 1.35 (1.31-1.39)* 1.37 (1.31-1.43)* 1.36 (1.23-1.51)* 
COPD 1.35 (1.31-1.39)* 1.36 (1.31-1.41)* 1.37 (1.30-1.43)* 1.42 (1.28-1.58)* 
Genito-Urinary     
Chronic kidney disease 1.12 (1.08-1.16)* 1.12(1.08-1.16)* 1.15 (1.10-1.19)* 1.16 (1.08-1.24)* 
Benign prostatic hypertrophy  1.38 (1.33-1.43)* 1.37 (1.32-1.43)* 1.37 (1.32-1.46)* 1.37 (1.24-1.53)* 
Renal stone 1.16 (1.09-1.25)* 1.21 (1.11-1.32)* 1.21 (1.08-1.36)* 1.31 (1.02-1.68) 
Neuro/Psychiatric     
Stroke  1.15 (1.11-1.19)* 1.15 (1.12-1.19)* 1.17 (1.13-1.22)* 1.24 (1.15-1.34)* 
Dementia  1.09 (0.99-1.19) 1.13 (1.03-1.24) 1.23 (1.11-1.36)* 1.44 (1.21-1.71)* 
Epilepsy 1.18 (1.08-1.29)* 1.24 (1.11-1.37)* 1.17 (1.03-1.35) 1.89 (1.40-2.54)* 
Multiple sclerosis 0.80 (0.69-0.93)* 0.95 (0.78-1.14) 0.95 (0.72-1.20) 1.55 (0.89-2.67) 
Parkinson’s disease 1.39 (1.23-1.57)* 1.39 (1.22-1.57)* 1.47 (1.27-1.70)* 1.75 (1.33-2.31)* 
Migraine 1.37 (1.33-1.41)* 1.42 (1.36-1.47)* 1.44 (1.37-1.53)* 1.40 (1.25-1.59)* 
Depression 1.49 (1.46-1.52)* 1.49 (1.46-1.52)* 1.49 (1.45-1.54)* 1.51 (1.42-1.61)* 
Psychosis  0.86 (0.75-1.00) 0.83 (0.69-0.98) 0.95 (0.75-1.19) 1.89 (1.06-3.39)* 
Schizophrenia 0.95 (0.87-1.04) 0.97 (0.87-1.08) 1.08 (0.92-1.26) 1.36 (0.95-1.96) 
Cancer 1.12 (1.09-1.16)* 1.12 (1.08-1.17)* 1.12 (1.08-1.18)* 0.96 (0.87-1.05) 
Circulatory      
Coronary heart disease 1.24 (1.21-1.27)* 1.22 (1.18-1.25)* 1.17 (1.12-1.21)* 1.12 (1.03-1.23) 
Arterial/Venous 1.29 (1.19-1.41)* 1.30 (1.19-1.43)* 1.35 (1.20-1.52)* 1.41 (1.10-1.81) 
Heart failure 1.52 (1.43-1.62)* 1.52 (1.43-1.63)* 1.53 (1.41-1.65)* 1.30 (1.11-1.52)* 
Hypertension 1.08 (1.06-1.10)* 1.06 (1.04-1.07)* 1.04 (1.02-1.06)* 1.03 (0.98-1.08) 
Peripheral vascular disease 1.45 (1.39-1.51)* 1.51 (1.44-1.59)* 1.54 (1.45-1.64)* 1.62 (1.43-1.84)* 
Metabolic/Endocrine     
High cholesterol 1.18 (1.16-1.20)* 1.18 (1.15-1.21)* 1.20 (1.16-1.23)* 1.20 (1.13-1.28)* 
Diabetes mellitus  1.06 (1.03-1.09)* 1.06 (1.02-1.10)* 1.06 (1.02-1.09)* 1.12 (1.04-1.20)* 
Hyperthyroid  1.09 (1.02-1.16)* 1.05 (0.97-1.14) 1.04 (0.93-1.15) 0.92 (0.71-1.17) 
Hypothyroidism  1.18 (1.15-1.22)* 1.17 (1.12-1.20)* 1.16 (1.11-1.21)* 1.19 (1.08-1.30)* 
Digestive     
Gastritis  1.42 (1.36-1.45)* 1.45 (1.39-1.50)* 1.45 (1.38-1.52)* 1.55 (1.39-1.72)* 
Gastrointestinal bleed 1.42 (1.33-1.52)* 1.44 (1.33-1.56)* 1.49 (1.34-1.64)* 1.66 (1.36-2.03)* 
Gall bladder stone 1.27 (1.22-1.31)* 1.26 (1.21-1.31)* 1.23 (1.17-1.30)* 1.05 (0.93-1.18) 
Inflammatory bowel disease 1.36 (1.32-1.41)* 1.42 (1.36-1.47)* 1.44 (1.36-1.52)* 1.33 (1.19-1.48)* 
Liver disease 1.42 (1.29-1.57)* 1.48 (1.32-1.67)* 1.45 (1.26-1.68)* 1.47 (1.09-1.99) 
Irritable bowel syndrome 1.52(1.47-1.56)* 1.55(1.49-1.60)* 1.58(1.51-1.66)* 1.59(1.23-1.95)* 
Others      
HIV infection/AIDS 2.08 (0.76-5.75) 1.49 (0.54-4.16) 3.17 (0.84-12.03) - 
Hearing  1.26 (1.23-1.29)* 1.26 (1.22-1.29)* 1.26 (1.22-1.30)* 1.30 (1.22-1.39)* 
Psoriasis  1.20 (1.14-1.25)* 1.24 (1.17-1.31)* 1.26 (1.17-1.36)* 1.32 (1.12-1.55)* 
Scleroderma 0.97 (0.65-1.44) 1.02 (0.64-1.64) 1.76 (0.94-3.30) 5.75 (1.22-22.09) 
Sleep disorder 1.35 (1.28-1.41)* 1.37 (1.30-1.44)* 1.37 (1.28-1.46)* 1.41 (1.24-1.59)* 
Tuberculosis 1.25 (1.08-1.45) 1.24 (1.04-1.50) 1.23 (0.95-1.59) 1.71 (0.91-3.18) 
Anaemia  1.25 (1.21-1.30)* 1.31(1.26-1.37)* 1.40(1.32-1.48)* 1.42(1.28-1.59)* 
Vision problem 1.11 (1.02-1.21) 1.13 (1.03-1.24) 1.17 (1.03-1.32) 0.96 (0.74-1.23) 
 *P value <0.01 adjusted for multiple testing using ‘False discovery rate’.  
 #Adjusted for age, gender, BMI, Smoking, Alcohol, multimorbidity and index year ^Only for men.  
 COPD- Chronic Obstructive Pulmonary Disease 





               Table 4.3-4. Association between joint specific OA and comorbidities diagnosed in the 20 years 
                                prior to the index date 
 Hip Knee Wrist/Hand Ankle/Foot 
 20 years 20 years 20 years 20 years 
Musculoskeletal     
Ankylosing Spondylitis 1.62(1.39-1.90)* 1.55(1.37-1.73)* 1.57(1.24-1.96)* 1.40(0.96-2.00) 
Back pain 1.66(1.59-1.73)* 1.51(1.47-1.56)* 1.58(1.49-1.69)* 1.59(1.45-1.73)* 
Gout 1.21(1.09-1.35)* 1.49(1.39-1.61)* 1.70(1.39-2.08)* 2.56(2.01-3.14)* 
Osteoporosis  1.30(1.16-1.46)* 1.25(1.13-1.34)* 1.26(1.05-1.53) 1.34(1.04-1.85) 
Polymyalgia  1.39(1.14-1.69)* 1.56(1.32-1.77)* 1.58(1.07-2.35) 1.38(0.81-2.37) 
Rheumatoid Arthritis 1.25(0.99-1.63) 1.43(1.21-1.70)* 1.57(0.99-1.99) 1.30(0.62-1.72) 
Sjogren’s syndrome 1.93(1.08-3.47) 1.47(1.04-2.09) 1.32(0.63-2.74) 1.30(0.32-5.22) 
SLE - 1.19(0.62-2.29) 0.38(0.09-1.38) - 
Fibromyalgia 1.51(1.17-1.92) 1.75(1.49-2.05)* 1.53(1.14-2.07) 1.29(0.81-2.03) 
Fatigue 1.32(1.09-1.60) 1.38(1.21-1.59)* 1.42(1.09-1.84) 1.10(0.66-1.53) 
Respiratory     
Asthma 1.19(1.11-1.28)* 1.38(1.31-1.46)* 1.31(1.18-1.47)* 1.38(1.18-1.62)* 
COPD 1.20(1.11-1.31)* 1.33(1.25-1.41)* 1.23(1.07-1.41) 1.25(1.02-1.52) 
Genito-Urinary     
CKD 1.10(0.99-1.21) 1.04(0.97-1.13) 0.92(0.77-1.10) 1.05(0.82-1.34) 
Benign prostatic 
hypertrophy^  
1.40(1.27-1.55)* 1.32(1.25-1.43)* 1.56(1.29-1.89)* 1.40(1.10-1.72)* 
Renal stone 1.05(0.87-1.28) 1.41(1.15-1.51)* 1.22(0.86-1.73) 1.60(1.07-2.39) 
Neuro/Psychiatric     
Stroke  1.09(1.00-1.16) 1.20(1.10-1.22)* 1.24(1.09-1.40)* 1.17(0.90-1.28) 
Dementia  1.11(0.86-1.44) 0.93(0.77-1.12) 0.72(0.44-1.17) 0.96(0.45-2.01) 
Epilepsy 1.27(0.99-1.61) 1.29(1.09-1.51) 1.12(0.76-1.66) 0.81(0.45-1.44) 
Multiple sclerosis 0.73(0.48-1.10) 0.96(0.70-1.29) 0.67(0.34-1.32) 0.63(0.25-1.61) 
Parkinson’s Disease 0.87(0.62-1.23) 1.20(0.96-1.52) 1.11(0.55-2.24) 1.49(0.66-3.35) 
Migraine 1.16(1.06-1.28)* 1.35(1.27-1.44)* 1.47(1.30-1.67)* 1.38(1.14-1.67)* 
Depression 1.32(1.25-1.39)* 1.46(1.43-1.49)* 1.48(1.34-1.57)* 1.40(1.27-1.60)* 
Psychosis  1.09(0.70-1.71) 1.05(0.82-1.44) 0.58(0.30-1.12)  
Schizophrenia 0.99(0.77-1.29) 1.15(0.96-1.38) 0.83(0.55-1.25) 0.56(0.38-1.13) 
Cancer 1.24(1.13-1.35)* 1.11(1.03-1.17) 0.92(0.79-1.07) 1.16(0.93-1.45) 
Circulatory      
CHD 1.18(1.10-1.26)* 1.15(1.09-1.21)* 1.02(0.90-1.16) 1.38(1.17-1.63)* 
Arterial/Venous 1.34(1.09-1.65) 1.21(1.03-1.42) 0.96(0.63-1.52) 0.84(0.47-1.51) 
Heart failure 1.38(1.16-1.63)* 1.34(1.20-1.53)* 1.17(0.89-1.83) 1.57(1.03-2.38) 
Hypertension 1.12(1.07-1.17)* 1.10(1.07-1.15)* 1.02(0.95-1.10) 1.08(0.97-1.20) 
PVD 1.37(1.21-1.55)* 1.29(1.16-1.38)* 1.50(1.22-1.86)* 1.44(1.09-1.89) 
Metabolic/Endocrine     
High Cholesterol 1.15(1.09-1.22)* 1.14(1.09-1.19)* 1.22(1.11-1.35)* 1.11(1.01-1.33) 
Diabetes Mellitus  1.06(0.98-1.13) 1.02(0.98-1.08) 0.97(0.85-1.10) 0.95(0.79-1.13) 
Hyperthyroid  1.13(0.94-1.38) 1.13(0.99-1.30) 1.05(0.79-1.39) 1.15(0.72-1.85) 
Hypothyroidism  1.23(1.13-1.34)* 1.17(1.10-1.24)* 1.21(1.07-1.38)* 1.11(0.91-1.37) 
Digestive     
Gastritis  1.22(1.11-1.34)* 1.39(1.30-1.47)* 1.26(1.09-1.45)* 1.45(1.18-1.78)* 
Gastrointestinal bleed 1.49(1.23-1.80)* 1.37(1.21-1.56)* 1.35(0.99-1.83) 1.48(0.96-2.31) 
Gall bladder stone 1.22(1.11-1.35)* 1.33(1.25-1.43)* 1.31(1.13-1.52)* 1.45(1.14-1.83)* 
IBD 1.23(1.11-1.37)* 1.35(1.26-1.44)* 1.22(1.04-1.40) 1.63(1.29-2.06)* 
Liver Disease 1.14(0.85-1.55) 1.32(1.08-1.62) 1.18(0.71-1.96) 1.51(0.74-3.06) 
Irritable bowel syndrome 1.33(1.22-1.46)* 1.38(1.29-1.48)* 1.25(1.08-1.42) 1.61(1.24-2.02)* 
Others      
HIV infection/AIDS 0.86(0.13-5.86) 2.05(0.20-20.69) - - 
Hearing  1.14(1.06-1.21)* 1.24(1.18-1.29)* 1.31(1.18-1.46)* 1.41(1.23-1.67)* 
Psoriasis  1.07(0.93-1.22) 1.13(1.04-1.25) 1.07(0.86-1.29) 1.15(1.01-1.81) 
Scleroderma 1.29(0.33-5.06) 072(0.26-1.52) -  
Sleep Disorder 1.25(1.-8-1.43) 1.44(1.26-1.53)* 1.44(1.15-1.78)* 1.48(1.09-2.02) 
Tuberculosis 0.86(0.56-1.32) 1.35(1.00-1.84) 3.44(1.23-9.58) 2.56(0.93-7.07) 
Anaemia 1.21(1.08-1.36)* 1.26(1.16-1.35)* 1.31(1.10-1.53) 1.14(0.87-1.49) 
Vision problem 1.05(0.83-1.33) 1.11(0.95-1.31) 1.27(0.85-1.90) 0.77(0.39-1.51) 
 *P value <0.05 adjusted for multiple testing using ‘False discovery rate’.  
 Adjusted for age, gender, body mass index (BMI), Smoking, Alcohol use and index year; ^for men only 
 SLE – Systemic Lupus Erythematous; COPD- Chronic Obstructive Pulmonary Disease; CHD- Coronary Heart 
Disease; PVD- Peripheral vascular disease; IBD- Inflammatory Bowel Disease 
For expanded version of this table, please refer to Appendix Table 7.(page 312)
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4.3.2 Comorbidities diagnosed after incident OA (prospective analysis) 
 
The adjusted cumulative probabilities of having multimorbidity at 5, 15 and 20 years 
following the index date were 27.3%, 68.4% and 77.4% in people with incident OA and 
19.5%, 42.9% and 70.7% in controls, respectively (Figure 4.3-2). The adjusted HR (aHR) 
for incident multimorbidity was 1.29 (95% CI 1.28-1.31) in OA cases compared with 
controls (Table 4.3-6) (log-rank test, p<0.001). The median time to develop any two 
comorbidities among patients with OA and matched controls was 7.15 years (IQR 3.60-
11.36) and 8.90 years (IQR 4.84-12.92) respectively.  
The cumulative probabilities of all comorbidities were higher in the OA group than the 
control group in each year of follow-up. (Table 4.3-5) Table 4.3-5 shows the cumulative 
probabilities of specific comorbidities in incident OA cases and controls diagnosed within 1 
year, 5 years, 10 years, 15 years, and 20 years after the index date. The cumulative risk 
of all comorbidities was higher in incident OA cases than matched controls (p<0.05).  
Figure 4.3-2 Cumulative probabilities of having additional multimorbidity after the index 
date 
 
OA: Osteoarthritis; Non-OA: Non-Osteoarthritis 
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Table 4.3-5. Cumulative probabilities (%) of incident comorbidities after index date 
 OA (years) Non-OA (Years) 
 1  5  10  15 20  1 5 10 15  20  
Additional 
multimorbidity 
18.5 27.3 53.00 68.37 77.40 10.3 19.5 42.91 59.56 70.73 
Musculoskeletal           
Ankylosing spondylitis 0.07 0.43 0.81 1.14 1.41 0.06 0.25 0.50 0.72 0.98 
Back pain 5.12 20.5 34.30 44.18 50.89 3.07 14.0 25.35 34.30 41.12 
Gout 0.36 2.12 4.42 6.73 8.63 0.25 1.27 2.67 4.24 5.91 
Osteoporosis 0.57 2.41 4.98 7.86 10.52 0.31 1.84 4.24 7.15 10.15 
Polymyalgia  0.22 0.71 1.39 2.07 2.94 0.08 0.42 0.94 1.52 2.42 
Rheumatoid arthritis 0.24 0.78 1.40 1.96 2.51 0.04 0.18 0.37 0.54 0.73 
Sjogren’s syndrome 0.02 0.09 0.16 0.26 0.26 0.01 0.04 0.09 0.12 0.23 
Systemic lupus 
erythematosus 
0.01 0.03 0.06 0.08 0.10 0.00 0.01 0.03 0.04 0.05 
Fibromyalgia 0.20 0.74 1.24 1.66 2.03 0.04 0.20 0.38 0.53 0.69 
Fatigue 0.15 0.78 1.53 2.27 3.00 0.10 0.53 1.97 1.57 2.08 
Respiratory           
Asthma 0.41 1.89 3.37 4.61 5.94 0.33 1.45 2.53 3.43 4.29 
COPD 0.42 1.99 4.05 6.16 8.64 0.31 1.52 3.33 5.34 7.07 
Genito-Urinary           
Chronic kidney disease 1.08 6.33 14.87 20.27 24.43 0.83 5.31 12.80 17.89 22.40 
Benign prostatic 
hypertrophy^  
0.45 2.09 3.92 5.56 7.18 0.30 1.59 3.12 4.54 5.75 
Renal stone 0.07 0.36 0.76 1.12 1.59 0.06 0.28 0.59 0.96 1.34 
Neuro/Psychiatric           
Stroke  0.81 4.05 8.29 12.75 16.98 0.65 3.25 6.92 10.79 14.93 
Dementia  0.23 1.50 3.94 7.30 11.00 0.12 0.98 2.85 5.71 9.22 
Epilepsy 0.05 0.25 0.50 0.75 1.17 0.04 0.18 0.38 0.57 0.70 
Multiple sclerosis 0.01 0.05 0.10 0.12 0.16 0.01 0.05 0.08 0.11 0.12 
Parkinson’s disease 0.08 0.39 0.81 1.19 1.58 0.04 0.24 0.55 0.94 1.50 
Migraine 0.32 1.36 2.37 3.19 4.11 0.22 1.00 1.78 2.38 2.85 
Depression 1.67 6.95 11.70 15.73 19.43 0.99 4.29 7.64 10.50 13.33 
Psychosis  0.01 0.09 0.18 0.28 0.38 0.02 0.09 0.17 0.26 0.35 
Schizophrenia 0.04 0.19 0.36 0.51 0.66 0.03 0.16 0.30 0.43 0.53 
Cancer 0.82 4.37 9.54 14.81 20.07 0.45 2.73 6.37 10.48 14.90 
Circulatory            
Coronary heart disease 0.69 3.23 6.12 8.70 11.29 0.47 2.37 4.52 6.68 8.48 
Arterial/Venous 0.10 0.54 1.15 1.89 2.55 0.06 0.34 0.84 1.38 1.95 
Heart failure 0.30 1.47 2.89 4.43 5.92 0.12 0.73 1.64 2.73 3.91 
Hypertension 2.83 11.8 21.01 27.99 33.75 2.17 10.2 18.90 25.59 31.54 
PVD 0.34 1.47 2.88 4.26 5.52 0.19 0.98 2.00 3.07 3.91 
Metabolic/Endocrine           
High cholesterol 1.52 7.00 12.59 16.95 19.36 1.17 5.76 10.82 14.71 17.77 
Diabetes Mellitus  1.03 5.28 11.18 17.30 23.19 0.77 3.94 8.43 13.58 18.98 
Hyperthyroid  0.09 0.37 0.71 1.00 1.29 0.07 0.31 0.58 0.84 1.10 
Hypothyroidism  0.54 2.41 4.46 6.26 7.45 0.41 2.02 3.92 5.53 6.79 
Digestive           
Gastritis  0.53 2.45 4.77 7.01 9.23 0.27 1.41 3.00 4.60 6.24 
Gastrointestinal bleed 0.13 0.70 1.42 2.09 2.65 0.07 0.40 0.83 1.35 1.94 
Gall bladder stone 0.36 1.96 3.91 5.96 7.66 0.27 1.33 2.72 4.10 5.49 
Inflammatory bowel 
disease 
0.41 1.97 3.87 5.44 6.85 0.27 1.31 2.58 3.84 4.60 
Liver disease 0.06 0.31 0.64 1.05 1.40 0.03 0.17 0.39 0.57 0.79 
Irritable bowel syndrome 0.90 2.00 3.48 4.63 5.66 0.40 1.33 2.31 3.13 3.85 
Others            
HIV infection/AIDS 0.00 0.00 0.000
1 
0.0001 0.0001 0.00 0.00 0.00 0.00 0.00 
Hearing  1.06 5.73 11.74 17.82 24.18 0.89 4.74 10.17 16.06 21.59 
Psoriasis  0.18 0.70 1..28 1.81 2.28 0.12 0.57 1.05 1.47 1.77 
Scleroderma 0.01 0.02 0.04 0.06 0.11 0.00 0.02 0.03 0.05 0.06 
Sleep Disorder 0.36 1.59 3.06 4.38 5.58 0.24 1.11 2.04 2.95 3.78 
Tuberculosis 0.02 0.06 0.12 0.17 0.25 0.01 0.05 0.09 0.11 0.14 
Anaemia 0.57 2.70 5.45 8.22 11.04 0.29 1.56 3.53 5.65 7.53 
Vision problem 0.07 0.37 0.79 1.15 1.57 0.05 0.28 0.68 1.11 1.53 
Cataract 1.45 4.74 9.87 15.30 20.45 1.20 4.18 9.10 14.35 19.20 
COPD- Chronic Obstructive Pulmonary Disease; ^ only for men; PVD -Peripheral vascular diseases 
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4.3.2.1 Relative risk of developing incident comorbidities  
 
Except for HIV/AIDS, psychosis, multiple sclerosis, tuberculosis, scleroderma, vision 
problem, schizophrenia, hypertension, and renal stones, the risks of developing each of 
the other comorbidities were significantly higher in people with OA. (Table 4.3-6) Patients 
with OA were over three times more likely to develop rheumatoid arthritis (aHR 3.56; 95% 
CI 3.26-3.89) and 2.6 times more likely to develop fibromyalgia (aHR 2.64; 95% CI 2.41-
2.89) than matched controls. Besides musculoskeletal conditions people with OA had 
significantly higher risk compared to matched controls of developing heart failure (aHR 
1.63; 95% CI 1.56-1.71), dementia (aHR 1.62; 95% CI 1.56-1.68), liver diseases (aHR 
1.51; 95% CI 1.37-1.67),  irritable bowel syndrome (IBS) (aHR 1.51; 95% CI 1.45-1.58), 
gastro-intestinal bleeding (aHR 1.49; 95% CI 1.39-1.59), cancer (aHR 1.49; 95% CI 1.46-
1.53), Parkinson’s disease (aHR 1.46; 95% CI 1.34-1.59), gastritis (aHR 1.45; 95% CI 
1.40-1.51), depression (aHR 1.43; 95% CI 1.39-1.47), anaemia (aHR 1.42; 95% CI 1.37-


















Table 4.3-6. Hazard ratio and 95% confidence interval for each comorbidity comparing 
incident OA cases and controls (Time varying covariate cox regression) 










Additional multimorbidity 77695(6.76) 74111(5.12) 1.37(1.36-1.39) 1.29(1.28-1.30)* 
Musculoskeletal     
Ankylosing spondylitis 218496 (0.8) 217711 (0.48) 1.63(1.49-1.77) 1.44(1.32-1.58)* 
Back pain 117392 (42.82) 144323 (28.99) 1.45(1.43-1.47) 1.38(1.36-1.41)* 
Gout 213278 (4.46) 214843 (2.77) 1.63(1.57-1.69) 1.41(1.35-1.46)* 
Osteoporosis  215723 (5.21) 215211 (4.47) 1.19(1.15-1.23) 1.28(1.24-1.32)* 
Polymyalgia  219904 (1.43) 218863 (0.9) 1.49(1.40-1.59) 1.48(1.39-1.58)* 
Rheumatoid arthritis 219874 (1.42) 219077 (0.36) 3.82(3.50-4.17) 3.56(3.26-3.89)* 
Sjogren’s disease 221805 (0.16) 219902 (0.08) 2.01(1.64-2.46) 1.87(1.52-2.29)* 
Systemic lupus erythematous 222027 (0.06) 220031 (0.02) 2.14(1.52-3.01) 1.90(1.34-2.69)* 
Fibromyalgia 219834 (1.28) 218978 (0.37) 3.32(3.04-3.63) 2.64(2.41-2.89)* 
Fatigue 219556 (1.54) 218276 (1.06) 1.45(1.36-1.54) 1.30(1.22-1.38)* 
Respiratory     
Asthma 197561 (3.5) 201834 (2.53) 1.35(1.29-1.40) 1.20(1.15-1.25)* 
COPD 207583 (4.13) 209489 (3.42) 1.22(1.17-1.26) 1.18(1.14-1.22)* 
Genito-Urinary     
Chronic Kidney Disease 212998 (1.46) 212652 (1.26) 1.17(1.15-1.19) 1.06(1.04-1.08)* 
Benign prostatic 
hypertrophy^  213434 (4.01) 213577 (3.13) 
1.27(1.22-1.32) 1.27(1.22-1.32)* 
Renal stone 219574 (0.74) 217980 (0.6) 1.25(1.15-1.36) 1.10(1.01-1.19) 
Neuro/Psychiatric     
Stroke  204629 (8.68) 204936 (7.26) 1.21(1.18-1.24) 1.22(1.19-1.26)* 
Dementia  221101 (4.05) 219204 (3.18) 1.36(1.32-1.42) 1.62(1.56-1.68)* 
Epilepsy 219002 (0.51) 217678 (0.37) 1.39(1.25-1.54) 1.31(1.18-1.46)* 
Multiple sclerosis 221632 (0.09) 219473 (0.07) 1.18(0.93-1.49) 1.09(0.86-1.39) 
Parkinson’s Disease 221470 (0.79) 219635 (0.58) 1.41(1.29-1.53) 1.46(1.34-1.59)* 
Migraine 205856 (2.44) 208048 (1.74) 1.36(1.29-1.43) 1.26(1.20-1.33)* 
Depression 170180 (12.86) 182837 (7.92) 1.58(1.54-1.62) 1.43(1.39-1.47)* 
Psychosis  221619 (0.19) 219562 (0.17) 1.10(0.93-1.29) 0.94(0.79-1.10) 
Schizophrenia 220303 (0.36) 218301 (0.29) 1.21(1.07-1.36) 1.08(0.96-1.22) 
Cancer 212110 (9.87) 211362 (6.72) 1.50(1.47-1.54) 1.49(1.46-1.53)* 
Circulatory      
Coronary Heart Disease 201870 (6.32) 204490 (4.6) 1.35(1.31-1.39) 1.22(1.18-1.26)* 
Arterial/Venous 220674 (1.17) 219035 (0.84) 1.43(1.33-1.53) 1.39(1.30-1.49)* 
Heart failure 219010 (2.92) 218309 (1.69) 1.74(1.66-1.83) 1.63(1.56-1.71)* 
Hypertension 161900 (23.68) 169134 (20.58) 1.13(1.11-1.15) 1.01(0.99-1.03) 
Peripheral vascular disease 216126 (2.93) 215876 (2.02) 1.45(1.38-1.51) 1.36(1.30-1.43)* 
Metabolic/Endocrine     
High Cholesterol 194351 (1.34) 197519 (1.11) 1.18(1.16-1.21) 1.08(1.05-1.10)* 
Diabetes Mellitus  204495 (11.83) 206477 (9.05) 1.33(1.30-1.36) 1.08(1.06-1.11)* 
Hyperthyroid  219061 (0.7) 217505 (0.57) 1.21(1.11-1.32) 1.12(1.03-1.22)* 
Hypothyroidism  208088 (4.59) 209156 (3.9) 1.16(1.12-1.20) 1.06(1.02-1.09)* 
Digestive     
Gastritis  207695 (4.94) 209676 (3.05) 1.62(1.57-1.68) 1.45(1.40-1.51)* 
Gastrointestinal bleed 219414 (1.4) 218162 (0.85) 1.65(1.54-1.76) 1.49(1.39-1.59)* 
Gall bladder stone 209651 (4.0) 211412 (2.76) 1.45(1.40-1.51) 1.23(1.18-1.28)* 
Inflammatory bowel Disease 211501 (3.89) 212175 (2.59) 1.49(1.45-1.55) 1.31(1.26-1.37)* 
Liver Disease 220977 (0.65) 219294 (0.38) 1.74(1.58-1.92) 1.51(1.37-1.67)* 
Irritable bowel syndrome  222101 (3.49) 222145 (2.45) 1.50(1.44-1.56) 1.51(1.45-1.58)* 
Others      
HIV infection/AIDS 222161 (0.001) 220123 (0.001) 3.79(1.23-11.65) 2.98(0.95-9.37) 
Hearing  200102 (12.48) 202329 (10.92) 1.16(1.13-1.19) 1.14(1.11-1.16)* 
Psoriasis  215401 (1.3) 214766 (1.03) 1.23(1.15-1.31) 1.14(1.06-1.21)* 
Scleroderma 222097 (0.03) 220060 (0.02) 1.50(1.05-21.3) 1.33(0.93-1.92) 
Sleep Disorder 216765 (3.11) 216231 (2.06) 1.49(1.43-1.56) 1.33(1.27-1.39)* 
Tuberculosis 220697 (0.1) 218804 (0.08) 1.45(1.16-1.79) 1.36(1.09-1.69) 
Anaemia 214130 (5.62) 213681 (3.62) 1.57(1.52-1.62) 1.42(1.37-1.47)* 
Vision problem 220721 (7.62) 218929 (6.89) 1.12(1.03-1.21) 1.09(1.00-1.18) 
Cataract  222200 (10.35) 222215 (9.63) 1.09(1.07-1.12) 1.13(1.10-1.16)* 
Adjusted for age, sex, BMI, alcohol, smoking status, multimorbidity count and index date; p-y person years.  




Figure 4.3-3. Comparison of Odds Ratio and Hazard Ratio for comorbidities in OA for 20 
years observation period 
 
COPD- Chronic obstructive pulmonary diseases; *p-value <0.05; ^Only for men 
Figure 4.3-3 depicts the comparison of adjusted ORs and HRs for comorbidities in OA. It 
shows that people who had musculoskeletal or other pain-related conditions before 
diagnosis of OA/index date are more likely to develop OA, and OA people are also more 
likely to develop other pain-related conditions after the diagnosis. Also, the HR of 
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diabetes, chronic kidney disease, schizophrenia, respiratory diseases, stroke, coronary 
heart disease, cancer, gastritis, dementia, gastro-intestinal bleeding, depression, sleep 
disorders and IBD were higher than the respective ORs. (Figure 4.3-3) 
Table 4.3-7. Adjusted hazard ratio and 95% confidence interval for each comorbidity 
comparing incident OA cases (joint wise) 












>=2 comorbidities 1.16(1.11-1.21)* 1.24(1.20-1.28)* 1.46(1.36-1.56)* 1.17(1.07-1.29)* 
Musculoskeletal     
Ankylosing Spondylitis 1.92(1.47-2.51)* 1.59(1.31-1.93)* 1.82(1.29-2.56)* 1.72(0.98-2.99) 
Back pain 1.36(1.29-1.43)* 1.41(1.36-1.46)* 1.30(1.21-1.39)* 1.38(1.24-1.53)* 
Gout 1.35(1.21-1.51)* 1.42(1.32-1.53)* 1.59(1.34-1.89)* 1.71(1.37-2.13)* 
Osteoporosis  1.28(1.17-1.40)* 1.37(1.28-1.46)* 1.45(1.27-1.66)* 1.22(0.98-1.52) 
Polymyalgia  1.42(1.18-1.69)* 1.38(1.20-1.58)* 1.67(1.27-2.20)* 1.43(0.90-2.27) 
Rheumatoid arthritis 3.20(2.40-4.27)* 2.64(2.20-3.17)* 2.27(1.76-2.91)* 2.22(1.28-3.87)* 
Sjogren’s Disease 0.95(0.49-1.83) 1.61(0.99-2.58) 1.72(0.86-3.45) 1.72(0.34-8.63) 
Systemic lupus erythematosus 1.38(0.58-3.31) 1.60(0.78-3.27) 1.39(0.38-5.04) - 
Fibromyalgia 2.32(1.69-3.19)* 2.32(1.88-2.86)* 1.68(1.24-2.28)* 1.68(0.93-3.05) 
Fatigue 1.42(1.18-1.72)* 1.32(1.15-1.50)* 1.17(0.92-1.50) 1.10(0.74-1.64) 
Respiratory     
Asthma 1.05(0.91-1.20) 1.16(1.07-1.28)* 1.25(1.05-1.49) 1.30(0.99-1.71) 
COPD 1.24(1.12-1.38)* 1.15(1.07-1.24)* 1.13(0.95-1.35) 0.99(0.77-1.25) 
Genito-Urinary     
Chronic Kidney Disease 1.14(1.08-1.20)* 1.12(1.07-1.17)* 1.25(1.13-1.38)* 1.23(1.07-1.41)* 
Benign prostatic hypertrophy^  1.27(1.14-1.42)* 1.42(1.32-1.53)* 1.22(1.01-1.47) 1.30(1.04-1.62) 
Renal stone 1.29(1.01-1.65) 1.30(1.10-1.54) 0.99(0.69-1.41) 1.29(0.73-2.31) 
Neuro/Psychiatric     
Stroke  1.21(1.13-1.31)* 1.24(1.18-1.31)* 1.15(1.02-1.30) 1.23(1.04-1.45) 
Dementia  1.66(1.51-1.84)* 1.72(1.60-1.85)* 1.89(1.57-2.28)* 1.95(1.49-2.55)* 
Epilepsy 1.58(1.17-2.12) 1.41(1.13-1.74) 1.34(0.81-2.19) 1.07(0.57-2.01) 
Multiple sclerosis 2.18(1.08-4.36) 1.05(0.61-1.80) 0.82(0.25-2.74) 1.33(0.38-4.69) 
Parkinson’s Disease 1.68(1.34-2.12)* 1.69(1.43-1.99)* 1.25(0.81-1.94) 1.83(1.04-3.20) 
Migraine 1.06(0.89-1.25) 1.23(1.09-1.37)* 1.27(2.05-2.54) 1.25(0.93-1.69) 
Depression 1.43(1.33-1.54)* 1.44(1.36-1.51)* 1.36(1.22-1.51)* 1.57(1.34-1.85)* 
Psychosis  0.94(0.57-1.55) 0.99(0.68-1.43) 1.23(0.53-2.83) 0.78(0.25-2.44) 
Schizophrenia 1.26(0.87-1.84) 0.96(0.74-1.24) 0.77(0.42-1.42) 0.91(0.42-1.97) 
Cancer 1.60(1.49-1.72)* 1.59(1.51-1.67)* 1.46(1.30-1.63)* 1.65(1.40-1.94)* 
Circulatory      
Coronary Heart Disease 1.29(1.17-1.41)* 1.30(1.22-1.39)* 1.32(1.14-1.53)* 1.09(0.89-1.34) 
Arterial/Venous 1.71(1.42-2.07)* 1.54(1.33-1.77)* 0.93(0.64-1.35) 1.64(1.01-2.67) 
Heart failure 1.64(1.45-1.86)* 1.82(1.66-2.00)* 1.58(1.24-1.99)* 1.36(0.97-1.90) 
Hypertension 1.05(0.99-1.11) 1.04(1.01-1.08) 1.08(0.99-1.17) 1.01(0.91-1.13) 
Peripheral vascular disease 1.52(1.34-1.73)* 1.41(1.29-1.55)* 1.46(1.19-1.79)* 1.42(1.05-1.93) 
Metabolic/Endocrine     
High Cholesterol 0.97(0.91-1.04) 1.08(1.03-1.12)* 1.09(0.99-1.19) 1.16(1.01-1.33) 
Diabetes Mellitus  1.07(1.00-1.15) 1.19(1.14-1.25)* 1.24(1.11-1.38)* 1.12(0.97-1.30) 
Hyperthyroid  1.02(0.79-1.34) 1.04(0.86-1.27) 1.52(1.04-2.22) 1.07(0.62-1.86) 
Hypothyroidism  1.02(0.92-1.14) 0.96(0.89-1.04) 1.16(0.99-1.34) 1.14(0.91-1.42) 
Digestive     
Gastritis  1.57(1.41-1.75)* 1.51(1.40-1.63)* 1.31(1.12-1.53)* 1.39(1.11-1.74)* 
Gastrointestinal bleed 1.62(1.34-1.96)* 1.97(1.71-2.26)* 1.28(0.94-1.74) 1.52(1.00-2.30) 
Gall bladder stone 1.33(1.19-1.50)* 1.31(1.20-1.42)* 1.45(1.23-1.70)* 1.13(0.88-1.46) 
Inflammatory bowel disease 1.41(1.25-1.59)* 1.41(1.29-1.53)* 1.33(1.12-1.58)* 1.62(1.26-2.08)* 
Liver Disease 1.48(1.09-2.02) 1.64(1.33-2.00)* 1.38(0.85-2.21) 1.49(0.82-2.72) 
Others      
Hearing  1.17(1.10-1.25)* 1.19(1.15-1.25)* 1.23(1.11-1.35)* 1.37(1.19-1.57)* 
Psoriasis  1.09(0.89-1.33) 1.05(0.91-1.20) 1.12(0.85-1.47) 0.97(0.64-1.48) 
Scleroderma 1.23(0.47-3.24) 1.31(0.54-3.22) 0.96(0.24-3.82) - 
Sleep Disorder 1.35(1.19-1.54)* 1.39(1.27-1.52)* 1.66(1.35-2.03)* 1.39(1.05-1.86) 
Tuberculosis 1.58(0.68-3.66) 1.36(0.85-2.19) 2.55(0.99-6.54) 0.87(0.24-3.12) 
Anaemia 1.74(1.59-1.92)* 1.61(1.51-1.72)* 1.33(1.14-1.55)* 1.55(1.25-1.92)* 
Vision problem 1.11(0.87-1.40) 1.09(0.93-1.29) 1.39(0.93-2.09) 1.37(0.76-2.48) 
Adjusted for age, sex, BMI, alcohol use, smoking status, and index date; p-y person years; *P-value <0.05 
‘False discovery rate’ (FDR) adjusted; COPD- Chronic Obstructive Pulmonary Disease 
 
 
The risks of developing comorbidities following a diagnosis of joint specific OA are given 
in Table 4.3-7. The risks of  additional multimorbidity were higher for people with 
wrist/hand OA (aHR 1.46; 95% CI 1.36-1.56), knee OA (aHR 1.24; 95% CI 1.20-1.28), 
ankle/foot OA (aHR 1.17; 95% CI 1.07-1.29) and hip OA (aHR 1.16; 95% CI 1.11-1.21).  
People with hip OA had higher risk of being subsequently diagnosed with rheumatoid 
arthritis (aHR 3.20; 95% CI 2.40-4.27), fibromyalgia (aHR 2.32; 95% CI 1.69-3.19), 
ankylosing spondylitis (aHR 1.92; 95% CI 1.47-2.51), anaemia (aHR 1.74; 95% CI 1.59-
1.92), arterial/venous diseases (aHR 1.71; 95% CI 1.42-2.07), Parkinson’s disease (aHR 
1.68; 95% CI 1.34-2.12)  and dementia (aHR 1.66; 95% CI 1.51-1.84). 
Whereas, among people with knee OA the leading comorbidities diagnosed prospectively 
were rheumatoid arthritis (aHR 2.64; 95% CI 2.20-3.17), fibromyalgia (aHR 2.32; 95% CI 
1.88-2.86), gastro-intestinal bleeding (aHR 1.97; 95% CI 1.71-2.26), heart failure (aHR 
1.82; 95% CI 1.66-2.00), dementia (aHR 1.72; 95% CI 1.60-1.85) and Parkinson’s 
disease (aHR 1.69; 95% CI 1.43-1.99). 
After incident wrist and hand OA, the risks of being diagnosed with comorbidities were, 
rheumatoid arthritis (aHR 2.27; 95% CI 1.76-2.91) , dementia (aHR 1.89; 95% CI 1.57-
2.28), ankylosing spondylitis (aHR 1.82; 95% CI 1.29-2.56), fibromyalgia (aHR 1.68; 95% 
CI 1.24-2.28), polymyalgia rheumatica (aHR 1.67; 95% CI 1.27-2.20), sleep disorders 
(aHR 1.66; 95% CI 1.35-2.03), gout (aHR 1.59; 95% CI 1.34-1.89) and heart failure (aHR 
1.58; 95% CI 1.24-1.99).   
In people with ankle/foot OA, prospectively there was an increased risk of diagnosis of 
rheumatoid arthritis (aHR 2.22; 95% CI 1.28-3.82), dementia (aHR 1.95; 95% CI 1.49-
2.55), gout (aHR 1.71; 95% CI 1.37-2.13), cancer (aHR 1.65; 95% CI 1.40-1.94), 
inflammatory bowel disease (aHR 1.62; 95% CI 1.26-2.08) and depression (aHR 1.57; 




4.3.3 Sensitivity analysis   
From the eligible individuals, cases and matched controls were  selected having no 
comorbidities diagnosed prior to or on the index date for the prospective analysis. Of 
221,807 incident OA cases 22,333 (10.1%) were without any of the comorbidities of 
interest on the index date. An equal number of controls without comorbidities was 
selected matched by age (+2 years), sex and practice area. The mean age was 56.7 
years (SD- 13.6) in OA cases and 56.5 years (SD- 13.6) in matched non-OA controls, 
52.4% in both groups being women. The median length of follow up after the index date 
was 8.05 years (IQR 4.15-19.96 years) and the mean length of follow up was 11.54 years 
















Table 4.3-8. Characteristics of incident OA patients and controls at the risk for 
comorbidities (without any comorbidities at the baseline) 










Age (years)     
<40 years 2484(12.09) 2577(12.57) NA  NA  
40-49 years 4017(17.99) 4101(18.36) NA  NA  
50-59 years 6594(29.53) 6496(29.09) NA  NA  
60-69 years 5477(24.52) 5490(24.58) NA  NA  
70-79 years 2949(13.20) 2885(12.92) NA  NA  
80-89 years 776(3.47) 746(3.34) NA  NA  
>90 years 36(0.16) 38(0.17) NA  NA  
Gender     
Men 10622(47.56) 10622(17.56) NA  NA  
Women 11711(52.43) 11711(52.43) NA  NA  
BMI (kg/m2)     
<18.5 279(1.25) 452(2.02) 0.85(0.74-0.97)* 0.82(0.71-0.96)* 
18.5- 24.9 6214(27.85) 8493(38.04) Reference  Reference  
25.0-29.9 8314(37.26) 8367(37.48) 1.40(1.34-1.46)* 1.38(1.32-1.44)* 
>30 7503(33.63) 5010(22.44) 2.09(2.01-2.19)* 2.09(1.99-2.20)* 
Missing  16(0.05) 28(0.10) NA  NA  
Alcohol use 
(units/week) 
    
Never  4318(19.33) 4139(18.53) Reference  Reference  
Ex-drinker 536(2.40) 465(2.08) 1.04(0.92-1.17) 1.10(0.96-1.26) 
Current 1-9 8052(36.05) 8245(36.92) 0.94(0.89-0.99)* 0.93(0.88-0.99)* 
Current >=10 4147(18.57) 4237(18.97) 0.93(0.88-0.98)* 0.93(0.87-0.98)* 
Current Unknown 5277(23.63) 5246(23.49) 0.94(0.89-0.99)* 0.96(0.91-1.02) 
Missing 3(0.01) 3(0.01) NA  NA  
Smoking Status     
Never smoked 11715(52.45) 12160(54.44) Reference  Reference  
Ex-smoker 6101(27.31) 5774(25.85) 1.12(1.07-1.16)* 1.10(1.05-1.12)* 
Current smoker 4516(20.22) 4399(19.69) 1.06(1.02-1.11)* 1.06(1.02-1.11)* 
Missing  0 1(0.003) NA  NA  
Age in years (Mean, 
SD) 
56.71(13.55) 56.53(13.58)   
BMI in Kg/M2(Mean, 
SD) 
28.44(5.68) 26.80(5.05)   
#Adjusted by age, index year and first year of registration; *P value <0.05; NA-not applicable; BMI- Body 
mass index; SD- Standard deviation 
Mean age (Men 56.67 years, sd-13.42 years; Women- 58.97, SD 13.76 years) 
 
The covariates adjusted cumulative probability of having multimorbidity was higher in 
incident OA cases compared to controls at all time-points after the index date (log-rank 
test, p<0.001). (Appendix Table 8, page 313) The cumulative probabilities of having 
multimorbidity at 5, 15 and 20 years following the index date were 0.64%, 22.14% and 
52.93% in people with incident OA and 0.25%, 15.53% and 38.00% in controls, 
respectively. (Appendix table 8 (page 313) and Appendix Figure 8 (page 315)) 
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The risk of having multimorbidity was 34% higher (aHR 1.34; 95% CI 1.28-1.41) in OA 
cases compared with controls after adjusting for other covariates such as age, BMI, 
smoking status, alcohol consumption and index date.  The risk of developing incident 
comorbidity in musculoskeletal, neurological, cardio-vascular, cancer and digestive 
systems was higher in patients with OA (Appendix Table 5, page 310). For example, 
patients with OA were five times more likely to develop fibromyalgia (aHR 5.29; 95% CI 
2.65-10.50), more than four times more likely to develop rheumatoid arthritis (aHR 4.31; 
95% CI 2.68-6.92) and three times more likely to develop liver diseases (aHR 3.36; 95% 
CI 1.89-5.97)  than matched controls. For dementia and ankylosing spondylitis, the risks 
were nearly two times higher in patients with OA compared to matched controls. Patients 
with OA were 1.5 to 2 times more likely to develop osteoporosis, benign prostatic 
hypertrophy, depression, peripheral vascular diseases, heart failure, gastrointestinal 
bleeding, sleep disorder, and anaemia compared to matched controls. Also, the risks of 
developing gastritis (aHR 1.41; 95% CI 1.15-1.74) and diabetes (aHR 1.26; 95% CI 1.11-
1.43) were significantly higher in patients with OA compared to the matched controls. 
(Appendix Table 9, page 314) 
Appendix Figure 9 (page 316) depicts the comparison of adjusted ORs and HRs for 
comorbidities in OA. It shows that people who had musculoskeletal or other pain-related 
conditions before diagnosis of OA/index date are more likely to develop OA, and OA 
people are also more likely to develop other pain-related conditions after the diagnosis. 
Appendix Figure 10 (page 317) compares the hazard ratio from the two samples.  
4.4 Discussion  
 
This study estimated the burden of comorbidities prior to the diagnosis of OA and the risk 
of developing comorbidities following the diagnosis of OA using a nationally 
representative large UK primary care database. The key findings  are: (1) people 
diagnosed with OA were significantly more likely to have multimorbidity both prior and 
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following the diagnosis of OA; (2) while musculoskeletal (MSK), gastrointestinal (GI), 
cardiovascular (CV) and psychological conditions (MH) were associated with OA in both 
temporal directions, dementia and systemic lupus erythematous (SLE) were only 
associated with OA after its diagnosis; and (3) additionally, there was a bidirectional 
association both before and after the diagnosis of OA with anaemia, inflammatory bowel 
disease (IBD), benign prostatic hypertrophy (BPH), gall bladder stones, liver diseases, 
cancer and hearing impairment. 
4.4.1 Associations in both retrospective and prospective analyses 
 
Multimorbidity associations with OA before and after the diagnosis reveal the important 
role of MSK conditions. Both multimorbidity and OA have positive relationships with 
ageing, which was accounted for in the analysis. Multiple shared risk factors such as 
obesity, physical inactivity, medication use and the possible role of inflammation in 
multimorbidity might lead to OA and vice-versa (Friedman E.M., Christ S.L., and Mroczek 
D.K., 2015; Chudasama et al., 2019). Especially in this work, the association with 
development of new multimorbidity after adjusting for comorbidity burden at the baseline 
was estimated. The adjusted HR of 1.29 indicates the higher burden of multimorbidity 
among people with OA after the diagnosis. 
Associations of OA with some of the identified MSK comorbidities in this study accord with 
previous studies, though the causes remain speculative (Reeuwijk et al., 2010). For 
example, systemic inflammatory disease, such as rheumatoid arthritis  might damage 
joints and lead to “secondary” OA, and a  lesser inflammatory component is increasingly 
recognised in OA pathogenesis (Berenbaum, 2013).  Association of OA with some of the 
musculoskeletal comorbidities are well known. For example, the association between OA 
and rheumatoid arthritis (RA) is very consistently reported (Reeuwijk et al., 2010; Ruiz-
Medrano, Espinosa-Ortega and Arce-Salinas, 2019). People presenting with RA are more 
at risk of developing OA in the future and the opposite is also reported. Although the latter 
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has not been studied in detail, Lu et al reported that the risk of RA diagnosis among 
people with OA was five times higher compared to controls (Lu et al., 2015), whereas in 
this study the risk was three fold. The exact reasons for the association are not well 
studied, but it can be hypothesized that OA triggers multiple factors for development of 
RA. For example, OA increases inflammatory chemicals such as pro-inflammatory 
cytokines, including interleukins, into the circulation which is also found in RA patients 
(Berenbaum, 2013). Also possession of HLA-DRB1 and citrulline proteins found in 
patients with OA in the presence of appropriate risk factors such as  genetics and 
environmental factors, including diet, may influence the autoimmune system to develop 
RA (Wojdasiewicz, Poniatowski and Szukiewicz, 2014). Other common risk factors for 
both OA and RA could be obesity. Studies have found that, obesity is linked with OA and 
adipokines - a type of cytokine secreted by adipose tissue which may increase the risk of 
RA (Gómez et al., 2011). In the retrospective analysis, the association of the multiple 
musculoskeletal conditions with OA was higher as the time-period before the index date 
shortens. This indicates there was possibilities of misdiagnosis or problem in differential 
diagnosis to exclude the probable diseases. Care must be taken to interpret such findings 
and more research is needed to understand the accuracy of the reporting of the MSK 
conditions in primary care. 
Similarly, the bidirectional associations with discrete chronic pain-related conditions such 
as fibromyalgia, back pain and IBS could result from shared non-restorative sleep and 
central pain sensitization, which result  in reduced pain threshold and exacerbation of 
other causes of pain (Whitehead et al., 2007; Kirkness, Yu and Asche, 2008).  This 
relationship is well researched (Kirkness, Yu and Asche, 2008; Hoogeboom, den Broeder, 
et al., 2012; Siemons et al., 2013; Zambon, Siviero, Denkinger, Limongi, Castell, van der 
Pas, Otero, Edwards, Peter, Pedersen, Sánchez-Martinez, Dennison, Gesmundo, 
Schaap, Deeg, van Schoor, Maggi and EPOSA Research Group, 2015). According to 
Kadam et al, the association of OA with pain-related conditions in the UK population are 
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nearly two times higher than the control group (Kadam, Jordan and Croft, 2004). People 
with OA are also reported to exhibit widespread hyperalgesia to mechanical pressure and 
cold (Moss, Knight and Wright, 2016). Hyperalgesia - an increased sensitivity to painful 
stimuli - is very common in widespread pain syndromes such as fibromyalgia. The 
commonality of hyperalgesia in OA and widespread pain syndromes suggests the 
possible following pathophysiology of developing painful conditions like back pain, 
fibromyalgia and ankylosing spondylitis (Staud, 2011). It is possible that OA structural 
joint changes  produce chronic stimuli to the nociceptors which decreases the pain 
threshold (peripheral sensitisation) causing hypersensitivity to pain. Furthermore, these 
lead to central nervous system (CNS) plasticity and central sensitisation through the 
stimulation of C-fibres and impairment of descending inhibitory systems (Coderre et al., 
1993; Melzack et al., 2001). Other possible reasons for the increased diagnosis of pain-
related conditions could be because of the release of NMDA (N-methyle-D-Aspartate) 
chemicals in OA which activates the COX-2 gene, substance P and nerve growth factor 
(NGF) which in turn increases the pain sensitivity. Mechanical factors introduced by 
obesity and OA pain (change in gait, joint deformities) may also contribute to the 
increased risk of back pain (Wolfe et al., 1996; W. Wang et al., 2016). OA related 
changes also can be seen in cartilages of spinal facet (apophyseal) joints, which might 
predispose to the back pain (Ashraf et al., 2014). 
The association of OA with gout was stronger before the diagnosis of OA than after, and 
this bidirectional relationship might in part be explained by  the “amplification loop” of 
cartilage damage enhancing urate crystal deposition and urate crystals causing cartilage 
damage (Ma and Leung, 2017). Even though epidemiological studies mention the 
increasing burden of co-existence, a recent systematic review has identified ‘obesity’ as 
the shared mediator for both hyperuricaemia and OA  (Ma and Leung, 2017). Another 
possible pathological explanation could be that cartilage disruption and exposure of 
cartilage fragments in OA (i.e. chondrocyte death) leads to local urate generation, which 
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might deposit on the cartilage and trigger cytokine and protease production (Hwang et al., 
2015; Charlier et al., 2016). These chemicals might produce the vicious cycle of OA 
degeneration and increased joint urate levels. Furthermore, OA cartilage  enhances the 
deposition of urate, as well as calcium, crystals in the joint due to increased promotors 
and reduced inhibitors of crystal nucleation. 
The hazard ratio for osteoporosis following diagnosis of OA to be higher than the odds 
ratio of OA following diagnosis of osteoporosis, but the evidence and explanations for an 
association between osteoporosis and OA remain controversial. Most studies have 
reported high bone density in OA (Dequeker, Aerssens and Luyten, 2003; Im and Kim, 
2014), while a few have reported the opposite (Hochberg, Lethbridge-Cejku and Tobin, 
2004). This study shows that OA increases the risk of developing osteoporosis. Possible 
reasons for this could be because of shared epidemiological risk factors or biomechanical 
factors. Geusens and Bergh have proposed the shared mechanism for OA and 
osteoporosis to be life-style factors, BMI and osteosclerosis (Geusens and Bergh, 2016). 
Immobility because of OA pain and obesity could lead to accelerated bone mass loss. 
Molecular studies have identified 12 specific proteins, of which 8 were closely related to 
the pathogenesis of osteoporosis and knee OA (Shi and Zhang, 2018). Moreover, the 
osteoporosis reported in OA varied from joint to joint, being more common in distal joints 
and spine compared to large weight-bearing joints. Use of ‘osteoporosis’ in any joint in 
this analysis, which could have overestimated the burden irrespective of the joint involved 
in OA, which warrants future research. 
Care must be taken in interpreting these associations, especially where joint pain is the 
reason for the consultations since GP diagnoses are predominantly clinical and not 
pathological. Also, although characteristics of these various MSK conditions differ there is 
still the possibility of misdiagnosis, especially for atypical cases. 
Cardiovascular diseases, such as coronary heart disease and heart failure (Rahman et 
al., 2013), stroke (Hsu et al., 2017; Swain et al., 2019), PVD (Findlay, 2007) and diabetes 
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(Louati et al., 2015) are well known to associate with OA. In this study prospective risks of 
developing diabetes, PVD and heart failure were greater in OA compared to risks of 
developing OA in people with these conditions. Firstly, OA reduces physical activity 
levels, which predisposes to hypertension and hyperlipidaemia (Hootman et al., 2003), 
and physiologically it increases the blood viscosity through endothelial damage (Koenig et 
al., 1997). The role of inflammatory substances such as CD40 and vascular cell adhesion 
molecule found in OA (Hoeven et al., 2015) increases the risk of carotid intimal thickening 
and carotid plaque (Wang et al., 2011) leading to atherosclerosis (Libby, Ridker and 
Maseri, 2002). Another possible factor could be the use of pain killers such as NSAIDs 
which also increase the risk of heart disease, hypertension and stroke (Haag, 2008). 
Insulin resistance and diabetes are part of metabolic syndrome, so the suggested 
mechanism for the association between diabetes and OA is like the association of 
metabolic syndrome and OA. There is a bidirectional association of diabetes and OA, i.e. 
the prevalence of OA in diabetes is increased (Louati et al., 2015) and so is the 
prevalence of diabetes in OA. However, the latter has been explored in more detail 
(Schett et al., 2013; Al-Jarallah et al., 2016) and the increased risk of diabetes in an OA 
population is the least examined. It is possible that OA and diabetes connect through a 
vicious cycle influencing each other’s outcome (King and Rosenthal, 2015). This indicates 
the role of risk factors such as obesity and hypercholesterolaemia in causing OA, and that 
screening for metabolic syndrome and CVD may be considered in people presenting with 
OA (NICE, 2014).   
One of the sparsely investigated comorbidities in OA is peripheral vascular diseases 
(PVD). This interesting association is harder to explain in the absence of any relevant 
mechanistic studies. Possibly, the vascular pathology such as circulating cytokines in OA 
also affects the smaller vessels mediating the PVDs (Findlay, 2007). The slowed blood 
circulation in smaller blood vessels in OA needs to be explored further in detail. However, 
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Lee et al found a significant association of PVD with use of pain killers in people with OA 
(Lee et al., 2016). 
Even though depression and OA had a significant bidirectional association, a higher risk 
of depression was seen in people following the diagnosis of OA. A similar finding was 
seen with sleep disorders. Depression and non-restorative sleep are well recognised to 
associate with chronic pain experience in OA (Stubbs et al., 2016b). Low affect and non-
restorative sleep can reduce descending pain inhibition and cause central sensitisation, 
and equally chronic pain and reduced participation can cause mood disturbance 
(Parmelee, Tighe and Dautovich, 2015). 
The risks of developing gastritis, GI bleeding, liver diseases and gallstones in OA were 
high compared to developing OA in these conditions. Gastritis, gastro-intestinal bleeding, 
liver cirrhosis and peptic ulcer are known comorbidities in OA that may result from NSAID 
usage (Zak and Pasiyeshvili, 2016). (Papatheodoridis, Sougioultzis and Archimandritis, 
2006). (Zak and Pasiyeshvili, 2016; Zak et al., 2019) However, increased recording of 
incident OA in people with these conditions could result from self-medication for OA pain 
before presenting to the general practitioner and being diagnosed with OA (i.e., 
protopathic bias). Interestingly, the risk of OA in liver cirrhosis is reported to be high but 
the reverse relationship has yet to be established (Arora et al., 2016). 
Another interesting finding was that the risk of developing cholelithiasis was higher in the 
OA compared to the control population, and this association with OA appeared 
bidirectional. It is hard to explain these associations mechanistically. Possibly, since both 
of these conditions share common risk factors, sometimes known as the four F’s (female, 
forty years of age, fatty tissue and fertile) (Schirmer, Winters and Edlich, 2005; Njeze, 
2013), the comorbidity pattern may reflect merely co-existence due to these risk factors 
rather than any linked pathogenesis such as genetic, environment and other 
comorbidities. Studies have shown an association between H. Pylori and gallstones but 
its association with OA is unclear (Popescu, Andrenscou and Babes, 2018). Also, the 
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analgesics which are commonly used in OA are not apparently linked with  gallstones 
(Sterling et al., 1995; Pazzi et al., 1998). Further research is needed to explain the 
biological link between these conditions. 
Other comorbidities with significant bi-directional associations with OA were respiratory, 
hypothyroidism and neurological conditions such as Parkinson’s disease, epilepsy, and 
migraine. Thyroid disease, epilepsy, migraine, and respiratory illness may have earlier 
age of onset than OA, which could have led to the early recording in the database prior to 
OA. Also, these comorbidities could be mediated through the systemic inflammation, 
medication use or other comorbidities in OA.  
Evidence suggests a higher prevalence of OA in asthma patients but the high prevalence 
of asthma in OA still needs to be proved (Mahmood and Malghooth, 2019). This is one of 
the least studied conditions in patients with OA. Wshah et al in their systematic review 
found that the prevalence of OA was higher in individuals with COPD (Wshah et al., 
2018). The reason for a direct association between COPD and OA is not well understood, 
but both chronic conditions share common risk factors such as obesity and physical 
activity.  
The four other conditions with bi-directional positive associations in this study were 
anaemia, BPH, cancer and hearing problems, which have all been reported before 
(Kramer et al., 2002; Zlateva et al., 2010). Release of inflammatory substances in OA has 
been  linked with sensorineural hearing loss (Takatsu et al., 2005), BPH (Chughtai et al., 
2011), cataract(Jonas et al., 2018) and cancer (Ziegler, 1998) and subclinical  systemic 
inflammation may occur for many years  before OA becomes symptomatic and clinically 
apparent. In addition, the rise in incidence of BPH in OA could result from the use of 
analgesics such as NSAIDs (Nygård et al., 2017). The incidence of these conditions in 
OA warrants further research. The association between OA and cancer is difficult to 
explain and has not been studied well. However, both OA and cancer share similar 
inflammatory mechanisms (Ziegler, 1998). Interestingly, the use of NSAIDs reduces the 
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spread of metastases in some cancer patients, which is against any potential role of pain 
medications (Wang et al., 2011; Zhao et al., 2006). Association of OA and hearing loss 
has not gained the attention of clinicians and researchers, though Kramer et al previously 
reported a significant association between these two conditions (Kramer et al., 2002). 
Cartilage damage  in the incudomalleolar joint between the malleus and incus bones and 
the incudostapedial joint between the incus and stapes bones in the ear, which impacts  
on hearing, has been reported in people with OA (Rawool and Harrington, 2007). Also the 
low-grade chronic inflammation in OA could lead to sensorineural hearing loss, just as it is 
reported to do in RA (Takatsu et al., 2005).  
4.4.2 Association in prospective analysis only 
 
Dementia was associated with OA only in the prospective analysis. This is similar with a 
recent systematic review of cross-sectional and case-control studies which reported that 
people with OA were 20% more likely to have dementia (Weber et al., 2019). Similar 
findings were reported by a longitudinal study from Taiwan (Huang et al., 2015). As 
dementia is predominantly an ageing problem, the association in the retrospective study 
may not have been significant because of the low prevalence of dementia in younger 
decades and difficulty in detecting OA symptoms and less consultations for OA in people 
with dementia. One of the possible explanations for the prospective association with 
dementia could be the role of inflammatory cytokines (IL-1), which result from joint 
inflammation and can reach the cerebral circulation causing neuro-inflammation 
(Kyrkanides et al., 2011). The association between OA and SLE is ill searched and 
difficult to explain, which needs further investigation.  
Association of comorbidities with joint specific OA are like the above-mentioned 
comorbidities. However, some of the additional findings are association of hip OA with 
chronic kidney disease and migraine, knee OA with COPD and migraine, and hand OA 
with renal stones and epilepsy, prospectively. These specific associations may be 
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mediated through the factors already discussed, but further investigation into mechanisms 
of linkage is still required.  
This study suggests that although structural changes of OA may appear relatively limited 
within the skeleton, pathologically and physiologically, its effect may be seen in almost 
every organ. Although the burden of comorbidities in RA and gout may be higher than that 
in OA, the significant associations of multiple chronic conditions with OA found in this 
study should not be neglected. A Versus Arthritis report on  multimorbidity in OA also 
highlighted the importance of understanding the presence of multiple comorbidities with 
OA for formulating a ‘patient-centred’ management plan (Loftis, Ellis and Margham, 
2014). Thus, close observation of people with OA through annual assessment in primary 
care appears warranted, as recommended by NICE (Conaghan et al., 2008). Recently, 
the European League Against Rheumatism (EULAR) and NICE, have emphasised the 
importance of diagnosis and management of specific comorbidities and understanding 
their pattern in OA when managing people with OA (Conaghan et al., 2008). 
Figure 4.4.1 depicts the possible pathogenesis of association with comorbidities in people 
with OA. As discussed above, age, obesity, pain, inflammation, and medication use are 
thought to be the drivers of incident of new comorbidities and vice versa. The strong 
association with MSK conditions and pain related diseases are largely explained through 
central pain mechanism and changes in inflammatory substances. Metabolic pathology 
related to obesity can cause many chronic conditions including CV and respiratory. 
Another aspect of OA least explored is the use of medication. Though there is no cure for 
OA, prescription of drugs such as pain killers and anti-inflammatory reduce the pain 
symptoms and slows down the disease progression bringing relief to the patient. 
However, these drugs are not immune to the side-effects. Commonly studied 
comorbidities associated with the drugs are gastrointestinal and CV. Further research is 

























?Indicates the possible association; IL- interleukins; TNF- Tumour Necrosis factor; 
NMDA- N-methyl-D-aspartate; CD40- Cluster of differentiation 40; NSAIDs- 













































































Figure 4.4-1 Schematic presentation of OA and possible associated factors with the comorbidities 
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4.4.3 Study limitations 
 
There are several caveats to this study. The possibility of misclassification of OA because 
of physician diagnosis rather than full clinical and imaging assessment has been 
emphasised already. Nevertheless, I tried to optimise identification of symptomatic OA 
cases through strict inclusion and exclusion criteria using similar methodology to that of 
previous studies (Swain et al., 2020) and there is some reassurance that the codes for hip 
OA have been shown to have good validity (Ferguson et al., 2019). Misclassification bias 
for comorbidities is also possible, though  most comorbidities in the study have previously 
been validated  (Herrett et al., 2010; Nada F. Khan, Harrison and Rose, 2010). Another 
important caveat is that risk factors such as diet and physical activity in the analysis could 
not be included, as these are not routinely recorded within CPRD. Therefore, the 
estimates from this study may not always relate to direct associations between OA and 
comorbidities, which could have been mediated through other unrecorded factors. 
Because of the indolent nature of OA, the recording of the OA in the database is possible 
to happen long after the initial symptoms and pathological changes in the body. Thus, the 
temporal association with comorbidity is difficult to assume in this study. The primary aim 
of the study was to estimate the associations and burden of comorbidities diagnosed prior 
to and after the diagnosis of OA, rather than to define risk factors. The associations could 
to some extent be due to ascertainment bias through increased numbers of hospital or 
GP visits in people with OA, especially for the stronger association with rheumatological 
conditions. Along with the possible Berkson bias, where patients assessed in hospital 
undergo more routine testing so may have occult comorbidity diagnosed more often, a 
chance of collider bias due to sampling design might exist. That means diagnosis of 
comorbidities might have been influenced by reporting of other chronic conditions, 
especially by the QOF guidelines where the quality of recording of certain conditions are 
much better than others. However, the controls were matched having a minimum 36 
months of registration and at least one consultation for any reasons. More focus was 
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given on the possible explanation of the association rather than the causes, which is 
beyond the scope of this study. The maximum follow-up in this study was for 20 years and 
the cases and controls were not matched for the length of follow-up which might have 
influenced the diagnosis of comorbidities. 
The sample size for the prospective analysis was nearly 440,000 with equal numbers of 
OA cases and matched controls and maximum follow-up for up to 20 years, making this 
the first prospective study  to provide such a clear picture of the burden of many 
comorbidities. The 49 chronic conditions studied using case-control design on the 
database that represents the general population. 
4.4.4 Conclusion  
 
In conclusion, the risk of multimorbidity is higher in people with OA. Musculoskeletal, 
gastrointestinal, CVD and psychological conditions are associated with OA both before 
and after diagnosis. Significant associations with gallstones, IBD, BPH, anaemia, hearing 
problems, liver disease and cancer highlight the discordant comorbidities in OA, which 
cannot readily be explained mechanistically. Bidirectional associations with multimorbidity 
and 40 comorbidities suggest the need to identify shared risk factor mechanisms. The 
temporal associations reported merit further investigation regarding causality and have 
important clinical implications with respect to optimal management of OA and its potential 
comorbidities. Future studies should investigate clustering of the comorbidities and 








Summary of  Chapter 4 
 
Chapter 4 explored the burden of comorbidities in people with OA compared to the 
controls (non-OA). Key findings from the chapters are: 
• The burden of comorbidities and multimorbidity (additional two chronic 
conditions) was more in people with OA compared to age and sex matched 
controls.  
• Of 49 chronic conditions examined, nearly 30 had significant association 
with OA both before and after the diagnosis of OA. 
• Musculoskeletal (MSK), gastrointestinal (GI), cardiovascular (CV) and 
psychological conditions (MH) were associated with OA  
• Interestingly, there was a significant association both before and after the 
diagnosis of OA with anaemia, inflammatory bowel disease (IBD), benign 
prostatic hypertrophy (BPH), gall bladder stones, liver diseases, cancer, 
and hearing impairment. 
 
Knowing the burden of the comorbidities in people with OA, the next research 
question to explore the pattern of co-existence of these chronic conditions in 
people with OA and their controls. Which means how the people are clustered 
or grouped based on the co-existence of the diseases. The next chapter 
(chapter 5)  investigates the research question.
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5 Chapter 5  
Clustering of comorbidities  
 
5.1 Introduction  
 
The prevalence of multimorbidity (> 2 long term conditions) is widely being reported 
worldwide (Nguyen et al., 2019). Multimorbidity affects 30% of adults (≥ 18 years) in the 
UK (Cassell A. et al., 2018). The association of graded effect of count of multimorbidity 
and health outcomes has been studied in detail (Brilleman and Salisbury, 2013). 
However, it is more important to study the types of conditions, rather than just the number 
that coexist in a single individual because of the following two reasons.  
Firstly, it is essential to understand the cluster or grouping of chronic conditions, which 
can provide clues about concordant or discordant patterns. There are different 
possibilities to explain the combination of conditions, but certain conditions often co-exist 
together. These groups of conditions can be concordant, that is, similar in their aetiology 
and/or treatments, or alternatively discordant, that is, unrelated etiologically and requiring 
different management approaches (Ricci-Cabello et al., 2015). The nature of clusters of 
conditions determines the treatment approaches, especially discordant clusters which 
increase the complexities of treatment and management (Guthrie et al., 2012). Secondly, 
understanding these patterns would also help identification of ‘at-risk’ populations for 
other conditions and the design of appropriate prevention, screening, and management 
strategies.  
Limited knowledge about the clustering of musculoskeletal conditions and its association 
with sociodemographic and lifestyle risk factors have led to more ‘disease specific’ 
management approaches rather than ‘person-centred’ individualised care (Duffield et al., 
2017). This may lead to the provision of contradictory, expensive, resource-draining and 
disjointed multiple care. Identification of the most commonly occurring clusters of 
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diseases can reduce disease burdens and health care costs, inform resource planning, 
and ultimately improve the quality of life of patients.  
Previous systematic review revealed the association of OA with multimorbidity, but also 
with specific conditions such as  CVD and depression (Swain et al., 2019). However, 
there is scant evidence on OA in terms of its multimorbidity pattern and which cluster it 
belongs to. The common clusters of conditions in people with OA are not known also, 
whether these differ from the non-OA population. Therefore, the large CPRD GOLD 
primary care database in the UK was used to explore the common clusters of conditions 
and the associated factors in the whole population, to compare findings between those 
with and those without OA. 
5.2 Methods 
 
CPRD GOLD database  was used where anonymised primary care clinical data are 
contributed by UK general practices (Herrett, Arlene M Gallagher, et al., 2015). 
5.2.1 Source population 
 
Data on a random selection of individuals were acquired from the CPRD. For this study 
two different population were chosen for: (1) studying the pattern of conditions in the 
complete CPRD population; and (2) exploring the pattern among the OA and non-OA sub-
populations. 
For the complete CPRD population patients were aged 20 years and above with valid 
registered-status in a practice with data classified by CPRD as UTS in January 2017 and 
a minimum 1 year of registration period with the database. 
For the comparison study, the OA cases and non-OA controls were selected using the 




5.2.2 Comorbidity definition and extraction 
Comorbidity was defined as the diagnosis of any of the 49 predefined chronic conditions 
(in the OA group, any additional diseases other than OA) in individuals of both groups. 
Details of the comorbidity extraction has been given in Chapter 4, section 4.2.5. 
5.2.3 Covariates  
Information on BMI, alcohol use and smoking status were used with age and gender. 
Details of the covariates are given in chapter 4 section 4.2.6. In a subgroup analysis the 
index of multiple deprivation was examined as a risk factor.  
5.2.4 Statistical analysis 
For this objective, a clustering analysis method was used. 
The clustering of the chronic diseases groups patients with similar morbidities. Various 
methods are available for doing such analyses (Saxena et al., 2017), however, few have 
methodologies to group the patients rather than variables. One  such method used in this 
study is latent class analysis (LCA) (Nylund et al., 2007, Lanza and Rhoades, 2013). I 
preferred LCA over other methods because it is data-driven and identifies distinct patterns 
(Muthen and Muthen, 2000).  In comparison to other commonly used clustering methods, 
such as hierarchical clustering (Bridges, 1966), LCA uses a probabilistic approach which 
is not sensitive to rotation of factors and does not require any subjective distance 
measures for pattern determination (Bartholomew, 2008; Collins and Lanza, 2009). Also, 
it handles categorical variables in better ways and provides greater reproducibility and 
stability of the latent class solutions (Feuillet et al., 2015).  
5.2.5 Selection of statistical methods 
Alternative approaches for clustering to select the best possible methods were tested. 
One of these was K-mode analysis. K-mode is a machine learning technique, which 
identifies patient groups with distinct profiles (Huang & Ng, 2003). It is an extension of the 
widely used K-mean method used for continuous outcomes with centroid based 
algorithms that calculate the distance between the groups using Euclidian distance or 
dissimilarity matrix (Wang Shunye, 2013). As variables used in this study are 
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dichotomous (‘yes’ or ‘no’), the distance measures used by K-means were not useful. 
Huang et al modified K-means method to K-mode for clustering of patients with 
categorical variables. K-mode determines the clusters based on the number of matching 
categories between data points, rather than the similarity index used in K-means. The 
optimal clusters were assessed using the Silhouette Coefficient (SC). The average SC is 
known as the Silhouette Index (SI) and evaluates the overall quality of separation 
between the clusters (Rousseeuw, 1987). The SC is calculated using its intra-cluster 
distance and its nearest cluster distance. The SC ranges from -1 to +1 explaining the 
least to the best classification. “diceR” package in R was used to choose the best model 
for clustering (Chiu and Talhouk, 2018). The selection of models from the three major 
indices are given in Appendix Method 2 (page 353). Appendix Table 10 (page 320), and 
Appendix Figure 11 and 12 (page 318-319), shows the clustering using machine learning 
approach (K-mode).  
5.2.6 Latent class modelling 
LCA was used to explore multimorbidity patterns from one to ten multimorbidity classes.  
It is a statistical technique for analysis of multivariate categorical data. The latent class 
model stratifies the data by observed (“manifest”) by unobserved variables (“latent”). The 
assumption is that the manifest variables are independent but conditional upon values of 
latent variables, commonly known as “local/ conditional dependence”. Latent class model 
probabilistically groups each observation into a “latent class," which in turn produces 
expectations about how that observation will respond on each manifest variable. The 
grouping is done by weighted sum of manifest variables calculated by the product of the 
frequency in a cell and the proportion of observation in cell and the probabilities of being 
in the cell conditional upon the latent variable. Observation with similar set of responses 
on manifest variables tend to cluster in same latent classes. 
One of the important tasks in LCA is to identify the best fit model and the number of latent 
classes. Established methods were followed to select the best model based on a 
combination of statistics, specifically, Akaike Information Criteria (AIC), Bayesian 
Information Criteria (BIC), sample size adjusted BIC (aBIC), log-likelihood ratio test, 
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entropy and clinical judgement (Nylund, Asparouhov and Muthén, 2007).  In theory, 
models with the lowest BIC are thought to be the best. The model selection is alternatively 
explained by calculating percentage change in log-likelihood ratio of K-class (LL2) with K-
1 class (LL1) using the formula (LL2-LL1)*100/(LL1). Additionally, the best model should 
have entropy more than 0.70 and should make more sense clinically. The latent classes 
were named after the posterior probabilities (PP) distribution of conditions to each cluster, 
ideally should be >= 60%. The group with lowest probabilities of all the conditions were 
named as the ‘relative healthy’ group. Once the best class was identified, the groups were 
attached to the original database and descriptive analysis was done for the covariates. 
Multinomial regression models to explore the risk factors using ‘relative healthy’ as the 
reference group to predict association with other latent classes by including the covariates 
in the model. The analysis was done in R software using “poLCA” package(Linzer and 
Lewis, 2011).  
5.2.7 Sensitivity analysis 
The whole dataset was divided into training and testing data, constituting randomly 
selected 80% and 20% of the study population. LCA was performed in both datasets 
separately. The agreement was measured using Janssen-Shannon index for similarity 
and the cluster types (Appendix Table 11, page 321). Appendix tables 12 and 13 (pages 
322-323) describe the sensitivity findings. The descriptive statistics of clusters from both 
training and testing data are given in Appendix tables 14 and 15 (pages 324-325).  
5.3 Results  
 
5.3.1 Total study population 
5.3.1.1 Descriptive statistics 
 
In total 1,425,823 patients had active registration with the CPRD database as of 1st Jan 
2017. Of these, nearly 50% were men and 29% were 60 years or older. The mean age of 
the total population was 54.49 years (SD 16.92). Almost 21% were obese and the mean 
BMI in the population was 26.91 Kg/m2 (SD 5.48). The prevalence of multimorbidity was 
48% and 34% had three or more chronic conditions. The mean number of morbidities was 
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2.19 and the range was 0-22.  The other sociodemographic details are given in Table 
5.3-1.  
Table 5.3-1. Characteristics of people with active registration status in CPRD (from 1st 
Jan-31st Dec 2017) 
 Variables  N= 1,425,823 
n (%) 
Multimorbidity  
(N= 682,474)  
n (%) 
Gender   Men  699553 (49.06) 299470 (43.88) 
   Women 726270 (50.94) 383004 (56.12) 
Age (as of 1st 
Jan 2017) 
(years) 
  20-35 194497 (13.64) 23182 (3.40) 
   36-50 387069 (27.15) 127831 (18.73) 
   51-65 427493 (29.98) 227428 (33.32) 
   66-80 311403 (21.84) 220597 (32.32) 
   >80 105361 (7.39) 83436 (12.23) 
Smoking   Never 
smoked 
770455 (54.04) 144152 (21.12) 
   Current 
smoker 
299849 (21.03) 365278 (53.52) 
   Ex-smoker 280807 (19.69) 170330 (24.96) 
   Missing  74712 (5.24) 2714 (0.40) 
Alcohol use   Never  223076 (15.65) 120610 (17.67) 
   Ex-drinker 26119 (1.83) 17657 (2.59) 
   Current (1-9) 418150 (29.33) 217314 (31.84) 
   Current 
(>=10) 
220244 (15.45) 120217 (17.61) 
   Current 
(Unknown) 
314538 (22.06) 167784 (24.58) 
   Missing  223696 (15.69) 38892 (5.70) 
BMI   Underweight  32193 (2.26) 11197 (1.64) 
   Normal  459535 (32.23) 214726 (31.46) 
   Overweight  418842 (29.38) 233200 (34.17) 
   Obese 295485 (20.72) 183254 (26.85) 
   Missing  219768 (15.41) 40097 (5.88) 
Age (Mean, 
SD) in years 
 54.49 (16.92)   
BMI (Mean, 
SD) 




 2.19 (2.50)   
BMI-Body Mass Index; SD- Standard deviation 
In the study population the prevalence of each chronic condition ever diagnosed is 
provided in Table 5.3-2. Overall, leading conditions were back pain (38.20%), depression 
(19.48%), hypertension (18.16%), OA (13.14%) and high cholesterol (10.82%). A similar 
pattern was seen in women whereas in men the prevalence of hypertension (17.85%) 
was higher than depression (14.07%). The prevalence of multimorbidity was higher in 
women (53%) compared to men (43%). 
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Table 5.3-2. Distribution of chronic conditions in men and women 






(N= 1425823) (%) 
Back pain 246185 35.19 298519 41.10 544704 38.20 
Depression 98423 14.07 179394 24.70 277817 19.48 
Hypertension 124883 17.85 134055 18.46 258938 18.16 
Osteoarthritis 73339 10.48 114084 15.71 187423 13.14 
High cholesterol 75664 10.82 78581 10.82 154245 10.82 
Hearing  64188 9.18 63386 8.73 127574 8.95 
Diabetes mellitus  61744 8.83 56060 7.72 117804 8.26 
Stroke  53246 7.61 57369 7.90 110615 7.76 
Asthma 41135 5.88 60506 8.33 101641 7.13 
Irritable bowel syndrome 27767 3.97 73573 10.13 101340 7.11 
Migraine 20700 2.96 64048 8.82 84748 5.94 
Chronic kidney disease 32873 4.70 46949 6.46 79822 5.60 
Benign prostatic hypertrophy 39143 5.60 0 0 39143 5.60 
Cataract  30552 4.37 44042 6.06 74594 5.23 
Hypothyroidism  12958 1.85 57305 7.89 70263 4.93 
Gastritis  33821 4.83 34402 4.74 68223 4.78 
Cancer (any) 28226 4.03 36980 5.09 65206 4.57 
Chronic heart disease 40490 5.79 23603 3.25 64093 4.50 
Gall stones 15381 2.20 44279 6.10 59660 4.18 
Inflammatory bowel disease 25582 3.66 34011 4.68 59593 4.18 
Anaemia 10713 1.53 45035 6.20 55748 3.91 
COPD 23487 3.36 26679 3.67 50166 3.52 
Gout  33164 4.74 9654 1.33 42818 3.00 
Osteoporosis  5269 0.75 35215 4.85 40484 2.84 
Psoriasis  17686 2.53 17645 2.43 35331 2.48 
Sleep Disorder 13614 1.95 15963 2.20 29577 2.07 
Peripheral vascular disease 12511 1.79 14378 1.98 26889 1.89 
Fatigue 6629 0.95 14787 2.04 21416 1.50 
Renal stone 10499 1.50 5211 0.72 15710 1.10 
Dementia  5766 0.82 9736 1.34 15502 1.09 
Hyperthyroid  2804 0.40 12095 1.67 14899 1.04 
Gastrointestinal bleed 8087 1.16 5877 0.81 13964 0.98 
Fibromyalgia 2016 0.29 10640 1.47 12656 0.89 
Ankylosing spondylitis 4167 0.60 8204 1.13 12371 0.87 
Epilepsy 5591 0.80 5359 0.74 10950 0.77 
Schizophrenia 5060 0.72 5260 0.72 10320 0.72 
Heart failure 6077 0.87 4293 0.59 10370 0.73 
Rheumatoid arthritis 2974 0.43 6613 0.91 9587 0.67 
Polymyalgia  2749 0.39 6050 0.83 8799 0.62 
Liver disease 4042 0.58 3631 0.50 7673 0.54 
Arterial/venous 4814 0.69 2259 0.31 7073 0.50 
Vision  2296 0.33 2870 0.40 5166 0.36 
Multiple sclerosis 1384 0.20 3068 0.42 4452 0.31 
Psychosis 2190 0.31 1869 0.26 4059 0.28 
Parkinson’s disease 2369 0.34 1616 0.22 3985 0.28 
Tuberculosis 1683 0.24 2209 0.30 3892 0.27 
Sjogren’s syndrome 224 0.03 1488 0.20 1712 0.12 
Systemic lupus erythematosus 106 0.02 615 0.08 721 0.05 
Scleroderma 77 0.01 380 0.05 457 0.03 
HIV infection/AIDS 120 0.02 70 0.01 190 0.01 
 Multiple Chronic Conditions       
Zero 259384 37.08 207992 28.64 467376 32.78 
One 140699 20.11 135274 18.63 275973 19.36 
Two 93036 13.30 102936 14.17 195972 13.74 
Three 64841 9.27 79405 10.93 144246 10.12 
Four 46238 6.61 60525 8.33 106763 7.49 
Five or more 95355 13.63 140138 19.30 235493 16.52 
AIDS – Acquired immune deficiency syndrome; COPD- Chronic Obstructive Pulmonary Disease; HIV - 




Figure 5.3-1 Pattern of comorbidities (numbers in the cell represents among the people 
having the column conditions what is the percentage with row conditions) 
 
Prevalence (%) 
The pattern and combination of chronic conditions is depicted in Figure 5.3-1. 
As an example of how to interpret this figure, in the top row (back pain) the second cell 
from the left (hypertension) has a value of 27 and this means that 27% of the people with 
BPH^- Benign prostatic hypertrophy (only for men); CHD- Chronic heart disease; 
CKD- Chronic kidney disease; COPD- Chronic obstructive pulmonary disease; GI- 
Gastrointestinal; IBD- Inflammatory bowel disease; IBS- Inflammatory bowel 
syndrome; PVD- Peripheral vascular diseases; SLE- Systemic lupus erythematous.  
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back pain have hypertension, whereas the first cell in the second to top row has the value 
62 which means that 62% of the people with hypertension have back pain.  
5.3.1.2 Clustering of comorbidities 
 
Table 5.3-3 shows AIC, BIC, aBIC, entropy, log likelihood and distribution of probabilities 
in class for each model. There was an increase in BIC and adjusted BIC values when the 
number of classes increased from seven to eight. This suggests that the seven-class 
model was good, but the likelihood ratio tests rejected the seven-class model over six-
class (p<0.001), which explains why the addition of one class from six to seven was not 
statistically significant. Also, one of the classes in the seven-class model comprised less 
than 1% of the sample. Therefore, the six-class model was selected as the optimal 
solution. All models had relatively low entropy (0.70 or close to this), which indicated that 
there was some overlap in the classification of classes. 








1 -1.1E+07 21961579 21959584 21959434 3462723  47 
2 -1E+07 20157016 20153876 20153574 1656326 0.75 95 
3 -9958232 19921034 19918515 19918061 1420277 0.65 143 
4 -9915683 19836036 19834105 19833498 1335179 0.63 191 
5 -9896793 19796128 19797013 19796253 1297398 0.63 239 
6 -9878616 19764272 19761347 19760435 1261044 0.64 287 
7 -9862727 19730398 19734619 19733532 1230675 0.6 335 
8 -9854203 19732930 19737756 19736512 1233109 0.58 383 
9 -9848211 19706904 19712334 19710935 1206984 0.59 431 
10 -9842969 19692013 19698049 19696494 1191996 0.58 479 
AIC- Akaike information criteria; Bayesian information criteria, aBIC- Adjusted Bayesian information criteria  
 
Based on the probabilities of class membership, six patterns of multimorbidity clusters 
were identified as shown in Figure 5.3-2, specifically: (a) relatively healthy class (42.47%) 
with lowest posterior probabilities of most diseases; (b) a back pain class (26.16%) with 
highest posterior probabilities of back pain; (c) a metabolic syndrome class (16.10%) with 
highest probabilities of hypertension, high cholesterol and diabetes; (d) a pain and 
depression cluster (7.02%) having back pain and depression as leading contributing 
conditions; (e) a cardiovascular and musculoskeletal (5.59%) cluster with back pain, 
hypertension and OA as major contributors to the class; and (f) a thyroid cluster (2.63%) 
with highest posterior probabilities from hypothyroidism.  
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Figure 5.3-2 Six-class model of multimorbidity pattern 
 
 
BPH- Benign Prostatic Hypertrophy; COPD- Chronic obstructive pulmonary disease. 
Cluster 1 -Relative healthy; Cluster 2 multiple comorbidities led by backpain and hypertension; Cluster 3- 
Back pain; Cluster 4- musculoskeletal and mental health; Class 5- thyroid cluster; Class 6- metabolic 
syndrome  
The clusters of conditions across different age group are given in the Appendix Table 17-
20 (pages 327-330). Appendix Table 16 (page 326) describes the best model for different 
age groups in OA. The statistics suggest a three class model in the age group 20-39 
years and five class clusters afterwards. Details of the posterior probabilities distribution 
of individual conditions are given in Appendix Table 17-20 (pages 327-330).
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5.3.2 OA and Non-OA populations 
 
For this analysis 221,807 people with OA and 221,807 age, sex and practice area 
matched non-OA controls were used. Study participant characteristics are given in the 
results section of Chapter 4, Table 4.3-1 (pages 114).  
Leading conditions reported in OA cases were back pain (48.02%), hypertension 
(38.06%), depression (29.95%), high cholesterol (20.22%) and hearing problems 
(17.41%). A similar pattern was observed in the non-OA population. (Table 5.3-4) The 
prevalence of multimorbidity was 77% and 70% in the OA and non-OA population, 
respectively. Single (14.9%) and two morbidities (15.4%) were more common in the non-
OA population compared to OA (single-11.5%, two morbidities- 13.1%), whereas the 
prevalence of four (13.5%) and five (36.8%) morbidities were higher in those with OA 
compared to non-OA (four morbidities-12.6%, five morbidities-27.0%). (Table 5.3-4)
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 OA  
(n=221807) % 
Total 
 (n=443614) % 
Back pain 75715 34.14 106535 48.02 182250 41.08 
Hypertension 78032 35.18 84420 38.06 162451 36.62 
Depression 49552 22.34 66431 29.95 116005 26.15 
High Cholesterol 40435 18.23 44849 20.22 85263 19.22 
Hearing  35733 16.11 38617 17.41 74350 16.76 
Diabetes Mellitus  29012 13.08 33781 15.23 62816 14.16 
Chronic Kidney Disease 29101 13.12 29678 13.38 58779 13.25 
Stroke  27548 12.42 29523 13.31 57049 12.86 
Coronary Heart Disease 23622 10.65 28924 13.04 52568 11.85 
Asthma 22669 10.22 29234 13.18 51903 11.70 
Cancer (any) 20606 9.29 24221 10.92 44849 10.11 
Hypothyroidism  17811 8.03 20562 9.27 38373 8.65 
Gastritis  15881 7.16 21404 9.65 37308 8.41 
COPD 16746 7.55 20428 9.21 37175 8.38 
Migraine 15194 6.85 19696 8.88 34912 7.87 
Gall stones 13663 6.16 18210 8.21 31851 7.18 
Irritable Bowel Syndrome 12710 5.73 18210 8.21 30920 6.97 
Anaemia 12931 5.83 16170 7.29 29101 6.56 
Inflammatory Bowel Disease 12576 5.67 16214 7.31 28791 6.49 
Osteoporosis  12931 5.83 14063 6.34 27016 6.09 
Benign prostatic Hypertrophy 12177 5.49 14551 6.56 26750 6.03 
Gout 10292 4.64 15371 6.93 25641 5.78 
Cataract  11490 5.18 13575 6.12 25064 5.65 
Peripheral Vascular Disease 7919 3.57 10358 4.67 18277 4.12 
Sleep Disorder 7675 3.46 10003 4.51 17700 3.99 
Psoriasis  7253 3.27 8695 3.92 15926 3.59 
Dementia  6765 3.05 7209 3.25 13974 3.15 
Heart failure 4968 2.24 7541 3.40 12510 2.82 
Fatigue 3815 1.72 4946 2.23 8739 1.97 
Gastrointestinal bleed 3571 1.61 4880 2.20 8429 1.90 
Ankylosing Spondylitis 3349 1.51 4880 2.20 8207 1.85 
Hyperthyroid  3704 1.67 4170 1.88 7896 1.78 
Polymyalgia  3039 1.37 4436 2.00 7453 1.68 
Epilepsy 3150 1.42 3948 1.78 7098 1.60 
Renal stone 3261 1.47 3726 1.68 7009 1.58 
Rheumatoid Arthritis 1730 0.78 4436 2.00 6166 1.39 
Fibromyalgia 1841 0.83 4259 1.92 6122 1.38 
Arterial/Venous 2662 1.20 5501 2.48 5944 1.34 
Vision problem 2506 1.13 2595 1.17 5102 1.15 
Schizophrenia 2396 1.08 2418 1.09 4791 1.08 
Liver Disease 1553 0.70 2196 0.99 3726 0.84 
Parkinson’s Disease 1575 0.71 1930 0.87 3505 0.79 
Tuberculosis 1486 0.67 1664 0.75 3150 0.71 
Psychosis 887 0.40 843 0.38 1730 0.39 
Multiple sclerosis 821 0.37 688 0.31 1508 0.34 
Sjogren’s syndrome 377 0.17 621 0.28 1020 0.23 
Systemic Lupus 
Erythematosus 
155 0.07 244 0.11 399 0.09 
Scleroderma 133 0.06 155 0.07 266 0.06 
HIV infection/AIDS 22 0.01 22 0.01 44 0.01 
Multiple chronic conditions       
Zero 33914 15.29 25508 11.50 59400 13.39 
One 33027 14.89 24510 11.05 57537 12.97 
Two 34180 15.41 28946 13.05 63126 14.23 
Three 32827 14.80 31319 14.12 64147 14.46 
Four 27926 12.59 29944 13.50 57847 13.04 
Five or more 59932 27.02 81581 36.78 141513 31.90 
AIDS – Acquired immune deficiency syndrome; COPD- Chronic Obstructive Pulmonary Disease; HIV - 
Human Immunodeficiency virus 
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5.3.3 Clustering of comorbidities in OA and non-OA 
Firstly, cluster analysis was done in the separate OA and non-OA populations followed by 
the same cluster analysis in men and women and different age groups of 20-39, 40-59, 
60-79 and >=80 years in both groups.  
5.3.3.1 Clustering in OA 
 
Table 5.3-5 summarises the AIC, BIC, aBIC, entropy, log likelihood and distribution of 
probabilities in each class for each model. It shows, there was a gradual decline in BIC 
and adjusted BIC values with increasing number of classes. Models for class 7 onwards 
had one group with <1% sample size, so these were not selected. Between class 6 and 
five, the change in likelihood ratio was less than 1%. This suggests that the five-class 
model was good and explains why the addition of one class from five to six was not 
statistically significant. Therefore, the five-class model was selected as the optimal 
solution. All models had relatively low entropy (0.60 or thereabouts), which indicated that 
there was some overlap in the classification of classes. 
Table 5.3-5. Model statistics for different classes in OA 
Model Parameters log-likelihood BIC aBIC AIC Entropy 
1  -2393224 - 4786905 4786548  
2 93 -2317774 4636791 4636470 4635750 0.69 
3 140 -2297448 4596767 4596284 4595200 0.67 
4 187 -2288014 4578527 4577882 4576434 0.64 
5 234 -2284016 4571158 4570351 4568540 0.65 
6 281 -2280824 4565402 4564433 4562258 0.63 
7 328 -2277791 4559964 4558833 4556294 0.63 
8 375 -2275128 4555266 4553972 4551070 0.62 
9 422 -2273244 4552125 4550670 4547403 0.61 
10 469 -2271431 4549128 4547511 4543881 0.60 
AIC- Akaike information criteria; BIC- Bayesian information criteria, aBIC- Adjusted Bayesian information 
criteria 
Cluster 1 was the relative healthy group sharing maximum class size (34.33%). Cluster 2 
had a 11.07% population of total OA and was dominated by hypertension (PP73%) and 
back pain (PP-64%). In cluster 3, the smallest cluster (3.04%) in the OA, thyroid problem 
was the leading contributor (PP-90%) among all conditions. Cluster 4 shared one third of 
the total population size, in which hypertension was the foremost chronic condition (PP-
63%). Cluster 5 had the strongest contribution from both back pain (PP-67%) and 




Summary statistics for model selection of clusters by gender is given in Appendix Table 
21 (page 325). There were four clusters in men, and five in women. Thyroid leading 




Figure 5.3-3 Five-class model clusters in the OA population overall 
 
 
Cluster 1- Relative healthy; Cluster 2- CV-MSK; Cluster 3 Thyroid ; Cluster 4 CV; Cluster 5 MSK-MH 
CV- Cardiovascular; MH- Mental health;  MSK- Musculoskeletal. COPD- Chornic obstructive 
pulmonary diseases; ^only for men 
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Figure 5.3-4 Four-class model clusters in the OA population in Men 
 
COPD: Chronic obstructive pulmonary disease; ^only for men 
Cluster 1- Relative healthy; Cluster 2- CV-MSK; Cluster 3- CV; Cluster 4- MSK-MH 
CV- Cardiovascular; MSK-Musculoskeletal; MH-Mental health 
161 
 
Figure 5.3-5 Five-class model clusters in the OA population in women 
 
COPD: Chronic obstructive pulmonary disease; ^only for men 
Cluster 1- Relative healthy; Cluster 2- Thyroid; Cluster 3- CV-MSK; Cluster 4- CV; Cluster 5- MSK-MH 





Similar approaches were used to identify clusters in different age groups within the OA 
population.  Details of the model summary are provided in the Appendix Table 22 (page 
332). A three class model was selected for age group 20-39 , and a five class model was 
selected for 40-59, 60-79 and >=80 years.  
 
In the age group 20-39 years the three class model identified MSK, MH and relatively 
healthy clusters. (Table 5.3-6) The five clusters in the age group 40-59 years were MSK 
(31%), CV-MSK (28%),  MSK-CV-MH (10%), thyroid (5%) and relatively healthy (26%). 
Individual probabilities of chronic conditions across the cluster can be seen in Table 5.3-7.  
In the age group 60-79 years five clusters were found, namely CV (27%), MSK (30%), 
CV-MSK (14%), MSK-CV-MH (13%), and relatively healthy (16%). Detailed contributions 
of the chronic conditions are provided in Table 5.3-8. Clusters identified in the elderly age 
had a slightly different pattern. Prominent clusters were CV-MSK (15%), MSK-CV-MH 
(17%), CV-Renal (25%), MSK-Hearing (29%), and relatively healthy group (14%). Details 
of the probailities by conditions are shown in Table 5.3-9.
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Table 5.3-6. Posterior probabilities distribution of chronic conditions to three-class model 








Anaemia 2.27 9.98 10.07 
Ankylosing Spondylitis 0.52 4.39 1.71 
Arterial/Venous 0.02 0.28 0.78 
Asthma 10.53 28.99 23.74 
Back pain 35.98 83.77 47.40 
Benign prostatic hypertrophy 0.41 0.61 2.41 
Cancer (any) 0.73 2.42 5.12 
Cataract 0.12 0.49 0.74 
Chronic Heart Disease 0.41 1.13 10.8 
Chronic Kidney Disease 0.6 1.34 11.08 
COPD 1.06 5.66 6.3 
Dementia 0 0.24 0.15 
Depression 15.45 54.74 66.01 
Diabetes 2.25 6.59 39.54 
Epilepsy 1.67 3.11 5.93 
Fatigue 0.27 5.8 1.75 
Fibromyalgia 0.01 8.85 5.45 
Gall stones 1.18 9.11 8.91 
Gastritis 1.69 12.1 12.75 
Gastrointestinal Bleed 0.28 3.34 4.87 
Gout 2.42 1.98 13.93 
Hearing Problem 4.35 11.65 10.92 
Heart Failure 0.02 0.02 1.58 
High Cholesterol 2.29 4.99 40.78 
HIV/AIDS 0.05 0.04 0.23 
Hypertension 4.08 6.99 58.50 
Hyperthyroidism  0.23 1.47 5.73 
Hypothyroidism 1.38 8.09 16.21 
Inflammatory Bowel Disease 3.37 17.26 12.69 
Irritable Bowel Syndrome 3.83 17.02 5.71 
Liver Disease 0.3 1.32 2.16 
Migraine 4.97 29.18 16.32 
Multiple Sclerosis 0.14 0.79 0.37 
Osteoporosis 0.22 1.1 2.43 
Parkinson’s Disease 0.03 0.06 0.28 
Peripheral Vascular Disease 0.94 3.45 5.27 
Polymyalgia 0 0.18 0 
Psoriasis 3.55 6.12 7.75 
Psychosis 0 0.73 2.6 
Renal Stone 0.43 1.51 3.89 
Rheumatoid Arthritis 2.37 5.73 5.16 
Schizophrenia 0 2.45 5.14 
Scleroderma 0.07 0.07 0.24 
Sjogren’s Syndrome 0.04 0.41 0.74 
Sleep Problem 0.75 6.83 6.71 
Stroke 6.06 5.28 9.75 
Systemic Lupus 
Erythematosus 0.04 0.2 0.38 
Tuberculosis 0.34 0.39 1.93 
Vision Problem 0.1 0.71 1.7 
COPD- Chronic obstructive pulmonary disease; *Cluster 1 – Relative healthy; Cluster 2 MSK; Cluster 3- MH 
MSK – Musculoskeletal; MH- Mental health 
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Table 5.3-7. Posterior probabilities distribution of chronic conditions to the five-class 












Anaemia 0.93 4.12 12.81 16.72 8.12 
Ankylosing Spondylitis 0 0.93 2.55 5.13 4.62 
Arterial/Venous 0 0.69 0.39 2.8 0.17 
Asthma 3.94 13.04 19.7 25.22 20.86 
Back pain 21.48 63.85 50.4 91.15 84.92 
Benign prostatic hypertrophy 0.58 6.81 0.71 7.5 2.22 
Cancer (any) 1.5 8.39 8.8 12.9 6.31 
Cataract 0.63 1.03 1.25 3.03 0.72 
Chronic Heart Disease 0.23 11.16 4.48 28.26 2.65 
Chronic Kidney Disease 0 9.23 12.26 23.89 1.57 
COPD 0.83 6.63 8.64 17.87 8.5 
Dementia 0.04 0.43 1.49 2.12 0.24 
Depression 7.01 24.06 54.53 67.93 55.48 
Diabetes 0.52 21.54 20.47 41.43 4.29 
Epilepsy 0.45 1.45 3.4 3.97 2.68 
Fatigue 0.11 0.57 4.67 6.76 4.4 
Fibromyalgia 0.02 0.11 4.3 9.38 5.74 
Gall stones 0.79 5.04 11.61 19.87 9.7 
Gastritis 0.61 5.88 8.21 26.93 11.5 
Gastrointestinal Bleed 0.08 1.13 1.34 6.69 2.1 
Gout 0.95 12.03 1.97 12.66 1.56 
Hearing Problem 2.69 13.19 14.57 23.64 14.73 
Heart Failure 0.02 0.91 0.35 5.23 0 
High Cholesterol 1.58 29.53 21.13 45.82 11.2 
HIV/AIDS 0 0.02 0.03 0.04 0.02 
Hypertension 3.2 53.13 30.44 66.92 13.58 
Hyperthyroidism  0.06 0 29.41 1.62 0 
Hypothyroidism 1.18 4.33 61.18 14.12 5.94 
Inflammatory Bowel Disease 0.87 4.97 8.7 20.35 11.17 
Irritable Bowel Syndrome 5.83 2.09 11.87 19.28 16.97 
Liver Disease 0.11 1.09 1.42 3.61 1.28 
Migraine 1.61 5.35 15.26 23.25 21.08 
Multiple Sclerosis 0.11 0.17 0.65 0.63 0.71 
Osteoporosis 0.34 1.77 4.97 8.01 4.77 
Parkinson’s Disease 0.06 0.25 0.6 0.48 0.19 
Peripheral Vascular Disease 0.39 2.89 3.43 10.89 3.25 
Polymyalgia 0.05 0.53 1.18 2.03 0.7 
Psoriasis 1.5 0 4.7 6.75 4.29 
Psychosis 0.02 2.25 7.51 0.49 0 
Renal Stone 0.21 1.89 0.79 3.64 1.54 
Rheumatoid Arthritis 0.43 0.12 4.06 4.32 3.01 
Schizophrenia 0.03 0.04 12.74 2.16 0.84 
Scleroderma 0 0.07 0.16 0.32 0.05 
Sjogren’s Syndrome 0.02 2.85 1.11 0.73 0.31 
Sleep Problem 0.12 9.11 5 12.88 5.76 
Stroke 9.48 0.03 9.79 17.41 5.79 
Systemic Lupus 
Erythematosus 0.02 0.73 0.14 0.51 0.18 
Tuberculosis 0.1 0.38 0.68 1.28 0.7 
Vision Problem 0.06 0.38 1.5 2.04 0.41 
COPD- Chronic obstructive pulmonary disease; Cluster 1- Relative healthy; Cluster 2 CV-MSK; Cluster 3 
Thyroid (metabolic); Cluster 4 MSK-MH-CV; Cluster 5 MSK 




Table 5.3-8. Posterior probabilities distribution of chronic conditions to the five-class 












Anaemia 0.16 19.05 17.46 5.12 4.59 
Ankylosing Spondylitis 0 2.93 5.71 0.32 3.26 
Arterial/Venous 0.02 9.1 1.33 1.68 0.82 
Asthma 0.98 12.05 23.17 11.92 12.9 
Back pain 4.91 80.88 87.98 53.36 75.46 
Benign prostatic hypertrophy 7.5 0.58 0.71 2.22 6.81 
Cancer (any) 1.25 25.01 16.32 15.76 16.1 
Cataract 6.03 15.02 12.69 6.9 4.25 
Chronic Heart Disease 0.44 53.58 21.03 18.24 8.38 
Chronic Kidney Disease 0 44.71 32.12 26.66 2.93 
COPD 0.55 27.42 14.41 7.14 12.24 
Dementia 0.17 9.13 9.64 4.04 3.09 
Depression 1.16 34.17 65.82 13.87 30.15 
Diabetes 0.51 40.16 26.14 27.8 6.14 
Epilepsy 0.11 2.65 2.8 1.06 1.86 
Fatigue 0.04 2.96 6.96 0.65 1.99 
Fibromyalgia 0 0.52 5.46 0.03 0.97 
Gall stones 0.46 14.52 22.06 6.79 8.5 
Gastritis 0.2 25.49 22.48 4.4 10.67 
Gastrointestinal Bleed 0 7.67 4.37 0.69 1.97 
Gout 0.3 22.55 6.04 12.24 3.58 
Hearing Problem 1.4 36.82 26.94 18.89 23.1 
Heart Failure 0.1 20.75 4.25 3.33 0.49 
High Cholesterol 1.17 41.73 37.75 30.59 18.97 
HIV/AIDS 0.01 0.01 0.01 0.01 0 
Hypertension 3.97 71.55 64.32 73.7 29.17 
Hyperthyroidism  0.03 0.99 9.5 1.98 0.56 
Hypothyroidism 0.59 10.16 31.94 10.99 6.51 
Inflammatory Bowel Disease 0.1 12.02 16.71 2.97 7.54 
Irritable Bowel Syndrome 4.97 5.07 21.66 1.58 8.72 
Liver Disease 0.01 2.04 1.86 0.67 0.79 
Migraine 0.17 5.62 17.47 3.13 9.39 
Multiple Sclerosis 0.01 0.29 0.4 0.15 0.43 
Osteoporosis 0.24 9.86 24.4 4.14 9.74 
Parkinson’s Disease 0.1 2.49 2.28 1.08 1.45 
Peripheral Vascular Disease 0.13 19.56 7.2 4.21 3.08 
Polymyalgia 0.1 4.5 6.51 2.57 2.09 
Psoriasis 0.29 5.56 5.14 4.05 4.18 
Psychosis 0 0.03 2.25 0 0.11 
Renal Stone 0.1 4.44 1.81 2.04 1.63 
Rheumatoid Arthritis 0.09 1.68 4.02 1.42 1.95 
Schizophrenia 0.04 0.53 5.32 0.27 0.67 
Scleroderma 0.01 0.18 0.23 0 0.05 
Sjogren’s Syndrome 0 0.33 1.38 0.03 0.31 
Sleep Problem 0.04 8.22 9.2 2.28 4.22 
Stroke 16.56 30.43 18.5 14.86 8.64 
Systemic Lupus Erythematosus 0 0.06 0.42 0.04 0.09 
Tuberculosis 0.02 1.48 1.49 0.6 1.01 
Vision Problem 0.03 3.71 2.67 0.83 0.79 
COPD- Chronic obstructive pulmonary disease; Cluster 1- Relative healthy; Cluster 2 CV-MSK; Cluster 3 CV-
MSK-MH; Cluster 4 CV; Cluster 5 MSK 
CV- Cardiovascular; MSK- Musculoskeletal; MH- Mental health 
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Table 5.3-9. Posterior probabilities distribution of chronic conditions to the five-class 










 Cluster 5* 
(28.44%) 
Anaemia 0.02 17.85 22.74 9.63 8.75 
Ankylosing Spondylitis 0 1.89 4.59 0 1.79 
Arterial/Venous 0 11.6 3.59 1.1 2.14 
Asthma 0.24 10.19 14.9 9.73 9.27 
Back pain 1.37 73.49 88.38 44.14 61.42 
Benign prostatic hypertrophy 6.81 2.22 0.58 7.5 0.71 
Cancer (any) 0.57 27.57 17.21 16.69 21.89 
Cataract 28.23 33.62 46.62 27.37 25.06 
Chronic Heart Disease 0.59 54.58 34.06 22.88 17.75 
Chronic Kidney Disease 0 54.78 46.42 56.82 7.33 
COPD 0.48 23.14 19.04 5.79 14.59 
Dementia 0.73 8.97 18.02 13.34 25.26 
Depression 0 20.63 69.19 12.74 24.1 
Diabetes 0.32 32.93 19.8 23.05 6.82 
Epilepsy 0 1.36 2.24 1.67 1.8 
Fatigue 0.01 2.1 4.73 0.7 1.36 
Fibromyalgia 0 0 1.09 0 0.09 
Gall stones 0.09 15.42 19.83 7.44 6.9 
Gastritis 0.13 22.91 19.61 4.01 10.62 
Gastrointestinal Bleed 0.09 8.49 5.96 1.13 3.71 
Gout 0.14 25.27 8.34 9.77 3.83 
Hearing Problem 1.06 45.7 43.14 27.59 47.33 
Heart Failure 0.28 27.87 18.16 10.8 9.21 
High Cholesterol 0 29.22 25.85 20.59 6.6 
Hypertension 3.7 72.00 71.59 80.56 39.42 
Hyperthyroidism  0.02 0.74 8.32 3.53 0.12 
Hypothyroidism 0.43 8.97 31.27 15.91 4.7 
Inflammatory Bowel Disease 0.04 12.03 15.67 2.41 6.93 
Irritable Bowel Syndrome 2.87 4.43 13.35 1.29 3.87 
Liver Disease 0.04 0.57 1.01 0.49 0.12 
Migraine 0 2.9 8.92 1.84 3.43 
Multiple Sclerosis 0 0.05 0.16 0.09 0.08 
Osteoporosis 0 5.71 38.82 11.18 13.28 
Parkinson’s Disease 0.18 2.10 2.24 0.86 2.98 
Peripheral Vascular Disease 0.09 21.67 11.58 4.91 4.66 
Polymyalgia 0.06 5.02 11.65 5.84 5.37 
Psoriasis 0.15 4.39 5.65 2.33 2.88 
Psychosis 0 0 1.19 0 0.36 
Renal Stone 0.01 3.44 1.1 0.74 1.52 
Rheumatoid Arthritis 0.12 1.15 2.47 0.8 1.16 
Schizophrenia 0 0.19 2.43 0.08 1.46 
Scleroderma 0 0 0.15 0.02 0.03 
Sjogren’s Syndrome 0 0.07 0.81 0.13 0.19 
Sleep Problem 0.16 10.63 14.46 4.23 13.11 
Stroke 25.19 32.09 31.97 23.43 20.82 
Systemic Lupus Erythematosus 0 0 0.37 0 0 
Tuberculosis 0.02 1.05 2.14 0.59 1.01 
Vision Problem 0.02 5.95 7.52 1.61 5.48 
COPD- Chronic obstructive pulmonary disease; Cluster 1- Relative healthy; Cluster 2 CV-MSK; Cluster3 
MSK-CV-MH; Cluster 4 CV-Renal; Cluster 5 MSK-Hearing 





The distribution of socio-demographic characteristics across the clusters in all OA cases 
is provided in Table 5.3-10. The proportion of women was higher in all the clusters except 
in cluster 4 (CV). The mean age was highest in cluster 2 (70.92 years) followed by cluster 
4 (65.67 years) and the lowest was found in the relative healthy group (56.83 years). 
Smoking prevalence was highest (54%) in cluster 2 (CV-MSK). The prevalence of obesity 
was 37.7% in cluster 3 (metabolic led by Thyroid), followed by 36% in cluster 4 (CV). The 
mean number of chronic conditions was highest for CV-MSK cluster (8.62; SD 1.97) and 
thyroid cluster (6.18; SD 2.00). (Table 5.3-10) 

















Gender      
  Men  33416 (43.88) 11153 (45.40) 823 (11.32) 36331 (53.74) 12189 (26.35) 
  Women 42734 (56.12) 13413 (54.60) 6445 (88.68) 31274 (46.26) 34073 (73.65) 
Age       
  <40 years 7254 (9.53) 85 (0.35) 167 (2.30) 984 (1.46) 3772 (8.15) 
  40-59 years 38906 (51.09) 3635 (14.80) 2583 (35.54) 20123 (29.77) 25866 (55.91) 
  60-79 years 26774 (35.16) 15923 (64.82) 3827 (52.66) 39292 (58.12) 15537 (33.58) 
  >=80 years 3216 (4.22) 4923 (20.04) 691 (9.51) 7206 (10.66) 1087 (2.35) 
Smoking       
  Never smoked 42708 (56.08) 11290 (45.96) 4140 (56.96) 36075 (53.36) 23336 (50.44) 
  Current smoker 15071 (19.79) 4004 (16.30) 1151 (15.84) 9926 (14.68) 11551 (24.97) 
  Ex-smoker 18362 (24.11) 9270 (37.74) 1976 (27.19) 21599 (31.95) 11369 (24.58) 
Alcohol use      
  Never  12763 (16.76) 6609 (26.90) 2090 (28.76) 12830 (18.98) 9811 (21.21) 
  Ex-drinker 1350 (1.77) 1183 (4.82) 234 (3.22) 1733 (2.56) 1540 (3.33) 
  Current (1-9) 28957 (38.03) 7452 (30.33) 2471 (34.00) 22473 (33.24) 16229 (35.08) 
  Current (>=10) 16240 (22.10) 3606 (14.68) 683 (9.40) 14998 (22.18) 7646 (16.53) 
  Current 
(Unknown) 
16827 (22.10) 5707 (23.23) 1787 (24.59) 15551 (23.00) 11013 (23.81) 
BMI      
  Underweight  912 (1.20) 468 (1.91) 128 (1.76) 739 (1.09) 784 (1.69) 
  Normal  25096 (32.96) 6300 (25.65) 1932 (26.58) 16076 (23.78) 14160 (30.61) 
  Overweight  28665 (37.64) 9219 (37.53) 2466 (33.93) 26452 (39.13) 15909 (34.39) 
  Obese 21430 (28.14) 8575 (34.91) 2742 (37.73) 24316 (35.97) 15404 (33.30) 
Mean age (SD) 56.83 (12.93) 70.92 (10.31) 63.99 (11.91) 65.57 (11.35) 56.13 (11.63) 
Mean BMI (SD) 27.67 (5.38) 28.52 (5.67) 28.95 (6.21) 28.80 (5.50) 28.30 (5.97) 
Mean CC (SD) 1.11 (0.98) 8.62 (1.97) 6.18 (2.00) 4.17 (1.47) 4.93 (1.70) 
BMI- Body mass index; CC- Chronic conditions; SD -Standard deviation 
CV-Cardiovascular; MH- Mental health; MSK- Musculoskeletal 
 
Table 5.3-11 describes the association of patient characteristic with cluster membership 
having the healthy cluster as the reference group. Women had a higher risk than men of 
being in metabolic cluster (OR 5.45; 95% CI 5.05-5.88) and cluster 5 (OR 2.25; 95% CI 
2.19-2.31)  when compared to the gender ratio in the healthy cluster. Being a current 
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smoker had an increased OR when compared to the smoker to non-smoker ratio in the 
healthy cluster. Obesity was found to be significantly associated with all the clusters when 
compared to the ratio in the healthy group.  
 
Table 5.3-11. Multinomial regression for association with clusters in the OA population 
Variables  Relative 
Healthy 




OR (95% CI) 
Thyroid 
OR (95% CI) 
CV 
OR (95% CI) 
MSK-MH 
OR (95% CI) 
Gender      
  Men  1 Reference Reference Reference Reference 
  Women 1 0.82 (0.79-0.84)* 5.55 (5.14-5.99)* 0.64 (0.62-0.65)* 2.25 (2.19-2.31)* 
Age       
  <40 years 1 Reference Reference Reference Reference 
  40-59 years  7.90 (6.36-9.82)* 2.67 (2.28-3.13)* 3.76 (3.51-4.03)* 1.25 (1.19-1.30)* 
  60-79 years  52.36 (42.22-64.93)* 5.73 (4.89-6.71)* 11.14 (10.40-11.94)* 1.11 (1.06-1.16)* 
  >=80 years  94.61 (74.16-114.53) 7.99 (6.70-9.54)* 19.99 (18.46-21.65)* 0.62 (0.57-0.68)* 
Smoking       
  Never smoked 1 Reference Reference Reference Reference 
  Current smoker 1 1.52 (1.44-1.58)* 1.13 (1.05-1.21)* 0.99 (0.97-1.03) 1.48 (1.44-1.53)* 
  Ex-smoker 1 1.78 (1.72-1.84)* 1.38 (1.30-1.46)* 1.16 (1.13-1.19)* 1.27 (1.23-1.31)* 
Alcohol use      
  Never  1 Reference Reference Reference Reference 
  Ex-drinker 1 1.70 (1.55-1.86)* 1.44 (1.24-1.68)* 1.27 (1.17-1.38)* 1.59 (1.47-1.73)* 
  Current (1-9 units) 1 0.51 (0.49-0.54)* 0.64 (0.59-0.68)* 0.76 (0.76-0.81)* 0.79 (0.77-0.82)* 
  Current (>=10 units) 1 0.48 (0.46-0.51)* 0.52 (0.47-0.57)* 0.89 (0.86-0.93)* 0.81 (0.78-0.84)* 
  Current (Unknown) 1 0.69 (0.66-0.72)* 0.77 (0.72-0.83)* 0.92 (0.88-0.95)* 0.90 (0.87-0.94)* 
BMI      
  Normal  1 Reference Reference Reference Reference 
  Underweight  1 1.55 (1.45-1.58)* 1.40 (1.15-1.70)* 1.21 (1.09-1.34)* 1.36 (1.23-1.50)* 
  Overweight  1 1.33 (1.28-1.38)* 1.31 (1.23-1.39)* 1.37 (1.33-1.40)* 1.10 (1.06-1.13)* 
  Obese 1 2.11 (2.03-2.20)* 1.88 (1.77-2.00)* 2.03 (1.97-2.09)* 1.26 (1.22-1.30)* 
      
CI- Confidence interval; OR- Odds ratio; *P value <0.05 













5.3.3.2 Clustering in non-OA 
 
Model statistics for different clusters in the non-OA population are given in Table 5.3-12.  
There was a gradual decline in BIC and adjusted BIC values with increase in number of 
classes. The model for class 6 onwards had one group with <1% sample size, so those 
were not selected. The change in likelihood ratio from class four to five was more than 
1%. This suggested that the five-class model was the best and this was selected as the 
optimal solution. All models had relatively low entropy (0.58-0.68), which indicated that 
there was some overlap in the classification of classes. 
 
Table 5.3-12. Model statistics for different clusters in non-OA 
Class Parameter log-likelihood BIC aBIC AIC Entropy 
2 93 -2074549 - 4149544 4149195  
3 140 -2002933 4007085 4006770 4006064 0.68 
4 187 -1987575 3976984 3976511 3975448 0.64 
5 281 -1979733 3961915 3961282 3959863 0.60 
6 328 -1975968 3955001 3954210 3952434 0.60 
7 375 -1972613 3948908 3947957 3945825 0.62 
8 422 -1970319 3944935 3943826 3941337 0.60 
9 469 -1968272 3941455 3940186 3937341 0.59 
10 516 -1966666 3938858 3937431 3934229 0.58 
AIC- Akaike information criteria; Bayesian information criteria, aBIC- Adjusted Bayesian information criteria 
 
LCA identified five clusters in the non-OA population, like OA but with different class 
sizes. Cluster 1 was relatively healthy (40.6%) with lowest contribution of all chronic 
conditions. Cluster 2 was the smallest  cluster and was led by thyroid (PP-54%) and 
depression (PP-44%). Cluster 3 shared 10.09% of the total population predominantly with 
hypertension (PP-72%) and back pain (PP-54%). Nearly 30% of the total population was 
grouped within cluster 4 with the highest contribution from hypertension (PP-66%). 






Figure 5.3-6 Five-class model clusters in the non-OA population overall 
 
COPD: Chronic obstructive pulmonary disease; ^only for men 
Cluster 1- Relative healthy; Cluster 2- Thyroid; Cluster 3- CV-MSK; Cluster 4- CV; Cluster 5- MSK-MH 
CV- Cardiovascular; MSK- Musculoskeletal; MH- Mental health 
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Figure 5.3-7 Five-class model clusters in the non-OA population in men 
 
COPD: Chronic obstructive pulmonary disease; ^only for men 
Cluster 1- Relative healthy; Cluster 3- CV-MSK; Cluster 4- CV; Cluster 4- MSK-MH 
CV- Cardiovascular; MSK- Musculoskeletal; MH- Mental health 
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Figure 5.3-8 Five-class model clusters in the non-OA population in women 
 
COPD: Chronic obstructive pulmonary disease; ^only for men 
Cluster 1- Relative healthy; Cluster 2- Thyroid ; Cluster 3- CV-MSK; Cluster 4- CV; Cluster 5- MSK-MH; CV- 
Cardiovascular; MSK- Musculoskeletal; MH- Mental health 
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Across gender, in people without OA there were four clusters in men and five in women. 
Details of the summary statistics of these clusters are given in Appendix Table 23 (page 
333). As in people with OA, women had an additional cluster led by thyroid disorders. 
(Figure 5.3-7 and Figure 5.3-8) 
Age group analysis in the non-OA population found three clusters, specifically healthy 
(59.7%), MSK (29.7%) and MH (10.6%) in the age group 20-39 years. (Table 5.3-13) 
However, in the age group 40-59 years, five classes were identified, specifically relatively 
healthy (36%), MSK (32%), CV (22%), MSK-MH (7%) and thyroid (3%). (Table 5.3-14) In 
the age group 60-79 years the five clusters identified were relatively healthy (29.8%), 
MSK (26.5%), CV (20%), CV-MSK (14%) and MSK-MH (10%). (Table 5.3-15) Similarly, in 
the age group of > 80 years, five distinct clusters were found, namely relatively healthy 
(28%), MSK (22%), CV-Renal (19%), CV-MSK-Renal (16%), and Hearing- vision (15%). 
(Table 5.3-16) Details of the summary statistics of the models are given in Appendix 
Table 24 (page 334).
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Table 5.3-13. Posterior probabilities distribution of chronic conditions to three-class model in 








Anaemia 1.96 8.83 8.38 
Ankylosing Spondylitis 0.03 0.86 3.24 
Arterial/Venous 0 0.41 0.24 
Asthma 8.62 19.48 21.9 
Back pain 26.86 50.61 77.24 
Benign prostatic hypertrophy^ 0.26 1.83 0.77 
Cancer (any) 0.9 4.36 1.92 
Cataract 0.16 0.22 0.18 
Chronic Heart Disease 0.37 6.32 0.74 
Chronic Kidney Disease 0.34 7.62 0.67 
COPD 1.07 3.96 4.14 
Dementia 0 0.18 0.01 
Depression 10.73 55.74 44.82 
Diabetes 1.52 28.27 2.95 
Epilepsy 0.66 3.2 2.24 
Fatigue 0.35 2.77 4.13 
Fibromyalgia 0 1.5 2.8 
Gall stones 0.57 4.97 7.85 
Gastritis 0.8 6.75 9.78 
Gastrointestinal Bleed 0.23 1.81 2.63 
Gout 0.81 4.75 1.09 
Hearing Problem 3.34 13.88 9.99 
Heart Failure 0.03 0.78 0 
High Cholesterol 2.3 23.78 3.3 
HIV/AIDS 0.01 0.07 0 
Hypertension 2.83 31.12 5.53 
Hyperthyroidism  0.07 8.83 0.17 
Hypothyroidism 0.71 18.33 3.47 
Inflammatory Bowel Disease 2.39 8.65 14.55 
Irritable Bowel Syndrome 2.44 6.65 11.45 
Liver Disease 0.35 1.71 0.86 
Migraine 3.4 12.51 23.21 
Multiple Sclerosis 0.19 0.48 0.55 
Osteoporosis 0.09 1.23 0.77 
Parkinson’s Disease 0 0.07 0 
Peripheral Vascular Disease 0.44 2.29 2.38 
Polymyalgia 0 0.07 0 
Psoriasis 1.8 5.16 4.54 
Psychosis 0 5.21 0 
Renal Stone 0.31 2.05 1.33 
Rheumatoid Arthritis 0.17 0.98 0.76 
Schizophrenia 0.07 7.76 0.97 
Scleroderma 0.02 0.09 0 
Sjogren’s Syndrome 0.03 0 0.15 
Sleep Problem 0.62 5.68 3.9 
Stroke 6.12 7.14 5.1 
Systemic Lupus Erythematosus 0.06 0.06 0.06 
Tuberculosis 0.31 1.03 0.67 
Vision Problem 0.14 0.68 0.15 
COPD- Chronic obstructive pulmonary disease; *Cluster 1- Relative healthy; Cluster 2 MSK-MH; Cluster 3 MSK; 
^only for men; MSK- Musculoskeletal; MH- Mental health 
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Table 5.3-14. Posterior probabilities distribution of chronic conditions to five-class model in 










Cluster 5  
(6.98%) 
Anaemia 1.25 12.79 6.35 4.50 13.89 
Ankylosing Spondylitis 0.00 1.00 3.17 0.93 4.49 
Arterial/Venous 0.06 0.27 0.06 1.27 1.81 
Asthma 4.78 14.28 15.22 11.16 21.34 
Back pain 17.84 58.74 73.97 55.39 81.84 
Cancer (any) 2.16 9.24 6.40 8.72 10.34 
Benign prostatic hypertrophy^ 0.70 0.44 2.48 6.58 5.17 
Cataract 0.58 1.01 0.52 1.23 1.85 
Chronic Heart Disease 0.73 3.68 1.77 14.36 15.77 
Chronic Kidney Disease 0.24 10.23 1.04 14.15 15.33 
COPD 1.11 5.16 6.36 7.78 16.00 
Dementia 0.03 0.27 0.26 0.55 2.03 
Depression 6.18 36.75 41.03 19.94 72.47 
Diabetes 1.26 21.49 3.25 26.20 24.71 
Epilepsy 0.62 1.61 1.65 1.44 4.78 
Fatigue 0.14 3.83 2.65 0.62 10.00 
Fibromyalgia 0.00 1.43 1.63 0.00 9.35 
Gall stones 1.04 8.55 6.34 5.26 17.43 
Gastritis 0.58 4.78 7.76 6.17 24.32 
Gastrointestinal Bleed 0.08 0.56 1.30 0.94 6.41 
Gout 0.87 1.30 1.35 9.62 4.37 
Hearing Problem 3.15 11.98 13.02 14.41 20.22 
Heart Failure 0.00 0.50 0.00 1.64 1.68 
High Cholesterol 3.30 19.09 10.33 35.63 33.86 
HIV/AIDS 0.00 0.00 0.01 0.00 0.05 
Hypertension 6.04 30.44 12.14 62.84 44.56 
Hyperthyroidism  0.16 33.84 0.19 0.37 2.39 
Hypothyroidism 1.05 90.75 4.33 4.26 14.48 
Inflammatory Bowel Disease 0.85 5.84 9.10 4.73 19.10 
Irritable Bowel Syndrome 3.06 7.85 10.70 1.90 22.45 
Liver Disease 0.12 0.48 0.83 1.03 3.47 
Migraine 1.86 14.11 14.72 4.98 23.92 
Multiple Sclerosis 0.16 0.52 0.83 0.24 0.88 
Osteoporosis 0.44 6.36 3.96 2.19 8.92 
Parkinson’s Disease 0.03 0.28 0.22 0.37 0.93 
Peripheral Vascular Disease 0.24 2.22 2.07 3.73 7.41 
Polymyalgia 0.08 0.71 0.33 0.72 1.08 
Psoriasis 1.45 3.90 4.07 4.43 5.46 
Psychosis 0.10 0.00 0.00 0.00 5.41 
Renal Stone 0.29 0.82 1.21 2.96 3.21 
Rheumatoid Arthritis 0.15 2.14 1.18 0.77 1.76 
Schizophrenia 0.31 0.77 0.54 0.38 10.19 
Scleroderma 0.01 0.20 0.08 0.00 0.19 
Sjogren’s Syndrome 0.00 0.46 0.24 0.04 0.58 
Sleep Problem 0.27 3.73 3.69 2.33 11.83 
Stroke 8.24 7.75 6.18 10.25 13.17 
Systemic Lupus Erythematosus 0.01 0.18 0.09 0.01 0.45 
Tuberculosis 0.18 0.65 0.75 0.56 1.14 
Vision Problem 0.08 0.30 0.35 0.69 1.94 
COPD- Chronic obstructive pulmonary disease; *Cluster 1- Relative healthy; Cluster 2- Metabolic; Cluster 3- 
MSK; Cluster 4- CV; Cluster 5 MSK-MH; ^only for men 
CV- Cardiovascular; MSK- Musculoskeletal; MH- Mental health 
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Table 5.3-15. Posterior probabilities distribution of chronic conditions to five-class model 












Anaemia 0.34 4.08 4.52 16.99 12.82 
Ankylosing Spondylitis 0.00 2.46 0.00 2.99 3.96 
Arterial/Venous 0.05 0.73 1.28 7.71 1.00 
Asthma 1.77 11.68 9.10 11.53 16.07 
Back pain 5.12 65.93 39.58 73.60 74.42 
Benign prostatic hypertrophy^ 0.70 6.58 0.44 2.48 5.17 
Cancer (any) 1.81 14.67 12.97 21.23 14.03 
Cataract 4.77 3.88 6.17 13.73 8.99 
Chronic Heart Disease 0.83 8.01 16.00 47.88 14.11 
Chronic Kidney Disease 0.00 2.55 30.89 48.75 28.45 
COPD 0.93 10.78 6.95 22.51 13.09 
Dementia 0.47 2.98 3.68 8.59 9.75 
Depression 1.94 23.31 10.27 28.53 53.02 
Diabetes 0.64 6.14 27.38 37.78 20.73 
Epilepsy 0.23 1.62 1.09 2.32 2.52 
Fatigue 0.02 1.57 0.43 2.87 6.34 
Fibromyalgia 0.00 0.48 0.00 0.32 3.95 
Gall stones 0.46 7.35 5.55 13.58 15.99 
Gastritis 0.27 9.39 2.96 23.68 14.26 
Gastrointestinal Bleed 0.00 1.47 0.38 6.91 3.42 
Gout 0.19 2.83 9.22 17.60 1.90 
Hearing Problem 2.24 23.89 17.81 36.87 25.63 
Heart Failure 0.03 0.40 2.36 14.34 2.32 
High Cholesterol 1.68 18.95 30.99 40.75 31.60 
HIV/AIDS 0.00 0.00 0.01 0.00 0.00 
Hypertension 5.06 29.19 75.68 73.51 54.34 
Hyperthyroidism  0.09 0.01 1.82 1.38 11.56 
Hypothyroidism 0.95 4.41 10.50 10.32 35.42 
Inflammatory Bowel Disease 0.21 6.72 2.37 11.75 11.26 
Irritable Bowel Syndrome 3.32 6.98 0.68 6.02 15.50 
Liver Disease 0.07 0.64 0.49 1.41 1.41 
Migraine 0.62 7.89 2.51 6.27 15.09 
Multiple Sclerosis 0.10 0.57 0.14 0.18 0.92 
Osteoporosis 0.78 9.52 4.60 11.40 23.09 
Parkinson’s Disease 0.10 1.31 0.74 1.95 2.13 
Peripheral Vascular Disease 0.26 2.96 3.35 17.22 4.66 
Polymyalgia 0.18 1.57 1.89 3.41 5.29 
Psoriasis 0.57 4.15 3.55 4.91 4.18 
Psychosis 0.05 0.00 0.00 0.01 3.64 
Renal Stone 0.11 1.95 1.59 4.03 0.77 
Rheumatoid Arthritis 0.14 0.87 0.68 1.20 2.09 
Schizophrenia 0.16 0.40 0.19 0.36 8.16 
Scleroderma 0.00 0.07 0.02 0.10 0.34 
Sjogren’s Syndrome 0.01 0.16 0.05 0.28 1.09 
Sleep Problem 0.02 3.72 1.90 7.07 8.01 
Stroke 14.39 8.67 14.14 28.97 17.28 
Systemic Lupus 
Erythematosus 0.00 0.05 0.03 0.16 0.31 
Tuberculosis 0.11 1.00 0.53 1.65 1.13 
Vision Problem 0.05 0.68 0.99 4.03 2.30 
COPD- Chronic obstructive pulmonary disease; *Cluster 1- Relative healthy; Cluster 2-MSK; Cluster 3-CV; 
Cluster 4-CV- MSK; Cluster 5-MSK-MH; ^only for men 




Table 5.3-16. Posterior probabilities distribution of chronic conditions to five-class model 












Anaemia 0.41 15.22 20.51 8.27 7.37 
Ankylosing Spondylitis 0.00 3.42 3.32 0.00 0.88 
Arterial/Venous 0.00 1.39 7.79 1.66 2.60 
Asthma 0.87 12.33 9.99 8.26 8.58 
Back pain 2.53 72.76 72.32 34.35 41.47 
Benign prostatic hypertrophy^ 6.58 0.70 2.48 0.44 5.17 
Cancer (any) 0.86 14.74 20.87 15.63 19.26 
Cataract 24.49 38.45 38.40 23.20 43.88 
Chronic Heart Disease 0.27 14.86 51.76 20.98 16.33 
Chronic Kidney Disease 0.11 32.93 61.53 52.40 8.27 
COPD 0.69 10.29 21.03 5.49 13.57 
Dementia 1.96 27.58 13.29 11.64 33.71 
Depression 0.59 39.67 25.44 11.44 14.06 
Diabetes 0.87 9.97 32.06 26.35 7.60 
Epilepsy 0.13 2.37 1.82 1.15 1.79 
Fatigue 0.04 3.83 2.74 1.13 0.88 
Fibromyalgia 0.00 0.51 0.36 0.00 0.02 
Gall stones 0.02 10.61 15.74 5.95 7.54 
Gastritis 0.06 9.84 22.73 3.65 10.11 
Gastrointestinal Bleed 0.00 4.09 7.69 1.07 3.53 
Gout 0.06 1.75 17.82 7.88 3.88 
Hearing Problem 1.83 44.84 48.16 25.87 47.30 
Heart Failure 0.04 4.97 23.66 7.04 6.56 
High Cholesterol 0.30 15.01 32.11 21.86 4.03 
HIV/AIDS 0.00 0.00 0.03 0.00 0.00 
Hypertension 5.65 58.96 76.19 83.76 35.56 
Hyperthyroidism  0.06 6.01 3.70 2.52 0.00 
Hypothyroidism 0.98 22.15 16.98 16.40 3.08 
Inflammatory Bowel Disease 0.00 9.18 12.15 2.51 6.16 
Irritable Bowel Syndrome 2.27 9.62 4.96 1.24 2.18 
Liver Disease 0.06 0.36 0.91 0.11 0.42 
Migraine 0.06 7.59 4.97 1.78 1.94 
Multiple Sclerosis 0.00 0.00 0.16 0.05 0.08 
Osteoporosis 0.54 37.95 15.27 8.24 9.67 
Parkinson’s Disease 0.15 2.82 1.87 0.90 1.98 
Peripheral Vascular Disease 0.00 4.97 16.70 5.46 3.56 
Polymyalgia 0.25 8.19 6.24 3.10 2.35 
Psoriasis 0.00 4.05 4.42 2.29 2.43 
Psychosis 0.00 2.65 0.00 0.00 0.00 
Renal Stone 0.00 0.67 2.85 0.44 2.24 
Rheumatoid Arthritis 0.03 1.26 1.07 0.41 0.73 
Schizophrenia 0.08 5.33 0.33 0.19 0.29 
Scleroderma 0.00 0.17 0.05 0.00 0.00 
Sjogren’s Syndrome 0.00 0.82 0.21 0.10 0.00 
Sleep Problem 0.59 13.96 14.84 3.84 11.41 
Stroke 21.24 26.03 36.05 21.09 18.09 
Systemic Lupus Erythematosus 0.00 0.14 0.04 0.00 0.00 
Tuberculosis 0.02 2.16 0.93 0.58 0.78 
Vision Problem 0.06 8.17 7.99 2.60 5.35 
COPD- Chronic obstructive pulmonary disease; *Cluster 1- Relative healthy; Cluster 2- MSK; Cluster 3- CV-
MSK-Renal; Cluster 4- CV-Renal; cluster 5- Hearing-vision problem; ^only for men 




The distribution of socio-demographic characteristics across the clusters in people without 
OA is provided in Table 5.3-17. The proportion of women was higher in all the clusters 
except in metabolic syndrome. Nearly 68% in the metabolic syndrome and 86% in the 
CVD and MSK clusters were aged 60 years or more, whereas the other three clusters had 
younger populations. Smoking prevalence was highest (52%) in the CV-MSK cluster 
(cluster n). The prevalence of obesity was 26% in CV cluster and 25% in the thyroid-MH 
cluster, followed by 23% in the CV-MSK cluster. The mean number of chronic conditions 
was highest for the CV-MSK (7.78; SD 1.84) and thyroid-MH(5.46; SD 2.01) clusters. 
(Table 5.3-17) 
Table 5.3-17. Socio-demographic distribution across clusters in the non-OA population 











Gender      
  Men  38510 (42.79) 1432 (18.98) 10363 (46.28) 33000 (49.83) 10590 (29.70) 
  Women 51483 (57.21) 6113 (81.02) 12027 (53.72) 33223 (50.17) 25066 (70.30) 
Age       
  <40 years 9224 (10.25) 295 (3.91) 47 (0.21) 880 (1.33) 2572 (7.21) 
  40-59 years 46747 (51.95) 3000 (39.76) 2633 (11.76) 20061 (30.29) 18838 (52.83) 
  60-79 years 30472 (33.86) 3597 (47.67) 14452 (64.55) 38548 (58.21) 13273 (37.23) 
  >=80 years 3550 (3.94) 653 (8.65) 5258 (23.48) 6734 (10.14) 973 (2.73) 
Smoking       
  Never smoked 52782 (58.66) 4173 (55.32) 10700 (47.79) 37516 (56.66) 18710 (52.48) 
  Current smoker 17743 (19.72) 1550 (20.55) 3372 (15.06) 9280 (14.01)   8292 (23.36) 
  Ex-smoker 19459 (21.62) 1821 (24.14) 8316 (37.14) 19420 (29.33)   8651 (24.26) 
Alcohol use      
  Never  14616 (16.24) 2053 (27.21) 5692 (25.43) 12423 (18.76)   6607 (18.54) 
  Ex-drinker 1444 (1.60) 344 (4.56) 1018 (4.55) 1599 (2.42)     944 (2.65) 
  Current (1-9) 35200 (39.12) 2494 (33.06) 7000 (31.27) 22544 (34.05) 13142 (36.87) 
  Current (>=10) 18808 (20.90) 819 (10.85) 3301 (14.75) 13746 (20.76)   6552 (18.38) 
  Current 
(Unknown) 
19906 (22.12) 1835 (24.32) 5376 (24.01) 15895 (24.01)   8397 (23.56) 
BMI      
  Underweight  1869 (2.08) 248 (3.29) 720 (3.22) 1034 (1.56)     939 (2.63) 
  Normal  39992 (44.46) 2858 (37.89) 7862 (35.12) 21168 (31.97) 14741 (41.35) 
  Overweight  32538 (36.17) 2592 (34.36) 8529 (38.10) 26914 (40.65) 12440 (34.90) 
  Obese 15549 (17.29) 1845 (24.46) 5277 (23.57) 17096 (25.82)   7527 (21.12) 
Mean age (SD) 56.30 (12.93) 62.27 (12.63) 72.23 (10.03) 65.42 (11.23) 57.18 (11.73) 
Mean BMI (SD) 26.02 (4.72) 26.87 (5.54) 26.83 (5.09) 27.42 (5.01) 26.45 (5.18) 
Multimorbidity 
(SD) 0.99 (0.94) 5.24 (1.94) 7.84 (1.87) 3.63 (1.44) 4.48 (1.51) 
      
      
BMI- Body mass index, SD- Standard deviation 




Table 5.3-18. Multinomial regression for associations between patient factors with cluster 




OR (95% CI) 
CV-MSK 
OR (95% CI) 
CV 
OR (95% CI) 
MSK-MH 
OR (95% CI) 
Gender      
  Men  1 Reference  Reference  Reference  Reference  
  Women 1 3.03 (2.85-3.23)* 0.81 (0.78-0.83)* 0.75 (0.73-0.77)* 1.86 (1.81-1.91)* 
Age       
  <40 years 1 Reference  Reference  Reference  Reference  
  40-59 years  1.97 (1.74-2.23)* 10.89 (8.15-14.55)* 4.39 (4.09-4.71)* 1.42 (1.36-1.49)* 
  60-79 years  3.61 (3.19-4.08)* 92.06 (69.05-122.73)* 13.38 (12.45-14.37)* 1.56 (1.49-1.64)* 
  >=80 years  5.26 (4.55-6.08)* 319 (239.32-427.73)* 22.81 (21.03-24.75)* 0.97 (0.89-1.05)* 
Smoking       
  Never smoked 1 Reference  Reference  Reference  Reference  
  Current smoker 1 1.43 (1.34-1.52)* 1.36 (1.30-1.42)* 0.87 (0.84-0.89)* 1.43 (1.39-1.48)* 
  Ex-smoker 1 1.38 (1.30-1.46)* 1.88 (1.81-1.95)* 1.17 (1.14-1.20)* 1.34 (1.30-1.39)* 
Alcohol use      
  Never  1 Reference  Reference  Reference  Reference  
  Ex-drinker 1 1.97 (1.75-2.26)* 1.76 (1.60-1.93)* 1.27 (1.17-1.38)* 1.50 (1.38-1.64)* 
  Current (1-9) 1 0.60 (0.56-0.64)* 0.58 (0.56-0.61)* 0.81 (0.78-0.83)* 0.88 (0.85-0.91)* 
  Current (>=10) 1 0.50 (0.46-0.55)* 0.55 (0.52-0.58)* 0.93 (0.89-0.96)* 0.93 (0.89-0.97)* 
  Current 
(Unknown) 
1 0.76 (0.71-0.82)* 0.77 (0.74-0.81)* 0.99 (0.95-1.02) 0.97 (0.93-1.01) 
BMI      
  Normal  1 Reference  Reference  Reference  Reference  
  Underweight  1 1.38 (1.19-1.59)* 1.40 (1.27-1.54)* 0.94 (0.87-1.02)* 1.23 (1.13-1.34)* 
  Overweight  1 1.27 (1.20-1.35)* 1.41 (1.35-1.46)* 1.52 (1.49-1.57)* 1.10 (1.07-1.14)* 
  Obese 1 1.85 (1.74-1.97)* 2.34 (2.24-2.45)* 2.39 (2.32-2.46)* 1.34 (1.29-1.39)* 
BMI- Body mass index, SD- Standard deviation; *P value<0.05 
CV- Cardiovascular; MSK- Musculoskeletal; MH- Mental health 
 
Table 5.3-18 describes the association of patient characteristics with cluster membership 
with healthy cluster as the reference group. Women had a higher risk than men of being 
in the thyroid-MH cluster (OR 3.01; 95% CI 2.83-3.20) and MSK-MH (OR 1.86; 95% CI 
1.81-1.91) clusters when compared to the gender ratio in the healthy cluster. Being an ex-
smoker increased the OR of being in all clusters when compared to the smoker to non-
smoker ratio in the healthy cluster. Obesity and overweight were found to be significantly 
associated with all the clusters when compared to the obesity to normal ratio in the 
healthy group cluster.  
5.3.4 Sensitivity analysis 
The sensitivity analysis revealed equal number and type of clusters in both the training 
and testing dataset. Identified cluster are relative healthy, MSK, CV, CV-MSK, MSK-MH 





This study used a patient-centred approach for examining clustering of the chronic 
conditions rather than the disease centred approach. Firstly, the whole population was 
examined to understand the clustering of other conditions with OA. Later, clusters within 
OA and non-OA population were explored separately. The following are the key findings 
from the study.  (1) There was a 54% probability that OA would be clustered with 
hypertension and back pain and a 35% probability that OA would  be in the back pain and 
depression cluster.  (2) Within both OA and non-OA people, clusters were centred around 
back pain, hypertension, depression, and thyroid problems. Within OA, the cluster size of  
CV-MSK, CV, and MSK-MH was more compared to that in non-OA. (3) In people with OA, 
age was strongly associated with MSK-MH (OR- 1.12; 95% CI 1.12-1.13), women had 
higher association with thyroid-MH cluster (OR- 5.45; 95% CI 5.05 -5.88), and obesity 
was associated with all the clusters with higher risk towards CV-MSK cluster (OR- 2.49; 
95% CI 2.39-2.59), and CV cluster (OR- 2.19; 95% CI 2.14-2.27).  (4) ex-smoker and ex-
drinkers had strong association with all the clusters, while current alcohol users were 
protective towards each cluster. Similar associations were found in the non-OA group. 
5.4.1 Clustering of OA in total study population  
 
For the clustering analysis in the total study population a sample of 1.4 million people was 
used. To my knowledge, this is the first  population based study to examine 50 chronic 
conditions, including OA. Two recently published studies on clustering of multimorbidity 
from a UK GP database (Zhu et al., 2020) and UK Biobank (Zemedikun D.T. et al., 2018) 
did not include OA as a chronic condition. It was unclear whether OA was grouped in the 
most commonly reported ‘painful’ clusters by Zhu et al. (Zhu et al., 2020) but OA was the 
fourth most chronic condition (13.14%) reported in this study among adults aged 20 years 
or more. Thus, ignoring this most common arthritis may not provide appropriate clinically 
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relevant patterns. Of six clusters identified, the interest for this study was to find the 
affinity of OA towards certain clusters. OA contributed mostly to the CV-MSK cluster 
(5.6%) followed by the MSK-MH cluster (7%). Some previous studies have included 
arthritis and rheumatological and musculoskeletal diseases (RMD). Islam et al found that 
arthritis with depression created a distinct cluster among people aged 50 years or above 
(Islam et al., 2014). A similar pattern was reported by Simoes et al who  found the 
clustering of RMDs with depression among adults aged 18 years and above (Simoes D. 
et al., 2018). As reported from the Spanish GP database study that examined the 
population  aged 65 years or above, I did not find a distinct musculoskeletal (MSK) cluster 
(Guisado-Clavero et al., 2018). LCA was used in the Newcastle 85+ study which identified 
clustering of OA and hypertension together (Collerton et al., 2016). Previous clustering 
analyses have varied widely in statistical methods used, age group of study population, 
the total number and types of chronic conditions included and the reporting of the 
conditions. In this study most of these MSK conditions coexisted with hypertension or 
depression and OA was not an exception. But looking at the clustering in different age 
groups, a clear shift in pattern for OA is observed. In the younger age group (20-39 years) 
OA did not appear in any clusters and in the age group 40-59 years it had the highest 
probability to be present with depression. However,  in later age it had equal probability to 
contribute to MSK, CV and depression clusters. The coexistence of OA with depression at 
each age group accords with findings from other studies. However, the distinct clustering 
with CV is of interest. The higher association with CV or metabolic syndrome and painful 
musculoskeletal conditions is well established (Hall et al., 2016) and has been explained 
through linkage of obesity, ageing, physical inactivity and subclinical inflammation leading 
to physiological changes (Prior et al., 2012; Rahman et al., 2013; Kim et al., 2016). 
Studies have shown the increased reporting of OA in MSK and vice versa (U. Kadam, 
Jordan, and Croft, 2004). Thus, perhaps people with both MSK and CVD are at increased 
risk of having OA within their clusters. A lot of research has been done to explain the 
nature of pain in OA in relation to  ‘central sensitization’ (Dua A. B et al., 2012; Lluch et 
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al., 2014) and the shared chronic pain mechanisms in  MSK conditions may explains the 
possible clustering. Even though the association of depression and OA were not 
conclusive (Stubbs et al., 2016b), a strong association was found both before and after 
the diagnosis of OA  (Chapter 4, Figure 4.3-3, page 125). It may be that depression is not 
directly associated with structural OA, but it can mediate the pain experience through 
sleep disturbances and pain sensitisation. The coexistence of OA with CVD and 
depression increases the challenges for management of all these conditions. People with 
OA should be assessed for CVD and psychological problems, and vice versa. Also, the 
clustering with CVD warrants further research to explain the pathophysiological 
association with OA and metabolic syndrome.  
5.4.2 Clustering in people with OA 
 
The five identified clustering patterns in OA for all the population from this study were a 
relatively healthy group, a cluster led by hypertension only (CV) cluster, a hypertension 
and back pain together (CV-MSK) cluster, a thyroid only (metabolic) cluster, and a 
combined back pain and depression (MSK-MH)  cluster. The largest cluster seen in 
people with OA after relative healthy group is led by CV followed by the MSK-MH cluster. 
This suggests that one third of the population with OA live with hypertension and nearly 
one fourth with depression and other MSK disorders. This together represents more than 
50% of total OA population indicating the common occurrence of other conditions. In a 
comparatively smaller sample of 769 patients, a previous study reported hypertension to 
be clustered with OA compared to other rheumatic musculoskeletal diseases (RMDs) 
(Ziade et al., 2020). A gender difference was found in the pattern of clusters within OA. 
Men had four clusters compared to women among whom the additional thyroid cluster 
was more prominent. Also, across age groups the clusters varied in numbers, type, and 
size. In the younger group aged 20-39 years, a clear group of MSK and MH was seen. 
Whereas, in the middle age group of 40-59 years thyroid appeared as one of the clusters. 
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Park et al reported that arthritis was clustered with thyroid and this cluster had a 
significant association with female (Park, Lee and Park, 2019). The change in clusters 
with age is understandable because of the strong associations of chronic conditions and 
multimorbidity with age. However, identification of depression and back pain clusters 
separately in younger age suggests a high burden of these two conditions. The CV 
clusters evolved with increasing age and were present in combination with back pain and 
other conditions in the later age group. This complexity of clusters gives idea about the 
possible patterns of co-existence of two or more chronic conditions. Their 
pathophysiology needs to be explored further. In older age (>80 years) chronic kidney 
disease and hearing problems became more prominent. Zhu et al also reported hearing 
problems as one of the leading conditions in one of their identified clusters (Zhu et al., 
2020). This could be because of the high prevalence of such conditions in the elderly 
population and survivor bias from CV.  
The demographic characteristics distribution across different clusters in OA partially 
explains the observed pattern. For example, people in the CV-MSK cluster were on 
average nearly 14 years older than those in the relative healthy cluster and the MSK-MH 
cluster. This suggests the combination of CV and MSK conditions is common in the older 
population, whereas the MSK-MH cluster had the youngest age which reinforces the 
findings from the age specific clusters. Overall, the percentage of women was high in 
thyroid-MH cluster which validates the gender specific analysis that had an additional 
cluster for thyroid diseases. The class size of the CV-MSK cluster was higher for men 
compared to women, whereas the percentage of women was higher  in the thyroid-MH, 
and MSK cluster. A similar finding was reported previously, where in women back pain 
was more frequent with depression while in men back pain was more frequent with CV 
(Scherer et al., 2016). 
It is interesting to know the burden of chronic conditions in each group. The mean number 
of chronic conditions was highest for the CV-MSK cluster and lowest for the CV group. 
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The burden of multimorbidity in CV-MSK cluster can be either related to age (as the 
cluster had the oldest age population) or the coexistence of these two conditions might 
have led to the appearance of other conditions. The second highest burden of 
multimorbidity was seen for the thyroid-MH cluster. Even though the cluster is led by 
thyroid, the contribution of hypertension and other CV is still high compared to other 
clusters. The association of all risk factors studied such as age, smoking, obesity, and 
alcohol use with cluster membership was the highest for the CV-MSK cluster. All these 
risk factors are well known for CV. This suggests the people of this clusters are with 
unhealthy lifestyle behaviours can be identified as the ‘high risk’ group from early dates. 
Women had a higher likelihood of being in  thyroid-MH clusters. This supports the results 
from multimorbidity in a chronic pain study (Scherer et al., 2016; Park, Lee, and Park, 
2019). Obesity was found to be strongly associated with clusters led by hypertension. As 
a well-established risk factor for both CVD and MSK, obesity can be considered to have a 
significant role in developing such a cluster.  
5.4.3 Clustering in people without OA 
 
A similar clustering pattern in the non-OA group across both gender and age was that of 
OA. The purpose of doing cluster analysis in the non-OA group was to identify any pattern 
that was different from OA. Even though the pattern in non-OA was like that in OA, two 
major notable differences are the class sizes and predominance of hypertension in most 
of the clusters. The reason of not finding very drastic differences in clustering pattern was 
due to the distribution of the chronic conditions in both groups. In OA and non-OA, the 
sequence of the leading conditions was the same except for few variations. In OA, the 
frequency of back pain was the highest whereas, in non-OA hypertension was top of the 
list. In non-OA there were nearly 7% of more people in the relatively healthy cluster 
compared to the OA group. This indicates the burden of chronic conditions was less in the 
non-OA group at all ages and in men and women, which underpins the findings from the 
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previous chapter. Also, the class size the cluster led by depression and back pain was 
higher in the OA group than that of non-OA, which indicates the nexus of chronic pain and 
depression in OA. A similar pattern was reported from the UK CPRD database (Cassell A. 
et al., 2018). In the elderly population, the non-OA group had a separate cluster of 
hearing and vision problems and a low contribution from ‘back pain’ to each cluster.  
In terms of membership of single conditions within clusters in both the OA and non-OA 
groups, back pain, depression, and hypertension played a central role in identification of 
clusters. Similar patterns have been reported in previous studies (Prados-Torres et al., 
2014; Deruaz-Luyet A. et al., 2017; Zemedikun D.T. et al., 2018; Zhu et al., 2020). The 
systematic review of 14 studies on multimorbidity clusters found three prominent clusters 
of  CVD, MH and MSK, similar to this study (Prados-Torres et al., 2014). In the OA 
population the class size of chronic pain either with hypertension or depression was high 
compared to non-OA. Both chronic pain and depression are recognised as having a major 
impact on health service use (Payne et al., 2013). Findings from this study emphasise the 
importance of ensuring psychological care and management of pain in younger life (Das, 
Naylor and Majeed, 2016). Chronic pain presence in most of the clusters and having 
highest multimorbidity burden with CV, needs further investigation. So, along with CV and 
depression, chronic pain should be considered as one of the major chronic conditions for 
multimorbidity clusters.  
5.4.4 Strength and limitations  
 
The clustering analysis in this study was done among 1.4 million patients and examined 
50 chronic conditions including OA. This is the first study in this area to use such a large 
sample size, such an extensive disease list, and to include OA as a condition. The use of 
a broad list of conditions, large database and real presentation of the health system 
strengthens the study. The gender and age strata specific clusters provide further insight 
into the changing nature of the pattern of clusters during the life course. Also, inclusion of 
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the adult population aged 20 years or more, compared to other studies which largely 
focus on the elderly population, which makes results from this study more representative 
to the total population. Although various clustering methods have been devised, I 
compared many of these including the machine learning approach and found LCA 
provided the best fit model. Another strength of this study is the examination of the 
association of baseline risk factors with identified clusters which provided clinically 
important information. Even though no wide diverse clusters were found, as  reported in 
some other studies, the distribution of age and multimorbidity across the clusters provides 
internal validity.  
There are some limitations to this study, most of which are inherent in  electronic health 
record research. There is the possibility of misdiagnosis, mis-recording and 
misclassification bias for OA and other conditions studied. However, all possible steps 
were taken to use the validated codes and those not validated were screened thoroughly 
by this study team. As data were from diagnoses recorded in a GP database the findings 
represent the burden on the health care system rather than the burden within the whole 
community. The chance of under/over reporting of conditions are inevitable in such 
databases. Clustering of binary data (disease yes/no) is an evolving methodological field 
of research. 
5.4.5 Conclusion  
 
Identified multimorbidity clusters provide information about the burden of the conditions in 
people with OA and in the non-OA control group. Firstly, the metabolic pathology of OA 
should be examined to understand its strong affinity toward CV. Within OA, the distinct 
groups represent the clear burden of conditions, especially CV, MH, and MSK. The 
pattern of MSK and MH clusters in the younger age group justifies  future study of 
longitudinal changes in clusters. Also, outcomes associated with  cluster membership can 
be studied to emphasize the severity of the clusters in each group. Improving care in 
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multimorbidity is a difficult challenge which has not been fully successful because of the 
complexity of disease patterns (Smith et al., 2012, 2016). One reason for the failure of 
previous interventions is that multimorbidity is heterogeneous, with very different 




Summary of  Chapter 5 
 
In the previous chapter (Chapter 5) we explored the pattern of existence of the 
chronic conditions in people with OA and matched controls.  
Key findings from the chapter are: 
• OA is more likely to be present in people with hypertension and back pain 
(54%), followed by people with back pain and depression (35%). 
• Hypertension, back pain, depression, and thyroid diseases were the leading 
conditions cluster wise. However, in people with OA a greater number of 
people had co-existence of cardiovascular and musculoskeletal, 
cardiovascular only, and musculoskeletal and depression together.  
• Age was significantly associated with cardiovascular and musculoskeletal 
cluster, while women had more likelihood of belonging to thyroid cluster. 
• Obesity, ex-smoker, and ex-drinkers had strong association with all the 
clusters, while current alcohol users were protective towards each cluster. 
 As the clusters centred around cardiovascular, musculoskeletal, depression and 
thyroid diseases are established through this chapter, the next question it brings to 
understand how people move from one cluster to another over time. Which 
clusters identified at the time of diagnosis of OA remain stable (does not change in 
size) and which does? Chapter 6 explores the transition of people across the 





6 Chapter 6  




In Chapter 5, the clustering pattern of comorbidities at the index date is reported. In both 
OA and non-OA groups, 5 clusters were identified. As the study population is dynamic 
and has been followed up to a maximum of 20 years, it is possible to examine whether 
identified clusters at the index date remain the same or change throughout follow-up. 
There are high possibilities of changes in the clusters over time because of ageing and 
the diagnosis of new conditions. Moreover, the dynamic properties of change in clusters 
are time-dependent and latent in nature and  may  be influenced by other factors not 
captured or recorded in the database. Thus, the basic assumption is that the clusters can 
be influenced not only by known and observable factors, but also by unknown latent 
conditions which change with time.  
Also, the clusters identified after the diagnosis of OA are related, so there is possible 
transition of people from one cluster to other. Understanding the proportion and 
probabilities of people transition from one cluster to another would be beneficial for 
clinicians. This would also help to understand the evolving path of each clusters. To my 
knowledge, no studies have explored the dynamic changes in clusters over time not even 
the repeated cross-sectional nature.  
In the previous chapter (chapter 5) it was seen, the nature of the clustering of 
comorbidities varied across different age group. In the younger population, psychological 
and musculoskeletal conditions were common while with increase in age, cardiovascular 
conditions were becoming prominent. Even though the study  
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population in each of the age group studied were not constant, the change in clusters 
suggest the dynamic nature of the comorbidities coexistence worth investigating. Also, it 
was not clear how these clusters change in an individual after the diagnosis of OA. This is 
only possible by following a group of people after the diagnosis of OA.  
Therefore, latent transition analysis (LTA) and repeated measures of LCA (RMLCA) were 
used to estimate the probabilities of transition of clusters over time. Using this 
methodology, the objectives of this study were to determine:  (1) the probability that an 
individual will be in different latent clusters over time; (2) whether there are changes 
between latent clusters across time; (3)  the probability of moving from one cluster at time 
t to another in time t+1; and (4) whether any change in latent clusters with time are 
influenced by the baseline characteristics? 
6.2 Methods 
 
6.2.1 Study subjects 
 
Data identified for LCA analysis (Chapter 4, section 4.2.2) in both OA and non-OA  
individuals were used for this analysis. Each person in the database was followed until 
31st December 2017 or until they died or left the database. All available data at each time 
point was used considering the missing data at each follow-up to be missing at random 
(MAR), an assumption required for the analysis. The missingness of data could be due to 
death, transfer out from the database or no observation being recorded. Details of the 
individual at each time point are provided in Figure 6.3-1. Very few individuals were 
available at the 20 years follow-up after index date. Therefore, the transition model was 
analysed up to 15 years after the index date to avoid biases due to small sample sizes at 
20 years.  




Forty-nine previously used chronic conditions were used for LTA. Covariates such as age, 
gender, BMI, smoking, alcohol, and time were also used in the model. The model was 
fitted to a patient database of OA and non-OA, separately with 49 chronic conditions 
coded as no ‘1’ or yes ‘2’. The status of chronic conditions was recorded at the index date 
and at each five years interval afterwards (i.e., at 5, 10 and 15 years). The reasons for 
selecting a five year gap were to reduce the number of transition points to avoid 
complexity, and because the chronical nature of the comorbidities.  Every 5 years may be 
more adequate than every year to catch the significant changes.  
6.2.3 Statistical analyses 
LTA was used for the main analysis. LTA was primarily developed for the analysis of 
longitudinal data and to deal with categorical response variables. Generally, it can be 
considered as an extension of LCA allowing each subject to move between the clusters 
over time. These models use time-specific discrete latent variables (Ryoo et al., 2018). 
Ryoo et al proposed six steps for doing LTA variables (Ryoo et al., 2018), specifically: 
1) Explore the cross-sectional data using LCA  
2) Test longitudinal measurement invariance using LTA 
3) Define latent statuses 
4) Test latent statuses and transition probabilities 
5) Include covariates 
6) Include distal outcomes 
Of these six steps, step 6 is not applicable to the current study. There is no outcome of 
interest for this study except to understand the nature of the transition.  
LMest package was used from R to do LTA. Advantages of this package are: (1) it can 
deal with univariate and multivariate categorical outcomes; (2) it allows for missingness, 
dropout, under the assumption of missing-at-random (MAR); (3) it is computationally 
easy; and (4) random effects can be added for Latent Markov models. LMest uses a log-
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likelihood maximization procedure as does LCA for parameter estimation. So, both BIC 
and AIC criteria were used to choose the best model and the change in log-likelihood ratio 
and percentage of observation in each class. LTA provides three parameters -  
conditional response probabilities, initial probabilities, and transition probabilities. 
Conditional probabilities explain the characteristics of latent classes, i.e., the probability of 
one condition being present given the condition belongs to the class. Initial probabilities 
describe the latent class structure and sizes at baseline. Lastly, transitional probabilities, 
which are the interest of this analysis, give information on the dynamics of the latent 
process at each time point.  
Step-1: The LTA approach used here is quite like models used elsewhere. Before 
running the model, the assumption of non-varying number of clusters was checked 
using RMLCA at each time point and the number of classes identified were matched 
with the statistical parameters obtained from LTA.  
Step-2: As same number of clusters and similar clusters at each time were obtained, 
this meets the assumption of longitudinal measurement invariance. So, no further 
statistical test was done for this purpose.  
Step-3: Latent classes were defined based on the conditional probabilities of chronic 
conditions in each class. Both initial probabilities and latent classes at each time point 
were estimated.  
Step-4: Latent status and transitional probabilities were estimated using the LTA 
model for each time point. 
Step-5: Along with time, age at each follow-up time, gender, smoking, alcohol, and 
BMI were included as covariates in the model while determining LTA. Association of 
covariate on transition probabilities could not be estimated due to different sample 
sizes at each time point. 
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6.2.4 Sensitivity analyses 
Sensitivity analyses was done among OA and non-OA group without any comorbidity at 
the index date using RMLCA, since there were high possibilities of a change in number of 
comorbidity clusters over time as they had none at the index date.  
Repeated measures latent class analysis (RMLCA) 
Another method used to explore the transition over time is RMLCA. It is an ideal method 
when the number of latent classes or clusters differ over time (i.e., not constant). It 
estimates LCA at each observation period cross-sectionally not considering the transition 
part. This means multiple LCA models are run for each of the time points and later these 
are merged with the patient unique identification number in the database to compute the 
change in clusters. Technically, this describes the changes in clusters more qualitatively 
than quantitatively. Individuals with similar clustering patterns are expected to be 
members of the same latent class. But at the same time, it captures and identifies the 
estimated size of subpopulations in each latent class over time. 
While estimating LCA at each time point, the same population was used as described in 
Table 1. A group for the missing data was created to understand the pattern of clusters. 
The change of individuals within each cluster at each time point was estimated by 
calculating the pattern of the trajectory. The plot was created using ‘ggparallel’ in R. The 
parallel diagram depicts the clusters and the size of the link from one time to another and 
indicates the volume of individuals who have moved from one cluster to another. Also, the 
pattern of 20 leading trajectories have been reported having a proportion of >= 1%. Model 





There was a high attrition rate in the OA group compared to the non-OA group at each time 
point. After five years from the index date, nearly 43% and 32% were missing in the OA and 
non-OA groups respectively, which further increased at each follow-up time.  
               OA             Non-OA 
Figure 6.3-1. Flow chart showing numbers at each time point in both OA and non-OA populations 
 
At the index date 
N=221,807 
After 5 years 
N=127,815 
After 10 years 
N=56,962 
After 15 years 
N=15,754 












At the index date 
N=221,807 
After 5 years 
N=152,130 
After 10 years 
N=81,075 
After 15 years 
N=26,043 














The baseline sample characteristics have been described previously in Chapter 4, Table 4.3-
1.  A summary  of the key population characteristics at each follow-up time  is given in Table 
6.3-1. In both OA and non-OA groups the percentage of women at baseline was 57.7% 
which declined faster in the OA compared to non-OA group over time. Mean age of 
individuals at the index date was nearly 61 years in both groups. However, at each follow-up 
time the mean age of the non-OA was higher compared to the OA group. Mean BMI was 
higher in the OA group at the index date and remained nearly consistent throughout  follow-
up in both groups. However, the mean number of comorbidities in the OA group at index 
date was 2.45 compared to 1.84 in the non-OA group, and it continued to increase to 4.02 
and 3.41 after 20 years in the OA and non-OA groups, respectively. (Table 6.3-1) 





















8712 (55.30) 516 (53.69) 
Age (Years)  
(Mean, SD) 




28.28 (5.63) 28.39 (5.63) 28.54 (5.63) 28.69 (5.65) 28.85 (5.54) 
Number of 
comorbidities 
(Mean, SD)  
2.45 (2.15) 3.07 (2.43) 3.60 (2.68) 4.01 (2.86) 4.02 (2.96) 








14492 (55.65) 939 (55.01) 
Age (Years) 
(Mean, SD) 




26.62 (4.98) 26.58 (4.94) 26.59 (4.92) 26.64 (4.87) 26.69 (4.90) 
Number of 
comorbidities 
(Mean, SD)  
1.84 (1.88) 2.36 (2.15) 2.83 (2.38) 3.21 (2.55) 3.41 (2.67) 




6.3.1 LTA defined latent classes (initial and conditional probabilities) in 
OA 
 
Appendix Table 25 (page 335) shows fit indices for different number of classes based on the 
LTA models. Based on the model statistics selected the five-class model to be the best for 
both the OA and non-OA groups, which is similar to clusters that were found in LCA. 
(Appendix Table 25, page 335) Five identified clusters were named as per the posterior 
probability distribution of the chronic conditions. Initial probabilities of clusters at baseline 
identified five clusters. Cluster 1 was the relatively healthy (37.6%) group with lower 
probability of each conditions. Cluster 2 was dominated by back pain and hypertension 
(8.11%) (known as CV-MSK), cluster 3 had higher contribution from back pain (16.71%) 
(MSK cluster), cluster 4 was predominantly hypertension (16.08%) (CV cluster), and cluster 
5 was led by depression (21.51%) (MH cluster). Details of the contribution from each 
condition are given in Appendix Table 26 (page 336). The percentage in the bracket against 
each cluster represents the initial probabilities at the index date. Figure 6.3-2 depicts the 
estimated probabilities of clusters at each time point in OA. Amongst the five clusters, CV-
MSK cluster increased in size at follow-up time from 8.11% at index date to 16.9% after 15 
years. A marginal increase in cluster size was seen for CV and MH clusters, whereas in both 
















Figure 6.3-2. Different latent classes at each time point in the OA population. 
 
 
CV- Cardiovascular; MSK- Musculoskeletal; MH- Mental health 
6.3.1.1 Transition between clusters and trajectory paths in OA (transitional 
probabilities) 
 
The LTA fitted model was used to classify individuals at each time-point according to their 
maximum posterior estimated class probability. Figure 6.3-3 depicts the path of transition of 
each cluster with time in the OA group. Detailed transition is provided in Appendix Table 28 
(page 338). 
The most common paths were those with membership of the same cluster over adjacent 
years. For example, all the people in CV-MSK cluster at index date stayed in the same 




Figure 6.3-3. Estimated frequency of cluster transitions in the OA population. 
 
  
The circles represent clusters (not proportionate to size). Thickness of each black line/bar is proportional to the 
estimated transition frequency. Dashed line represents 5-10% frequencies. For clear presentation, transition 
frequencies <5% are not shown here. For detail, please refer to Appendix Table 28 (page 338).  
From the index date to year 5 all the transitions into subsequent clusters were stable, while 
nearly 15% in each moved from CV to CV-MSK and from relative healthy to cluster CV. 
During the year 5 to year 10 period, besides moving to the same clusters nearly 20% 
individuals from CV, MH and relative healthy clusters moved to CV-MSK and 15% moved 
from relative healthy to CV. Transition during years 15 to 20 to the same clusters was less in 
MH and CV clusters compared to the rest. Nearly 40% of individuals moved from CV, 
relative healthy clusters, and MH to CV-MSK cluster. After year five, the most common path 
was towards CV-MSK cluster from each cluster and at each time point nearly 12% of 
individuals moved from relatively healthy to CV cluster.  
Of the total transition pattern, 30% happened in the relative healthy cluster path, 20% 
occurred in MH cluster path and 12% were in CV clusters path. Nearly 8% of total transition 
had from MSK cluster to CV-MSK cluster at year 10 or 15. Transitions more than 1% are 
given in Appendix Table 30 (page 334).  
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6.3.2 Different latent classes at each time point in the non-OA population 
 
Five clusters were identified in the non-OA group at the index date. These were cluster 1 
(41.36%) which was the relative healthy group, cluster 2 (8.91%) which was dominated by 
back pain and hypertension (CV-MSK), cluster 3 (7.69%) which was led by thyroid disorder 
(hence known as metabolic cluster), cluster 4 (19.36%) which was largely led by 
hypertension (CV cluster), and cluster 5 (22.67%) which was led by depression (MH cluster). 
Figure 6.3-4 presents the size of different clusters identified at each time in the non-OA 
group. Metabolic cluster size reduced from 7.7% to 4.6% after 15 years and relative healthy 
cluster size decreased by 7% after 15 years. The size of MH cluster remained mostly 
constant at each time, whereas the size of CV-MSK and CV increased from the index date. 
Details of the distribution of the conditions in each class is given in Appendix Table 27 (page 
337). 
Figure 6.3-4 Different latent classes at each time point in the non-OA population. 
 
CV- Cardiovascular; MSK- Musculoskeletal; MH- Mental health 
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6.3.2.1 Transition across clusters in the non-OA population 
 
In the non-OA group, less frequent transition was seen compared to the OA group. Similar 
trajectory paths seen in OA group were seen but became more distinct after year 10. From 
the index date to year 5, 15% of individuals moved from relative healthy to CV cluster and 
10% combined moved from CV and MH clusters to cluster CV-MSK. CV-MSK cluster was 
seen to be more stable during the transition period. During years 5 to 10 and 10 to 15, nearly 
30% of individuals moved from CV and MH clusters to CV-MSK cluster at each phase. 
During the period year 10 to 15 a small proportion of <5% were seen to move from relative 
healthy to CV cluster. (Figure 6.3-5) Details of the transition are given in Appendix Table 29 
(page 339). 
Figure 6.3-5 Estimated frequency of cluster transitions in the non-OA population 
 
 
The circles represent clusters (not proportionate to size). Thickness of each black line/bar is proportional to the 
estimated transition frequency. Dashed line represents 5-10% frequencies. For clear presentation, transition 






6.3.3 Sensitivity analysis 
 
Transition analysis was done in the second patient cohort i.e., OA cases and controls 
without any comorbidities at the index date and matched for age, sex, and practice.  

















An equal number (n=22,333) of cases and controls were followed until 20 years.  Details of 
the number of individuals at each time point are given in Figure 6.3-6.  After 15 years, only 
38% of OA and 42% of non-OA patients were left in the group. The attrition rate was higher 
in the OA group compared to the non-OA group.   
Figure 6.3-6 Flow chart showing numbers at each time point (sensitivity analysis) in both groups 
At the index date 
N=22333 
After 5 years 
N=14963 
After 10 years 
N=8000 








At the index date 
N=22333 
After 5 years 
N=15533 
After 10 years 
N=9475 










At the beginning of the follow-up 52.4% were female in each group which reduced to 50% in 
both OA and non-OA group after 15 years from index date. Similarly, mean age at baseline 
increased from 57 years to 66 years in OA and to 67 years in the non-OA group.  At index 
date, mean BMI was higher in the OA group which continued to increase at each follow-up 
time, while in the non-OA group it remained nearly constant. The mean number of 
comorbidities increased subsequently in both the groups. (Table 6.3-2) 











OA N=22333 N=14963 N=8000 N=3200 
Gender (% Female) 11711 (52.43) 8084 (51.32) 4216 (49.99) 1644 (48.67) 
Age (Years)  
(Mean, SD) 
56.71 (13.55) 60.26 (13.38) 63.19 (12.81) 65.97 (12.30) 
Body mass index 
(Mean, SD)* 
28.44 (5.68) 28.55 (5.63) 28.70 (5.63) 28.85 (5.65) 
Number of 
comorbidities 
(Mean, SD)  
0 (0) 0.43 (0.80) 0.84 (1.30) 1.27 (1.72) 
Non-OA N=22333 N=15533 N=9475 N=3506 
Gender (% Female) 11711 (52.43) 8425 (51.53) 4997 (50.03) 1823 (49.25) 
Age (Years) 
(Mean, SD) 
56.53 (13.58) 60.55 (13.46) 64.01 (13.37) 66.54 (13.12) 
Body mass index 
(Mean, SD)* 
26.80 (5.05) 26.73 (5.00) 26.74 (4.99) 26.84 (4.98) 
Number of 
comorbidities 
(Mean, SD)  
0(0) 0.32 (0.66) 0.64 (1.07) 1.05 (1.52) 
SD- Standard deviation; *value at baseline 
6.3.3.1 Clusters in OA at each time point 
 
Clusters identified among OA at each time point through LCA are given in Figure 6.3-7. 
Three clusters at 5 and 10 years and five clusters at 15 years were selected based in the 
statistical parameters. (Appendix Table 31, page 341). Three identified clusters at 5 and 10 
years were CV, relative healthy and MSK. The cluster size of CV cluster increased from 
6.66% at the index date to 14.36% at 15 years, while the cluster size of the relatively healthy 
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group reduced at each follow-up time. Details of the posterior class distribution for each time 
point are given in Appendix Table 33-35 (page 343-345).  
Figure 6.3-7. Different clusters in OA at each time point (Sensitivity analysis) 
 
Cluster 1- CV; Cluster 2- Relatively healthy; Cluster 3- MSK; Cluster 4- CV-MSK and Cluster 5 – MSK-MH 
CV- Cardiovascular; MH- Mental Health; MSK- Musculoskeletal 
 
Figure 6.3-8 represents the top 20 transitions pattern across the clusters in OA. Leading 
trajectory paths identified in the group are given in Table 6.3-5. Nearly 47% of the total 
transition occurred within the healthy group in subsequent years. Followed by moving to CV 
cluster 3.35% and 2.80% and MSK to MSK to MSK-MH (2.30%).  
Table 6.3-3 Leading transition paths in OA (sensitivity analysis) 
 
Year 5 Year 10 Year 15 n 
Transition 
 % 
Path 1 Healthy     (83.58%) Healthy (74.19%) Healthy (66.99%) 2262 47.37 
Path 2 Healthy     (83.58%) Healthy (74.19%) CV (14.36%) 160 3.35 
Path 3 Healthy     (83.58%) CV (12.05%) CV (14.36%) 134 2.80 
Path 4 MSK (9.76%) MSK (13.76%) MSK-MH (8.93%) 110 2.30 
Path 5 CV (6.66%) CV (12.05%) CV (14.36%) 98 2.05 
Path 6 MSK (9.76%) MSK(13.76%) MSK (6.81%) 61 1.27 
Path 7 Healthy (83.58%) MSK (13.76%) MSK-MH (8.93%) 61 1.27 
Path 8 Healthy (83.58%) Healthy (74.19%) MSK (6.81%) 50 1.04 
Path 9 Healthy (83.58%) MSK (13.76%) MSK (6.81%) 48 1.00 
Path 10 Healthy (83.58%) MSK (13.76%) Healthy (66.99%) 48 1.00 
Names in each cell at each time point represent the cluster and the percentage represents the class size. 




















At index date After 5 years  After 10 years After 15 years
Cluster1 Cluster2 Cluster3 Cluster4 Cluster5 OA
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Figure 6.3-8. Transition of individuals across clusters in OA (sensitivity analysis) 
 
 
Cluster 1- CV; Cluster 2- Relatively healthy; Cluster 3- MSK; Cluster 4- CV-MSK; and Cluster 5 – MSK-MH. 
Thickness of line represents the size of the transition and the colour represents the cluster colours. Percentages 
in the bracket represents the cluster size. 
CV- Cardiovascular; MH- Mental health; MSK- Musculoskeletal  
6.3.3.2 Clusters in the non-OA population at each time point 
 
Clusters identified in the  non-OA population at each time point through LCA are given in 
Figure 6.3-9. Four clusters at 5 years and five clusters at 10 and 15 years were selected 
based on the statistical parameters. (Appendix Table 32, page 342) The four clusters 
identified at 5 years were: cluster 1 (led by hypertension), cluster 2- relatively healthy, cluster 
3 (led by back pain) and cluster 4 (led by hypertension and back pain). The  size of cluster 1 
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(led by hypertension) increased from 3.87% at index date to 9.32% at 15 years. Similarly, 
cluster 2 increased from 11.88% at year 5 to 17.02% at year 15, while the size of the 
relatively healthy cluster reduced at each follow-up time. Details of the posterior class 
distribution for each time point are given in Appendix Table 36-38 (page 346-348).  
Figure 6.3-9 Different clusters in the non-OA group at each time point (sensitivity analysis) 
 
 
Cluster 1- CV; Cluster 2- Relatively healthy; Cluster 3- MSK; Cluster 4- CV-MSK; and Cluster 5- Thyroid 
CV- Cardiovascular; MSK- Musculoskeletal  
 
Figure 6.3-10 represents the top 20 transitions pattern across the cluster in the non-OA 
population. Leading trajectory paths identified in the group are given in Table 4. Nearly 69% 
of the total transition was within the relatively healthy cluster in subsequent years. Transition 
within cluster 3 in subsequent years was second highest with 6.55% followed by moving to 
























At index date After 5 years  After 10 years After 15 years
Cluster1 Cluster2 Cluster3 Cluster4 Cluster5 Non-OA
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Figure 6.3-10 Transition of individuals across cluster in the non-OA group (sensitivity 
analysis) 
 
Cluster 1- CV; Cluster 2- Relatively healthy; Cluster 3- MSK; Cluster 4- CV-MSK; and Cluster 5- Thyroid 
CV- Cardiovascular; MSK- Musculoskeletal  
 
Table 6.3-4 Leading transition paths in the non-OA population (sensitivity analysis) 
 
 Year 5 Year 10 Year 15 N % 
Path 1 Healthy   (83.00%) Healthy (76.12%) Healthy  (68.22%) 3316 69.44 
Path 2 MSK       (11.88%) MSK     (13.26%) MSK      (17.02%) 313 6.55 
Path 3 Healthy   (83.00%) MSK     (13.26%) MSK      (17.02%) 225 4.71 
Path 4 Healthy   (83.00%) Healthy (76.12%) MSK      (17.02%) 156 3.26 
Path 5 Healthy   (83.00%) CV        (6.67%) CV         (9.32%) 109 2.28 
Path 6 CV          (3.87%) CV        (6.67%) CV         (9.32%) 91 1.90 
Path 7 Healthy   (83.00%) Healthy (76.12%) CV         (9.32%) 64 1.34 
Path 8 Healthy   (83.00%) CV        (6.67%) Healthy  (68.22%) 36 0.75 
Path 9 MSK       (11.88%) CV        (6.67%) CV         (9.32%) 29 0.60 
Path 10 MSK       (11.88%) Healthy (76.12%) Healthy  (68.22%) 26 0.54 
Names in each cell at each time point represent the leading conditions in the cluster and the percentage 
represents the class size. CV- Cardiovascular; MSK- Musculoskeletal  
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6.4 Discussion  
 
This study identified latent clusters and transition pattern of comorbidities in OA and non-OA 
controls using LTA. LTA differs from LCA by using longitudinal approaches considering the 
disease status at each follow-up time, rather than cross-sectional or at a single time point in 
LCA. This dynamic nature of LTA makes it possible to explore the transition and explains the 
life course changes in clusters. Tracing the evolution of multimorbidity clusters and their 
clinical trajectories over time in OA and non-OA led to three major findings. The first was 
over 15 years, cluster size change and peoples’ transitions from one cluster to another 
generated a well-defined dynamic clinical trajectory. In OA, most of the identified clusters at 
the index date were stable during the study period. The large dynamic transition in the OA 
group started to appear after five years, by which time nearly 30% of people had moved 
towards the CV-MSK clusters and CV cluster only. The class size of CV-MSK clusters 
increased over time while the size of the MH cluster remained nearly constant. Thirdly, in the 
non-OA group the transition was less frequent compared to OA and mainly was towards the 
CV-MSK cluster, which was more prominent after 10 years of index date. 
Studies on multimorbidity have explored the pattern and progress of clusters of chronic 
conditions in different settings, countries, and populations but mostly have been cross-
sectional in nature (Prados-Torres et al., 2014). Some studies have focused on a single 
index disease and its comorbidities (Xu et al., 2018). Recently three studies have explored 
the transition pathways in multimorbidity clusters (Jensen et al., 2014; Guisado-Clavero et 
al., 2018; Vetrano et al., 2020) but so far, no studies have been done for multimorbidity 
trajectory paths in OA. Also, the mentioned previous studies varied widely due to the nature 
of the data, study population, number of chronic conditions included and methodology. For 
example, Vetrano et al examined the transition path of multimorbidity among older  people 
aged 50 years or more (Vetrano et al., 2020). Absence of available literature on transition of 
multimorbidity in OA makes any comparisons difficult.  
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6.4.1 Transition in the OA population 
 
This longitudinal clustering analysis done by LTA provided five clusters in both the OA and 
non-OA groups. Firstly, there was higher attrition rate in the OA compared to the non-OA 
group. The higher attrition could be due to the higher mortality rate in the OA population 
(Hawker et al., 2014; Barbour et al., 2015) and ageing. The reduction in population size at 10 
and 15 years of follow-up could be explained by the long follow-up period. Even though 
different method was used compared to the LCA in the previous chapter, the consistency of 
the clustering patterns is encouraging. The class size of the relatively healthy group was the 
highest (37.6%) which decreased over time indicating the transition of people from this 
cluster to other disease specific clusters. This is probably again could be due to ageing. 
Quite stable transition patterns were seen for MSK, and CV-MSK cluster. This means that 
most people belonging to these clusters at baseline tend to remain in the same clusters until 
15 years. Stability of these clusters explains the non-evolving patterns. This could be due to 
the early and accurate diagnosis of conditions at baseline, and it is possible that these 
people have undergone thorough screening for other conditions, or they have developed the 
diseases much earlier due to some other reasons or risk factors. However, some clusters 
were highly dynamic in nature and evolved with time, for example the CV, MH, and the 
relatively healthy cluster. All the clusters had overlapping conditions and were dominated by 
a few diseases. Thus, the evolving dynamic clusters may be influenced by many factors 
such as other conditions with low prevalence, and biological, pharmacological and socio-
psychological factors which increase the susceptibility of future diagnosis (Calderón-
Larrañaga et al., 2019).   
After five years from the diagnosis date of OA, nearly 15% of people from the relatively 
healthy group moved to the CV cluster suggesting dominance of hypertension in later age. 
People with OA are reported to have a higher risk of developing CV, which is supported by  
the change in clusters in this study (Hall et al., 2016). A similar explanation applies to the 
transition of people from the clusters led by MSK or CV only to the complex cluster of CV-
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MSK.  Extensive scientific evidence supports the association of chronic pain in OA (Scherer 
et al., 2016) and coexistence of MSK and CV (Goodman et al., 2016). Apart from the  
explanation above, the transition to CV clusters could be due to shared risk factors such as 
obesity and ageing and to treatment choices such as NSAIDs especially cox-2 inhibitors 
(Zhang et al., 2019). Another major transition was seen after 10 years from the index date 
from the MH cluster to the CV-MSK cluster. Coexistence of depression in OA and other 
painful conditions is common  (Bair et al., 2003). The incidence of CVD in depression is well 
studied (Lespérance et al., 2002) and the path of OA to depression and at a later stage to 
CVD may be explained by the theory of inflammation, and other factors (Vaccarino et al., 
2007). Observed transition path suggests accrual of multiple chronic conditions after OA 
diagnosis and the evolution of clusters. Large number of transitions to other clusters could 
be due to initial missed diagnosis or under-diagnosis such as for depression in other 
clusters. Also, due to the overlapping nature of conditions in each cluster the names of the 
clusters used needs cautious interpretation.  
The associated risk factors for transition probabilities could not be estimated due to large 
attrition. One of the major requirements for such an analysis is ‘complete-case’ observation 
for all the time points. However, selecting only people with complete observations for each 
time point (“survivors”) might lead to selection bias.  
6.4.2 Transition in the non-OA population  
 
In the non-OA group, five clusters were found with different cluster sizes and with thyroid 
disease as a new cluster (i.e., metabolic) compared to the OA group. Slightly more than 40% 
of the total population was in the relatively healthy cluster at  baseline which was higher than 
that of the OA group. The size of the CV-MSK cluster increased at each time point from the 
index date. This indicates that a large number of people were having the combination of two 
conditions at a later age, as would be expected from  ageing which is a recognised risk 
factor for  both CV and MSK diseases. In the OA group MSK was more prominent from the 
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index date, whereas, in the non-OA group it developed later. The clusters in the non-OA 
group were more stable than OA, which means once assigned to a cluster, the person tends 
to remain in the same cluster for a longer period. As with  OA, the transition path was either 
from the CV or MH clusters to the cluster led by both CV-MSK, together. However, the 
transition became more frequent after 10 years from the index date. The mediating disease 
for these people was hypertension. That is, they moved to the CV cluster first, then moved 
on to the CV-MSK cluster. The less frequent transition pathways seen in non-OA contrasted 
to OA could be due to the disease itself or the consequences. However, the delayed 
transition pattern in non-OA compared to OA group indirectly suggests some underlying role 
of OA in early evolution of clusters. The transition paths relay the importance of both 
physical and psychological conditions and their progress also the crucial coexistence of 
painful MSK conditions. Current evidence on the nexus of these conditions is confined to 
cross-sectional data (Zhu et al., 2020).  
In the sensitivity analyses, the clusters in both the groups changed in numbers, types, and 
sizes at each time point. Even though RMLCA method was used, a similar pathway was 
reported in both the OA and non-OA groups. People in the relatively healthy group moved to 
the cluster led by hypertension in later life then to the cluster led by hypertension and back 
pain together. Whereas people belonging to the back pain cluster moved to the cluster led 
by both back pain and depression later. This reflects consistency with the main analysis. As 
the population used for the sensitivity analysis did not have any chronic conditions at the 
index date, the clusters of MSK become more frequent compared to other conditions. Xu et 
al reported that the development of CVD in middle-aged women during 20 years follow-up 
was higher among those with pre-existing arthritis and/or mental disorders. (Xu et al., 2018) 
In both the analyses, the accumulation of comorbidities becomes more evident with time, 
which in turn increases the complexity of management, exposure to pharmacological effects, 
and reduces the functional impairment and increases load to the health system. Similar 
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findings have been suggested by a few published previous multimorbidity transition analysis 
(Jensen et al., 2014; Ibarra-Castillo et al., 2018, p. ; Vetrano et al., 2020).  
6.4.3 Strengths and limitations 
 
The major strengths of this study are the inclusion of many chronic conditions (n=49), use of 
a representative wide age-range of adults, long follow-up period and use of a large GP 
database. Even though it was possible to estimate the disease clustering at every year, five 
years follow-up was done to allow sufficient time for diagnosis of new comorbidity. This is the 
first study to explore the transition pattern in OA and matched controls. LTA, which is a 
robust method was used to account for the dynamic change in clusters and the missing data. 
Another advantage of LTA  is that it provides a probability of membership for each condition 
to each cluster, which is the true clinical feature than a distinct exclusive group. Each person 
was assigned a probability of belonging to a cluster. Inclusion of a wide variety of conditions 
allowed examination of clusters and trajectories centred around both physical and mental 
health conditions. The advantage of sensitivity analysis was it could find the full trajectory of 
cluster formation from people at risk. This sub-cohort had low attrition rate(death or moved 
out) which allows better estimate for the transition.  
There are several limitations to the study. The first is the possible misclassification bias 
mentioned in previous chapters. Also, consideration of the diseases without considering the 
severity or chronicity of the condition, but it is likely that the more complex or severe the 
disease is the chances of developing comorbidities increase. Nevertheless, the evolution of 
disease patterns in this study covers an important knowledge gap in OA. Secondly, the high 
dropout rate of participants due to death or leaving the practice did not allow for calculation 
of transition probabilities associated risk factors. Even though LTA has inbuilt methods to 
adjust for missingness at random, the availability of complete data would have allowed  
exploration of further risk factors. Heterogeneous clusters were not found as in  other studies 
and the cluster trajectories used in this study were centred around three common conditions 
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namely, hypertension, back pain, and depression. Non finding of exclusive patterns of other 
conditions could be because of the population structure, younger population, and high 
prevalence of these diseases. But the clusters evolution reported in this study has covered 
both physical and mental conditions making it more holistic.  
6.4.4 Clinical implication 
Over their life course, individuals develop multiple diseases. Understanding the diseases 
clusters, and importantly pathways of these over subsequent years not only help in 
understanding the complexity and dynamic evolution of multimorbidity clusters but also 
informs  clinicians and health policy makers to plan better management and resource 
allocation. This study identifies the people at risk of progressing to complex severe disease 
clusters that may  associate with worse outcomes. Reported clusters of conditions here is 
based on the patients rather than diseases, which provides crucial information for a person-
centred care approach. Nearly one third pf people remained in the ‘relatively healthy’ group 
with the lowest count of comorbidities. Results from this study can encourage the planning of 
future randomised clinical trials toward the better management of multimorbidity clusters in 
OA. Also, this can help for economical calculation for the prediction of burden of diseases. 
6.4.5 Conclusion 
In conclusion, clusters of multimorbidity in OA and non-OA are characterized by great 
dynamism and complexity but can still be tracked over time. Large database with a wide 
range of conditions allowed to find and map evolution of clusters. Few definite pathways 
were found such as developing a single chronic condition at a young age and later moving to 
complex clusters. These could be due to shared risk factors, pathophysiology, drug use, or 
merely unrelated coexistence. Future studies can be focused within each cluster to examine 
the biological and physiological linkages in these conditions. Also, the outcomes of these 
evolving clusters must be studied to determine the severity. Last but not the least the 
identified clusters and their possible transitions can guide every health care practice level for 
better tailoring of the target population in future interventions for comorbidities in OA. 
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Summary of  Chapter 6 
 
Chapter 6 described the transition or the movement of people from one identified 
cluster to another over time among people with OA and the matched controls. The 
key messages are:  
• Nearly 30% of the people with OA after five years of the diagnosis move to 
the cluster of cardiovascular only or cardiovascular-musculoskeletal. 
• The size of the cardiovascular only or cardiovascular-musculoskeletal clusters 
in people with OA increases over time, whereas number of people in 
depression cluster remains almost unchanged. 
• Among people without OA the transition was less frequent compared to OA 
and mainly was towards the cardiovascular-musculoskeletal cluster, which 
was more prominent after 10 years of index date. 
As seen, the development of cardiovascular and cardiovascular-musculoskeletal 
disease clusters growing by size in both the group, indicates the people with OA 
develop or get diagnosed with cardiovascular sooner compared to their non-OA 
counterparts.  
However, the progression with the number of comorbidities is not understood clearly. 
That is how does the progression of multimorbidity happens in people with OA and 
non-OA and how can the population be grouped based on the rate of progression is 




7 Chapter 7  
Trajectories of multimorbidity 
7.1 Introduction 
 
As demonstrated in Chapter 4, Table 4.3-6, the risk of multimorbidity was nearly 1.3 times 
greater in people with OA compared to those without. One of the interests I had was the 
trajectories of cumulative multimorbidity. This means how the accumulation of chronic 
conditions grows over period after the index date. Identifying such clusters or group of 
individuals would help to prepare the prevention strategy in advance. Understanding the 
development of multimorbidity in people with OA could help to identify long-term associated 
outcomes, prognostic factors, and design interventions. Studies have measured 
multimorbidity at single time points and examined associations and clusters. A study from 
the USA found the rate of increasing multimorbidity varied rapidly over  5-6 years (Quinones 
A.R. et al., 2011).  No studies have attempted to describe the accumulation of morbidities 
based on many diverse conditions and to identify whether there are distinct trajectories of 
multimorbidity over time in OA using primary care consultations.  
In the UK, a multimorbidity trajectory was reported in a consultation database including 37 
conditions (Strauss et al., 2014). However, such trajectories in the OA population have not 
been reported. Therefore, latent class growth analysis (LCGA) was used to group (cluster) 
people into distinct trajectories of multimorbidity using a primary care database and a wide 
range of 49 conditions after the index date. Therefore, the aim of this chapter is to identify 
the trajectories of the accumulation of multimorbidity over time in both OA and non-OA group 







7.2.1 Study subjects 
The same population described in Chapter 6 for OA and non-OA transition modelling was 
used. Details are provided on pages 185. 
7.2.2 Measurements and covariates 
The outcome in this study was the number of comorbidities present in people with OA and in 
the non-OA group at and after the index date. The term multimorbidity was used as numbers 
to describe the burden of comorbidities. Covariates considered were the same as described 
in previous chapters such as age, sex, smoking, alcohol, BMI, and multiple deprivation 
index. 
7.2.3 Statistical analysis 
There are various approaches to examine how time and age influence changes in 
multimorbidity score across the adult life span. One approach is to use LCGA to examine 
changes and identify the groups. Latent growth curve modelling allows study of the sample 
as a single population, with the ability to examine model-implied changes and to assess 
whether there are between-person differences in level and rates of change over time 
(Grimm, Ram, & Estabrook, 2017).  
The guideline for reporting on latent trajectory studies (GRoLTs checklist) was used to 
assess the feasibility of the trajectory modelling in the study population (van de Schoot et al., 
2017). (Appendix Table 39, page 349). 
For assessment of trajectory, all the registered patients were followed from their first date of 
registration until up to 20 years. Twenty years follow-up was done due to maximum data 
availability. The outcome was the cumulative number of chronic conditions over the years. 
Trajectories of multimorbidity were assessed using LCGA. LCGA models were fitted starting 
with a one-cluster model, assuming that all subjects have the same trajectory, and then 
successively increasing the number of clusters until most of the heterogeneity in the data 
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was explained (Muthén and Asparouhov, 2009). Counts in each period were assumed to be 
Poisson distributed. Cubic growth curves were applied for all clusters identified within the 
LCGA models. For each model, people were assigned to the cluster where their posterior 
probability of membership was highest (the maximum probability assignment rule). Hence, 
people could only belong to one cluster.  
LCGA can be considered as an extension to the fixed effect growth model. Fixed effect 
growth models are used to measure between group variability, whereas random effect  
models are used to address the within group variability. LCGA using a random effect growth 
model is a type of growth mixture model (GMM). For this study, as participants have different 
ages at the index date, age was used as a random effect in the model. A series of trajectory 
models of multimorbidity as a function of age, with a class number ranging from 2 to 10, 
were assessed using the lcmm (version 1.7.9) package in R (version 3.5.0) (Proust-Lima et 
al., 2020). The age of the participants was centred at the median age of the population and 
divided by 10 to reduce problems associated with high ages in quadratic and cubic terms in 
the model. Three possible polynomial specifications of the longitudinal response of 
multimorbidity as a function of age, namely linear, quadratic, and cubic were considered, to 
allow for non-linear patterns in both fixed and random effect components. For each model, 
class-specific variance covariance random-effects was considered, which allowed for 
between subjects’ trajectory variability to differ between classes. To avoid convergence 
towards local maxima, all models were rerun several times with different starting values and 
initial values obtained via grid searching (with a maximum of 15 iterations from 30 random 
vectors of values from the 1-class model). 
The optimal number of classes in each of the above three methods was decided using a 
combination of statistics Bayesian Information Criteria (BIC), sample size adjusted BIC 
(SBIC), log-likelihood ratio test (LLRT), entropy for classification quality, minimum of 1% total 
patients in each cluster and clinical judgement. Within the datasets, conditions were present 
(i.e., recorded) or not by definition, so missing data methods were not needed for cluster 
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analysis. The optimal model is that which has the lowest BIC value while the LLRT assesses 
whether adding one further cluster significantly improves the model fit. The model selection 
is alternatively explained by examining if the model with K-class is better than K-1 class by 
calculating percentage change in log-likelihood ratio of these two models using the formula 
(LL2-LL1)*100/(LL1). Additionally, the best model should have entropy more than 0.70 and 
should make more sense clinically. The clusters were named after the three most 
contributing chronic conditions (posterior probabilities) in each cluster. Once the best class 
was identified, the groups were attached to the original database and descriptive analysis 
was done for the covariates. Multinomial regression model was used to explore the risk 
factors using the ‘relatively healthy’ cluster as the reference group.  
7.2.4 Sensitivity analysis 
 
Sensitivity analysis was done among the subgroups of people with OA and controls without 
any comorbidities at the index date. A similar method was used to find the trajectory groups. 
7.3 Results 
 
Of the 221,807 people with OA, information on the English index of multiple deprivation was 
available for 88,957. In the non-OA group 88,434 of 221,807 people had data on the English 
index of multiple deprivation. Only people with complete information on the deprivation index 
were included in the analysis. The patient flow diagram for each follow-up time is given in 





























IMD- Index of multiple deprivation; NA- Not available 
 
 
Figure 7.3-1. Flow diagram showing the number of people at each time of follow up 
At the index date 
N=221,807 
At the index date 
N=88957 
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After 15 years 
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7.3.1 Descriptive statistics 
Table 7.3-1 describes the sample characteristics at each time point. Nearly 57% were 
female at index date in both groups, which stayed the same in the non-OA group and 
reduced to 53% in the OA population after 20 years. The mean age was increasing over time 
in both the groups, with a younger population being in the non-OA group. The prevalence of 
obesity (measured at baseline) in the OA group was constantly high than in the non-OA 
group at each time. A wide difference was observed in prevalence of multimorbidity. Nearly 
85% of the OA population had multimorbidity at the index date compared to 51% in the non-
OA group. However, it increased in both groups at each time point.  






















3136 (55.41) 122 (53.51) 
Age at index date 










Obesity (%)* 28105 (31.59) 
16551 
(32.33) 
7372 (33.31) 1924 (33.99) 76 (33.33) 





5351 (94.54) 213 (93.42) 
Number of 
comorbidities 
(Mean, SD)  
3.56 (2.11) 4.22 (2.39) 4.75 (2.59) 5.21 (2.78) 5.35 (2.89) 








5428 (56.32) 248 (57.01) 
Age at index date 
in years 









Obesity (%)* 18369 (20.77) 
12685 
(20.57) 
6622 (20.42) 2008 (20.83) 77 (17.70) 





7214 (74.85) 333 (76.55) 
Number of 
comorbidities 
(Mean, SD)  
1.97 (1.89) 2.52 (2.13) 3.02 (2.35) 3.43 (2.50) 3.75 (2.63) 
SD- Standard deviation; * at the baseline 
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7.3.2 Trajectories of multimorbidity in OA  
 
For the OA group, the five class model provided the best fit based on the statistical 
parameters. Average posterior probability (PP) of people ranged from 0.66 to 0.99 across 
each cluster. Also, the lowest BIC and AIC value suggested a five class solution to be the 
best one. (Table 7.3-2) 








parameters BIC AIC 
Entropy 
(%) 
1 -296515 12 593166.3 593053.5 100 
2 -294226 15 588623.6 588482.6 78 
3 -293946 18 588097.4 587928.3 76 
4 -293997 21 588267.9 588042.3 72 
5 -293323 24 586885.6 586688.3 74 
6 -293379 27 586985.7 586703.5 70 
7 -293694 31 587068.3 586832.1 68 
8 -293753 33 587357.1 586957.3 67 
9 -293892 36 587525.7 587203.5 65 
10 -293894 39 587532.9 587285.8 65 
BIC- Bayesian information criteria, AIC- Akaike information criteria 
Cluster specific trajectories suggested these can be described as per the growth pattern. In 
people with OA after the index date, five patterns were seen: multimorbid with very rapidly 
progressing (11.8%), multimorbid at index date with rapidly progressing (5.73%), high 
multimorbid at index date but gradual progress (50.83%), multimorbid with slow progress 
(3.54%) and non-multimorbid with very slow progressing (28.2%). One cluster (28.2%) had 
zero to one chronic condition at the index date and continued to have less than 20 chronic 
conditions until 20 years of follow up. This group was referred to as ‘very slow progressing’ 
for further analysis. Nearly 12% of people had <2 chronic conditions at the index date but 
within five years they had nearly 4 which increased sharply to nearly 9 after 20 years. This 
group was termed the very rapidly progressing group and can be considered as high-risk 
group of developing multimorbidity. Half of the population had an average of five conditions 
at the index date, and this continued to increase slowly over the years. (Figure 7.3-2) 
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Another 5.7% of the OA population had multimorbidity at the index date which was doubled 
at each five years of follow up.  
Figure 7.3-2. Clusters of multimorbidity trajectories over time in the OA group 
Solid line represents the observed mean number of chronic conditions at each time. Shaded area represents the 
confidence interval. MM-multimorbid at the index date 
Table 7.3-3 describes the characteristics of variables at the index date across the identified 
clusters. The highest proportion of women was found in the cluster of ‘ multimorbid with 
gradual progress’ (60%). Multimorbid with very rapid progress and rapid progress clusters 
had higher mean age compared to other groups. The prevalence of ex-smokers (31.50%) 
and ex-drinkers (3.26%) was highest in the ‘multimorbid with very rapid progress’ group. 
Nearly 34% in the ‘ multimorbid with gradual progress’ and 32% in ‘multimorbid with very 
rapid progress’ cluster were obese. In the ‘ multimorbid with gradual progress’ and ‘ 
multimorbid with very rapid progress’ clusters 16% belonged to the highest deprivation 































Gender      
  Men  11212(45.43) 1443(44.90) 19470(39.56) 1732(44.73) 3572(44.77) 
  Women 13467(54.57) 1771(55.10) 29743(60.44) 2140(55.27) 4407(55.23) 
Age  60.77(13.01) 60.51(13.91) 61.47(13.12) 61.11(13.10) 62.00(12.69) 
Smoking       
  Never smoked 13834(56.06) 1758(54.70) 25352(51.51) 2112(54.55) 4084(51.18) 
  Current smoker 4337(17.57) 565(17.58) 9358(19.02) 618(15.96) 1382(17.32) 
  Ex-smoker 6508(26.37) 891(27.72) 14503(29.47) 1142 (29.49) 2513(31.50) 
Alcohol use      
  Never  4088(16.56) 543(16.89) 10034(20.39) 685(17.69) 1674(20.98) 
  Ex-drinker 483(1.96) 68(2.12) 1553(3.16) 110(2.84) 260(3.26) 
  Current (1-9) 9261(37.53) 1180(36.71) 16630(33.79) 1329(34.32) 2668(33.44) 
  Current (>=10) 5589(22.65) 730(22.71) 9713(19.74) 853(22.03) 1607(20.14) 
  Current 
(Unknown) 
5258(21.31) 693(21.56) 11283(22.93) 895(23.11) 1770(22.18) 
BMI      
  Normal  8089(32.78) 1066(33.17) 13499(27.43) 1092(28.20) 2252(28.22) 
  Underweight  320(1.30) 37(1.15) 690(1.40) 61(1.58) 134(1.68) 
  Overweight  9753(39.52) 1250(38.89) 18057(36.69) 1503(38.82) 3049(38.21) 
  Obese 6517(26.41) 861(26.79) 16967(34.48) 1216(31.40) 2544(31.88) 
      
Multiple 
deprivation 
     
  IMD1 (Lowest) 5996(24.30) 837(26.04) 11018(22.39) 926(23.92) 1703(21.34) 
  IMD2 5728(23.21) 768(23.90) 11001(22.35) 921(23.79) 1914(23.09) 
  IMD3 5327(21.59) 705(21.94) 10175(20.68) 802(20.71) 1689(21.17) 
  IMD4 4318(17.50) 489(15.21) 9016(18.32) 683(17.64) 1415(17.73) 
  IMD5 (Highest) 3310(13.41) 415(12.91) 8003(16.26) 540(13.95) 1258(15.77) 
BMI- Body mass index; IMD- Index of multiple deprivation. 
7.3.3 Factors associated with trajectory groups 
Multinomial regression model findings are provided in Table 7.3-4. Women had 1.2 times 
higher risk of being in the multimorbid with gradual progress cluster compared to men. Being 
ex-smokers and ex-drinkers increased the risk by 1.2 times to be in all the clusters except for 
‘non- multimorbid and slow progress’ compared to non-smokers and non-drinkers, 
respectively. Obesity had the highest association with the ‘multimorbid with gradual 
progress’ cluster (OR 1.56; 95% CI 1.49-1.62) followed by the multimorbid with very rapid 
progress (OR 1.37; 95% CI 1.28-1.47) and multimorbid with rapid progress (OR 1.36; 95% 
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CI 1.24-1.49) clusters. Also, being underweight had significant associations with the 
multimorbid with gradual progress (OR 1.17; 95% CI 1.02-1.34), multimorbid with very rapid 
progress (OR 1.40; 95% CI 1.27-1.67) and multimorbid with rapid progress (OR 1.39; 95% 
CI 1.05-1.84) clusters. Higher deprivation index score had significant association with the 
multimorbid with gradual progress (OR 1.19; 95% CI 1.15-1.24) and multimorbid with very 
rapid progress (OR 1.15; 95% CI 1.05-1.23) clusters,. 
























OR (95% CI) 
Gender      
  Men  1 Reference  Reference  Reference  Reference  
  Women 1 1.03 (0.96-1.08) 1.28 (1.24-1.33) * 1.04 (0.97-1.11) 1.02 (0.98-1.06) 
Age  1 1.00 (0.99-1.01) 1.00 (1.00-1.01) * 1.00 (1.00-1.01) * 1.01 (1.01-1.02) * 
Smoking       
  Never smoked 1 Reference  Reference  Reference  Reference  
  Current smoker 1 1.03 (0.95-1.11) 1.23 (1.18-1.29) * 0.94 (0.86-1.05) 1.11 (1.03-1.19) * 
  Ex-smoker 1 1.09 (1.01-1.19) * 1.25 (1.21-1.29) * 1.14 (1.05-1.23) * 1.30 (1.22-1.38) * 
Alcohol use      
  Never  1 Reference  Reference  Reference  Reference  
  Ex-drinker 1 1.04 (0.79-1.37) 1.29 (1.16-1.44) * 1.35 (1.08-1.68) * 1.24 (1.06-1.46) * 
  Current (1-9) 1 0.93 (0.84-1.04) 0.78 (0.75-0.82) * 0.86 (0.78-0.96) * 0.72 (0.67-0.78) * 
  Current (>=10) 1 0.95 (0.84-1.08) 0.79 (0.75-0.84) * 0.93 (0.83-1.04) 0.71 (0.66-0.78) * 
  Current (Unknown) 1 0.97 (0.86-1.10) 0.89 (0.85-0.94) * 1.01 (0.91-1.13) 0.83 (0.78-0.87) * 
Body mass index      
  Normal  1 Reference  Reference  Reference  Reference  
  Underweight  1 0.88 (0.62-1.24) 1.17 (1.02-1.34) * 1.39 (1.05-1.84) * 1.40 (1.27-1.67) * 
  Overweight  1 0.98 (0.89-1.06) 1.14 (1.10-1.19) * 1.13 (1.04-1.23) * 1.12 (1.08-1.17) * 
  Obese 1 1.00 (0.91-1.10) 1.56 (1.49-1.62) * 1.36 (1.24-1.49) * 1.37 (1.28-1.47) * 
      
Multiple deprivation      
IMD3 1 Reference  Reference  Reference  Reference 
IMD1 (Lowest) 1 1.06 (0.96-1.18) 1.02 (0.99-1.06) 1.05 (0.98-1.12) 0.94 (0.87-1.01) 
IMD2 1 1.01 (0.91-1.13) 1.02 (0.98-1.08) 1.09 (1.02-1.16) * 1.07 (0.99-1.16) 
IMD4 1 0.85 (0.75-0.96) * 1.05 (1.01-1.09) * 1.02 (0.95-1.09) 1.01 (0.93-1.07) 
IMD5 (Highest) 1 0.93 (0.82-1.06) 1.19 (1.15-1.24) * 1.07 (0.99-1.16) 1.15 (1.05-1.23) * 









7.3.4 Trajectories of multimorbidity in the non-OA group 
 
In the  non-OA group, four trajectory clusters were found based on the summary statistics 
shown in Table 7.3-5. 







parameters BIC AIC 
Entropy 
(%)  
1 -305288 12 610712.2 610599.6 100 
2 -302407 15 604984.4 604843.6 81 
3 -301535 18 603274.4 603105.4 79 
4 -300848 21 601935.7 601738.5 78 
5 -305304 24 610881 610655.7 76 
6 -305130 27 610568.4 610314.9 75 
7 -306312 30 610681.8 610479.5 75 
8 -307175 33 611068.7 610932.3 73 
9 -308285 36 611154.1 611349.1 70 
10 -308276 40 611152.4 611337.4 69 
BIC- Bayesian information criteria; AIC- Akaike information criteria 
The clusters  were very rapidly progressing (2.72%), rapidly progressing (17.39%), gradual 
progressing (57.27%) and very slow progress (22.62%). The cluster of relative healthy 
always had less than one chronic condition in 20 years. Nearly 3% of the population in the 
very rapid group had zero chronic conditions at the index date which then it increased 
suddenly to five at the end of 10 years and to 8 after 20 years. The average number of 
chronic conditions in the gradually progressing group at index date was three and this 
increased at a slower rate to 4 at 20 years. Another rapid progress had less than one chronic 
condition at index date, which then increased faster to four at the end of follow up date. 
(Figure 7.3-3) Even though the non-OA group had similar clusters to that of the OA group,  
the burden of multimorbidity was less in each cluster compared to the OA group. For 
example, the gradual progressing cluster in OA had an average of 5-7 chronic conditions, 





Figure 7.3-3 Clusters of multimorbidity trajectories over time in non-OA 
 
 
Shaded area represents 95% confidence interval. MM- multimorbid at index date 
Table 7.3-6 describes the characteristics of the variables reported at the index date across 
the identified clusters in the non-OA group. The proportion of women was highest in the non-
multimorbid with gradual progressing group (59.55%) followed by the multimorbid with 
rapidly progressing group (56.21%). The multimorbid with very rapidly progressing cluster 
had the oldest population with a mean age of 68.5 (SD 13.0) years. The prevalence of ex-
smokers (29.43%) and ex-drinkers (3.41%) was higher in the multimorbid with very rapidly 
progressing cluster compared to others. More than 20% of the population in the multimorbid 
with gradual progressing (22.78%) and multimorbid with very rapid progressing (20.16%) 
clusters were obese. The proportion in the most deprived category was higher in the 
multimorbid with very rapidly progressing (16.92%) and non-multimorbid with gradual 
progressing (14.23%) groups, than the other groups.  
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Table 7.3-6 Descriptive characteristics of baseline variables across the clusters in non-OA 
Variables  Non-
multimorbid 











very rapid progress 
n=2406 
Gender     
  Men  8888(44.42) 20488(40.45) 6732(43.79) 1080(44.89) 
  Women 11120(55.58) 30157(59.55) 8643(56.21) 1326(55.11) 
Age at index date 62.68(13.41) 63.78(13.56) 65.71(12.79) 68.51(12.97) 
Smoking      
  Never smoked 11959(59.77) 27573(54.44) 8727(56.76) 1284(53.37) 
  Current smoker 3356(16.77) 9208(18.18) 2430(15.80) 414(17.21) 
  Ex-smoker 4693(23.46) 13864(27.37) 4218(27.43) 708(29.43) 
Alcohol use     
  Never  3310(16.54) 9327(18.42) 2753(17.91) 507(21.07) 
  Ex-drinker 328(1.64) 1391(2.75) 369(2.40) 82(3.41) 
  Current (1-9) 7791(38.94) 17866(35.28) 5556(36.14) 824(34.25) 
  Current (>=10) 4409(22.04) 10240(20.22) 3249(21.13) 438(18.20) 
  Current (Unknown) 4170(20.84) 11821(23.34) 3448(22.43) 555(23.07) 
Body mass index     
  Normal  8897(44.47) 19140(37.79) 6112(39.75) 924(38.40) 
  Underweight  441(2.20) 1088(2.15) 348(2.26) 80(3.33) 
  Overweight  7319(36.58) 18881(37.28) 5918(38.49) 917(38.11) 
  Obese 3351(16.75) 11536(22.78) 2997(19.49) 485(20.16) 
     
Multiple deprivation     
  IMD1 (Lowest) 5109(25.53) 12612(24.90) 3862(25.12) 575(23.90) 
  IMD2 4728(23.63) 11722(23.15) 3644(23.70) 553(22.98) 
  IMD3 4302(21.50) 10504(20.74) 3306(21.50) 478(19.87) 
  IMD4 3366(16.82) 8599(16.98) 2597(16.89) 393(16.33) 
  IMD5 (Highest) 2503(12.51) 7208(14.23) 1966(12.79) 407(16.92) 
IMD- Index of multiple deprivation  
7.3.5 Factors associated with trajectory groups in the non-OA group 
 
In the non-OA group, women were 1.2 times more likely to be in the ‘non-multimorbid with 
gradually progressing’ group compared to that of in very slow progress group and men. Age 
was consistently associated with all the clusters, compared to the relatively healthy cluster. 
Either being a smoker or ex-smoker increased the risk of being in any of the non-healthy 
clusters. Smokers (OR 1.31; 95% CI 1.15-1.48) and ex-smokers (OR 1.30; 95% CI 1.18-
1.44) were at greater risk of being in the multimorbid with very rapidly progressing group. 
Similarly, ex-drinkers had nearly 1.3 times higher association with the non-multimorbid with 
gradually progressing and very rapidly progressing clusters compared to the non-
multimorbid with very slow progress cluster. Both overweight and obesity were significantly 
associated with all the non-healthy clusters. Obesity had relative risk ratios of 1.6 and 1.5 for 
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being in the non-multimorbid with gradual progressing and multimorbid with very rapidly 
progressing group, respectively. Being underweight also increased the risk of being in the 
multimorbid with very rapidly progressing group (OR 1.43; 95% CI 1.12-1.84).  The most 
deprived people were more likely to be in the multimorbid with very rapidly progressing 
cluster (OR 1.42; 95% CI 1.23-1.64) compared to the other clusters. (Table 7.3-7) 











OR (95% CI) 
Multimorbid with 
rapid progress 
OR (95% CI) 
Multimorbid with 
very rapid progress 
OR (95% CI) 
Gender     
  Men  1 Reference  Reference  Reference  
  Women 1 1.23(1.19-1.27) * 1.06(1.01-1.10) * 0.97(0.89-1.06) 
Age at index date 1 1.01(1.01-1.02) * 1.02(1.01-1.02) * 1.03(1.03-1.04) * 
Smoking      
  Never smoked 1 Reference  Reference  Reference  
  Current smoker 1 1.26(1.20-1.32) * 1.08(1.01-1.15) * 1.31(1.15-1.48) * 
  Ex-smoker 1 1.29(1.24-1.34) * 1.18(1.12-1.24) * 1.30(1.18-1.44) * 
Alcohol use     
  Never  1 Reference  Reference  Reference  
  Ex-drinker 1 1.46(1.28-1.66) * 1.31(1.12-1.53) * 1.49(1.15-1.94) * 
  Current (1-9) 1 0.85(0.81-0.89) * 0.90(0.84-0.96) 0.77(0.68-0.87) * 
  Current (>=10) 1 0.88(0.83-0.93) * 0.95(0.88-1.02) 0.73(0.64-0.85) * 
  Current (Unknown) 1 1.02(0.96-1.07) 1.02(0.95-1.09) 0.92(0.81-1.05) 
BMI     
  Normal  1 Reference  Reference  Reference  
  Underweight  1 1.05(0.93-1.17) 1.05(0.91-.121) 1.43(1.12-1.84) * 
  Overweight  1 1.22(1.18-1.27) * 1.18(1.12-1.23) * 1.21(1.10-1.33) * 
  Obese 1 1.61(1.53-1.68) * 1.34(1.26-1.42) * 1.47(1.31-1.66) * 
     
Multiple deprivation     
  IMD3 1 Reference  Reference  Reference 
  IMD1 (Lowest) 1 1.06(1.01-1.12) * 1.01(0.95-1.08) 1.07(0.94-1.22) 
  IMD2 1 1.03(0.98-1.08) 1.01(0.95-1.07) 1.07(0.94-1.21) 
  IMD4 1 1.01(0.96-1.07) 0.99(0.93-1.07) 1.02(0.89-1.18) 
  IMD5 (Highest) 1 1.11(1.05-1.18) * 1.01(0.94-1.10) 1.42(1.23-1.64) * 
CI- Confidence interval; IMD- Index of multiple deprivation; OR- Odds ratio; *p value <0.05 
7.3.6 Sensitivity analysis 
 
Same LCGA method was used for detecting clusters of trajectories for multimorbidity among 
the OA and non-OA group without any comorbidities at the index date. Each group had 
22,333 patients matched for age (+2), sex and practice. Four clusters in the non-OA and five 
in the OA group were found to give the best fit model according to the model statistics. The 
models were selected based on the change in likelihood ratio and each group in the clusters 
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should have a size of minimum 1%. Details of the model statistics for each group are given 
in Table 7.3-8.   
Table 7.3-8. Statistical parameters of optimal number of clusters from LCGA in the OA group 
Classes  Parameters LL AIC BIC aBIC Entropy 
OA 
1 4 -214039 428085.7 428118.1 428105.4  
2 9 -119739 239495.2 239568.1 239539.5 0.969 
3 14 -108897 217821.2 217934.6 217890.1 0.925 
4 19 -106181 212399.5 212553.4 212493 0.85 
5 24 -104933 209913.2 210107.6 210031.3 0.803 
6 29 -104274 208606.2 208841.1 208749 0.79 
7 34 -103920 207908.8 208184.2 208076.2 0.783 
8 39 -103762 207601.2 207917.1 207793.1 0.747 
9 44 -96661.2 193410.4 193766.8 193627 0.736 
10 49 -96513.3 193124.6 193521.5 193365.7 0.721 
Non-OA 
1 4 -207493 414994.4 415026.8 415014.1  
2 9 -116016 232049.9 232122.8 232094.2 0.972 
3 14 -105835 211698.2 211811.6 211767.1 0.931 
4 19 -102747 205531.5 205685.4 205625 0.858 
5 24 -101481 203010.4 203204.8 203128.6 0.828 
6 29 -100790 201638.3 201873.2 201781.1 0.813 
7 34 -100486 201040.6 201316 201207.9 0.817 
8 39 -100281 200639.7 200955.6 200831.6 0.779 
9 44 -93233.4 186554.8 186911.2 186771.4 0.77 
10 49 -93048.5 186195 186591.9 186436.2 0.766 
AIC- Akaike information criteria; BIC- Bayesian information criteria; aBIC- Sample size adjusted BIC; LL – Log 
Likelihood  
Among people with OA, five clusters were identified to explain the trajectories. Most people 
(73.9%) continued to be in the healthy group with nearly zero comorbidities. Only 2.3% of 
the study population developed fewer than two comorbidities after 10 years from the index 
date. Another group constituting 11.6% subjects developed multimorbidity slowly after the 
index date, but the mean number of conditions was always less than two. Only two groups 
distinctively showed a multimorbidity trajectory with rapid onset (2.7%) or gradual onset 
(9.5%). The mean number of conditions after 20 years of the index date was 7 in the rapidly 
multimorbidity developing group and 4 in the group with gradual onset. (Figure 7.3-4) 
In the non-OA group, the four cluster model was found to give the best fit for trajectory. Of 
these only one group had a very distinct path of developing multimorbidity named as gradual 
onset (4.6%). Nearly two thirds of the subjects were relatively healthy and 14.3% developed 
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multimorbidity after the index date but at a slower pace. Another group (5.1%) started 













Figure 7.3-5 Trajectories clusters of multimorbidity in non- OA without any comorbidities at 
index date 
Figure 7.3-4. Trajectories clusters of multimorbidity in people with OA 





This study examined the multimorbidity trajectories of chronic diseases in the OA and non-
OA groups over a time span of 20 years. Trajectories of developing multimorbidity has not 
been studied before in people with OA. Five clusters within the OA group and four within the 
non-OA group were identified using the LCGA method. Key findings from this study are: (1) 
the burden of multimorbidity was high in the OA group compared to the non-OA group;  (2) a 
group of nearly 17.5% of people with OA accumulated multimorbidity rapidly and 28% had a 
low risk of rising multimorbidity over 20 years; (3) people who were obese, smokers and ex-
drinkers at  baseline had higher risks of rapidly developing multimorbidity compared to the 
relatively healthy group; and (4) within the non-OA group nearly 3% developed 
multimorbidity rapidly after the index date. 
7.4.1 Trajectories in OA 
 
To my knowledge this is the first study to explore the trajectories of multimorbidity within 
people with OA. The accumulation of multimorbidity depends on multiple factors such as 
age, chronic conditions present at the index date, lifestyle (e.g., smoking, diet and physical 
activity) and pharmacological effects. Very few studies have explored the trajectories of 
multimorbidity without any index date. However, these studies varied in their methods, study 
population, follow-up time span, nature of database and number of conditions studied. 
Jackson et al examined the factors associated with multimorbidity trajectory among middle-
aged women in Australia and identified five clusters (Jackson et al., 2015). Similarly, Strauss 
et al, using a UK primary care database (CiPCA) to explore the trajectories, also reported 
five clusters (Strauss et al., 2014). Though these studies are not comparable with population 
of the current study, they provide some information on general population cohorts. 
Compared to 40% in the Strauss et al study, this study had only 28% in the very slow 
progress group in OA population. This group of people had the lowest percentage of 
obesity/overweight compared to other cohorts. As obesity is one of the biggest risk factors 
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for many comorbidities (Dhalwani N.N. et al., 2017), the lower BMI in this group of people 
might have been keeping them healthy.  Also, the prevalence of smoking was low in this 
group compared to others, which further supports the explanation of healthy lifestyle practice 
keeping them less prone to accumulating multimorbidity over time (Singer et al., 2019). 
Nearly 50% of the cohorts in both the groups had high multimorbidity count at the index date 
and continued to grow gradually. A high multimorbidity burden at the index date indirectly 
suggests the high GP consultations reflecting better health literacy and awareness (Cassell 
A. et al., 2018). Patient education, counselling and supportive therapies might have 
moderated the high-risk factors at the index date allowing for slow building up of 
multimorbidity. Women had nearly 1.3 times higher risk compared to men to be in gradual 
progress group . People from this group (nearly 2/3rd were women) may have had better 
adherence to management of chronic conditions and drugs as they had higher consultation 
rates compared to men (Mukhtar et al., 2018). Another crucial factor affecting the trajectory 
is the nature, rather than just the count of conditions at the index date. These gradual 
progress group had higher burden of all the conditions and nearly 50% of them had back 
pain at the index date and 40% had hypertension. Despite a high burden of chronic 
conditions in this gradual progress group, further study is needed to understand the further 
slow development of multimorbidity, needed for successful chronic are model.  
Nearly 12% of people with OA (very rapid progress group) had less than two comorbidities at 
the index date which increased sharply to four after five years and to nearly 10 after 20 
years. These represent a  high risk group developing multimorbidity more rapidly than 
others. The distribution of population characteristics shows that the people in this group are 
older and have a higher prevalence of smoking, alcohol use and obesity compared to other 
groups. All these are well documented risk factors for multimorbidity (Dhalwani N.N. et al., 
2017). Jackson et al reported the association of obesity with longitudinal changes in 
multimorbidity (Jackson et al., 2015). Another study from the UK among primary care 
patients also mentioned the strong association of all the above risk factors with 
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multimorbidity (Booth, 1994). Having fewer than two comorbidities at the age of 60s 
suggests  two possibilities - either these are a comparatively healthy group, or they had 
fewer consultations leading to less diagnosis of conditions. However, the trajectory does not 
favour the first assumption of being healthy. Possibly, these group of people despite having 
high risk behaviours did not visit GPs often, but after the diagnosis of OA, there might have 
been increase in consultations leading to more diagnosis of comorbidities. Previously 
reported high consultation rates in the most deprived areas of UK echoes the findings from 
this study (Mukhtar et al., 2018). Also, in this study people from this very rapid progress 
group had nearly equal proportions of CVD and MSK, which might have influenced the 
trajectories (Lappenschaar et al., 2013). This provides with the opportunity to explore other 
associated factors on the illness course in people with OA. Another interesting finding from 
this study was the trajectory cluster of 5.7% people with OA developing multimorbidity 
rapidly. Again, the association with the least deprived group could have influenced the health 
seeking behaviour. No significant association was seen with gender and the most deprived 
group.  
7.4.2 Trajectories in non-OA 
In the non-OA group, four trajectory clusters were found. However, the burden of 
multimorbidity in each cluster in terms of mean number of comorbidities was less than in 
respective groups in the OA group. This supports the previous findings of a high burden of 
multimorbidity in people with OA. Only 3% of people without OA developed multimorbidity at 
a faster rate. The mean age in this group among non-OA was 68.5 years at the index date. 
Also, a strong association was found with other risk factors similar that to found in OA. The 
four trajectory groups in the non-OA group and the slower progression of multimorbidity in a 
similar population structure suggests a possible contribution of OA towards multimorbidity. 
The additional presence of OA might have accelerated the accumulation of multimorbidity 
due to the pathophysiology, shared risk factors, increased health care visits or due to the 
drugs used to manage chronic pain. Two studies that looked at the trajectory of 
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multimorbidity reported that the presence of chronic conditions at the index date led to 
evolution of multiple other related and non-related comorbidities during the life course (Hsu, 
2015; Vos et al., 2015).  
For sensitivity analyses, people without any comorbidities at the index date in both the OA 
and non-OA groups were used. Even though there was the possibility of selecting a relative 
healthy group, a linear trajectory path was identified. Five clusters within the OA group and 
four within the non-OA group were estimated,  with the burden of multimorbidity being higher 
in the OA group. The sensitivity analyses suggest that after the diagnosis of OA the chances 
of being diagnosed with other comorbidities increases. This could be because of the 
mentioned shared risk factors or differences in health care utilisation. 
There is strong evidence from this study that in people with OA there are five distinct 
trajectory paths for multimorbidity. Longitudinal studies on multimorbidity report strong 
associations with poorer health outcomes, poor prognosis and early mortality (Wang et al., 
2009; Aarts et al., 2012). This study is consistent with other findings in identifying different 
subgroups, despite the change in study population, methods and diseases included. Similar 
to this study, a birth cohort study has reported higher trajectories of multimorbidity among 
women and obese people (Canizares et al., 2018). Another study used the LCGA method to 
explore trajectories of pain in  a knee pain population reported worse outcomes in the group 
with comorbidities (Dowsey, Smith and Choong, 2015). Along with disease specific 
approaches, a broad system theory and non-specific approaches should be used to 
understand the different trajectories. Chronic health problems such as OA may affect 
multiple sites in the body due to a wide range of pathophysiological and mechanical factors. 
Thus, clinicians need to recognise that people with OA experience different morbidities and 
accrual of comorbidities over time. It is not only the number of comorbidities but also the type 
of condition diagnosed that determines the trajectory, together  with other socio-economic 
factors. Subgrouping the people with OA based on the trajectories provides methods for 
differentiating level of risks and designing different intervention approaches. 
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7.4.3 Strengths and limitations 
Our study benefits from several strengths. To my knowledge this is first study to explore the 
multimorbidity trajectory in people with OA. The LCGA model overcomes the problems of 
cross-sectional analysis of multimorbidity, as reported before. Age was included as a 
random factor accounting for the variation in the age during the life course, which has not 
been considered in previous studies. A long follow-up of 20 years and consideration of 49 
conditions  adds to the strength of the study. Because of the longer follow-up more distinct 
patterns could be studied. Even though there were high attrition rates at each year, the 
‘lcmm’ package of R could handle the missingness on the assumption of missing at random. 
Inclusion of baseline risk factors helped to establish the association with the trajectory 
groups, which can help with early diagnosis. The analysis examined non-linear patterns with 
age (linear, quadratic, and cubic) and the number of classes ranged from 2 to 10. Thus, the 
obtained model is the best model possible. The sensitivity analysis also reflected the same 
number of trajectory groups, reinforcing the validity of the findings.  
There are some limitations to consider. The severity of the chronic conditions could not be 
included in the modelling, which might have influenced the trajectory groups. The other 
inherent limitations of database research, such as  recording, or diagnosis biases of chronic 
conditions, could also have been influenced the results. Even though 49 chronic conditions 
were included it would be ideal to study an even larger number of conditions. Inclusion of the 
deprivation index limited the risk factor association analysis to England only, which could be 
expanded for other regions. Other caveats could be the healthcare utilisation pattern and 
health behaviour of individuals which might have delayed the diagnosis of chronic 
conditions. The attrition and deaths that occurred between the follow-up periods represent 







The trajectories identified represent the high burden and diversity of multimorbidity after the 
index date in people with OA. This provides better understanding for care and illness 
pathways, which can be used for designing an appropriate care model. More detailed 
studies can be done among gradual onset multimorbidity cohort to recognize the success 
stories behind slowing down the further development of multimorbidity. Early identification of 
chronic conditions in the population with associated modifiable risk factors such as obesity 
and lifestyle may be able to prevent the future occurrence and worsening of multimorbidity. 
The time point of likely growth of multimorbidity can be set differently for different trajectory 
cohorts, in terms of screening and follow-up based on the rate of growth. Identifying the 
high-risk population can help the health system for effective resource allocation. Finally, a 














Summary of Chapter 7 
Chapter 7 used LCGA to group people based on the trajectories of accumulation of 
number of chronic conditions with time in both people with OA and non-OA.  
The key findings from the study are: 
• Five groups in people with OA and four in people with non-OA were identified. 
Groups are based on the number of chronic conditions at the time of 
diagnosis and the rate of accumulation of additional comorbidities.  
• A group of nearly 17.5% of people with OA with low multimorbid status at 
index date, accumulated multimorbidity rapidly and 28% had a low risk of 
rising multimorbidity over 20 years, 
• People with obesity, smokers, and ex-drinkers at  baseline had higher risks of 
rapidly developing multimorbidity compared to the relatively healthy group 
• In non-OA group nearly 3% developed multimorbidity rapidly after the index 
date. 
Chapter 7 tells us the rapid accumulation of chronic conditions in people with OA 
compared to non-OA. The burden of multiple chronic conditions is more in people 
with OA. 
I was further interested to understand the outcome of being diagnosed with OA and 
the comorbidity clusters in both the groups. The outcomes of study interest are 
number of GP consultations recorded, hospital admission, all-cause mortality, and 
the loss in-terms of DALYs. Chapter 8 explores the association with these outcomes 




8 Chapter 8 
Outcomes in OA and associated comorbidities 
8.1 Introduction  
 
Association of all-cause mortality with OA is nonconclusive (Hochberg, 2008). Studies have 
shown significant associations with cause-specific mortality such as CVD, and with all-cause 
mortality (Cleveland, Nelson and Callahan, 2019). The causes of death in people with OA 
depend on various associated factors and are less likely to be attributed to structural OA 
itself. Thus, understanding the mortality risk in OA would provide information on the burden 
or the risk of mortality rather than the association.  
Even though it is assumed, that the people with OA would have increased health utilisation, 
this has not been studied in detail especially in the primary care population of the UK. 
Healthcare utilisation in primary care depends on a wide range of factors such as 
socioeconomic, demographic, accessibility, and availability. There are various ways to 
measure healthcare utilisation from a health system perspective. Two commonly used 
indicators are the number of hospital visits and number of inpatient admissions per person 
(Andersen and Newman, 1973).  
According to the Global Burden of Diseases (GBD), hip and knee OA are the 11th highest 
contributor to global disability and the 38th highest in disability adjusted life years (DALYs).  
Increasing life expectancy and the ageing population are expected to make OA the fourth 
leading cause of disability by the year 2020 (Woolf and Pfleger, 2003). Years of life with 
disability (YLDs) for hip and knee OA increased by 6.6 million over the period 1990 to 2010 
(10.5 million in 1990 to 17.1 million in 2010).  The demerits of the GBD burden of disease 
evaluation that OA itself is not regarded as a valid clinical cause of death. The burden of 
disease measured so far is disease specific, rather than person-specific. In the context of 
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multimorbidity, it is important  to evaluate the burden within a person as a whole considering 
all the diseases the person has.  
Another important understudied aspect is the variation of disease pattern within people with 
OA. As seen in previous chapters, there are various groups within OA according to the 
multimorbidity clusters and they follow different illness pathways. So, exploring the health 
outcomes in these subgroups would provide more information towards person-centred care. 
Therefore, the current study explored all-cause mortality, GP visits, inpatient admission, and 
the burden of multimorbidity in people with OA and matched controls. Also, the distribution of 
above-mentioned health outcomes was studied within OA and matched controls subgroups.  
8.2 Methods  
 
8.2.1 Participants 
The same identified group of OA cases and matched non-OA controls described in the 
previous Chapter 4, Section 4.3.2 for this analysis were used for the analysis. 
8.2.2 Outcomes 
• Average GP consultations per year 
This is defined as the average number of consultations per year recorded in the 
database for each person within the period of 1st Jan 1997 until the last record 
available for the person or the 31st of Dec 2017. The average was calculated by 
dividing the total number of GP consultations recorded by the  number of years of 
registration in the database. The consultation includes visit to a GP or nurse or any 
other healthcare practitioner which has been recorded in the CPRD GOLD database 
for any purposes such as diagnosis, test or follow up. 
For example, if a person had a total of 15 years of registration  with the database 
after 1997, and had 120 consultations recorded  during that period, then the average 
number of consultations for that person is:   
= 120 /15 = 8 consultations per year 
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• Inpatient admission 
Information on inpatient admissions was obtained from the HES linkage data. The 
number of hospitalisations irrespective of any cause was used for the calculation of 
average hospitalisations per year. A similar formula to that used for calculation of GP 
consultations was used to estimate average inpatient admissions.  
• Disability adjusted life years (DALY) 
For estimation of the burden of the comorbidities, the WHO proposed disability 
adjusted life years (DALY) method was used. However, interpretation of the burden 
of disease in terms of DALYs can be complicated if multiple conditions co-exist within 
individuals. A multiplicative methods was used for the estimation DALY in multiple 
conditions (Mathers, Iburg and Begg, 2006). This method has been used previously 
for calculating disease burden in comorbidity and multimorbidity (Hilderink et al., 
2016).  
• All-cause mortality  
All-cause mortality data were obtained from the HES linkage data. The death date 
recorded in the database was used in the model to estimate the mortality risk in the 
OA group compared to that in the non-OA group. 
 
8.2.3 Calculation of DALY for multiple chronic conditions  
 
DALY is calculated by YLD+YLL  
YLD (Years of living with disability)- Years lived with conditions x disability weight (Dw) 
YLL (Years of life loss) – Years lost because of the condition (Life expectancy – age of 
death) 
For independent comorbidities 
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For independent comorbidities, the probability of having two (comorbid) conditions is 
assumed to equal the product of the probabilities for having each of the diseases. (Mathers, 
Iburg and Begg, 2006) 
Disability weight for multiple chronic conditions can be calculated by a multiplicative 
method 
DW1+2 = 1 - (1-DW1) × (1-DW2)     (equation 1) 
Where DW1 is the Disability weight of the first chronic condition, and DW2 is the disability 
weight for the second chronic condition 
For Disability Adjusted Life Years (DALYs)- 
DALY 1+2 = 1- {(1-DALY1) x (1-DALY2)}  -   (equation 1) 
DALY1 is the DALY for 1st condition 
DALY2 is the DALY for 2nd condition 
In the presence of multiple conditions:    
DALY total = 1- πi(1-DALYi) 
π  is the product operator and i= 1 to nth chronic condition 
 
For dependent comorbidities (Mathers, Iburg and Begg, 2006) 
In the presence of dependent comorbidities, the severity of conditions is shared with each 
other rather than being additive. For estimating the DALY for dependent comorbidities, the 
shared factor f1+2 can be calculated as below 
f1+2 =  DALY1+2 / (DALY1 X DALY2)                 - (equation 2) 
DALY1+2  - calculated from equation 1 
DALY1- DALY for 1st condition 





DALY for dependent comorbidities:    
DALY1+2 = DALY1+DALY2 – (f1+2 × DALY1 × DALY2) 
f1+2 – as per equation 2 
DALY1- DALY for 1st condition 
DALY2 – DALY for 2nd condition 
The disability weight was adopted from WHO, European version. (Appendix Table 40, page 




All information available at the index date such as gender, age at index date, smoking, 
alcohol, and BMI was used in the analysis.  
The Elixhauser comorbidity index (ECI) at baseline was calculated to estimate the burden of 
comorbidities. The ECI groups comorbidities of patients based on the international 
classification of diseases (ICD) diagnosis. Each comorbidity is categorised dichotomously as 
either present or not. The original index contained 30 comprehensive categories of 
comorbidity based on ICD-9-CM coding found in hospital abstracts data (Elixhauser et al., 
1998), but later the list was expanded to 31 conditions and the scoring system was modified 
to reflect "the strength of each comorbidity group's independent association with hospital 
death." (van Walraven et al., 2009) It is reported that the Elixhauser comorbidity system can 
be condensed to a single numeric score that summarizes disease burden and is adequately 
discriminative for death in hospital.  Details of the list of condition are given in Appendix 






8.2.5 Statistical analysis 
 
All the analyses were performed in two group of samples. Firstly, the outcomes were 
compared for the OA and the non-OA group. Secondly, the association of each outcome 
was explored within each group across the identified cluster .  
Descriptive statistics of each outcome are reported as both mean (standard deviation) and 
median (inter quartile range). Normality distribution of outcomes was tested using histogram 
and shaprio-wilk test.  
Firstly, the association of GP consultation rate with OA was assessed by linear regression 
and the residuals were checked for normality assumption. Because the outcome was 
continuous and skewed with non-zero distribution, a ‘gamma regression’ model with log link 
function was used.  For inpatient admissions, because of the excessive ‘zeros’ the 
assumptions for a linear regression method could not be met. So, to account for excessive 
zeros and continuous data a two-part model was used. In the two-part model, a binary 
choice model is fit for probability of observing a positive-versus-zero outcome. Then, 
conditional on a positive outcome, an appropriate regression model is fit for the positive 
outcome. Logistic regression was used for the first part to compute the association for 
positive outcome, and linear regression in the second part to predict the association with 
increased hospitalisation. After the model, post model margin effects were estimated and 
compared with the observed estimates. The association with DALY was explored using a 
linear regression method. In the adjusted model covariates such as age, gender, smoking, 
alcohol, BMI and ECI were included.  
For all-cause mortality, a cohort study design was used. The death after the index date was 
assessed. Both the OA and matched non-OA cohorts were followed for up to 20 years after 
the index date. For people with non-OA the start date was the assigned index date that of 
corresponding matched OA case. The follow-up period was until the earliest date of death, 
transfer out or end of the study (31st Dec 2017). The Kaplan-Meir method was used to 
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display the cumulative probability of death in people with incident OA and matched controls. 
HRs) and 95% CI were calculated adjusting for age, gender, BMI, smoking, alcohol use, and 
ECI at the index date. For association of death within each group identified clusters at the 
index date, at year 5, 10, 15 and 20 were considered as time varying covariates. In the 
adjusted model, gender, age, BMI, smoking, alcohol use and multimorbidity count at the 
index date were included. The interaction of OA with identified clusters for all-cause mortality 
was examined in cox model. Proportionality assumption for each comorbidity was examined 
with Schoenfeld residual tests. The statistical analyses were performed using STATA 
statistical software V.15 (STATA corp, Texas) and R software V3.5.  
8.2.6 Sensitivity analysis 
As a sensitivity analysis for the association with all-cause mortality, the analysis was re-run 
for people with OA and matched controls without any comorbidities before or on the index 
date. Time varying covariate Cox proportional hazard models were used to estimate the HR 
for all-cause mortality adjusted for, smoking, alcohol use, BMI and identified clusters at each 
five years interval. 
8.3 Results  
 
A total of 221,807 OA cases and 221,807 age, sex and practice matched non-OA controls 
were included in the analysis. Details of the description of the baseline characteristics in the 
two groups are provided in Chapter 4, Table 4.3-1(page 115). 
8.3.1 Outcomes in OA 
8.3.1.1 GP consultations for any purposes per year 
 
The mean number of GP consultations in the OA group per year after 1st January 1997 was 
19 compared to 15 in the non-OA group. However, the median difference between the 





Table 8.3-1. Summary of the GP consultations per year in the OA and non-OA groups  
OA (n=221,807) Non-OA (n=221,807) 
Mean, SD 19.40 (13.14) 15.31 (11.27) 
Median, IQR 16.28 (10.27-25.05) 12.53 (7.42-20.11) 
IQR-Inter quartile range; SD- Standard deviation 
People with OA had 1.27 times more GP consultations without adjusting for other covariates. 
However, in the adjusted model that decreased to 1.16 (95%CI 1.15-1.17) times compared 
to the non-OA group. (Table 8.3-2) 
Table 8.3-2. Gamma regression for association of GP consultations for any reasons with OA 
 Unadjusted 
Incidence rate ratio 
95% CI 
Adjusted# 
Incidence rate ratio 
 (IRR) 95% CI 
Non-OA Reference Reference  
OA 1.27(1.26-1.28) * 1.16(1.15-1.17) * 
#Adjusted for smoking, alcohol, BMI, ECI and number of comorbidities at baseline 
*P-value <0.05; IRR- Incidence rate ratio; CI-confidence interval 
 
8.3.1.2 Inpatient admission per year  
 
The mean number of hospitalisations per year was higher in the OA (0.25) compared to the 
non-OA group (0.15). Hospitalisation data was highly skewed towards the right side with a 
large proportion of zeros. Nearly 63% of all people with OA were not hospitalised at all 
compared to 66% in the non-OA group. (Table 8.3-3) 
Table 8.3-3. Summary for the number of hospitalizations per year in the OA and non-OA 
groups  
OA (n=221807) Non-OA (n=221807) 
Mean, SD 0.25 (1.25) 0.15 (0.80) 
Median, IQR 0 (0-0.25) 0 (0-0.13) 
SD- Standard deviation; IQR- Inter quartile range 
The two-part regression model showed a significant association of OA with hospitalisation. In 
the first part model, the odds of being hospitalised was 1.09 (95% CI 1.07-1.14) in OA 
compared with non-OA after adjusting for the covariates. In the second part of the model the 
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association of OA with numbers of hospitalisations was 1.16 (95% CI 1.14-1.17) times more 
compared to non-OA controls. (Table 8.3-4) 
Table 8.3-4. Two-part regression model for association of number of hospitalisations per 
year in the OA and non-OA groups 
 Unadjusted Exp (B) 95% CI Adjusted Exp (B) 95% CI 
First part model   
Non-OA Reference  Reference  
OA 1.11(1.10-1.12) * 1.09 (1.07-1.14) * 
Second part model   
Non-OA Reference Reference 
OA 1.16 (1.14-1.17) * 1.13 (1.11-1.15) * 




DALY was calculated for each group accounting for the multiple comorbidities. On average a 
person with OA loses 13.23 years of life due to the comorbidities compared to 11.51 years in 
non-OA controls. The median number of years lost was 2 years more in people with OA than 
in non-OA controls. (Table 8.3-5) 
Table 8.3-5. Disability adjusted life years (DALYs) in the OA and non-OA groups 
DALY (in years) OA (n=221807) Non-OA (n=221807) 
Mean, SD 13.23 (12.76) 11.51 (12.01) 
Median, IQR 10.01 (3.43-19.39) 8.09 (2.13-17.04) 
IQR- Interquartile range; SD- Standard deviation 
Linear regression model showed that having OA increased the DALY by 3.25 (95% CI 3.02-
3.49) years compared to non-OA after adjusting for other covariates. (Table 8.3-6) 
Table 8.3-6. Linear regression for DALY for association with OA 
 Unadjusted  
Exp (B) 95% CI 
Adjusted  
Exp (B) 95% CI 
Non-OA Reference Reference 
OA 5.62(5.22-6.04) 3.25(3.02-3.49) 





8.3.1.4 All-cause mortality 
 
Of those with OA, 20,617 (9.3%) died during the study period, compared with 13,087 (5.9%) 
in those who did not have OA. The mortality rate was nearly two times higher in the OA 
group (13.52 per 1000 person-years compared to 7.14 per 1000 person-years in the non-OA 
group). The unadjusted HR was 2.02 (95% CI 1.98 - 2.06) which reduced to 1.89 (95% CI 
1.85-1.93) after adjustment for other covariates including multimorbidity and ECI. (Table 
8.3-7)  
Table 8.3-7. All-cause mortality in the OA and non-OA  
 Total 
deaths 









Non-OA (n=221807) 13087 7.14 (7.02-7.27) Reference  Reference  
OA (n=221807) 20617 13.52 (13.34-13.70) 2.02 (1.98-2.06) * 1.89 (1.85-1.93) * 
#Adjusted for smoking, alcohol, BMI, ECI and number of comorbidities at baseline; *P-value <0.05; HR- Hazard 
ratio 
The cumulative probability of death at 5 years was 6% in OA compared to 2% in the non-OA 
group compared to. This increased to 30% in the OA group after 20 years of follow-up 
compared to 20% in the non-OA group. (Figure 8.3-1) 





8.3.1.4.1 Sensitivity analysis 
 
In the cohorts without any comorbidities at the index date, the mortality rate among people 
with OA was 6.26 per 1000 person-years compared to 2.99 in non-OA controls. The 
unadjusted HR was 2.22 (95% CI 2.02 - 2.44) which reduced to 2.15 (95% CI 2.00-2.43) 
after adjustment for other covariates including multimorbidity and ECI. (Table 8.3-8) The 
cumulative probability of death at year 5 was 1% in the non-OA group compared to 2% in the 
OA group. This increased to 9% after 20 years of follow-up in the non-OA group compared 
to 16% in the OA group. (Figure 8.3-2) 
Table 8.3-8. All-cause mortality in people with OA and non-OA controls without any 













Non-OA(n=22333) 653 2.99 (2.77-3.23) Reference  Reference  
OA (n=22333) 1197 6.26 (5.92-6.63) 2.22 (2.02-2.44) * 2.15 (2.00-2.43) * 
#Adjusted for smoking, alcohol, and BMI; *P-value <0.05 
 
Figure 8.3-2. Cumulative probability of all-cause mortality in people with OA and non-OA 





8.3.2 Outcomes within OA across the clusters 
 
8.3.2.1 GP Consultations per year  
 
Within OA clusters the mean number of GP consultations for any reasons varied from 15.35 
per year in relative healthy cluster to 34.36 per year in CV-MSK cluster. The same pattern 
was observed with the median number of visits across the clusters. In the non-OA group 
clusters, the lowest mean number of outpatient visits was reported in relative healthy group 
with 11.99 per year and the highest was 29.50 per year in CV-MSK cluster. The same 
pattern was seen for median number of visits. The Kruskal-Wallis test detected statistically 
significant differences in median number of visits across the clusters in both OA and non-OA 
with p value <0.05. (Table 8.3-9) 
Table 8.3-9. GP consultations per year within OA and non-OA clusters 
 Mean (SD) Median (IQR) 
OA   
Relatively Healthy (n=118220) 15.35 (10.72) 12.68 (8.11-19.53) 
CV-MSK (n=11234) 34.36 (17.09) 31.22 (22.47-42.26) 
Thyroid (n=7049) 23.09 (14.24) 19.87 (13.56-28.96) 
CV (n=47976) 23.37 (13.03) 20.59 (14.32-29.41) 
MSK-MH (n=37311) 21.98 (12.99) 19.13 (13.08-27.65) 
Non-OA   
Relatively Healthy (n=129891) 11.99 (9.14) 9.68 (5.77-15.50) 
CV-MSK (n=9007) 29.50 (14.57) 26.73 (19.19-36.50) 
Thyroid (n=6183) 18.87 (11.97) 16.06 (10.94-23.67) 
CV (n=42793) 20.50 (11.72) 18.11 (12.29-26.02) 
MSK-MH (n=31553) 17.20 (10.95) 14.69 (9.77-21.70) 
IQR- Interquartile range; SD- Standard deviation; CV- Cardiovascular; MH- Mental health; MSK- Musculoskeletal 
 
8.3.2.2 Inpatient admission 
 
The mean number of inpatient admissions per year was highest for CV-MSK in the OA 
group, followed by CV cluster. On average a person from CV-MSK cluster was hospitalised 
0.43 times in a year compared to 0.31 times in CV cluster. In the non-OA group, the mean 
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number of hospitalisations was lower compared with the OA group,  the mean number of 
hospitalisations in CV-MSK being 0.34 per year followed by 0.20 in CV cluster. The Kruskal-
Wallis test detected statistically significant differences in the median number of 
hospitalisations across the clusters in both OA and non-OA with p value <0.05. (Table 
8.3-10) 
Table 8.3-10 Mean inpatient admission within OA and non-OA clusters 
 
 Mean (SD) Median (IQR)  
OA    
Relatively Healthy (n=118220) 0.20 (0.74) 0 (0-0.19)  
CV-MSK (n=11234) 0.43 (2.57) 0 (0-0.30)  
Thyroid (n=7049) 0.27 (0.79) 0 (0-0.55)  
CV (n=47976) 0.31 (1.96) 0 (0-0.33)  
MSK-MH (n=37311) 0.27 (0.72) 0 (0-0.31)  
Non-OA    
Relatively Healthy (n=132,183) 0.12 (0.59) 0 (0-0.10)  
CV-MSK (n=9019) 0.34 (1.81) 0 (0-0.40)  
Thyroid (n=6190) 0.18 (0.45) 0 (0-0.19)  
CV (n=42841) 0.20 (1.14) 0 (0-0.20)  
MSK-MH (n=31574) 0.17 (0.53) 0 (0-0.18)  
IQR- Interquartile range; SD- Standard deviation; CV- Cardiovascular; MH- Mental health; MSK- Musculoskeletal 
 
8.3.2.3 DALYs across the clusters 
 
The mean DALY was calculated across the clusters in the OA and non-OA groups. As the 
number and type of comorbidity clusters are associated with DALY, no further analysis was 
done to examine the association.  
In the OA group, CV-MSK cluster had a mean DALY of 33.53 years compared to 21.42 
years in metabolic cluster and 20.60 years in MSK-MH. This means that people in CV-MSK 
on average lose 33.53 years of their lives due to the multiple comorbidities. Nearly 20 years 






Table 8.3-11 DALYs across the clusters in OA and non-OA 
  Mean (SD)  Median (IQR) 
OA   
Relatively Healthy (n=118,279) 6.41 (7.24) 4.32 (0.57-9.60) 
CV-MSK (n=11,235) 33.53 (16.01) 31.02 (21.87-42.66) 
Thyroid (n=7049) 21.42 (15.20) 17.91 (10.27-28.74) 
CV (n=47,976) 18.38 (11.14) 16.35 (10.23-24.29) 
MSK-MH (n=37,312) 20.60 (12.21) 18.30 (11.73-26.97) 
Non-OA   
Relatively Healthy (n=132,183) 5.73 (6.87)  3.64 (0.05-8.45) 
CV-MSK (n=6190) 20.68 (15.53) 16.75 (9.15-28.40) 
Thyroid (n=9019) 32.83 (15.73) 30.54 (21.32-41.63) 
CV (n=42,841) 18.02 (10.88) 16.07 (10.18-23.84) 
MSK-MH (n=31,574) 18.95 (11.78) 16.69 (10.42-24.99) 
IQR- Interquartile range; SD- Standard deviation; CV- Cardiovascular; MH- Mental health; MSK- Musculoskeletal 
A similar pattern was seen in the non-OA group. CV-MSK had the highest DALY  compared 
to other clusters. Clusters in the OA group had slightly higher DALYs compared to the non-
OA group for each cluster. The Kruskal-Wallis test detected a statistically significant 
difference between the median number of DALYs across the groups in both OA and non-OA 
with p value <0.05. 
8.3.2.4 All-cause mortality 
 
People with OA and non-OA were grouped into five clusters based on the LCA (Chapter 5, 
Figure 5.3-3, and Figure 5.3-6). Reported mortality across the OA group showed CV-MSK 
cluster had 19.63% of deaths followed by 14.96% in CV cluster. The  all-cause mortality rate 







Table 8.3-12. All-cause mortality across the clusters within the OA group 
 Total death  
N (%) 
Mortality rate per 
1000 person-
years 
Crude HR  
(95% CI) 
Adjusted# HR 
 (95% CI) 
Healthy (n=118279) 8100 (6.84) 8.9(8.7-9.1) Reference  Reference  
CV-MSK (n=11235) 2206 (19.63) 42.2(40.5-44.0) 2.08(1.88-2.30) * 1.82(1.65-2.02) * 
Thyroid (n=7049) 674 (9.56) 15.8(14.7-17.1) 1.53(1.35-1.74) * 1.52(1.33-1.72) * 
CV (n=47976) 7181 (14.96) 24.9(24.3-25.5) 1.71(1.56-1.89) * 1.53(1.39-1.68) * 
MSK-MH (n=37312) 2456 (6.58) 10.4(9.90-10.8) 1.27(1.13-1.42) * 1.23(1.09-1.38) * 
#Adjusted for smoking, alcohol, BMI, ECI and number of comorbidities at baseline; HR- Hazard ratio; CI- 
Confidence interval; *P-value <0.05 
 
The mortality rate in OA was highest for CV-MSK cluster aHR 1.82 (95% CI 1.65-2.02), 
followed by 1.53 (95% CI 1.39-1.68) and 1.52 (95% CI 1.33-1.72) in CV and metabolic 
clusters respectively, after adjusting for other covariates and time varying aspect of the 
clusters change. Figure 8.3-3 depicts the cumulative probabilities of all-cause mortality 
across the clusters in OA and shows that CV-MSK had consistently higher probabilities of 
death over the time compared to other clusters.  
Figure 8.3-3. Cumulative probability of death across the clusters in the OA group 
 
 




Among non-OA people  five clusters were identified as described in Chapter 5, Figure 5.3-6. 
The highest proportion of deaths was observed in CV-MSK cluster (14.58%) and  CV cluster 
(10.39%). The mortality rate was 25.8 per 1000 person-years in CV-MSK which was two 
times higher than the mortality rate in CV cluster (13.6 per 1000 person-years). The lowest 
rate was seen in relatively healthy at 4.8 per 1000 person-years. (Table 8.3-13) 
Table 8.3-13. All-cause mortality across the clusters in the non-OA group 
 Total death Mortality rate per 
1000  
person-years 




Healthy (n=132,183) 5739 (4.34) 4.8(4.7-4.9) Reference  Reference  
Thyroid (n=6190) 425 (6.86) 9.4(8.5-10.3) 1.78(1.45-2.19) * 1.69(1.37-2.08) * 
CV-MSK (n=9019) 1315 (14.58) 25.8(24.5-27.3) 3.14(2.60-3.77) * 2.51(2.08-3.03) * 
CV (n=41841) 4348 (10.39) 13.6(13.2-14.1) 2.49(2.07-2.99) * 2.05(1.70-2.47) * 
MSK (n=31574) 1260 (3.99) 5.4(5.1-5.7) 1.85(1.48-2.32) * 1.63(1.29-2.06) * 
#Adjusted for smoking, alcohol, BMI, ECI and number of comorbidities at baseline; HR- Hazard ratio; CI- 
Confidence interval; *P-value <0.05 
 
The adjusted hazard ratio for all-cause mortality in CV-MSK cluster compared with the 
healthy cluster was 2.51 (95% CI 2.08-3.03), followed by 2.05 (95% CI 1.70-2.47) in CV 
cluster, after adjusting for other covariates and change in clusters over time. (Table 8.3-13) 
Figure 8.3-4 shows that the cumulative probability of death was highest for CV-MSK followed 










Figure 8.3-4. Cumulative probability of death across clusters in the non-OA group 
 
Red- Relative healthy; Green- CV-MSK cluster; Yellow- Metabolic cluster; Blue- CV cluster, Purple- MSK-MH 
cluster. CV- Cardiovascular; MH- Mental Health; MSK- Musculoskeletal 
8.3.2.4.1 Interaction between OA and clusters  
 
The interaction between OA and the identified clusters were tested and used in the cox 
hazard model to identify the association with all-cause mortality. (Table 8.3-14) 
Combination of OA with identified clusters had higher mortality probabilities compared to 
non-OA cluster groups. People with OA belong to CV cluster had four times higher chances 
of death (aHR 4.09 95% CI 3.91-4.26), followed by people with OA and CV-MSK cluster with 
hazard ratio of 3.29 (95% CI 3.03-3.56). The observed mortality risk was high in combination 
with OA compared to non-OA clusters. Non-OA group with MSK cluster had 20% less risk of 





Table 8.3-14. Contribution of interaction between OA and identified cluster on mortality 
 Crude HR (95% CI) Adjusted# HR (95% CI) 
Non-OA*Healthy (n=132,183) Reference  Reference  
Non-OA*CV-MSK (n=9019) 6.76 (6.36-7.17)* 1.98 (1.82-2.15)* 
Non-OA*thyroid (n=6190) 2.14 (1.94-2.36)* 1.40 (1.26-1.56)* 
Non-OA*CV (n=42841) 3.14 (3.01-3.26)* 2.10 (2.01-2.20)* 
Non-OA*MSK-MH (n=31574) 1.23 (1.16-1.31)* 0.80 (0.75-0.86)* 
OA*Healthy (n=118,279) 1.98 (1.92-2.05)* 2.05 (1.98-2.12)* 
OA*CV-MSK (n=11235) 11.91 (11.33-12.52)* 3.29 (3.03-3.56)* 
OA*thyroid (n=7049) 3.91 (3.61-4.24)* 2.45 (2.23-2.67)* 
OA*CV (n=47976) 6.24 (6.03-6.46)* 4.09 (3.91-4.26)* 
OA*MSK-MH (n=37312) 2.49 (2.39-2.61)* 1.59 (1.50-1.68)* 
#Adjusted for smoking, alcohol, BMI, ECI and number of comorbidities at baseline; HR- hazard ratio, CI-
confidence interval. CV- Cardiovascular; MH- Mental Health; MSK- Musculoskeletal 
8.4 Discussion  
 
Outcomes in OA are variable and have been well studied with respect to pain progression, 
activity limitations, and functional decline, participation restriction and quality of life.  
However, health utilisation outcomes and the burden of the disease have not been well 
studied, especially in the presence of multimorbidity. Four outcomes were studied namely: 
GP consultations, hospitalisations (inpatient admission),  disease burden measured as 
DALY and all cause morality. Firstly, these outcomes were explored for OA cases compared 
to controls,  and then across the clusters identified within the separate OA and non-OA 
control groups. In the OA group, all the studied outcomes were higher than in  non-OA 
controls, as were the studied associations. People with OA had:  (1) 1.2 times more GP 
consultations;  (2) 1.1 times higher risk of hospitalisation  (3) nearly 1.9 times higher risk of 
all-cause mortality;  (4) 3.2 years increased DALY compared to non-OA. Within the OA 
group, people with the cluster of conditions led by back pain and hypertension had the 
highest number of outpatient visits, hospital admissions and DALYs and the risk of mortality 
was nearly 1.82 times higher compared to the relatively healthy group;  (5) clusters of CV 
and CV-MSK in OA had higher risk mortality compared to non-OA group. A similar pattern 
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was seen in the non-OA control population, with the cluster of people having hypertension 
and back pain having the worst outcomes.  
8.4.1 GP consultations 
One of the major outcomes in OA is the number of consultations in primary care. An 
increased consultations per year in the OA group was seen compared to the non-OA 
controls, as well as  the higher associations. Multiple factors could influence the number of 
GP consultations in people with OA. Bedson et al reported that joint pain and the severity of 
pain are the strongest factors for increased consultations (Bedson et al., 2007). However, 
they did not find any difference in the median number of consultations for comorbidities 
between knee pain consulters and knee non-consulters. In the analysis, adjustment was 
done for the number of comorbidities and the severity of comorbidities measured as ECI. 
There are not enough studies on the consultation rates of different conditions in the UK 
primary care setting. According to one report, nearly one third of people consulted GPs for 
musculoskeletal (MSK) problems (Versus Arthritis, 2009). The results of this study confirm 
the higher consultation rates in people with OA after the diagnosis. It is possible to have 
multiple consultations after the first recording in the GP database to confirm the diagnosis 
through tests such as radiographs, but it seems likely that most subsequent visits are for 
management. The increased consultations support the high burden of MSK conditions in 
primary care, which merits more detailed investigation and comparison with other chronic 
conditions.  
Within OA, increased consultation rate was seen for CV-MSK cluster followed by the CV 
cluster only. Even though comorbidity count and severity were adjusted, the increased 
consultation rates in these groups suggests the compounding effect of comorbidity. For 
example, the adjustment for number of comorbidities is not sufficient to address the severity 
of pain related diseases, one of the factors for frequent GP visits. Zhu et al reported similar 
findings with higher consultation rates among multimorbidity clusters with pain related 
conditions (Zhu et al., 2020). The increased consultation rates found in clusters with CVD 
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and depression could be due to the emphasised targeting of these conditions in the QOF 
guidelines for UK National Health Services (Forbes et al., 2017). The cluster specific 
consultation rate pattern in the OA group was similar to that found in the control group,  
which suggests that the combination of both MSK, and CVD increases the number of 
healthcare visits and that this  becomes even more frequent in people with OA. The causality 
association between the number of conditions and GP visits is difficult to establish in this 
study. However,  the identified clusters with multiple conditions clearly increase the burden 
to primary care.  
8.4.2 Hospitalisations  
Another important outcome was hospitalisations for any cause in OA cases compared to 
non-OA controls. Using HES data the average number of hospitalisations per year was 
higher in people with OA. After adjusting for other covariates, comorbidities and ECI, firstly 
the risk of being hospitalised remained high and then the risk of hospitalisation was nearly 
1.1 times higher than in controls. The severity of the conditions was adjusted using the ECI 
index, thus the excess hospitalisation could be related to OA related conditions. Morgan et al 
found an increased trend of hospitalisations due to OA in the UK (Morgan et al., 2019). The 
excess hospitalisation in OA could be due to the increased risk of falls and  injury  (Dore A et 
al., 2013) and to requirement for joint replacement, especially of the knee (Culliford D et al., 
2015; Ackerman et al., 2019,  Dixon, 2004; Ibrahim et al., 2010). Another important 
associated factor could be the use of NSAIDs in OA (Tramèr et al., 2000). Studies have 
shown that long-term use of NSAIDs causes increased hospitalisations especially due to 
gastrointestinal bleeding  (Henry et al., 1996; MacDonald et al., 1997) and CVD  (Jüni et al., 
2004; Hippisley-Cox and Coupland, 2005).  
Within both the OA and non-OA group, the mean number of hospitalisations was highest for 
the clusters with hypertension and back pain followed by the cluster led by hypertension 
only. This is comparable to the results of a previous study (Zhu et al., 2020). The presence 
of CVD increases the chances of inpatient admission due to known outcomes such as 
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myocardial infarction, arrhythmias, and heart failure. In the OA group, the average admission 
rate was higher than in the non-OA controls. The association of OA with CVD might in part 
explain these  increased hospitalisations (British Heart Foundation, 2019). Also, the mean 
number of conditions in these clusters was higher compared to other clusters. Cassell et 
reported in the UK that nearly 56% of the hospitalisations were due to multimorbidity 
(Cassell A. et al., 2018). Increased inpatient admissions in these clusters indicates the 
severity and risk of the complex multimorbidity. In both the OA and non-OA groups the 
average hospitalisation for pain related clusters and depression and/or thyroid clusters were 
analogous. Further studies are required to understand the pattern of hospitalisation after 
adjusting for medication use and healthcare access.  
8.4.3 All-cause mortality 
In this large and matched cohort study, people with OA had an excess all-cause mortality 
compared with non-OA controls. The association of all-cause mortality with OA is 
inconclusive (Cleveland, Nelson and Callahan, 2019). Both significant and non-significant 
associations have been reported previously. A systematic review in 2008 reported a 
moderate increase in mortality among people with OA (Hochberg, 2008), but a primary care 
database study from Sweden found no significant association of excess all-cause mortality in 
OA (Turkiewicz et al., 2016). However, findings from this study is similar to that reported by 
Nuesch et al in a UK GP database (Nuesch et al., 2011). Reasons for the discordant findings 
may be due to methodological differences, including the definition of OA, age range, study 
design, length of follow-up, and whether variables that can change and develop over time, 
such as measures of OA,BMI and comorbidities were accounted for. In this study, 
comorbidity counts and the severity of comorbidities at the index date along with other socio-
economic variables at the index date were adjusted in the models. The risk of mortality in 
people with OA was also higher in the sensitivity analysis. Because in the sensitivity analysis 
people at the index date did not have any comorbidities at baseline, the increased mortality 
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risk could be due to the subsequent higher comorbidity incidence in the OA group after the 
index date.  
Within the OA and non-OA groups, the mortality rate in this study was highest for the 
complex cluster led by hypertension and back pain, followed by the cluster led by 
hypertension only, and clusters led by depression. Previous studies have reported excess 
mortality related to CVD in people with OA, which accords with results of this study 
(Cleveland, Nelson and Callahan, 2019). There is a lack of studies on the association of 
depression or psychological disease related mortality in OA. This study found that the all-
cause mortality rate in people with OA and depression and/or thyroid conditions is quite high, 
and a similar pattern of mortality was seen across clusters in the non-OA group. The 
reported higher risks across clusters within non-OA controls compared to that of 
corresponding clusters within the OA group could be due to the relatively healthy control 
population. Because the estimated HR is a relative risk compared to the reference group, the 
people within that group in the non-OA population appear to be healthier compared to those 
in the OA group. Cause-specific mortality in OA was not investigated, but the excess 
mortality in each identified cluster can be a surrogate indicator of this. The lowest mortality 
rates were seen among people with chronic pain after relative healthy group, even though 
the association was significant in both the groups. A recently published systematic review on 
chronic pain and mortality found no significant association and reported wide heterogeneity 
across the studies (Smith et al., 2014).  
Studies on multimorbidity clusters and mortality have consistently reported a higher 
association with CVD clusters (Haug et al., 2020). A 15-year longitudinal study reported 
higher mortality (nearly two times) in clusters led by MSK and CVD (Willadsen et al., 2018) 
and another study in an elderly population reported higher mortality among people with 
arthritis and depression (Teh et al., 2018). Similar findings have been reported by other 
studies,  including Zhu et al who found an increased proportion of all-cause mortality among 
clusters with painful conditions and depression (Zhu et al., 2020). 
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Various reasons, apart from comorbidities, have been shown  to help explain the higher 
mortality in people with OA. For example, obesity, pain, and disability or functional 
limitations. These factors limit physical activity levels in people with OA, thus reducing the 
protection against CVD. Nuesch et al reported that walking disability was associated with 
increased mortality in people with OA (Nuesch et al., 2011). Another possible explanation 
could be chronic subclinical  inflammation which may predispose to an increase in 
comorbidities, especially CVD and degenerative diseases (Couzin-Frankel, 2010). Also, the 
use of analgesics such as NSAIDs in OA increases the risk of CVD comorbidities (Trelle et 
al., 2011). Even though cause-specific mortality was not part of the current research, further 
studies to explore the pattern of mortality within the clusters, especially with depression and 
chronic pain appear warranted. 
8.4.4 DALYs 
Measuring DALYs in multimorbidity is an active medical research field (Hilderink et al., 2016; 
Boshuizen et al., 2017). The latest available method was used for estimation of DALYs 
accounting for the comorbidities in the OA and non-OA groups. People with OA lose an 
average of 13 years of productive life due to comorbidities. The burden of comorbidities was 
higher in the OA compared to non-OA group. Losina et al reported a loss of 12 years 
productive life due to OA (without accounting for mortality) (Losina E et al., 2011).  
In both the groups the DALYs was highest for the cluster led by hypertension and back pain, 
followed by pain clusters and depression. The increased DALY in the complex cluster of 
MSK and CVD could be due to the high death rate among people in this cluster. Whereas 
the high burden in pain clusters, despite low death rates, suggests that the burden of chronic 
pain in an individual in the presence of other conditions is a key reason for high DALYs. In 
these clusters chronic pain played a major role as the leading chronic condition, especially 
back pain. The Global burden of disease study reported the high burden of low back pain 
and highest DALY in Western Europe (Hoy et al., 2014; Blyth et al., 2019).. People with 
depression have been found to lose nearly 28 good quality years of their life (including loss 
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due to suicide) (Jia et al., 2015). There was higher clustering of depression at a younger age 
and the DALY was nearly 16 years in both groups. Such loss of productive live due to 
multiple chronic conditions suggest the importance of prevention and management of 
multiple conditions in people with OA and controls. A paradigm shift is needed towards pain 
comorbidity, especially with coexisting conditions. Data from this study indicate that public 
health and policy measures aimed at decreasing the multimorbidity and disability in OA may 
have the potential to produce large health gains. 
8.4.5 Strengths and limitations 
This study has several strengths. This is the first study to provide information on health 
utilisation and burden in people with OA compared to age, sex matched controls in the UK. 
Also, the association of these outcomes within OA and controls were examined with respect 
to  multimorbidity clusters. One of the major strengths is the inclusion of multimorbidity for 
estimation of all-cause mortality and the burden of diseases in OA. The study population had 
a long follow-up time of maximum 20 years and considered 49 chronic conditions during the 
modelling. The time varying analysis accounted for the change in clusters and incidence of 
new conditions after the index disease, making the model more powerful. Another important 
strength is consideration of multimorbidity in the estimation of DALYs, which gives a true 
picture of the burden in a person rather than the disease.  
There are several limitations to this study. Because focus of the study was on the burden of 
OA and the identified clusters, perform joint-specific OA analysis were not done. Findings 
are likely to differ in joint specific analysis, as discussed before. The conditions and the 
clusters identified are linked to the recording pattern in the GP database. Therefore, 
ascertainment biases due to misdiagnosis, miscoding and delayed recording may all be 
present. Only all-cause mortality was estimated, whereas cause-specific mortality might 
provide better information about the clusters. The inpatient admission data was gathered 
from the HES linkage, which was not available for all people. For DALY, the used disability 
weights can vary as per the UK population and assumed the comorbidities are dependent on 
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each other. However, in the absence of these estimates for the UK, the best possible 
matched available information was used as per the WHO guidelines. The hospital 
admissions and GP visits were calculated irrespective of any specific cause, which could 
have been influenced by other incidence of other conditions. The consultation definition in 
this may not be accurate as it includes recording of visit to the primary care for any 
purposes. Possibly, people who visited more frequent had more chance of being diagnosed 
with multiple chronic conditions and vice versa. This is difficult to establish through the study. 
However, both the number and severity of the chronic conditions were adjusted at the index 
date. The change in lifestyle health behaviour pattern and drug use for the reported 
outcomes were not considered, which might have confounded the association with OA 
and/or the clusters within them.  
8.4.6 Conclusion  
The burden of health utilisation, disease severity and mortality were high in the people with 
OA. Within them, people with clusters of conditions led by hypertension and back pain, and 
by depression, had a higher burden compared to others. The findings from this study 
strengthen the importance of identified clusters in people both with and without OA. 
Coexistence of MSK and CVD leads to the worst health outcomes and incurs an increased 
burden on the health system. It was found that clusters with pain and depression also have 
high healthcare utilisation and more loss of years of productive life, which needs further 
investigation. Further research is warranted to better understand the causes and patterns in 
detail. Further studies could also be done to calculate the economic losses incurred among 







Summary of Chapter 8 
Chapter 8 explored the outcomes associated with OA and the identified disease 
clusters in both OA and non-OA population. Key findings from the study are  
• All the outcomes are worse in people with OA compared to non-OA with 
nearly 2 times higher risk of all-cause mortality and 3.2 years increased DALY 
compared to non-OA.  
• Within the OA group, people with cardiovascular only or both cardiovascular 
and musculoskeletal conditions had highest risk of mortality compared to 
other groups (1.82 times more) and higher number of hospital visits, inpatient 
admissions, and high DALY.  
• A similar pattern was seen in the non-OA control population, with the cluster 
of people having hypertension and back pain having the worst outcomes.  
Chapter 8 reveals OA has significant burden on the primary care and increased risk 
of mortality. Within OA people with cardiovascular and musculoskeletal clusters have 
worse outcomes and increase burden to the GP practice.  
 
Chapter 9 summarises the findings together and describes the possible clinical 






9 Chapter 9  
Discussion  
9.1 Key findings and interpretation 
 
This PhD thesis documents the epidemiology of OA and associated comorbidities in the UK 
using a large primary care database. Six different studies were conducted to investigate 
various aspects of OA and its comorbidities, including the epidemiology and trends of OA 
prevalence and incidence, comorbidities associated with OA prior to and post the diagnosis, 
common clusters of comorbidities, transitions between clusters over time, multimorbidity 
trajectories over time, and outcomes such as GP visits, hospitalisations, DALYs and 
mortality, which are relevant from both clinical and health policy perspectives.  
Key findings are:  
1. The prevalence of OA in UK primary care in 2017 was 10.7% and the incidence was 
6.8 per 1000 person-years in people aged 20 and over, more common in women 
than men, and increased with age. 
2. The prevalence has increased at a rate of 1.4% per year since 1998, whereas the 
incidence has been  declining at a rate of 1.6% per year. 
3. People with OA are more likely to have comorbidities and multimorbidity, both prior to 
and following the diagnosis of OA, than people without OA. 
4. Musculoskeletal (MSK), gastrointestinal (GI), cardiovascular (CV) and psychological 
conditions were associated both before and after the diagnosis of OA, whereas 
dementia and SLE were only associated with OA after its diagnosis. Other conditions 
that showed significant prior and after associations with OA, were anaemia, 
inflammatory bowel disease, benign prostatic hypertrophy , gallstones, liver disease, 
cancer, and hearing impairment. 
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5. Five multimorbidity clusters were identified in people with OA, namely, relatively 
healthy, MSK, CV, CV-MSK, and mental health clusters.  
6. After the diagnosis of OA, both the type and size of comorbidity clusters changed 
over time. 
7. Nearly 30% of people moved from  MSK or CV clusters  to CV-MSK  clusters in 10 
years since the OA diagnosis. 
8. Five progressive trajectories of multimorbidity (i.e., number of comorbidities) in 
people with OA were identified, namely, very slow, slow, gradual, rapid, and very 
rapid progression, of which 17.5% of people developed multimorbidity very rapidly 
over time. Obesity and smoking in people with OA are strongly associated with faster 
development of multimorbidity. 
9. OA is associated with an increased number of GP visits and hospitalisations, and 
with increased mortality and DALYs 
10. Within OA, people with CV-MSK, metabolic and CV comorbidity clusters have 
increased mortality, DALYs, and health utilisations 
There was an increasing trend to record joint pain and a change in  recording patterns for 
OA and joint pain after 2005. Regardless of the coding pattern, there is a clear indication of a 
high burden of OA or joint pain in the primary care. A high recording of ‘unspecified’ OA was 
seen, which needs to be investigated further to avoid misclassification. The knee was the 
most reported site of OA, but the increasing trend of reporting hand and ankle/foot OA 
suggests increasing recognition of the clinical importance of these common forms of  OA.  
There is a relative paucity of evidence about comorbidity and multimorbidity in people with 
OA. Available evidence has limitations, including  study of just one  or a small number of 
conditions, a sole focus on the elderly population, small sample sizes and differing 
methodology. This thesis shows that comorbidities in OA are common. Besides the well-
known CV and MSK conditions, the newly found conditions that associate with OA merit 
furthers investigation. For example, the associations of IBD or gallstone with OA have not 
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been studied before, and the reason for these associations is unknown. Also, this 
epidemiological study can help to identify the burden of multimorbidity and specific 
comorbidities in OA and inform the development  of improved person-centred care.  
This study found OA to be more likely to be clustered with CVDs rather than with MSK 
disorders. Even though there are some shared risk factors for both conditions, the affinity 
towards CVDs might provide more insights into the pathophysiology of the conditions. 
Identification of multimorbidity clusters in OA has been studied for the first time in this study. 
This study found a divergence in clustering pattern, across gender and different age groups. 
The identified clusters were centred around hypertension, back pain, and depression. These 
clusters might be identified due to the study population, methodology, and high prevalence 
of these conditions in the study population. The identified clusters in OA had higher burden 
from the controls. Complex multimorbidity clusters, such as presence of both painful 
conditions and CVDs, had the worst outcomes studied here. Findings from this study support 
the proposal that interventions to improve outcomes in multimorbidity may be more 
appropriately targeted on distinct types, and future management guidelines for multimorbidity 
including in OA should consider these patterns and lead conditions. 
The analysis of distinct trajectories and transitions of clusters in the OA and control 
populations  also is the first of its kind. This helps to fill the gaps in understanding of the 
evolution of a patient’s health journey rather than the disease itself. People with high risk 
lifestyles smoking and obesity develop multimorbidity faster, which provides clues for early 
and effective interventions to prevent or reduce the risk factors and to minimise the future 
multimorbidity burden. Another interesting group of people had a high burden of 
multimorbidity at the index date but subsequently had slower progression of multimorbidity 
over time. The transition of people from one cluster to another over time indicates the 
increasing complexity of multimorbidity with increasing age. People with only back pain or 
hypertension at the index date develop more complex multimorbidity in later life and people 
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that initially belonged to the relatively healthy group move to clusters led by back pain or 
hypertension only. 
Finally, the burden of the OA and the clusters within people with OA indicates the severity of 
the condition. The OA group in this study had uniformly  worst outcomes and higher mortality 
compared to the controls. Within the OA group, people with complex multimorbidity had the 
worst health outcomes and highest mortality rates. The varied section of people with 
different patterns of comorbidity had different burden of the conditions and need from the 
health care system. For example, people with both CVD and MSK lose more years of their 
productive life compared to others and have early mortality and increased health visits.  
9.2 Strengths and limitations 
 
The strength of the study is the large database and consistent methodology. Furthermore, 
data in the CPRD are collected prospectively, reducing recall bias. Latent class approaches 
were used to examine the clusters and used the extension version of the same for analysing 
the trajectories and transitions to have uniform results. In the database the conditions were 
recorded by GPs reflecting the real-world medical practice in the UK. The findings can be 
adopted for clinical policies or recommendations review. In addition, the results from this 
thesis can be used for other developed countries, with a similar population structure and 
health system in place. The statistical methods used here can be used for other diseases for 
studying the trends and comorbidity patterns.  
The CPRD, has many linked datasets and a more robust coding system through the HES 
data. Use of such linked data can provide more representative in both primary and 
secondary care and give more accuracy about the coding. A recently published study which 
used HES data to estimate the trends of OA had similar results to this study (Morgan et al., 
2019). The inclusion of CPRD primary care data only restricts the disease burden seen in 
primary care and raises questions on the quality of disease coding and confirmatory 
diagnosis. One of the limitations is, I did not include HES or secondary data to confirm the 
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diagnosis which uses ICD-10 code. The CPRD is limited by the mobility of the participating 
patients who can move in and out of registered practices thus limiting available data to 
periods of active registration. The use of joint pain definition in the chapter one has its 
limitation, which cannot be relied in the younger population, which needs to be interpreted 
carefully. However, joint pain definition in the older population could be an alternative 
approach to investigate the OA epidemiology. The estimates of prevalence and incidence of 
CPRD GOLD database therefore are “period” estimates, rather than lifetime estimates. More 
detailed research on the associations between OA and cancer or myocardial infarction (MI) 
can be performed using the cancer and MI linkages. Though most of the code groups have 
been validated before, validation of all the code groups would be helpful.  
Throughout the study of comorbidities and the clusters the same matched cohorts were 
used. The purpose was to compare the results in people with OA with age and sex matched 
controls. Because often OA is studied as controls for many outcomes. Thus, the restricted 
matched sample might have different results of clustering of multimorbidity, because the 
latter is more reliant on the size of the study population. However, the sampled population 
here is a true representation of the whole OA population. Although with access to linkage 
data of IMD, it could not be used for all the analyses  because IMD is restricted to the 
practices in the England, which could have affected the analyses. Obesity was included as a 
covariate in this study rather than a morbidity. Recent studies are debating on the inclusion 
of obesity as a disease entity rather than a risk factor. Though there is no correct answer to 
this, I considered BMI categories as a covariate in the analysis to understand the role of it 
towards each clusters and comorbidities, which could be one of the limitations.  Similarly, 
metabolic syndrome which is group of symptoms such as central obesity, high cholesterol, 
hypertension, and uncontrolled diabetes could not be derived due to lack of information on 
lipid levels, which adds to the limitation of the study. The association of health utilisation and 
burden is dependent on the number of comorbidities reported. As it is difficult to ascertain 
the relationship between the number of conditions reported and consultations, the analysis 
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was limited within OA and non-OA to descriptive only. Multimorbidity clusters with respect to  
joint specific OA were not studied due to the small number of people in each group with 
exclusive single joint specific OA.   
9.3 Clinical implications 
 
The work in this thesis has very significant clinical implications as well as implications for 
policy makers. Some of them have been discussed in each chapter. The first important 
clinical message is from the burden of OA in the primary care. The  prevalence of GP 
diagnosed OA is nearly 10% which increases  further after including consultations for joint 
pain. Primary care needs to be prepared to handle the burden and the future trends of OA. 
As OA was associated with most of the chronic conditions, people with OA might be 
considered for screening for early diagnosis of the linked comorbidities and the associated 
risk factors. The OA management plan should consider the presence of known 
comorbidities. Another important implication is the clustering of OA. People with OA should 
be examined for potential CVDs and vice versa after the age of 40 years. People with OA 
can further be grouped into different subgroups based on the clinical comorbidities present. 
For example, a person with both CVD and MSK should be given some priority due to the 
worse outcomes. An integrated person-centred care package can be developed for each 
cluster within OA, which is more feasible than developing one for all instances of 
multimorbidity. Each person with OA and comorbidity should be monitored for early detection 
of further  comorbidities  so that the trajectory of the multimorbidity can be slowed.  
Due to the lack of appropriate management protocol, multimorbidity constitutes a challenge 
for the organisation of health and social. As mentioned, there is need to provide person-
centred integrated care as vis-a-vis fragmented and single-disease focused care. The 
evidence toward success of integrated model is convincing, however there lies the 
complexity in development of such care model. For instance, integrated care model in 
multimorbid people with OA has not been developed yet. Few researchers are focusing on 
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OA and CVDs or pain comorbidities. It is in real a tough task to design care models based 
on the diseases as multiple risk factors, medications prescribed and the health system’s 
readiness each contributes to its complexity. A systematic review looked at the integrated 
care models in the Europe for multimorbidity, concluded the complexities of the diseases 
was not accounted in different models (Struckmann et al., 2018). A cost-utility analysis on 
integrated model discarded the suitability of implementing for all age groups and not efficient 
(Lanzeta, Mar and Arrospide, 2016). One integrated care model trail for people with OA 
focused in improving the OA symptoms but not on comorbidities (Østerås et al., 2019). 
Various MSK model of care was found to be successful in improving the joint pain 
symptoms, however it’s impact on other diseases were not studied (Dziedzic et al., 2016).  
9.4 Future work 
 
Some important questions have been addressed in this thesis, but others remain  
unanswered.  
The burden of unspecified OA site in primary care, and the reasons for such recording, 
needs to be explored further. Although regional diversity was seen in the prevalence and 
incidence of OA, this can be better studied using a more complete primary care database of 
the UK. This study documented broadly that people with OA have higher risk of 
comorbidities at diagnosis and risk of some comorbidities also increased after the diagnosis, 
but  more detailed studies to confirm and to further explore these associations are required. 
For example, the association between OA and hearing problems is interesting but hard to 
explain, and merits further research. Both epidemiological and biological studies need to be 
conducted to support the identified associations. Especially, the role of the disease and the 
associated drug treatments need to be differentiated and quantified to understand the major 
contributors towards the comorbidities. A different methodology in a different database may 
also be used to validate the findings. 
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For clustering of comorbidities, a different set of analytical approaches could be used to 
verify the clusters. Though results of alternative machine learning method is provided in the 
Appendix Method 2 (Page 347). More joint specific analysis should  be helpful to understand 
the underlying potential pathophysiology. Even though age and BMI are thought to be a 
significant shared risk factor for comorbidities in people with OA, the new evidence of 
inflammatory substances needs further attention. The details of the possible pathophysiology 
of the comorbidities in people with OA is given in  Figure 4.41, page 141 . As OA is a slow 
progressing disease and often diagnosed in advanced stage of joint degeneration, the 
inflammatory changes start appearing much before whose association with other 
comorbidities need to be explored. The emergence of association with new comorbidities in 
this study makes worth wondering the causal association with some of the conditions such 
as hearing loss, gall bladder stone and BPH. Both biological and genetic studies can be 
done to understand the shared risk factors or any hidden causal factor for the disease and 
their temporal associations. New methods such as mendelian randomisation and genome 
wise study can help in understanding the underlying pathophysiology for the disease. 
Further research should be done within the identified clusters for shared risk factors. The 
cluster with high multimorbidity at the index date but slower progress afterwards might be 
studied in detail to determine the most effective chronic care model. More dynamic modelling 
can be used to find the factors associated with the transition of people between the clusters. 
More robust methodological research must be done into methods for analysing clustering of 
binary data. The evolving nature of multimorbidity should be modelled with dynamic changes 
in associated risk factors. More risk factors such as medicines use, diet, physical activity, 
and ethnicity can be included. 
Further research should be carried out to understand the care complexities in identified 
clusters from both patient and physician’s perspectives. Health seeking behaviour and 
access to health care factors should be considered in the analysis of comorbidities, 
particularly while using the electronic health records. Alternatively, large scale community 
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studies should be encouraged among representative samples. Qualitative research among 
people within each cluster can help with identifying the facilitators and barriers towards 
chronic care for OA. The complexity of chronic conditions, drugs and management protocols 
can be studied in detail for designing effective care packages. The association of drugs used 
for other conditions such as CVDs or GI on OA should not be ignored. A life course 
epidemiology design can be used to understand the evolving nature of OA and other 
multimorbidity. The associated risk factors must be studied long  before  the clinical 
presentation or time of diagnosis of OA. The contribution of biological markers should be 
explored in detail, especially for inflammation and depression towards developing 
multimorbidity.  
 Economic analysis of loss due to OA and its multimorbidity can provide great insight for 
better resource allocation. The mortality accounted for by drug use in OA (NSAIDs, opioids) 
need to be investigated further. A risk prediction model could be developed for illness 




In conclusion, CPRD GOLD data have been used successfully to address the  
epidemiological and clinical research questions in OA. The thesis provides evidence for the 
current epidemiology of OA, associated comorbidities, comorbidity clusters, their evolution 
and trajectory of development, and the severity of each cluster for mortality and health 
utilisation. All these address clinically relevant questions for primary care. The 
methodologies established using this thesis lay the foundation for future research in 
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11 Appendices  
  
Appendix Table 1 Read codes for Joint pain 
Read Code Name 
N094000 Arthralgia of unspecified site 
N094900 Arthralgia of multiple joints 
N094600 Arthralgia of the lower leg 
N094F00 Arthralgia of wrist 
N094M00 Arthralgia of knee 
N094400 Arthralgia of the hand 
N094D00 Arthralgia of elbow 
N094300 Arthralgia of the forearm 
N094J00 Arthralgia of DIP joint of finger 
N094700 Arthralgia of the ankle and foot 
N094B00 Arthralgia of sternoclavicular joint 
N094500 Arthralgia of the pelvic region and thigh 
N094200 Arthralgia of the upper arm 
N094G00 Arthralgia of MCP joint 
N094H00 Arthralgia of PIP joint of finger 
N094z00 Arthralgia NOS 
N094K00 Arthralgia of hip 
N094P00 Arthralgia of ankle 
N094800 Arthralgia of other specified site 
N094C00 Arthralgia of acromioclavicular joint 
N094V00 Arthralgia of IP joint of toe 
N094T00 Arthralgia of 1st MTP joint 
N094R00 Arthralgia of talonavicular joint 
N094U00 Arthralgia of lesser MTP joint 
N094S00 Arthralgia of other tarsal joint 
N094N00 Arthralgia of tibio-fibular joint 
N094Q00 Arthralgia of subtalar joint 
N094E00 Arthralgia of distal radio-ulnar joint 
N094W Anterior knee pain 
N245012 Finger pain 
N245000 Hand Pain 
N245011 Thumb Pain 
N245100 Foot pain 
N245111 Toe Pain 
1M10 Knee pain 
1M11 Foot pain 









Appendix Table 2 Read codes for Osteoarthritis 
Read Code      Name of the condition 
N05zJ00 Osteoarthritis NOS, of hip 
N053512 Hip osteoarthritis NOS 
N05z511 Hip osteoarthritis NOS 
N053500 Localised osteoarthritis, unspecified, pelvic region/thigh 
N051500 Localised, primary osteoarthritis of the pelvic region/thigh 
N052500 Localised, secondary osteoarthritis of pelvic region/thigh 
N054500 Oligoarticular osteoarthritis, unspecified, of pelvis/thigh 
N05z500 Osteoarthritis NOS, pelvic region/thigh 
Nyu2E11 [X] Unilateral secondary coxarthrosis 
Nyu2200 [X]Other dysplastic coxarthrosis 
Nyu2300 [X]Other post-traumatic coxarthrosis 
Nyu2100 [X]Other primary coxarthrosis 
Nyu2E00 [X]Other secondary coxarthrosis 
Nyu2400 [X]Other secondary coxarthrosis, bilateral 
N051900 Primary coxarthrosis, bilateral 
N05zL00 Osteoarthritis NOS, of knee 
N05z611 Knee osteoarthritis NOS 
N053600 Localised osteoarthritis, unspecified, of the lower leg 
N05z600 Osteoarthritis NOS, of the lower leg 
N051600 Localised, primary osteoarthritis of the lower leg 
N052600 Localised, secondary osteoarthritis of the lower leg 
N054600 Oligoarticular osteoarthritis, unspecified, of lower leg 
N053611 Patellofemoral osteoarthritis 
N05zM00 Osteoarthritis NOS, of tibio-fibular joint 
Nyu2511 [X] Unilateral primary gonarthrosis 
N051B00 Primary gonarthrosis, bilateral 
Nyu2811 [X] Unilateral secondary gonarthrosis 
Nyu2800 [X]Other secondary gonarthrosis 
Nyu2700 [X]Other secondary gonarthrosis, bilateral 
Nyu2500 [X]Other primary gonarthrosis 
N052C00 Post-traumatic gonarthrosis, unilateral 
N05zN00 Osteoarthritis NOS, of ankle 
N05z700 Osteoarthritis NOS, of ankle and foot 
N05zU00 Osteoarthritis NOS, of IP joint of toe 
N05zT00 Osteoarthritis NOS, of lesser MTP joint 
N05zS00 Osteoarthritis NOS, of 1st MTP joint 
N05zR00 Osteoarthritis NOS, of other tarsal joint 
N05zP00 Osteoarthritis NOS, of subtalar joint 
N05z712 Foot Osteoarthritis NOS 
N05zQ00 Osteoarthritis NOS, of talonavicular joint 
N053700 Localised osteoarthritis, unspecified, of the ankle and foot 
N051700 Localised, primary osteoarthritis of the ankle and foot 
N051E00 Localised, primary osteoarthritis of toe 
N052700 Localised, secondary osteoarthritis of the ankle and foot 
N05z713 Toe osteoarthritis NOS 
N05z711 Ankle osteoarthritis NOS 
N054700 Oligoarticular osteoarthritis, unspecified, of ankle/foot 
Nyu2900 [X]Other primary arthrosis of first carpometacarpal joint 
N051C00 Primary arthrosis of first carpometacarpal joints, bilateral 
Nyu2A00 [X]Other post-traumatic arthrosis/1st carpometacarpal joint 
Nyu2B00 [X]Other 2ndry arthrosis/1st carpometacarpal joints, bilateral 
N053400 Localised osteoarthritis, unspecified, of the hand 
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N051400 Localised, primary osteoarthritis of the hand 
N05011 Heberden’s node 
N052400 Localised, secondary osteoarthritis of the hand 
N05z412 Thumb osteoarthritis NOS 
N050700 Heberden’s node with arthropathy 
N054400 Oligoarticular osteoarthritis, unspecified, of hand 
N050112 Bouchard’s node 
N05zH00 Osteoarthritis NOS, of DIP joint of finger 
N050300 Bouchard’s node with arthropathy 
N05zG00 Osteoarthritis NOS, of PIP joint of finger 
N05z311 Wrist osteoarthritis NOS 
N05z400  Osteoarthritis NOS, of the hand 
N051D00 Localised, primary osteoarthritis of the wrist 
N05z411 Finger osteoarthritis NOS 
N05zE00 Osteoarthritis NOS, of wrist 
N05zF00 Osteoarthritis NOS, of MCP joint 
N050100 Generalized OA of hand  
N06z311 Wrist arthritis NOS 
N053100 Localised osteoarthritis, unspecified, of shoulder region 
N051100 Localised, primary osteoarthritis of the shoulder region 
N052200 Localised, secondary osteoarthritis of the upper arm 
N052000 Localised, secondary osteoarthritis of unspecified site 
N054100 Oligoarticular osteoarthritis, unspecified, of shoulder 
N054200 Oligoarticular osteoarthritis, unspecified, of upper arm 
N05z900 Osteoarthritis NOS, of shoulder 
N05z100 Osteoarthritis NOS, of shoulder region 
N052100 Localised, secondary osteoarthritis of the shoulder region 
N05zC00 Osteoarthritis NOS, of elbow 
N05zD00 Osteoarthritis NOS, of distal radio-ulnar joint 
N06z211 Elbow arthritis NOS 
N051300 Localised, primary osteoarthritis of the forearm 
N051F00 Localised, primary osteoarthritis of elbow 
N051800 Localised, primary osteoarthritis of other specified site 
N051.00 Localised, primary osteoarthritis 
N051z00 Localised, primary osteoarthritis NOS 
N051000 Localised, primary osteoarthritis of unspecified site 
N052.00 Localised, secondary osteoarthritis 
N052z00 Localised, secondary osteoarthritis NOS 
N052800 Localised, secondary osteoarthritis of other specified site 
N050000 Osteoarthritis and allied disorders 
N054.00 Oligoarticular osteoarthritis, unspecified 
N054900 Oligoarticular osteoarthritis, unspecified, multiple sites 
Nyu2.00 [X]Arthrosis 
Nyu2000 [X]Other polyarthrosis 
N054000 Oligoarticular osteoarthritis, unspec, of unspecified sites 
N05z000 Osteoarthritis NOS, of unspecified site 
N05..00 Osteoarthritis and allied disorders 
N054800 Oligoarticular osteoarthritis, unspecified, other spec sites 
N05z.00 Osteoarthritis NOS 
N053z00 Localised osteoarthritis, unspecified, NOS 
N053800 Localised osteoarthritis, unspecified, of other spec site 
N05zz00 Osteoarthritis NOS 
N053000 Localised osteoarthritis, unspecified, of unspecified site 
N05..11 Osteoarthritis 
N05z800 Osteoarthritis NOS, other specified site 
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N054z00 Osteoarthritis of more than one site, unspecified, NOS 
N06z.11 Arthritis 
N050500 Secondary multiple arthrosis 
N050400 Primary generalized osteoarthrosis 
N050Z00 Generalized OA NOS 
N050200 Generalised OA Multiple sites 































































Total number of people registered in 
CPRD- 17,480,766 
Total OA incidence cases – 3,480,613 
GP recoded OA- 928,310 
OA related pain-  2,719,159 
Total Joint Replacement with no recording of OA- 
26761 
Other rheumatic conditions and 
musculoskeletal conditions within 
+/-three years of diagnosis – 28837 
Joint pain or injury within +/- one 
year of diagnosis date - 239688 
Records non-acceptable- 2,238,558 
Less than 20 years of age – 
1,940,540 
More than 110 years of age- 
1,855,26 
Registered with GP <1 year- 
3,846,099 
Event date after stop date- 2567 
Unavailability of year of birth- 47882 
Total available population for the study- 
8,931,085 
Physician diagnosed incident OA- 812,142 
OA related joint pain incident- 2,185,203 
 
CPRD, Patient database 
OA (Clinical Database) 
Merged 
Excluded 






























A Yes Yes Yes Yes Yes 
B Yes Yes No Yes Yes 
C Yes Yes No Yes Yes 
D Fail No No No No 









Circle: Up to standard; Triangle: Current Registration; Diamond: Diagnosis date; Square: 
Death/Transfer out/LCD  
Appendix Figure  2 Selection of study population for incidence and prevalence 
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Appendix Figure  3 Crude incidence trends across length of data contribution for 
incidence (A) and prevalence (B) 
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Appendix Figure  4 At-risk and eligible population at the study year for incidence (A) and 
prevalence (B) calculation across length of data contribution 
A. Incidence            
 
B. Prevalence  
 





















































































   
 
 
       






































Total number of people registered in CPRD- 
17,480,766 
 
Acceptable data for matching 
 (n= 9,219,594)  
(OA= 812,142) 
(Non-OA = 8407452) 
Matched pair = 497510 
Cases= 248755 
Controls = 248755 
Final Cases= 221,807 
Final Controls= 221,807 
Records non-acceptable- 2,238,558 
Less than 20 years of age – 1,940,540 
More than 110 years of age- 1,855,26 
Registered with GP <3 year- 3,846,099 
Event date after stop date- 2567 
Unavailability of year of birth- 47882 
 
Unmatched OA cases- 
563,387 1:1 matching  
with age, sex,  
practice 
and first year 
of 
registration 
26,948 pairs had the 
controls being selected 
more than once.  
So, only one matched pair  
was kept and the pairs 
with multiple controls 
were removed. 






























Non matched observation 
(n= 9012) 
Comorbidities on or 
before index date 
(n=378.090) 
Total number of 
matched case-control (n = 443614) 
 
Without any Comorbidity at index date 
(n= 64,524) 
 
Final observation for cohort 
study (n=55,512) 
OA Cases = 22333 
Controls= 22333 
Appendix Figure  7 Selection of matched OA cases (exposed) with controls (unexposed) for 
cohort studies (No comorbidities on or before the index date) 
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Appendix Table 4 Code list of key comorbidities 
Group Diseases Initials of major read codes  
Musculoskeletal Rheumatoid Arthritis N040.0; N040..; N043… ;N04y… 
 Back pain N11….; N12…; N14….; N3…; Nyu…; S10.…; S49…; S57…;  
 Crystal arthropathy C34…; N02z…; N02y…; N022..; N021… 
 Osteoporosis  N33… 
 Fibromyalgia N248.00; N239.00; F286… 
Cardio-vascular Coronary Heart Disease G3…00; G30….; G30z….; G34…; G35…; G54….; G57….; Gyu… 
 Arterial/Venous G70…; G71…; G72….; G74… 
 Heart failure G580…; G81….; G232.00; G234.00 
 Hypertension G20…; G21…; G24…; G25…; G26… 
Respiratory Asthma 663…; 66Y…;  
 COPD H31…; H32…; H33…;  
Genito-urinary  Chronic Kidney Disease 1Z12.00; 1Z13.00; 1Z14.00; 1Z15.00; 1Z16.00; K01…; K02… 
 Renal stone 4G4…; 7B07…; K120….  
Neurological Stroke  9Om0.00; 9Om…; 8HBJ.oo; G60…; G61…; F22…; G64…; G63… 
 Dementia  E00…; Eu0…; F11…. 
 Parkinson Disease F12… 
 Migraine F26…. 
Psychiatric  Depression Eu1…; Eu3… 
 Psychosis  Eu2Z.11; Eu0z.11 
 Schizophrenia Eu2… 
Metabolic/Endocrine High Cholesterol C324.00; C322.00; C328.00  
 Diabetes Mellitus  9OL...00; 2BB…; 2G5…; 66A…; C10…; F42… 
 Hyperthyroid  C02… 
 Hypothyroidism  C03…; C04… 
Digestive Gastritis  J11…; J12…; J15…14C1… 
 Gastrointestinal bleed J110…; J111….; J120…; J121…; J13….; J14…. J681… 
 Gall bladder stone J65…; 4G2… 
 Liver Disease J61…; J63…; A70…;  
Other Hearing  F59…. 
 Sleep Disorder Fy0… 
 Anaemia D00… 
The codes are initials of the read codes representing the comorbidities.  
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Appendix Table 5 Comorbidities in the past years prior to the diagnosis of OA at any joint (Expanded version) 
  1 year  5 years  10 years  15 years  20 years  
 Non-OA  OA Non-OA OA  Non-OA  OA  Non-OA  OA  Non-OA  OA 
  n % n % n % n % n % n % n % n % n % n % 
Musculoskeletal                     
Ankylosing Spondylitis 132 0.06 215 0.09 674 0.30 1092 0.49 1358 0.61 2163 0.98 1889 0.87 2891 1.33 2158 1.03 3258 1.55 
Back pain 4452 2.02 7632 3.44 21452 9.73 30343 13.72 40443 18.44 55334 25.20 54194 25.11 73749 34.11 61835 29.61 84092 40.12 
Crystal arthropathy 493 0.22 749 0.34 2162 0.98 3625 1.64 3564 1.62 5995 2.73 4382 2.03 7325 3.38 4829 2.31 8013 3.82 
Osteoporosis  632 0.28 1166 0.52 2622 1.19 3680 1.66 4028 1.84 5267 2.39 4664 2.61 5961 2.75 4896 2.34 6260 2.98 
Polymyalgia  170 0.08 323 0.14 659 0.29 1285 0.58 980 0.45 1885 0.86 1161 0.54 2129 0.98 1243 0.59 2226 1.06 
Rheumatoid Arthritis 91 0.04 367 0.16 387 0.17 1015 0.46 710 0.32 1586 0.72 865 0.40 1904 0.88 972 0.46 1956 0.93 
Sjogren’s syndrome 18 0.01 48 0.02 71 0.03 171 0.08 137 0.06 265 0.12 173 0.08 314 0.14 202 0.09 340 0.16 
Systemic lupus 
erythematous 
5 0.00 11 0.00 26 0.01 46 0.02 49 0.02 80 0.03 73 0.03 109 0.05 81 0.04 122 0.05 
Fibromyalgia 115 0.05 404 0.18 490 0.22 1192 0.54 827 0.37 1829 0.83 1027 0.47 2129 0.98 1073 0.51 2162 1.03 
Fatigue 218 0.09 360 0.16 915 0.41 1363 0.62 1445 0.66 2099 0.95 1693 0.78 2386 1.10 1739 0.83 2453 1.17 
Respiratory                     
Asthma 691 0.31 1081 0.48 3636 1.64 5338 2.41 7458 3.40 10628 4.84 10482 4.86 14770 6.83 12320 5.90 17029 8.12 
COPD 602 0.27 927 0.42 2984 1.35 4209 1.90 5886 2.68 8126 3.70 8043 3.72 11088 5.12 9296 4.45 12642 6.05 
Genito-Urinary                     
Chronic kidney disease 1566 0.71 2002 0.90 5549 2.51 6789 3.07 7369 3.36 8768 3.99 7513 3.48 8960 4.14 7527 3.60 8965 4.27 
Prostate^  639 0.29 989 0.45 2899 1.31 4038 1.83 4884 2.22 6543 2.98 5972 2.76 7901 3.65 6365 3.05 8436 4.02 
Renal stone 114 0.05 158 0.07 542 0.24 698 0.31 989 0.45 1261 0.57 1325 0.61 1635 0.76 1567 0.75 1923 0.91 
Neuro/Psychiatric                     
Stroke  1354 0.61 1773 0.80 6025 2.73 7141 3.22 10314 4.70 11902 5.42 13042 6.04 14826 6.85 14200 6.80 16158 7.70 
Dementia  235 0.11 355 0.16 741 0.33 908 0.41 929 0.42 1036 0.47 978 0.45 1061 0.49 990 0.47 1068 0.51 
Epilepsy 72 0.03 144 0.06 414 0.19 511 0.23 702 0.30 897 0.41 966 0.45 1196 0.55 1125 0.54 1376 0.65 
Multiple sclerosis 22 0.01 35 0.01 127 0.57 124 0.56 236 0.11 230 0.10 329 0.15 293 0.13 433 0.20 348 0.17 
Parkinson’s Disease 80 0.03 161 0.07 318 0.14 481 0.22 450 0.20 629 0.29 489 0.23 680 0.31 502 0.24 696 0.33 
Migraine 500 0.23 745 0.33 2487 1.12 3561 1.61 5093 2.32 7065 3.21 7203 3.33 9802 4.53 8489 4.06 11359 5.41 
Depression 1799 0.82 2978 1.34 9051 4.10 13588 6.14 17610 8.03 25398 11.57 24076 11.15 34044 15.74 27362 13.10 38417 18.32 
Psychosis  18 0.001 41 0.01 154 0.07 161 0.07 291 0.13 268 0.12 377 0.17 354 0.16 419 0.20 398 0.19 
Schizophrenia 51 0.02 84 0.04 325 0.14 389 0.17 657 0.29 692 0.31 888 0.41 928 0.43 1034 0.49 1073 0.51 
Cancer 874 0.39 902 0.41 3697 1.67 4287 1.94 5951 2.71 6795 3.09 7294 3.38 8248 3.81 7984 3.80 8972 4.28 
Circulatory                      
Coronary heart disease 967 0.44 1257 0.56 5059 2.29 6390 2.89 9472 4.32 12171 5.54 12496 5.79 16162 7.47 14262 6.83 18302 8.73 
Arterial/Venous 116 0.05 176 0.08 513 0.23 731 0.33 825 0.37 1123 0.51 989 0.46 1337 0.62 1062 0.51 1429 0.68 
Heart failure 289 0.13 444 0.20 1045 0.47 1795 0.81 1568 0.71 2658 1.21 1777 0.82 3011 1.39 1847 0.88 3113 1.48 
Hypertension 3906 1.77 4805 2.16 18204 8.25 20969 9.48 32449 14.80 37418 17.04 41348 19.16 48042 22.22 46012 22.03 53659 25.60 
Peripheral vascular 
disease 
413 0.18 753 0.34 1767 0.80 2734 1.23 2939 1.34 4411 2.00 3614 1.67 5191 2.40 3906 1.87 5539 2.64 
Metabolic                     
High Cholesterol 2239 1.02 3053 1.37 9875 4.47 12467 5.63 16604 7.57 20458 9.32 20291 9.40 24714 11.43 21865 10.47 26558 12.67 
Diabetes Mellitus  1397 0.63 1948 0.88 6188 2.80 7954 3.59 9945 4.53 12677 5.77 11856 5.49 15129 6.99 12656 6.06 16147 7.70 
Hyperthyroid  137 0.06 142 0.06 665 0.30 712 0.32 1205 0.55 1294 0.59 1579 0.73 1732 0.80 1843 0.88 2047 0.97 
Hypothyroidism  895 0.40 1203 0.54 4075 1.84 5067 2.29 7050 3.21 8732 3.97 8922 4.13 11096 5.13 9793 4.69 12276 5.85 
Digestive                     
Gastritis  610 0.28 997 0.45 2771 1.25 4069 1.84 4915 2.24 7070 3.22 6542 3.03 9198 4.25 7551 3.61 10527 5.02 
Gastrointestinal bleed 155 0.07 270 0.12 672 0.30 1032 0.47 1133 0.52 1675 0.76 1431 0.66 2072 0.96 1570 0.75 2253 1.07 
Gall bladder stone 533 0.24 660 0.30 2490 1.13 3438 1.55 4296 1.95 6077 2.76 5602 2.59 7971 3.68 6461 3.09 9189 4.38 
Inflammatory Bowel 
Disease 
578 0.26 805 0.36 2548 1.15 3695 1.67 4514 2.05 6379 2.90 5824 2.69 7983 3.69 6409 3.06 8704 4.15 
Liver Disease 73 0.03 135 0.06 329 0.15 508 0.23 506 0.23 796 0.36 637 0.29 950 0.44 689 0.32 1029 0.49 
Irritable bowel 
syndrome 
986 0.44 1421 0.63 3134 1.42 4787 2.16 6266 2.85 9261 4.21 8653 4.01 12589 5.82 10015 4.79 14335 6.83 
Others                      
Hearing  1666 0.75 2357 1.06 7193 3.26 9172 4.14 11807 5.38 14748 6.71 14329 6.64 17855 8.26 15587 7.46 19315 9.21 
Vision problem 130 0.06 136 0.06 510 0.23 625 0.28 860 0.39 1015 0.46 1059 0.49 1209 0.56 1136 0.54 1313 0.62 
Psoriasis  277 0.12 439 0.19 1286 0.58 1751 0.79 2379 1.08 3127 1.42 3174 1.47 4086 1.89 3655 1.75 4602 2.19 
Scleroderma 2  12  17 0.01 29 0.01 37 0.02 41 0.02 46 0.02 51 0.02 54 0.02 55 0.02 
Sleep Disorder 481 0.22 724 0.32 2061 0.93 2877 1.30 3169 1.44 4340 1.97 3677 1.70 4978 2.30 3820 1.82 5148 2.45 
Tuberculosis 16 0.01 32 0.01 112 0.05 139 0.06 215 0.09 269 0.12 310 0.14 360 0.17 342 0.16 417 0.19 
Anaemia 588 0.26 920 0.41 2389 1.08 3385 1.53 4010 1.83 5268 2.40 4927 2.28 6269 2.90 5406 2.59 6732 3.21 
Comorbidities (count)                     
No comorbidity 195859 88.10 184311 82.91 131897 59.33 109920 49.44 95710 43.05 73856 33.22 81303 36.57 61335 27.59 77845 35.01 59752 26.88 
Single comorbidity 22891 10.29 31971 14.38 57054 25.66 64354 28.95 60358 27.15 59574 26.80 56157 25.26 51005 22.94 51546 23.18 44541 20.03 
Any two comorbidities 3058 1.37 5042 2.26 22617 10.17 30264 13.61 35762 16.08 42647 19.18 39244 17.65 43511 19.57 38897 17.49 41327 18.59 
Any three 
comorbidities 
415 0.19 787 0.35 7618 3.42 11901 5.35 17810 8.01 24647 11.09 23302 10.48 30336 13.64 25282 11.37 
31429 
14.14 
Four or more  67 0.03 179 0.08 3104 1.39 5851 2.63 12650 5.69 21568 9.70 22284 10.02 36103 16.24 28720 12.92 45241 20.35 
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Appendix Table 6 Association between any OA and comorbidities in the past years prior to the index date (Expanded version) 
 20 years  15 years  10 years 5 years  1 year  
 Unadjusted OR Adjusted OR# Unadjusted OR Adjusted OR# Unadjusted OR Adjusted OR# Unadjusted OR Adjusted OR# Unadjusted OR Adjusted OR# 
>=2 comorbidities  1.86 (1.83-1.88)* 1.71(1.69-1.74)* 1.80(1.77-1.82)* 1.66(1.63-1.68)* 1.71(1.68-1.73)* 1.58(1.56-1.60)* 1.63(1.60-1.65)* 1.53(1.49-1.55)* 1.64 (1.56-1.71)* 1.52 (1.45-1.59)* 
Musculoskeletal           
Ankylosing Spondylitis 1.53 (1.45-1.62)* 1.53 (1.44-1.62)* 1.55 (1.46-1.64) 1.56 (1.46-1.65)* 1.61 (1.50-1.72)* 1.63 (1.52-1.75)* 1.61 (1.46-1.77)* 1.63 (1.47-1.79)* 1.55 (1.24-1.92)* 1.49 (1.19-1.86)* 
Back pain 1.70 (1.67-1.72)* 1.67 (1.64-1.69)* 1.61 (1.59-1.64)* 1.59 (1.56-1.61)* 1.52 (1.50-1.55)* 1.51 (1.48-1.53)* 1.47 (1.44-1.50)* 1.45 (1.43-1.48)* 1.61 (1.55-1.68)* 1.60 (1.54-1.69)* 
Crystal arthropathy 1.69 (1.64-1.76)* 1.52 (1.46-1.57)* 1.70 (1.63-1.77)* 1.52 (1.45-1.58)* 1.69 (1.63-1.77)* 1.52 (1.45-1.59)* 1.67 (1.58-1.76)* 1.49 (1.41-1.58)* 1.39 (1.24-1.56)* 1.26 (1.11-1.42)* 
Osteoporosis  1.27 (1.22-1.32)* 1.41 (1.35-1.47)* 1.27 (1.22-1.32)* 1.41 (1.35-1.46)* 1.29 (1.23-1.34)* 1.42 (1.36-1.49)* 1.36 (1.29-1.43)* 1.49 (1.42-1.58)* 1.59 (1.44-1.76)* 1.74 (1.57-1.93)* 
Polymyalgia  1.80 (1.68-1.93)* 1.74 (1.62-1.87)* 1.84 (1.71-1.98)* 1.78 (1.65-1.92)* 1.92 (1.78-2.08)* 1.86 (1.72-2.01)* 1.93 (1.76-2.12)* 1.86 (1.69-2.05)* 1.80 (1.49-2.17)* 1.71 (1.41-2.08)* 
Rheumatoid Arthritis 1.97 (1.83-2.13)* 1.95 (1.80-2.11)* 2.16 (1.99-2.34)* 2.14 (1.97-2.32)* 2.18 (1.99-2.39)* 2.17 (1.98-2.38)* 2.51 (2.23-2.83)* 2.50 (2.21-2.82)* 3.60 (2.85-4.54)* 3.69 (2.90-4.68)* 
Sjogren’s syndrome 1.64 (1.38-1.96)* 1.67 (1.39-2.00)* 1.77 (1.47-2.13)* 1.82 (1.50-2.20)* 1.86 (1.52-2.29)* 1.94 (1.56-2.40)* 2.31 (1.75-3.05)* 2.47 (1.85-3.30)* 2.27 (1.30-3.96) 2.60 (1.44-4.69) 
Systemic lupus 
erythematous 
1.49 (1.12-1.98) 1.54 (1.15-2.07) 1.48 (1.09-1.99) 1.54 (1.10-2.05) 1.63 (1.14-2.33) 1.59 (1.09-2.29) 1.77 (1.09-2.86) 1.72 (1.05-2.82) 2.19 (0.76-6.33) 2.31 (0.76-7.05) 
Fibromyalgia 1.95 (1.81-2.10)* 1.89 (1.75-2.04)* 2.01 (1.86-2.16)* 1.95 (1.80-2.11)* 2.12 (1.95-2.31)* 2.07 (1.89-2.25)* 2.27 (2.03-2.53)* 2.19 (1.96-2.45)* 2.71 (2.18-3.36)* 2.77 (2.21-3.46)* 
Fatigue 1.42 (1.33-1.51)* 1.42 (1.32-1.51)* 1.42 (1.33-1.51)* 1.42 (1.33-1.52)* 1.46 (1.36-1.56)* 1.46 (1.36-1.57)* 1.49 (1.36-1.62)* 1.48 (1.36-1.62)* 1.59 (1.34-1.88)* 1.56 (1.30-1.86)* 
Respiratory           
Asthma 1.41 (1.38-1.45)* 1.33 (1.30-1.37)* 1.44 (1.40-1.48)* 1.35 (1.31-1.39)* 1.44 (1.40-1.49)* 1.35 (1.31-1.39)* 1.46 (1.40-1.53)* 1.37 (1.31-1.43)* 1.47 (1.34-1.63)* 1.36 (1.23-1.51)* 
COPD 1.40 (1.37-1.45)* 1.35 (1.31-1.39)* 1.42 (1.38-1.46)* 1.36 (1.32-1.41)* 1.40 (1.36-1.46)* 1.36 (1.31-1.41)* 1.40 (1.34-1.47)* 1.37 (1.30-1.43)* 1.46 (1.31-1.62)* 1.42 (1.28-1.58)* 
Genito-Urinary           
Chronic kidney disease 1.25 (1.20-1.29)* 1.12 (1.08-1.16)* 1.24 (1.20-1.29)* 1.12 (1.08-1.16)* 1.24 (1.20-1.29)* 1.12(1.08-1.16)* 1.27 (1.22-1.32)* 1.15 (1.10-1.19)* 1.27 (1.18-1.36)* 1.16 (1.08-1.24)* 
Prostate  1.38 (1.32-1.43)* 1.38 (1.33-1.43)* 1.37 (1.32-1.42)* 1.37 (1.32-1.42)* 1.37 (1.31-1.42)* 1.37 (1.32-1.43)* 1.39 (1.32-1.46)* 1.37 (1.32-1.46)* 1.39 (1.25-1.53)* 1.37 (1.24-1.53)* 
Renal stone 1.22 (1.14-1.31) 1.16 (1.09-1.25)* 1.23 (1.15-1.33)* 1.16 (1.08-1.26)* 1.28 (1.17-1.39)* 1.21 (1.11-1.32)* 1.28 (1.14-1.43)* 1.21 (1.08-1.36)* 1.34 (1.05-1.71) 1.31 (1.02-1.68) 
Neuro/Psychiatric           
Stroke  1.17 (1.14-1.20)* 1.15 (1.11-1.19)* 1.17 (1.14-1.20)* 1.15 (1.11-1.19)* 1.18 (1.15-1.21)* 1.15 (1.12-1.19)* 1.19 (1.15-1.24)* 1.17 (1.13-1.22)* 1.26 (1.18-1.37)* 1.24 (1.15-1.34)* 
Dementia  1.07 (0.97-1.17) 1.09 (0.99-1.19) 1.07 (0.98-1.17) 1.09 (1.00-1.20) 1.10 (1.01-1.21) 1.13 (1.03-1.24) 1.21 (1.09-1.33)* 1.23 (1.11-1.36)* 1.45 (1.23-1.72)* 1.44 (1.21-1.71)* 
Epilepsy 1.20 (1.11-1.30)* 1.18 (1.08-1.29)* 1.22 (1.12-1.33)* 1.20 (1.10-1.31)* 1.26 (1.14-1.39)* 1.24 (1.11-1.37)* 1.20 (1.05-1.37) 1.17 (1.03-1.35) 1.85 (1.39-2.47)* 1.89 (1.40-2.54)* 
Multiple sclerosis 0.79 (0.68-0.91)* 0.80 (0.69-0.93)* 0.88 (0.75-1.03) 0.89 (0.75-1.04) 0.97 (0.81-1.16) 0.95 (0.78-1.14) 0.98 (0.76-1.25) 0.95 (0.72-1.20) 1.59 (0.93-2.71) 1.55 (0.89-2.67) 
Parkinson’s Disease 1.36 (1.21-1.53)* 1.39 (1.23-1.57)* 1.36 (1.21-1.53)* 1.39 (1.24-1.57)* 1.36 (1.21-1.54)* 1.39 (1.22-1.57)* 1.46 (1.27-1.68)* 1.47 (1.27-1.70)* 1.79 (1.36-2.35)* 1.75 (1.33-2.31)* 
Migraine 1.36 (1.32-1.39)* 1.37 (1.33-1.41)* 1.38 (1.33-1.42)* 1.39 (1.34-1.43)* 1.40 (1.35-1.45)* 1.42 (1.36-1.47)* 1.42 (1.34-1.49)* 1.44 (1.37-1.53)* 1.36 (1.21-1.53)* 1.40 (1.25-1.59)* 
Depression 1.53 (1.50-1.56)* 1.49 (1.46-1.52)* 1.52 (1.49-1.55)* 1.49 (1.46-1.52)* 1.52 (1.49-1.55)* 1.49 (1.46-1.52)* 1.52 (1.48-1.56)* 1.49 (1.45-1.54)* 1.54 (1.45-1.64)* 1.51 (1.42-1.61)* 
Psychosis  0.94 (0.82-1.08) 0.86 (0.75-1.00) 0.93 (0.81-1.08) 0.86 (0.74-0.99) 0.90 (0.76-1.07) 0.83 (0.69-0.98) 1.02 (0.82-1.27) 0.95 (0.75-1.19) 2.05 (1.17-3.61)* 1.89 (1.06-3.39)* 
Schizophrenia 1.03 (0.95-1.12) 0.95 (0.87-1.04) 1.03 (0.95-1.14) 0.95 (0.86-1.05) 1.05 (0.94-1.17) 0.97 (0.87-1.08) 1.17 (1.01-1.36) 1.08 (0.92-1.26) 1.59 (1.12-2.27) 1.36 (0.95-1.96) 
Cancer 1.13 (1.09-1.17)* 1.12 (1.09-1.16)* 1.14 (1.09-1.17)* 1.12 (1.09-1.16)* 1.15 (1.10-1.18)* 1.12 (1.08-1.17)* 1.15 (1.10-1.20)* 1.12 (1.08-1.18)* 0.98 (0.89-1.08) 0.96 (0.87-1.05) 
Circulatory            
Coronary heart disease 1.33 (1.30-1.36)* 1.24 (1.21-1.27)* 1.34 (1.31-1.37)* 1.24 (1.20-1.27)* 1.31 (1.28-1.35)* 1.22 (1.18-1.25)* 1.26 (1.21-1.32)* 1.17 (1.12-1.21)* 1.22 (1.12-1.33)* 1.12 (1.03-1.23) 
Arterial/Venous 1.34 (1.23-1.45)* 1.29 (1.19-1.41)* 1.34 (1.24-1.46)* 1.30 (1.19-1.42)* 1.34 (1.23-1.47)* 1.30 (1.19-1.43)* 1.39 (1.24-1.57)* 1.35 (1.20-1.52)* 1.39 (1.09-1.77)* 1.41 (1.10-1.81) 
Heart failure 1.72 (1.62-1.82)* 1.52 (1.43-1.62)* 1.73 (1.62-1.83)* 1.52 (1.44-1.62)* 1.72 (1.61-1.84)* 1.52 (1.43-1.63)* 1.72 (1.59-1.86)* 1.53 (1.41-1.65)* 1.48 (1.27-1.72)* 1.30 (1.11-1.52)* 
Hypertension 1.24 (1.22-1.26)* 1.08 (1.06-1.10)* 1.22 (1.20-1.24)* 1.08 (1.05-1.09)* 1.18 (1.16-1.20)* 1.06 (1.04-1.07)* 1.15 (1.12-1.17)* 1.04 (1.02-1.06)* 1.13 (1.08-1.18)* 1.03 (0.98-1.08) 
Peripheral vascular disease 1.41 (1.35-1.47)* 1.45 (1.39-1.51)* 1.42 (1.36-1.49)* 1.45 (1.39-1.53)* 1.48 (1.41-1.55)* 1.51 (1.44-1.59)* 1.49 (1.41-1.59)* 1.54 (1.45-1.64)* 1.58 (1.40-1.79)* 1.62 (1.43-1.84)* 
Metabolic/Endocrine           
High Cholesterol 1.27 (1.24-1.29)* 1.18 (1.16-1.20)* 1.26 (1.24-1.29)* 1.18 (1.15-1.20)* 1.27 (1.24-1.29)* 1.18 (1.15-1.21)* 1.27 (1.23-1.31)* 1.20 (1.16-1.23)* 1.27 (1.20-1.35)* 1.20 (1.13-1.28)* 
Diabetes Mellitus  1.31 (1.27-1.34)* 1.06 (1.03-1.09)* 1.30 (1.27-1.34)* 1.06 (1.03-1.08)* 1.29 (1.26-1.33)* 1.06 (1.02-1.10)* 1.29 (1.24-1.33)* 1.06 (1.02-1.09)* 1.35 (1.26-1.45)* 1.12 (1.04-1.20)* 
Hyperthyroid  1.10 (1.03-1.17)* 1.09 (1.02-1.16)* 1.09 (1.01-1.17) 1.08 (1.00-1.15) 1.06 (0.98-1.15) 1.05 (0.97-1.14) 1.05 (0.94- 1.16) 1.04 (0.93-1.15) 0.94 (0.74-1.20) 0.92 (0.71-1.17) 
Hypothyroidism  1.27 (1.23-1.30)* 1.18 (1.15-1.22)* 1.25 (1.22-1.29)* 1.18 (1.14-1.21)* 1.24 (1.20-1.28)* 1.17 (1.12-1.20)* 1.22 (1.17-1.28)* 1.16 (1.11-1.21)* 1.25 (1.14-1.36)* 1.19 (1.08-1.30)* 
Digestive           
Gastritis  1.42 (1.37-1.46)* 1.42 (1.36-1.45)* 1.43 (1.37-1.47)* 1.42 (1.37-1.47)* 1.45 (1.39-1.50)* 1.45 (1.39-1.50)* 1.46 (1.39-1.53)* 1.45 (1.38-1.52)* 1.55 (1.39-1.71)* 1.55 (1.39-1.72)* 
Gastro-intestinal bleed 1.43 (1.34-1.53)* 1.42 (1.33-1.52)* 1.45 (1.36-1.55)* 1.43 (1.34-1.54)* 1.47 (1.36-1.59)* 1.44 (1.33-1.56)* 1.52 (1.38-1.68)* 1.49 (1.34-1.64)* 1.69 (1.39-2.07)* 1.66 (1.36-2.03)* 
Gall bladder stone 1.44 (1.39-1.49)* 1.27 (1.22-1.31)* 1.43 (1.36-1.49)* 1.27 (1.22-1.31)* 1.42 (1.37-1.48)* 1.26 (1.21-1.31)* 1.37 (1.30-1.44)* 1.23 (1.17-1.30)* 1.18 (1.06-1.33) 1.05 (0.93-1.18) 
Inflammatory Bowel 
Disease 
1.38 (1.33-1.43)* 1.36 (1.32-1.41)* 1.39 (1.34-1.44)* 1.38 (1.33-1.43)* 1.43 (1.37-1.48)* 1.42 (1.36-1.47)* 1.45 (1.38-1.53)* 1.44 (1.36-1.52)* 1.34 (1.20-1.49)* 1.33 (1.19-1.48)* 
Liver Disease 1.47 (1.33-1.62)* 1.42 (1.29-1.57)* 1.46 (1.32-1.62)* 1.42 (1.27-1.56)* 1.55 (1.38-1.73)* 1.48 (1.32-1.67)* 1.49 (1.30-1.72)* 1.45 (1.26-1.68)* 1.64 (1.23-2.19)* 1.47 (1.09-1.99) 
Irritable Bowel Syndrome 1.47 (1.43-1.51)* 1.52(1.47-1.56)* 1.50(1.45-1.54)* 1.54(1.49-1.58)* 1.50(1.46-1.55)* 1.55(1.49-1.60)* 1.54(1.47-1.61)* 1.58(1.51-1.66)* 1.62(1.20-2.04)* 1.59(1.23-1.95)* 
Others            
HIV infection/AIDS 1.99 (0.75-5.32) 2.08 (0.76-5.75) 1.66 (0.65-4.22) 1.64 (0.62-4.33) 1.38 (0.52-3.62) 1.49 (0.54-4.16) 2.99 (0.81-11.08) 3.17 (0.84-12.03) - - 
Hearing  1.26 (1.24-1.29)* 1.26 (1.23-1.29)* 1.27 (1.24-1.30)* 1.26 (1.23-1.29)* 1.26 (1.23-1.29)* 1.26 (1.22-1.29)* 1.27 (1.23-1.31)* 1.26 (1.22-1.30)* 1.32 (1.24-1.41)* 1.30 (1.22-1.39)* 
Psoriasis  1.24 (1.19-1.30)* 1.20 (1.14-1.25)* 1.27 (1.22-1.33)* 1.22 (1.16-1.28)* 1.30 (1.23-1.37)* 1.24 (1.17-1.31)* 1.32 (1.23-1.42)* 1.26 (1.17-1.36)* 1.39 (1.19-1.64)* 1.32 (1.12-1.55)* 
Scleroderma 0.98 (0.67-1.43) 0.97 (0.65-1.44) 1.06 (0.71-1.59) 1.05 (0.69-1.59) 1.05 (0.67-1.65) 1.02 (0.64-1.64) 1.59 (0.86-2.91) 1.76 (0.94-3.30) 4.99 (1.09-22.82) 5.75 (1.22-22.09) 
Sleep Disorder 1.43 (1.36-1.49)* 1.35 (1.28-1.41)* 1.44 (1.37-1.51)* 1.35 (1.29-1.42)* 1.45 (1.38-1.53)* 1.37 (1.30-1.44)* 1.45 (1.37-1.55)* 1.37 (1.28-1.46)* 1.46 (1.29-1.64)* 1.41 (1.24-1.59)* 
Tuberculosis 1.21 (1.04-1.39) 1.25 (1.08-1.45) 1.16 (0.99-1.35) 1.19 (1.02-1.39) 1.25 (1.04-1.50) 1.24 (1.04-1.50) 1.21 (0.94-1.55) 1.23 (0.95-1.59) 1.87 (1.02-3.44) 1.71 (0.91-3.18) 
Anaemia  1.25 (1.20-1.29)* 1.25 (1.21-1.30)* 1.28(1.23-1.33)* 1.28(1.23-1.33)* 1.32(1.26-1.37)* 1.31(1.26-1.37)* 1.41(1.33-1.49)* 1.40(1.32-1.48)* 1.47(1.32-1.63)* 1.42(1.28-1.59)* 
Vision problem 1.15 (1.07-1.25) 1.11 (1.02-1.21) 1.14 (1.05-1.24) 1.11 (1.00-1.19) 1.17 (1.07-1.29) 1.13 (1.03-1.24) 1.21 (1.07-1.36) 1.17 (1.03-1.32) 0.99 (0.78-1.27) 0.96 (0.74-1.23) 






Appendix Table 7 Association between joint specific OA and comorbidities prior to the index date (Expanded version) 
 Hip Knee Wrist/Hand Ankle/Foot 
 1 year 10 years  20 years 1 year 10 years  20 years 1 year 10 years  20 years 1 year 10 years  20 years 
Musculoskeletal             
Ankylosing Spondylitis 1.37(0.76-2.49) 1.82(1.49-2.22)* 1.62(1.39-1.90)* 0.91(0.57-1.43) 1.55(1.34-1.79)* 1.55(1.37-1.73)* 2.01(0.90-4.46) 1.57(1.20-2.06) 1.57(1.24-1.96)* 3.58(0.57-22.34) 1.41(0.91-2.18) 1.40(0.96-2.00) 
Back pain 2.22(1.99-2.47)* 1.53(1.47-1.61)* 1.66(1.59-1.73)* 1.21(1.11-1.31)* 1.36(1.33-1.41)* 1.51(1.47-1.56)* 1.28(1.06-1.54) 1.40(1.31-1.50)* 1.58(1.49-1.69)* 1.25(0.98-1.60) 1.31(1.19-1.44)* 1.59(1.45-1.73)* 
Crystal arthropathy 0.74(0.50-1.09) 1.14(1.01-1.29) 1.21(1.09-1.35)* 1.03(0.81-1.31) 1.47(1.35-1.60)* 1.49(1.39-1.61)* 0.86(0.45-1.59) 1.78(1.42-2.23)* 1.70(1.39-2.08)* 3.07(1.61-5.84) 2.66(2.08-3.40)* 2.56(2.01-3.14)* 
Osteoporosis  1.62(1.23-2.14) 1.28(1.13-1.46)* 1.30(1.16-1.46)* 1.25(1.00-1.56) 1.25(1.16-1.40)* 1.25(1.13-1.34)* 0.88(0.56-1.38) 1.25(1.01-1.53) 1.26(1.05-1.53) 1.69(0.83-3.42) 1.33(0.98-1.82) 1.34(1.04-1.85) 
Polymyalgia  2.16(1.24-3.74) 1.53(1.22-1.90)* 1.39(1.14-1.69)* 1.20(0.79-1.83) 1.58(1.35-1.86)* 1.56(1.32-1.77)* 1.65(0.53-5.13) 1.78(1.15-2.76) 1.58(1.07-2.35) 0.38(0.07-1.91) 1.37(0.76-2.48) 1.38(0.81-2.37) 
Rheumatoid Arthritis 2.95(1.29-6.72) 1.25(0.93-1.67) 1.25(0.99-1.63) 1.21(0.75-1.93) 1.38(1.13-1.69) 1.43(1.21-1.70)* 4.76(1.54-14.79) 1.55(1.07-2.26) 1.57(0.99-1.99) 1.98(0.47-8.30) 1.35(0.77-2.36) 1.30(0.62-1.72) 
Sjogren’s syndrome 0.80(0.05-13.88) 1.86(0.94-3.64) 1.93(1.08-3.47) 1.59(0.49-5.09) 1.81(1.20-2.71) 1.47(1.04-2.09) - 0.88(0.36-2.15) 1.32(0.63-2.74) - 1.24(0.26-5.93) 1.30(0.32-5.22) 
SLE -  - 1.92(0.10-36.03) 1.21(0.54-2.69) 1.19(0.62-2.29) - 0.28(0.03-2.62) 0.38(0.09-1.38) - - - 
Fibromyalgia 1.12(0.52-2.45) 1.49(1.13-1.96) 1.51(1.17-1.92) 1.87(1.21-2.87) 1.84(1.54-2.21)* 1.75(1.49-2.05)* 0.97(0.35-2.74) 1.57(1.13-2.19) 1.53(1.14-2.07) 1.46(0.49-4.31) 1.47(0.90-2.41) 1.29(0.81-2.03) 
Fatigue 1.54(0.93-2.55) 1.31(1.06-1.62) 1.32(1.09-1.60) 1.21(0.85-1.71) 1.36(1.17-1.58)* 1.38(1.21-1.59)* 2.32(1.05-5.12) 1.43(1.07-1.89) 1.42(1.09-1.84) 1.41(0.58-3.40) 1.11(0.72-1.70) 1.10(0.66-1.53) 
Respiratory             
Asthma 1.16(0.87-1.55) 1.14(1.04-1.25) 1.19(1.11-1.28)* 1.45(1.17-1.79) 1.45(1.36-1.55)* 1.38(1.31-1.46)* 1.46(0.90-2.37) 1.34(1.16-1.54)* 1.31(1.18-1.47)* 1.01(0.54-1.88) 1.47(1.22-1.79)* 1.38(1.18-1.62)* 
COPD 1.42(1.06-1.90) 1.21(1.10-1.35)* 1.20(1.11-1.31)* 1.56(1.25-1.94)* 1.36(1.26-1.46)* 1.33(1.25-1.41)* 0.73(0.41-1.28) 1.24(1.05-1.47) 1.23(1.07-1.41) 0.71(0.32-1.57) 1.18(0.93-1.50) 1.25(1.02-1.52) 
Genito-Urinary             
CKD 0.97(0.80-1.18) 1.09(0.99-1.20) 1.10(0.99-1.21) 1.02(0.88-1.18) 1.04(0.97-1.12) 1.04(0.97-1.13) 0.80(0.54-1.19) 0.89(0.74-1.07) 0.92(0.77-1.10) 1.08(0.68-1.71) 1.05(0.82-1.34) 1.05(0.82-1.34) 
Prostate^  1.67(1.26-2.21)* 1.42(1.27-1.58)* 1.40(1.27-1.55)* 1.09(0.90-1.33) 1.31(1.21-1.41)* 1.32(1.25-1.43)* 1.80(1.06-3.07) 1.56(1.21-1.87)* 1.56(1.29-1.89)* 1.54(0.88-2.71) 1.44(1.14-1.82) 1.40(1.10-1.72)* 
Renal stone 0.99(0.47-2.12) 1.13(0.89-1.44) 1.05(0.87-1.28) 2.30(1.30-4.08) 1.41(1.19-1.68)* 1.41(1.15-1.51)* 1.47(0.32-6.78) 0.90(0.58-1.38) 1.22(0.86-1.73) 0.49(0.12-2.04) 1.22(0.76-1.97) 1.60(1.07-2.39) 
Neuro/Psychiatric             
Stroke  1.09(0.89-1.34) 1.12(1.04-1.22) 1.09(1.00-1.16) 1.20(1.03-1.39) 1.20(1.13-1.27)* 1.20(1.10-1.22)* 1.40(0.98-1.99) 1.19(1.04-1.37) 1.24(1.09-1.40)* 1.37(0.83-2.24) 1.18(0.97-1.43) 1.17(0.90-1.28) 
Dementia  1.44(0.89-2.34) 1.16(0.89-1.50) 1.11(0.86-1.44) 1.28(0.89-1.82) 0.96(0.79-1.16) 0.93(0.77-1.12) 0.63(0.23-1.70) 0.72(0.44-1.18) 0.72(0.44-1.17) 1.89(0.47-7.53) 0.97(0.46-2.06) 0.96(0.45-2.01) 
Epilepsy 1.95(0.76-4.97) 1.21(0.90-1.63) 1.27(0.99-1.61) 1.21(0.67-2.18) 1.33(1.08-1.64) 1.29(1.09-1.51) 1.89(0.41-8.73) 1.11(0.66-1.87) 1.12(0.76-1.66) 0.96(0.06-15.51) 1.11(0.50-2.43) 0.81(0.45-1.44) 
Multiple sclerosis 1.09(0.29-4.21) 0.95(0.56-1.63) 0.73(0.48-1.10) 0.72(0.19-2.79) 0.97(0.65-1.46) 0.96(0.70-1.29) 1.71(0.10-29.60) 0.90(0.39-2.10) 0.67(0.34-1.32) 2.09(0.33-13.28) 0.95(0.25-3.70) 0.63(0.25-1.61) 
Parkinson’s Disease 1.34(0.66-2.73) 0.91(0.64-1.29) 0.87(0.62-1.23) 1.43(0.84-2.45) 1.21(0.95-1.55) 1.20(0.96-1.52) 0.15(0.02-1.17) 1.04(0.50-2.17) 1.11(0.55-2.24) - 1.30(0.55-3.12) 1.49(0.66-3.35) 
Migraine 1.05(0.73-1.53) 1.24(1.10-1.40)* 1.16(1.06-1.28)* 1.29(0.99-1.68) 1.38(1.28-1.49)* 1.35(1.27-1.44)* 1.35(0.83-2.18) 1.40(1.20-1.63)* 1.47(1.30-1.67)* 1.23(0.56-2.69) 1.42(1.13-1.79) 1.38(1.14-1.67)* 
Depression 1.43(1.18-1.73)* 1.37(1.28-1.46)* 1.32(1.25-1.39)* 1.52(1.34-1.73)* 1.47(1.41-1.54)* 1.46(1.43-1.49)* 1.26(0.97-1.64) 1.48(1.35-1.63)* 1.48(1.34-1.57)* 1.50(1.05-2.15) 1.34(1.18-1.53)* 1.40(1.27-1.60)* 
Psychosis  - 1.13(0.67-1.89) 1.09(0.70-1.71) 2.59(0.94-7.16) 1.04(0.75-1.47) 1.05(0.82-1.44) - 0.54(0.23-1.27) 0.58(0.30-1.12)    
Schizophrenia 0.90(0.31-2.58) 0.98(0.70-1.36) 0.99(0.77-1.29) 1.51(0.69-3.27) 1.09(0.87-1.37) 1.15(0.96-1.38) 1.98(0.18-21.97) 0.83(0.49-1.42) 0.83(0.55-1.25) - 0.54(0.25-1.18) 0.56(0.38-1.13) 
Cancer 1.13(0.86-1.47) 1.27(1.15-1.41)* 1.24(1.13-1.35)* 0.84(0.68-1.01) 1.11(1.03-1.19) 1.11(1.03-1.17) 0.92(0.56-1.51) 0.92(0.78-1.09) 0.92(0.79-1.07) 1.25(0.68-2.31) 1.30(1.01-1.67) 1.16(0.93-1.45) 
Circulatory              
CHD 1.06(0.83-1.36) 1.17(1.08-1.27)* 1.18(1.10-1.26)* 1.09(0.92-1.29) 1.15(1.08-1.21)* 1.15(1.09-1.21)* 0.94(0.58-1.53) 1.05(0.90-1.23) 1.02(0.90-1.16) 1.07(0.59-1.93) 1.36(1.11-1.66) 1.38(1.17-1.63)* 
Arterial/Venous 1.00(0.55-1.85) 1.35(1.07-1.71) 1.34(1.09-1.65) 1.87(1.13-3.10) 1.17(0.97-1.40) 1.21(1.03-1.42) 1.88(0.51-6.93) 0.96(0.60-1.54) 0.96(0.63-1.52) 0.56(0.09-3.19) 0.68(0.35-1.33) 0.84(0.47-1.51) 
Heart failure 1.72(1.11-2.67) 1.34(1.12-1.61) 1.38(1.16-1.63)* 1.27(0.93-1.74) 1.33(1.17-1.52)* 1.34(1.20-1.53)* 1.44(0.44-4.69) 1.17(0.79-1.72) 1.17(0.89-1.83) 1.13(0.33-3.90) 1.82(1.14-2.89) 1.57(1.03-2.38) 
Hypertension 1.10(0.97-1.24) 1.10(1.05-1.15)* 1.12(1.07-1.17)* 1.06(0.97-1.16) 1.06(1.03-1.10)* 1.10(1.07-1.15)* 0.85(0.67-1.07) 1.00(0.92-1.09) 1.02(0.95-1.10) 0.93(0.69-1.24) 1.05(0.93-1.17) 1.08(0.97-1.20) 
PVD 1.86(1.34-2.59)* 1.41(1.23-1.62)* 1.37(1.21-1.55)* 1.58(1.22-2.04)* 1.29(1.17-1.43)* 1.29(1.16-1.38)* 1.89(1.04-3.43) 1.50(1.18-1.90) 1.50(1.22-1.86)* 1.60(0.82-3.11) 1.56(1.15-2.12) 1.44(1.09-1.89) 
Metabolic/Endocrine             
High Cholesterol 1.18(0.99-1.39) 1.13(1.06-1.21)* 1.15(1.09-1.22)* 1.13(1.01-1.26) 1.14(1.09-1.19)* 1.14(1.09-1.19)* 1.29(0.99-1.67) 1.23(1.11-1.37)* 1.22(1.11-1.35)* 1.16(0.81-1.66) 1.10(0.95-1.27) 1.11(1.01-1.33) 
Diabetes Mellitus  1.06(0.86-1.31) 1.06(0.98-1.16) 1.06(0.98-1.13) 1.04(0.90-1.19) 1.01(0.96-1.07) 1.02(0.98-1.08) 1.11(0.78-1.57) 1.01(0.87-1.16) 0.97(0.85-1.10) 1.23(0.78-1.96) 1.01(0.83-1.22) 0.95(0.79-1.13) 
Hyperthyroid  0.93(0.45-1.92) 1.09(0.85-1.39) 1.13(0.94-1.38) 0.96(0.57-1.64) 1.08(0.92-1.28) 1.13(0.99-1.30) 0.38(0.10-1.43) 0.90(0.64-1.28) 1.05(0.79-1.39) 0.56(0.14-2.25) 1.22(0.71-2.12) 1.15(0.72-1.85) 
Hypothyroidism  1.34(1.02-1.74) 1.16(1.05-1.28) 1.23(1.13-1.34)* 1.04(0.94-1.39) 1.10(1.02-1.17) 1.17(1.10-1.24)* 1.13(0.75-1.75) 1.23(1.06-1.43) 1.21(1.07-1.38)* 1.21(0.65-2.24) 0.99(0.78-1.25) 1.11(0.91-1.37) 
Digestive             
Gastritis  1.21(0.90-1.61) 1.23(1.10-1.37)* 1.22(1.11-1.34)* 1.53(1.23-1.89)* 1.42(1.32-1.54)* 1.39(1.30-1.47)* 1.30(0.79-2.14) 1.32(1.10-1.59) 1.26(1.09-1.45)* 0.76(0.33-1.74) 1.68(1.31-2.16)* 1.45(1.18-1.78)* 
GI bleed 2.62(1.44-4.79) 1.43(1.14-1.78) 1.49(1.23-1.80)* 1.86(1.27-2.72) 1.43(1.23-1.66)* 1.37(1.21-1.56)* 1.06(0.42-2.68) 1.47(1.04-2.09) 1.35(0.99-1.83) 0.92(0.19-4.31) 1.69(1.01-2.85) 1.48(0.96-2.31) 
Gall bladder stone 0.95(0.67-1.34) 1.19(1.05-1.34) 1.22(1.11-1.35)* 1.11(0.87-1.42) 1.30(1.20-1.41)* 1.33(1.25-1.43)* 1.08(0.65-1.77) 1.25(1.05-1.49) 1.31(1.13-1.52)* 0.31(0.11-0.85) 1.43(1.09-1.88) 1.45(1.14-1.83)* 
IBD 1.14(0.84-1.54) 1.28(1.13-1.44)* 1.23(1.11-1.37)* 1.25(0.99-1.56) 1.38(1.27-1.50)* 1.35(1.26-1.44)* 1.32(0.82-2.12) 1.34(1.12-1.59) 1.22(1.04-1.40) 0.92(0.42-2.05) 1.45(1.12-1.88) 1.63(1.29-2.06)* 
Liver Disease 0.91(0.37-2.25) 1.24(0.88-1.76) 1.14(0.85-1.55) 1.33(0.75-2.33) 1.33(1.14-1.83) 1.32(1.08-1.62) - 0.95(0.56-1.76) 1.18(0.71-1.96) - 1.58(0.65-3.84) 1.51(0.74-3.06) 
Irritable Bowel syndrome 1.17(0.89-1.57) 1.26(1.13-1.39)* 1.33(1.22-1.46)* 1.28(0.99-1.56) 1.35(1.23-1.47)* 1.38(1.29-1.48)* 1.30(0.80-2.10) 1.26(1.10-1.65) 1.25(1.08-1.42) 0.98(0.47-2.02) 1.51(1.23-1.78)* 1.61(1.24-2.02)* 
Others              
HIV infection/AIDS - 2.25(0.33-15.46) 0.86(0.13-5.86) - 1.94(0.26-14.61) 2.05(0.20-20.69) - - - - - - 
Hearing  1.19(0.98-1.45) 1.13(1.05-1.21) 1.14(1.06-1.21)* 1.32(1.16-1.50)* 1.24(1.17-1.30)* 1.24(1.18-1.29)* 1.26(0.94-1.69) 1.32(1.17-1.49)* 1.31(1.18-1.46)* 1.07(0.72-1.60) 1.40(1.18-1.66)* 1.41(1.23-1.67)* 
Psoriasis  1.04(0.66-1.63) 1.10(0.93-1.30) 1.07(0.93-1.22) 1.10(.80-1.53) 1.13(1.01-1.26) 1.13(1.04-1.25) 2.31(1.02-5.25) 1.07(0.83-1.39) 1.07(0.86-1.29) 1.92(0.61-6.04) 1.11(0.79-1.56) 1.15(1.01-1.81) 
Scleroderma - 1.88(0.43-8.25) 1.29(0.33-5.06) 1.15(0.08-16.35) 0.78(0.29-2.14) 072(0.26-1.52) - - -    
Sleep Disorder 1.15(0.81-1.62) 1.28(1.09-1.48) 1.25(1.-8-1.43) 1.29(1.02-1.65) 1.44(1.30-1.60)* 1.44(1.26-1.53)* 1.74(1.05-2.86) 1.45(1.15-1.85) 1.44(1.15-1.78)* 1.87(0.85-4.10) 1.47(1.06-2.06) 1.48(1.09-2.02) 
Tuberculosis 0.92(0.7-12.02) 0.72(0.43-1.21) 0.86(0.56-1.32) 0.90(0.16-5.04) 1.45(0.98-2.15) 1.35(1.00-1.84) - 2.32(0.53-10.13) 3.44(1.23-9.58) - 1.99(0.69-5.71) 2.56(0.93-7.07) 
Anaemia 1.35(0.96-1.90) 1.27(1.11-1.46)* 1.21(1.08-1.36)* 1.29(1.04-1.59) 1.26(1.16-1.38)* 1.26(1.16-1.35)* 1.19(0.76-1.89) 1.31(1.09-1.59) 1.31(1.10-1.53) 0.83(0.39-1.79) 1.24(0.92-1.68) 1.14(0.87-1.49) 
Vision problem 0.88(0.43-1.80) 1.13(0.87-1.48) 1.05(0.83-1.33) 0.87(0.51-1.48) 1.11(0.93-1.34) 1.11(0.95-1.31) 1.21(0.32-4.58) 2.6(0.79-2.01) 1.27(0.85-1.90) - 0.59(0.26-1.32) 0.77(0.39-1.51) 
*P-value <0.05 adjusted for multiple testing using ‘False discovery rate’; Adjusted for age, gender, body mass index (BMI), Smoking, Alcohol use and index year; ^for men only 
SLE – Systemic Lupus Erythematous; COPD- Chronic Obstructive Pulmonary Disease; CHD- Coronary Heart Disease; PVD- Peripheral vascular disease; GI – Gastrointestinal; IBD- Inflammatory Bowel Disease
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Appendix Table 8 Cumulative probabilities (%) of incident comorbidities after index date 
 Osteoarthritis cases Non-Osteoarthritis controls 




15 years  20 years  
 




15 years  20 years 
 
Musculoskeletal           
Ankylosing Spondylitis 0.01 0.05 0.14 0.26 0.26 0.01 0.02 0.03 0.10 0.21 
Back pain 0.87 2.57 6.30 13.13 18.60 0.36 1.43 4.13 9.20 12.32 
Crystal arthropathy 0.03 0.15 0.53 1.70 2.47 0.01 0.06 0.25 0.81 1.41 
Osteoporosis 0.05 0.14 0.48 1.58 2.31 0.02 0.05 0.25 1.15 2.36 
Polymyalgia  0.01 0.04 0.09 0.18 0.51 0.00 0.01 0.07 0.15 0.29 
Rheumatoid Arthritis 0.04 0.06 0.23 0.53 1.00 0.01 0.02 0.07 0.13 0.16 
Sjogren’s Disease 0.00 0.01 0.02 0.02 0.02 0.00 0.00 0.00 0.04 0.07 
Systemic lupus 
erythematous 
0.00 0.00 0.00 0.03 0.03 0.00 0.00 0.00 0.02 0.02 
Fibromyalgia 0.02 0.05 0.13 0.31 0.45 0.00 0.01 0.01 0.05 0.08 
Fatigue 0.01 0.04 0.21 0.51 0.62 0.00 0.02 0.12 0.22 0.49 
Respiratory           
Asthma 0.09 0.32 0.80 1.73 2.42 0.09 0.28 0.60 1.24 1.50 
COPD 0.04 0.13 0.46 1.29 2.17 0.04 0.11 0.31 0.96 1.48 
Genito-Urinary           
Chronic kidney 
disease 
0.01 0.02 1.20 3.09 4.48 0.00 0.00 0.97 2.85 4.51 
Prostate^  0.06 0.21 0.53 1.79 2.61 0.03 0.09 0.40 0.92 1.38 
Renal stone 0.00 0.02 0.07 0.36 0.63 0.01 0.04 0.11 0.32 0.47 
Neuro/Psychiatric           
Stroke  0.24 0.77 2.53 6.17 9.74 0.22 0.69 2.00 4.91 8.61 
Dementia  0.01 0.06 0.27 0.95 1.78 0.00 0.01 0.10 0.52 1.11 
Epilepsy 0.02 0.05 0.07 0.13 0.13 0.00 0.01 0.06 0.11 0.14 
Multiple sclerosis 0.01 0.01 0.03 0.05 0.05 0.00 0.01 0.03 0.05 0.05 
Parkinson’s Disease 0.01 0.02 0.04 0.15 0.26 0.00 0.01 0.04 0.10 0.35 
Migraine 0.08 0.17 0.39 0.87 1.17 0.03 0.10 0.31 0.71 0.92 
Depression 0.38 1.15 2.48 4.78 7.69 0.17 0.63 1.43 2.80 4.41 
Psychosis  0.01 0.01 0.01 0.06 0.06 0.00 0.00 0.01 0.03 0.14 
Schizophrenia 0.01 0.01 0.03 0.15 0.22 0.01 0.01 0.05 0.14 0.17 
Cancer 0.07 0.23 0.87 2.57 4.74 0.02 0.13 0.51 1.71 3.31 
Circulatory            
Coronary heart 
disease 
0.11 0.35 0.89 1.79 2.61 0.08 0.29 0.57 1.08 1.51 
Arterial/Venous 0.00 0.02 0.06 0.32 0.40 0.00 0.01 0.05 0.16 0.29 
Heart failure 0.01 0.06 0.16 0.54 0.70 0.01 0.04 0.11 0.28 0.56 
Hypertension 0.46 1.55 4.46 7.79 10.58 0.30 0.93 3.22 7.00 9.89 
Peripheral vascular 
disease 
0.02 0.10 0.32 0.91 1.17 0.03 0.09 0.18 0.52 0.65 
Metabolic/Endocrine           
High Cholesterol 0.11 0.42 1.57 4.11 5.86 0.06 0.30 1.29 3.31 5.10 
Diabetes Mellitus  0.09 0.36 1.20 3.67 6.18 0.03 0.12 0.60 2.31 4.01 
Hyperthyroid  0.02 0.06 0.13 0.13 0.23 0.00 0.03 0.12 0.20 0.25 
Hypothyroidism  0.10 0.20 0.64 1.45 1.81 0.02 0.12 0.48 1.26 1.67 
Digestive           
Gastritis  0.09 0.19 0.49 1.32 1.92 0.01 0.06 0.23 0.82 1.94 
Gastro-intestinal bleed 0.01 0.03 0.11 0.25 0.60 0.01 0.01 0.06 0.21 0.35 
Gall bladder stone 0.04 0.17 0.42 1.22 2.06 0.04 0.09 0.24 0.68 1.09 
IBD 0.04 0.15 0.43 1.14 1.45 0.03 0.13 0.35 0.79 1.29 
Liver Disease 0.01 0.04 0.09 0.29 0.44 0.00 0.00 0.04 0.12 0.41 
Irritable bowel 
syndrome 
0.65 2.00 3.48 4.63 5.66 0.32 1.33 2.31 3.13 3.85 
Others            
HIV infection/AIDS           
Hearing  0.14 0.42 1.30 3.80 6.77 0.06 0.23 0.94 2.76 4.73 
Psoriasis  0.02 0.07 0.22 0.72 1.00 0.02 0.07 0.17 0.46 0.66 
Scleroderma 0.00 0.01 0.02 0.04 0.11 0.00 0.00 0.00 0.00 0.00 
Sleep Disorder 0.03 0.10 0.34 0.84 1.56 0.02 0.03 0.20 0.45 1.06 
Tuberculosis 0.00 0.00 0.00 0.03 0.03 0.00 0.01 0.06 0.06 0.06 
Anaemia 0.06 0.18 0.46 1.41 2.27 0.00 0.08 0.32 0.67 1.26 
Vision problem 0.01 0.04 0.11 0.12 0.25 0.01 0.03 0.05 0.11 0.18 








Appendix Table 9 Hazard ratio and 95% confidence interval for each comorbidity comparing 
incident OA cases and controls without any comorbidities at the index date 










Ankylosing Spondylitis 1.86(1.13-3.05) 1.85(1.13-3.10) 0.028* 
Back pain 1.46(1.37-1.55) 1.45(1.36-1.54) 0.001* 
Gout 1.57(1.30-1.91) 1.40(1.15-1.70) 0.002* 
Osteoporosis  1.38(1.13-1.69) 1.61(1.32-1.98) 0.001* 
Polymyalgia  1.48(0.92-2.38) 1.60(0.99-2.59) 0.088 
Rheumatoid Arthritis 4.25(2.65-6.82) 4.31(2.68-6.92) 0.001* 
Sjogren’s syndrome 2.12(0.62-7.26) 2.22(0.64-7.70) 0.279 
Systemic lupus erythematosus 2.24(0.41-12.30) 2.45(0.44-13.62) 0.369 
Fibromyalgia 5.28(2.66-10.48) 5.29(2.65-10.50) 0.001* 
Fatigue 1.25(0.89-1.76) 1.25(0.89-1.77) 0.265 
Respiratory    
Asthma 1.15(0.97-1.36) 1.09(0.92-1.29) 0.368 
COPD 1.22(0.99-1.49) 1.19(0.98-1.46) 0.088 
Genito-Urinary    
Chronic Kidney Disease 1.17(1.02-1.35) 1.14(0.99-1.32) 0.098 
Benign prostatic hypertrophy^  1.55(1.27-1.88) 1.56(1.28-1.90) 0.001* 
Renal stone 0.91(0.61-1.37) 0.81(0.54-1.22) 0.369 
Neuro/Psychiatric    
Stroke  1.15(1.05-1.22) 1.14(1.06-1.24) 0.001* 
Dementia  1.43(1.07-1.90) 1.77(1.32-2.38) 0.001* 
Epilepsy 0.87(0.49-1.54) 0.88(0.49-1.56) 0.698 
Multiple sclerosis 0.85(0.32-2.28) 0.75(0.28-2.03) 0.608 
Parkinson’s disease 1.21(0.68-2.12) 1.32(0.74-2.34) 0.398 
Migraine 1.28(1.02-1.59) 1.27(1.02-1.59) 0.064 
Depression 1.58(1.43-1.74) 1.55(1.40-1.71) 0.001* 
Psychosis  1.44(0.63-3.35) 1.38(0.59-3.24) 0.488 
Schizophrenia 1.30(0.73-2.31) 1.25(0.70-2.23) 0.488 
Cancer 1.46(1.27-1.69) 1.43(1.24-1.65) 0.001* 
Circulatory     
Coronary Heart Disease 1.27(1.07-1.51) 1.19(1.01-.142) 0.075 
Arterial/Venous 1.18(0.72-1.96) 1.27(0.76-2.11) 0.398 
Heart failure 1.61(1.09-2.35) 1.62(1.10-2.39) 0.022* 
Hypertension 1.15(1.06-1.24) 1.06(0.98-1.14) 0.225 
Peripheral Vascular Disease 1.56(1.18-2.05) 1.57(1.19-2.09) 0.002* 
Metabolic/Endocrine    
High Cholesterol 1.19(1.08-1.33) 1.15(1.04-1.29) 0.014* 
Diabetes Mellitus  1.43(1.26-1.62) 1.26(1.11-1.43) 0.001* 
Hyperthyroid  1.06(0.68-1.66) 1.05(0.67-1.66) 0.832 
Hypothyroidism  1.21(1.02-1.45) 1.15(0.96-1.37) 0.204 
Digestive    
Gastritis  1.46(1.18-1.79) 1.41(1.15-1.74) 0.002* 
Gastrointestinal bleed 1.95(1.16-3.28) 1.93(1.14-3.27) 0.027* 
Gall bladder stone 1.48(1.18-1.85) 1.31(1.05-1.64) 0.034* 
Inflammatory bowel disease 1.33(1.08-1.65) 1.31(1.06-1.62) 0.026* 
Liver Disease 3.55(2.01-6.26) 3.36(1.89-5.97) 0.001* 
Irritable bowel syndrome 1.43(1.26-1.62) 1.43(1.27-1.63) 0.001* 
Others     
HIV infection/AIDS 1.23(0.08-19.65) 0.85(0.50-14.21) 0.907 
Hearing  1.30(1.15-1.46) 1.31(1.16-1.48) 0.001* 
Psoriasis  1.37(1.05-1.79) 1.31(1.00-1.72) 0.082 
Scleroderma 3.57(0.37-34.52) 3.79(0.39-37.19) 0.324 
Sleep Disorder 1.95(1.50-2.53) 1.95(1.50-2.55) 0.001* 
Tuberculosis 0.47(0.16-1.33) 0.48(0.17-1.38) 0.251 
Anaemia 1.58(1.28-1.93) 1.57(1.27-1.95) 0.001* 
Vision problem 1.35(0.64-2.85) 1.56(0.73-3.34) 0.324 
Cataract  1.07(0.99-1.5) 1.12(1.04-1.21) 0.005* 
Adjusted for age, sex, BMI, alcohol use, smoking and index date; *p <0.05 ‘False discovery rate’ (FDR) adjusted; 




Appendix Figure  8 Cumulative probabilities of developing multimorbidity in cases with OA 
and matched non-OA controls without any comorbidities at the index date
 




























Appendix Figure  9 Comparison of adjusted Odds Ratio and Hazard Ratio for comorbidities 
in OA for 20 years observation period among OA and matched controls without any 
comorbidities at the index date
 
 
COPD- Chronic obstructive pulmonary diseases; SLE- Systemic lupus erythematous; *p <0.05; ^Benign prostate 
hypertrophy -Only men 





Appendix Figure  10 Comparison of the adjusted hazard ratios comparing the analyses for “OA without any comorbidity” at index date and “OA 
without the specific comorbidity” at the index date with respective matched controls
 
COPD- Chronic Obstructive Pulmonary Disease; SLE- Systemic Lupus Erythematous ; ^Benign prostate hypertrophy -Only men 
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 22.22 2.90 57.29 12.27 1.40 3.92 
Anaemia 4.95 2.95 1.95 8.39 7.71 11.92 
Ankylosing Spondylitis 1.84 0.03 0.03 2.71 0.05 2.8 
Arterial/Venous 0.65 0.17 0.22 0.84 1.3 2.54 
Asthma 9.5 5.73 3.98 14.97 12.65 14.27 
Back pain 100 0 0 100 0 94.85 
Benign prostatic hypertrophy^ 4.4 1.43 1.29 4 4.75 10.92 
Cancer 6.28 2.6 2.54 7.45 9.93 15.08 
Cataract  2.09 3.57 3.34 4.88 10.99 50.96 
Chronic Heart Disease 5.84 1.61 2.11 7.96 11.97 20.34 
Chronic Kidney Disease 6.18 2.32 2.66 9.18 18.68 31.77 
COPD 4.67 1.66 1.46 8.43 7.81 11.57 
Gout 4.12 1.16 1.65 4.16 7.03 12.81 
Dementia  0.97 0.4 0.55 2.05 4.56 5.77 
Depression 0 16.72 8.75 100 100 8.11 
Diabetes   10.21 3.92 4.48 14.59 25.47 29.71 
Epilepsy 0.89 0.43 0.5 1.59 1.79 1.39 
Fatigue 1.79 1.72 0.62 4.47 2.73 2.88 
Fibromyalgia 0.84 1.16 0.24 3.76 1.57 1.19 
Gall stones 5.37 3.51 1.87 9.7 8.7 12.92 
Gastritis  6.61 3.67 1.99 11.38 8.79 14.07 
Gastrointestinal bleed 1.23 0.7 0.44 2.43 1.95 2.77 
Hearing problem 12.47 5.24 4.5 16.2 16.77 31.3 
Heart failure 0.8 0.21 0.35 1.15 2.11 4.33 
High Cholesterol 14.93 5.45 5.41 19.55 28.21 36.94 
HIV/AIDS 0.01 0.01 0.01 0.02 0.03 0.01 
Hypertension 19.61 6.33 9.03 27.9 100 92.46 
Hyperthyroid  1.34 0.83 0.56 2.16 2.19 2.69 
Hypothyroidism  6.09 3.76 2.6 10.31 11.76 13.9 
Inflammatory bowel disease 5.91 4.31 1.91 9.98 5.87 8.72 
Irritable Bowel Syndrome 7.81 100 0 16.2 8.03 9.52 
Liver Diseases 0.61 0.28 0.34 1.17 1.38 0.89 
Migraine 8.08 6.33 2.85 15.4 8.81 8.17 
Multiple sclerosis 0.36 0.28 0.21 0.69 0.53 0.25 
Osteoarthritis 9.53 12.52 7.73 21.4 21.27 84.45 
Osteoporosis  3.72 1.5 1.09 5.85 5.92 13.84 
Parkinson’s Disease 0.38 0.09 0.13 0.54 0.86 1.02 
Peripheral Vascular Diseases 2.47 1.19 0.85 3.92 3.94 7.12 
Polymyalgia  0.77 0.25 0.23 1.06 1.48 3.92 
Psoriasis  3.43 1.79 1.54 4.37 4.34 4.74 
Psychosis  0.15 0.21 0.21 0.8 1.11 0.2 
Renal stone 1.69 0.7 0.57 2.01 1.78 2.72 
Rheumatoid Arthritis 0.85 0.44 0.33 1.47 1.36 2.19 
Schizophrenia 0.29 0.57 0.51 2.32 3.35 0.44 
Scleroderma  0.04 0.03 0.02 0.07 0.09 0.08 
Sjogren’s Syndrome 0.15 0.15 0.04 0.28 0.29 0.51 
Sleep problem 2.36 1.49 0.86 6.11 4.67 5.08 
Stroke  7.85 7.79 6.62 9.12 13.84 17.41 
Systemic Lupus Erythematosus  0.07 0.05 0.02 0.13 0.09 0.11 
Tuberculosis 0.39 0.14 0.16 0.43 0.37 0.8 
Vision problem 0.36 0.12 0.18 0.66 0.95 2.09 
COPD- Chronic obstructive pulmonary disease; CVD- Cardiovascular; IBS- Irritable bowel syndrome; 




Appendix Table 11 Janssen Shannon Index for similarity 
  Training data 
  Healthy MSK CV CV-MSK MSK-MH THY 
Testing  
data 
Healthy 0.026 2.33 6.85 15.68 13.78 19.89 
MSK 2.35 0.029 0.89 5.59 4.4 8.45 
CVD 5.69 1.12 0.003 2.28 1.52 4.36 
MSK, 
CVD 14.32 6.24 2.03 0.001 0.065 0.42 
MSK, 
DEP 13.41 5.61 1.65 0.029 0.013 0.63 
THY 18.78 9.58 4.24 0.42 0.865 0.001 
 
 
Janssen Shannon Index for similarity  
 
Jensen-Shannon distance (JSD, range = [0-1], high values indicate a higher degree of 
divergence) for the similarities between corresponding clusters profiles (for 50 chronic 
conditions) in the training (rows) and test sets (columns). Each cluster in the test set is matched 
with a cluster in the training set with the smallest JSD (with zero indicating perfect similarity). 
Matched clusters are shaded in dark grey (secondary choices ae shaded in light grey). 
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Appendix Table 12 Class distribution in Training data 
 Healthy MSK CV CV-MSK MSK-MH Metabolic 
 (41.90%) (26.68%) (15.97%) (5.55%) (7.20%) (2.67%) 
Anaemia 0.29 4.38 3.31 18.35 10.93 10.23 
Ankylosing Spondylitis 0.00 0.81 0.52 2.96 5.45 0.51 
Arterial/Venous 0.01 0.06 1.10 4.80 0.43 0.19 
Asthma 0.99 9.78 9.28 15.40 19.88 11.65 
Back pain 6.16 55.65 52.85 80.77 90.10 50.16 
Benign Prostatic Hypertrophy^ 0.12 1.15 8.27 13.61 4.06 0.81 
Cancer 0.38 2.66 11.36 19.20 8.81 7.34 
Cataract 2.63 0.08 10.12 36.26 4.96 4.09 
Chronic Heart Disease 0.12 0.73 11.70 34.28 5.61 2.80 
Chronic Kidney Disease 0.03 0.33 14.46 46.42 5.50 7.64 
COPD 0.10 2.05 6.76 17.53 10.39 4.96 
Dementia 0.03 0.07 2.18 10.27 0.89 2.57 
Depression 1.77 31.78 15.34 37.45 62.52 45.07 
Diabetes 0.51 3.31 22.00 38.22 13.39 20.66 
Epilepsy 0.11 0.87 1.13 2.24 1.78 2.13 
Fatigue 0.02 1.57 0.54 4.05 9.25 3.66 
Fibromyalgia 0.00 0.50 0.00 1.31 8.82 1.57 
Gall stones 0.20 3.42 5.54 17.34 16.08 6.82 
Gastritis 0.15 4.14 5.54 21.79 19.40 4.70 
Gastrointestinal Bleed 0.01 0.96 0.98 4.95 3.55 1.00 
Gout 0.27 1.22 9.31 15.31 2.59 0.82 
Hearing Problem 0.74 7.03 18.06 39.09 19.90 10.53 
Heart Failure 0.00 0.01 1.40 8.68 0.11 0.40 
High Cholesterol 0.61 4.86 29.72 43.17 23.69 15.56 
HIV/AIDS 0.00 0.03 0.02 0.01 0.01 0.03 
Hypertension 1.21 5.88 57.15 75.66 29.30 23.60 
Hyperthyroidism  0.04 0.00 0.00 4.23 1.09 26.35 
Hypothyroidism 0.28 2.35 5.39 19.72 11.87 51.60 
Inflammatory Bowel Disease 0.29 5.74 3.40 11.85 16.92 4.22 
Irritable Bowel Syndrome 3.90 7.84 2.51 10.72 30.17 8.44 
Liver Disease 0.06 0.58 0.76 1.65 1.55 1.22 
Migraine 0.52 9.68 3.60 8.78 25.27 9.57 
Multiple Sclerosis 0.04 0.55 0.28 0.28 0.93 0.83 
Osteoarthritis 6.81 3.22 22.66 54.73 33.76 12.39 
Osteoporosis 0.08 0.96 4.79 18.54 8.61 5.51 
Parkinson’s Disease 0.01 0.05 0.75 1.79 0.36 0.73 
Peripheral Vascular Disease 0.10 1.29 2.94 11.85 4.44 2.14 
Polymyalgia 0.01 0.05 1.22 5.33 1.24 0.68 
Psoriasis 0.47 3.36 3.96 5.62 4.94 3.40 
Psychosis 0.00 0.00 0.00 0.37 0.03 9.54 
Renal Stone 0.10 1.05 2.44 3.49 2.36 0.78 
Rheumatoid Arthritis 0.05 0.44 0.92 2.51 2.85 1.09 
Schizophrenia 0.01 0.49 0.02 1.27 0.99 16.14 
Scleroderma 0.00 0.02 0.04 0.13 0.13 0.13 
Sjogren’s Syndrome 0.00 0.05 0.07 0.59 0.66 0.45 
Sleep Problem 0.00 2.25 2.23 7.26 8.31 4.07 
Stroke 6.03 4.33 11.90 24.66 8.24 7.70 
Systemic Lupus 
Erythematosus 0.00 0.04 0.03 0.14 0.29 0.20 
Tuberculosis 0.05 0.30 0.40 1.04 0.49 0.39 
Vision Problem 0.03 0.09 0.55 3.05 0.49 1.17 




Appendix Table 13 Class distribution in Testing data 
 Healthy MSK CV CV-MSK MSK-MH Metabolic 
 (43.78%) (24.92%) (16.47%) (5.73%) (6.53%) (2.57%) 
Anaemia 0.39 4.89 3.27 18.20 11.39 9.05 
Ankylosing Spondylitis 0.00 0.98 0.57 2.57 5.69 0.24 
Arterial/Venous 0.00 0.07 1.02 4.71 0.48 0.15 
Asthma 1.26 10.49 9.43 14.59 20.78 11.45 
Back pain 7.15 58.97 53.26 78.64 90.62 47.01 
Benign Prostatic Hypertrophy^ 0.12 1.25 7.89 13.95 3.95 0.97 
Cancer 0.38 2.86 10.84 19.58 8.81 7.23 
Cataract 2.48 0.03 9.56 36.60 5.96 4.29 
Chronic Heart Disease 0.12 0.79 10.99 33.95 6.04 3.40 
Chronic Kidney Disease 0.04 0.35 13.22 47.20 6.46 8.02 
COPD 0.12 2.24 6.24 17.78 11.09 4.86 
Dementia 0.02 0.07 1.97 10.68 0.91 2.68 
Depression 2.42 34.00 15.47 35.97 64.74 45.84 
Diabetes 0.52 3.31 21.49 38.23 14.37 21.93 
Epilepsy 0.12 0.92 1.01 2.66 1.67 1.96 
Fatigue 0.02 1.98 0.51 3.32 10.02 2.82 
Fibromyalgia 0.00 0.72 0.00 0.93 9.71 1.20 
Gall stones 0.27 3.66 5.48 17.19 16.74 6.41 
Gastritis 0.16 4.88 5.38 21.15 19.75 4.15 
Gastrointestinal Bleed 0.02 1.09 0.89 4.95 3.65 1.30 
Gout 0.33 1.29 8.84 15.85 2.97 1.29 
Hearing Problem 0.83 7.57 17.23 38.95 20.57 10.00 
Heart Failure 0.00 0.00 1.07 9.05 0.17 0.56 
High Cholesterol 0.57 5.20 28.95 42.75 25.46 14.93 
HIV/AIDS 0.00 0.02 0.01 0.00 0.04 0.01 
Hypertension 1.22 5.51 55.95 75.90 32.13 24.08 
Hyperthyroidism  0.04 0.00 0.00 4.16 1.82 27.27 
Hypothyroidism 0.30 2.70 4.98 19.13 13.53 50.05 
Inflammatory Bowel Disease 0.42 6.29 3.39 10.84 16.97 4.36 
Irritable Bowel Syndrome 3.96 8.71 2.73 9.69 30.22 7.08 
Liver Disease 0.07 0.62 0.79 1.70 1.35 1.41 
Migraine 0.64 10.93 3.74 7.73 25.40 9.03 
Multiple Sclerosis 0.05 0.60 0.29 0.14 1.00 0.66 
Osteoarthritis 6.56 3.56 22.04 53.94 36.82 11.41 
Osteoporosis 0.08 1.04 4.54 17.99 9.19 4.81 
Parkinson Disease 0.01 0.07 0.64 1.71 0.49 0.67 
Peripheral Vascular Disease 0.11 1.35 2.83 11.75 4.74 1.73 
Polymyalgia 0.01 0.07 1.13 5.30 1.47 0.42 
Psoriasis 0.53 3.31 4.01 5.45 5.20 3.42 
Psychosis 0.00 0.00 0.00 0.37 0.09 10.54 
Renal Stone 0.10 1.13 2.38 3.78 2.40 1.11 
Rheumatoid Arthritis 0.05 0.57 0.89 2.49 3.58 0.84 
Schizophrenia 0.02 0.45 0.00 1.40 1.24 18.42 
Scleroderma 0.00 0.02 0.04 0.16 0.19 0.12 
Sjogren’s Disease 0.01 0.04 0.09 0.61 0.80 0.25 
Sleep Problem 0.04 2.50 2.31 6.89 8.80 4.03 
Stroke 5.87 4.36 11.50 24.65 9.24 7.96 
Systemic Lupus Erythematous 0.00 0.05 0.02 0.16 0.32 0.22 
Tuberculosis 0.07 0.35 0.40 1.01 0.51 0.30 
Vision Problem 0.01 0.12 0.50 3.23 0.58 1.20 




Appendix Table 14 Descriptive statistics Training dataset (N= 11,40,658)  
 
BMI- Body mass index; SD- Standard deviation; CV- Cardiovascular; MH- Mental Health; MSK- Musculoskeletal 
  






Gender       
  Men  249,736 (53.68) 135,165 (45.16) 97,024 (57.48) 22,446 (42.19) 16,510 (25.30) 4,665 (25.04) 
  Women 215,498 (46.32) 164,158 (54.84) 71,772 (42.52) 30,755 (57.81) 48,755 (74.70) 13,964 (74.96) 
Age        
  20-39 156,189 (33.57) 70,028 (23.40) 1,800 (1.07) 16 (0.03) 1,613 (2.47) 1,538 (8.26) 
  40-59 188,756 (40.57) 169,747 (56.71) 38,715 (22.94) 1,845 (3.47) 26,134 (40.04) 8,319 (44.66) 
  60-79 97,769 (21.02) 56,378 (18.84) 97,738 (57.90) 24,198 (45.48)  33,014 (50.58) 7,434 (39.91) 
  >80 22,520 (4.84) 3,170 (1.06) 30,543 (18.09) 27,142 (51.02) 4,504 (6.90) 1,338 (7.18) 
Smoking        
  Never smoked 251,165 (53.99) 165,247 (55.21) 92,545 (54.83) 26,359 (49.55) 33,229 (50.91) 9,735 (52.26) 
  Current smoker 91,914 (19.76) 77,355 (25.84) 27,572 (16.33) 7,665 (14.41) 15,837 (24.27) 4,893 (26.27) 
  Ex-smoker 70,359 (15.12) 53,567 (17.90) 48,033 (28.46) 19,043 (35.79) 16,083 (24.64) 3,909 (20.98) 
  Missing  51,796 (11.13) 3,154 (1.05) 646 (0.38) 134 (0.25) 116 (0.18) 92 (0.49) 
Alcohol use       
  Never  65,565 (14.09) 42,709 (14.27) 27,429 (16.25) 14,089 (26.48) 13,098 (20.07)  4,539 (24.37) 
  Ex-drinker 5,293 (1.14) 5,076 (1.70) 4,012 (2.38) 2,320 (4.36) 2,063 (3.16) 742 (3.98) 
  Current (1-9) 124,391 (26.74) 95,186 (31.80) 52,051 (30.84) 15,314 (28.79) 21,777 (33.37) 5,722 (30.72) 
  Current (>=10) 59,386 (12.76) 51,731 (17.28) 35,787 (21.20) 6,868 (12.91) 9,405 (14.41) 2,004 (10.76) 
  Current (Unknown) 91,023 (19.56) 67,720 (22.62) 42,431 (25.14) 13,416 (25.22) 16,658 (25.52) 4,673 (25.08) 
   Missing  119,576 (25.70) 36,901 (12.33) 7,086 (4.20) 1,194 (2.24) 2,264 (3.47) 949 (5.09) 
BMI       
  Underweight  12,964 (2.79) 7,181 (2.40) 1,661 (0.98) 891 (1.67) 1,194 (1.83) 384 (2.06) 
  Normal  146,825 (31.56) 115,370 (38.54) 42,375 (25.10) 13,365 (25.12) 20,694 (31.71) 6,413 (34.42) 
  Overweight  116,024 (24.94) 87,705 (29.30) 64,455 (38.19) 19,676 (36.98) 21,294 (32.63) 5,757 (30.90) 
  Obese 73,667 (15.83) 52,655 (17.59) 52,529 (31.12) 17,766 (33.39) 19,780 (30.31) 5,061 (27.17) 
Missing 115,754 (24.88) 36,412 (12.16) 7,776 (4.61) 1,503 (2.83) 2,303 (3.53) 1,014 (5.44) 
Mean age (SD) 48.94 (16.62) 49.20 (12.43) 68.20 (12.07) 78.78 (9.59) 62.01 (11.68) 58.94 (13.77) 
Mean BMI (SD) 26.30 (5.43) 26.22 (5.22) 28.37 (5.31) 28.47 (5.54) 27.95 (5.91) 27.51 (5.89) 
Mean Multimorbidity (SD) 0.29 (0.56) 2.01 (0.98) 3.93 (1.37) 8.72 (2.00) 6.04 (1.61) 4.63 (1.72) 
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Appendix Table 15 Descriptive statistics Testing dataset (n=285167) 
BMI- Body mass index; SD- Standard deviation; CV- Cardiovascular; MH- Mental Health; MSK- Musculoskeletal 






Gender       
  Men  84,504 (53.14) 43,417 (44.57) 32,371 (56.87) 8,090 (43.16) 4,818 (24.19) 1,589 (26.57) 
  Women 74,516 (46.86) 53,994 (55.43) 24,552 (43.13) 10,654 (56.84) 15,102 (75.81) 4,392 (73.43) 
Age        
  20-39 53,242 (33.48) 22,379 (22.97) 676 (1.19) 5 (0.03) 390 (1.96) 493 (8.24) 
  40-59 64,660 (40.66) 55,434 (56.91) 13,543 (23.79) 579 (3.09) 7,423 (37.26) 2,671 (44.66) 
  60-79 33,607 (21.13) 18,611 (19.11) 32,916 (57.83) 8,410 (44.87) 10,604 (53.23) 2,402 (40.16) 
  >80 7,511 (4.72) 987 (1.01) 9,788 (17.20) 9,750 (52.02) 1,503 (7.55) 415 (6.94) 
Smoking        
  Never smoked 86,292 (54.26) 53,276 (54.69) 31,500 (55.34) 9,363 (49.95) 10,124 (50.82) 3,136 (52.43) 
  Current smoker 31,136 (19.58) 25,738 (26.42) 9,151 (16.08) 2,558 (13.65) 4,858 (24.39) 1,539 (25.73) 
  Ex-smoker 24,171 (15.20) 17,382 (17.84) 16,050 (28.20) 6,767 (36.10) 4,898 (24.59) 1,283 (21.45) 
  Missing  17,421 (10.96) 1,015 (1.04) 222 (0.39) 56 (0.30) 40 (0.20) 23 (0.38) 
Alcohol use       
  Never  22,497 (14.15) 14,036 (14.41) 9,217 (16.19) 4,826 (25.75) 4,119 (20.68) 1,462 (24.44) 
  Ex-drinker 1,839 (1.16) 1,767 (1.81) 1,345 (2.36) 777 (4.15) 691 (3.47) 267 (4.46) 
  Current (1-9) 42,405 (26.67) 30,859 (31.68) 17,507 (30.76) 5,524 (29.47) 6,553 (32.90) 1,768 (29.56) 
  Current (>=10) 20,527 (12.91) 16,841 (17.29) 12,163 (21.37) 2,450 (13.07) 2,909 (14.60) 633 (10.58) 
  Current (Unknown) 31,249 (19.65) 22,267 (22.86) 14,342 (25.20) 4,747 (25.33) 5,042 (25.31) 1,540 (25.75) 
   Missing  40,503 (25.47) 11,641 (11.95) 2,349 (4.13) 420 (2.24) 606 (3.04) 311 (5.20) 
BMI       
  Underweight  4,378 (2.75) 2,234 (2.29) 565 (0.99) 300 (1.60) 362 (1.82) 125 (2.09) 
  Normal  50,338 (31.66) 37,824 (38.83) 14,453 (25.39) 4,625 (24.67) 6,142 (30.83) 2,054 (34.34) 
  Overweight  39,589 (24.90) 28,470 (29.23) 21,447 (37.68) 6,984 (37.26) 6,493 (32.60) 1,803 (30.15) 
  Obese 25,169 (15.83) 17,355 (17.82) 17,922 (31.48) 6,317 (33.70) 6,255 (31.40) 1,707 (28.54) 
Missing 39,546 (24.87) 11,528 (11.83) 2,536 (4.46) 518 (2.76) 668 (3.35) 292 (4.88) 
Mean age (SD) 49.95 (16.54) 49.30 (12.39) 67.83 (12.05) 79.08 (9.39) 62.94 (11.51) 58.87 (13.72) 
Mean BMI (SD) 26.29 (5.42) 26.24 (5.24) 28.37 (5.32) 28.46 (5.47) 28.08 (5.94) 27.63 (6.02) 
Mean Multimorbidity (SD) 0.32 (0.57) 2.10 (1.04) 3.88 (1.34) 8.61 (2.03) 6.31 (1.66) 4.58 (1.73) 
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20-39 1 -1718985 - 3438911 213464.53 3438161  100.0         
 2 -1659095 3320688 3320081 93684.34 3318573 0.49 32.0 68.0        
 3 -1652903 3309559 3308647 81300.32 3306381 0.45 5.2 61.3 33.6       
 4 -1649374 3303754 3302537 74240.8 3299513 0.46 34.1 0.6 4.3 61.0      
 5 -1646748 3299759 3298237 68990.27 3294454 0.44 0.6 3.6 39.3 2.0 54.4     
 6 -1645008 3297534 3295707 65510.56 3291167 0.43 44.9 0.5 0.6 46.7 2.0 5.3    
 7 -1643412 3295597 3293465 62318.47 3288167 0.42 0.9 10.6 1.0 40.4 2.0 0.6 44.5   
 8 -1641847 3293721 3291283 59186.8 3285227 0.47 4.4 0.6 0.5 0.9 1.7 1.0 48.3 42.7  
 9 -1640820 3292923 3290180 57133.51 3283366 0.4 13.7 0.8 53.1 1.3 9.7 0.6 3.1 17.3 0.4 
                 
40-59 1 -3548501 - 7097968 682613.61 7097191  100.0         
 2 -3391442 6785436 6784829 368497.4 6783267 0.6 41.6 58.4        
 3 -3376753 6757339 6756427 339118.34 6754080 0.53 14.6 56.9 28.5       
 4 -3363678 6732472 6731255 312968.92 6728122 0.5 12.6 34.4 44.7 8.3      
 5 -3354553 6715503 6713981 294718.15 6710064 0.52 3.3 10.6 35.8 6.0 44.4     
 6 -3346478 6700636 6698809 278568.72 6694106 0.54 0.9 10.3 2.3 36.6 44.0 5.9    
 7 -3343006 6694974 6692842 271624.35 6687354 0.54 4.5 2.3 1.6 35.6 44.8 0.9 10.4   
 8 -3341037 6692318 6689880 267685.71 6683607 0.5 2.1 35.1 9.5 3.3 0.9 1.7 9.6 38.0  
 9 -3339240 6690007 6687264 264092.5 6680206 0.48 0.8 2.1 6.8 8.7 1.3 33.5 8.8 35.9 2.0 
                 
60-79 1 -4006131 - 8012733 1209659 8012357  100.0         
 2 -3810862 7622987 7622679 819121.97 7621918 0.73 58.0 42.0        
 3 -3785035 7571970 7571506 767467.46 7570362 0.63 28.7 18.5 52.8       
 4 -3766934 7536406 7535787 731265.79 7534258 0.59 12.8 32.1 23.9 31.3      
 5 -3759021 7521219 7520444 715440.86 7518531 0.59 22.3 5.2 31.3 31.7 11.2     
 6 -3753196 7510206 7509275 703789.75 7506978 0.61 30.6 22.5 0.9 11.2 3.6 31.3    
 7 -3747887 7500226 7499139 693171.51 7496458 0.59 30.4 9.7 6.9 28.3 0.8 20.9 3.1   
 8 -3744862 7494815 7493572 687122.47 7490507 0.58 8.3 3.1 8.7 29.9 4.6 24.2 20.4 0.8  
 9 -3742212 7490152 7488753 681821.4 7485303 0.58 17.1 24.3 4.6 0.8 4.4 9.3 28.8 2.8 7.9 
                 
>= 80  1 -1553617 - 3107648 769866.79 3107330  100.0         
 2 -1454818 2910782 2910474 572269.48 2909831 0.9 27.8 72.2        
 3 -1442426 2886575 2886111 547483.76 2885143 0.7 48.8 24.4 26.8       
 4 -1437531 2877365 2876746 537694.85 2875452 0.64 26.1 26.7 22.3 24.9      
 5 -1434154 2871190 2870414 530940.31 2868796 0.62 13.5 24.1 24.4 15.6 22.4     
 6 -1432432 2868325 2867394 527497.23 2865451 0.61 13.6 23.2 12.5 24.5 21.1 5.1    
 7 -1430977 2865993 2864906 524586 2862637 0.62 13.2 20.4 12.7 3.3 23.2 2.8 24.4   
 8 -1429598 2863814 2862571 521828.28 2859978 0.61 0.7 2.7 21.6 17.7 23.2 8.6 15.3 10.2  
 9 -1428522 2862242 2860843 519677.56 2857925 0.59 8.6 8.0 13.9 22.5 16.7 17.1 3.1 2.8 7.3 

























Anaemia 0.48 5.51 7.22 
Ankylosing Spondylitis 0 0.85 0.21 
Arterial/Venous 0 0.05 0.17 
Asthma 1.13 8.67 7.68 
Back pain 9.37 58.40 35.14 
Benign Prostatic Hypertrophy^ 0.04 0.34 0.06 
Cataract 0.12 0.18 0.72 
Chronic Heart Disease 0.02 0.13 0.77 
Chronic Kidney Disease 0.06 0.75 3.08 
COPD 0.04 0.51 0.46 
Dementia 0.01 0.06 0.36 
Depression 4.51 40.54 49.17 
Diabetes 0.43 3.40 20.14 
Epilepsy 0.15 0.86 1.59 
Fatigue 0.10 2.77 2.86 
Fibromyalgia 0 1.32 1.31 
Gall stones 0.20 4.03 2.93 
Gastritis 0.28 4.62 2.68 
Gastrointestinal Bleed 0.08 1.58 0.82 
Gout 0.17 0.83 1.59 
Hearing Problem 0.79 5.33 4.40 
Heart Failure 0 0.02 0.21 
High Cholesterol 0.11 1.15 6.19 
HIV/AIDS 0.01 0.02 0.04 
Hypertension 0.25 2.47 8.17 
Hyperthyroidism  0 0 13.28 
Hypothyroidism 0.21 1.82 27.95 
Inflammatory Bowel Disease 0.72 8.25 4.23 
Irritable Bowel Syndrome 3.22 11.91 6.25 
Liver Disease 0.1 0.53 0.91 
Migraine 1.23 14.62 8.31 
Multiple Sclerosis 0.05 0.42 0.54 
Osteoarthritis 0.24 0.91 0.89 
Osteoporosis 0.01 0.19 0.22 
Parkinson Disease 0 0 0.02 
Peripheral Vascular Disease 0.15 1.37 0.87 
Polymyalgia 0 0.01 0.02 
Psoriasis 0.61 3.15 2.17 
Psychosis 0 0 9.10 
Renal Stone 0.11 0.97 0.43 
Rheumatoid Arthritis 0.03 0.47 0.61 
Schizophrenia 0.02 0.30 15.21 
Scleroderma 0 0.02 0.06 
Sjogren’s syndrome 0 0.05 0.22 
Sleep Problem 0.10 2.85 2.95 
Stroke 0.42 3.39 5.19 
Systemic Lupus Erythematous 0 0.07 0.23 
Tuberculosis 0.07 0.36 0.54 
Vision Problem  0.02 0.13 0.89 
^For men only 
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Anaemia 0.62 5.48 3.69 14.74 10.57 
Ankylosing Spondylitis 0 1.38 0.52 4.99 0.32 
Arterial/Venous 0.01 0.08 0.44 0.53 0.08 
Asthma 2.07 12.17 10.99 23.12 12.04 
Back pain 11.09 65.4 44.68 88.64 49.04 
Benign Prostatic Hypertrophy^ 0.18 1.19 2.33 2.01 0.35 
Cancer 0.55 3.05 3.75 4.84 4.89 
Cataract 0.52 0.41 2.03 1.95 1.13 
Chronic Heart Disease 0.13 0.6 6.94 5.34 1.52 
Chronic Kidney Disease 0.07 0.6 7.35 5.88 4.26 
COPD 0.18 2.54 3.01 8.56 3.09 
Dementia 0 0.06 0.08 0.34 1.12 
Depression 3.31 37.91 23.11 73.82 49.08 
Diabetes 0.8 2.68 24.11 18.42 20.68 
Epilepsy 0.18 1.02 1.12 2.25 2.22 
Fatigue 0.05 2.09 0.63 12.59 3.4 
Fibromyalgia 0 0.86 0.01 13.64 1.34 
Gall stones 0.4 4.25 4.09 16.31 5.35 
Gastritis 0.3 5.33 4.95 19.74 3.66 
Gastrointestinal Bleed 0.03 1.14 1.14 4.38 1.03 
Gout 0.52 1.27 9.08 2.88 0.7 
Hearing Problem 1.14 8.49 8.33 15.56 7.51 
Heart Failure 0 0 0.89 0.44 0.3 
High Cholesterol 1.13 5.33 25.74 20.2 11.58 
HIV/AIDS 0 0.03 0.06 0.02 0.05 
Hypertension 1.66 5.15 57.61 27.31 13.85 
Hyperthyroidism  0.05 0 0 2.02 23.78 
Hypothyroidism 0.47 2.76 3.36 13.42 56.7 
Inflammatory Bowel Disease 0.52 7.13 4.62 19.68 3.9 
Irritable Bowel Syndrome 3.89 10.17 2.92 33.84 7.75 
Liver Disease 0.1 0.65 1.21 2.01 1.32 
Migraine 0.91 11.98 5.27 30.98 9.77 
Multiple Sclerosis 0.09 0.67 0.31 1.08 0.86 
Osteoarthritis 3.34 4.82 8.86 21.46 5.34 
Osteoporosis 0.05 0.8 0.69 3.27 1.23 
Parkinson Disease 0.01 0.05 0.07 0.12 0.14 
Peripheral Vascular Disease 0.17 1.61 1.66 4.93 1.7 
Polymyalgia 0 0.07 0.1 0.52 0.07 
Psoriasis 0.81 3.82 4.35 4.88 3.24 
Psychosis 0 0 0 0.3 10.09 
Renal Stone 0.19 1.27 2.58 2.37 0.94 
Rheumatoid Arthritis 0.1 0.7 0.7 3.11 0.93 
Schizophrenia 0.03 0.31 0.12 2.11 18.44 
Scleroderma 0 0.02 0.04 0.1 0.07 
Sjogren’s syndrome 0.01 0.07 0.03 0.59 0.27 
Sleep Problem 0.09 2.75 3 10.15 3.89 
Stroke 0.64 5.36 8.46 8.44 5.85 
Systemic Lupus Erythematous 0.01 0.05 0.04 0.45 0.12 
Tuberculosis 0.08 0.32 0.52 0.56 0.38 
Vision Problem 0.02 0.09 0.46 0.71 1.25 

















Anaemia 0.19 3.66 13.94 3.32 12.22 
Ankylosing Spondylitis 0.00 1.61 3.36 0.00 4.70 
Arterial/Venous 0.02 0.45 4.92 1.15 0.42 
Asthma 0.91 10.09 14.80 9.25 20.57 
Back pain 4.13 65.02 83.77 45.55 84.74 
Benign Prostatic 
Hypertrophy^ 0.25 7.17 16.23 6.49 2.16 
Cancer 0.87 10.26 16.71 10.91 12.29 
Cataract 5.81 4.00 20.52 8.29 9.75 
Chronic Heart Disease 0.38 4.95 35.54 12.60 7.19 
Chronic Kidney Disease 0.00 1.35 32.51 17.86 13.98 
COPD 0.28 7.71 19.90 5.47 11.47 
Dementia 0.04 0.88 4.01 0.88 1.85 
Depression 1.28 25.80 42.00 13.53 61.51 
Diabetes 0.56 5.02 43.49 28.64 18.82 
Epilepsy 0.09 1.15 2.65 0.92 1.91 
Fatigue 0.01 1.33 3.31 0.53 9.10 
Fibromyalgia 0.00 0.31 1.25 0.00 8.52 
Gall stones 0.33 5.70 14.61 5.72 18.99 
Gastritis 0.13 7.72 24.32 3.58 17.95 
Gastrointestinal Bleed 0.00 1.20 5.46 0.54 2.63 
Gout 0.30 2.75 17.85 10.99 2.54 
Hearing Problem 1.01 17.77 31.39 13.71 21.54 
Heart Failure 0.01 0.13 6.90 1.58 0.34 
High Cholesterol 1.16 17.22 46.82 33.54 32.04 
HIV/AIDS 0.00 0.01 0.01 0.01 0.02 
Hypertension 2.38 20.83 72.27 68.89 42.73 
Hyperthyroidism  0.04 0.14 1.17 2.12 8.39 
Hypothyroidism 0.46 4.53 9.70 9.96 28.01 
Inflammatory Bowel Disease 0.15 5.64 12.82 2.48 13.75 
Irritable Bowel Syndrome 5.11 7.51 11.17 1.68 27.38 
Liver Disease 0.03 0.66 2.47 0.81 1.54 
Migraine 0.27 7.93 9.47 3.05 22.23 
Multiple Sclerosis 0.05 0.70 0.35 0.21 0.83 
Osteoarthritis 18.39 30.25 57.54 19.66 55.93 
Osteoporosis 0.31 6.29 8.45 2.61 14.79 
Parkinson Disease 0.02 0.67 1.40 0.48 0.85 
Peripheral Vascular Disease 0.06 2.47 12.83 2.94 4.59 
Polymyalgia 0.05 0.74 2.40 1.07 2.61 
Psoriasis 0.37 3.90 6.53 3.91 4.91 
Psychosis 0.00 0.15 0.21 0.00 2.06 
Renal Stone 0.09 1.76 5.13 2.23 1.81 
Rheumatoid Arthritis 0.05 0.96 2.48 0.79 3.74 
Schizophrenia 0.03 0.66 0.89 0.25 4.34 
Scleroderma 0.00 0.05 0.14 0.03 0.24 
Sjogren’s syndrome 0.01 0.15 0.34 0.07 1.12 
Sleep Problem 0.02 2.73 6.97 1.70 7.96 
Stroke 1.36 7.02 21.15 11.17 10.51 
Systemic Lupus 
Erythematous 0.00 0.04 0.13 0.03 0.33 
Tuberculosis 0.04 0.34 0.69 0.28 0.46 
Vision Problem 0.03 0.32 1.89 0.36 0.85 

















Anaemia 0.10 5.48 7.29 19.37 21.02 
Ankylosing Spondylitis 0.00 1.58 0.00 2.31 4.69 
Arterial/Venous 0.02 1.38 1.46 8.91 2.03 
Asthma 0.34 10.09 8.52 11.91 17.59 
Back pain 1.04 66.14 41.86 78.03 91.21 
Benign Prostatic Hypertrophy^ 0.19 16.28 5.43 32.06 2.21 
Cancer 0.43 18.75 14.92 23.45 17.01 
Cataract 24.12 26.25 28.31 43.71 55.95 
Chronic Heart Disease 0.21 11.43 16.45 49.96 24.12 
Chronic Kidney Disease 0.00 7.31 44.48 67.88 47.49 
COPD 0.26 11.37 6.74 19.24 15.67 
Dementia 0.52 10.79 11.03 9.41 15.74 
Depression 0.27 18.00 12.12 21.35 57.76 
Diabetes 0.25 7.88 26.99 52.40 26.06 
Epilepsy 0.05 1.64 1.18 1.93 1.65 
Fatigue 0.00 1.84 0.63 3.28 6.00 
Fibromyalgia 0.00 0.22 0.00 0.21 1.85 
Gall stones 0.20 8.73 7.52 16.32 21.59 
Gastritis 0.11 11.13 4.85 23.84 21.73 
Gastrointestinal Bleed 0.01 2.28 0.97 6.35 4.56 
Gout 0.05 3.33 8.78 25.45 7.92 
Hearing Problem 0.68 38.26 25.83 47.38 43.17 
Heart Failure 0.03 1.29 3.74 15.55 5.86 
High Cholesterol 0.16 16.20 29.45 45.07 40.70 
HIV/AIDS 0.00 0.00 0.00 0.00 0.01 
Hypertension 1.86 38.27 80.48 77.93 74.64 
Hyperthyroidism  0.00 0.56 2.88 0.76 7.10 
Hypothyroidism 0.19 6.95 15.46 9.96 28.75 
Inflammatory Bowel Disease 0.06 5.80 2.19 10.00 15.45 
Irritable Bowel Syndrome 3.70 6.43 1.22 6.03 18.00 
Liver Disease 0.01 0.41 0.25 1.06 1.11 
Migraine 0.04 5.07 2.12 4.77 12.34 
Multiple Sclerosis 0.01 0.27 0.16 0.12 0.24 
Osteoarthritis 30.15 39.39 29.51 62.15 68.45 
Osteoporosis 0.29 17.61 11.53 7.56 37.88 
Parkinson Disease 0.05 2.33 1.09 1.78 1.67 
Peripheral Vascular Disease 0.05 3.33 3.64 15.40 8.79 
Polymyalgia 0.06 4.09 3.18 4.14 8.88 
Psoriasis 0.09 3.43 3.11 5.39 5.71 
Psychosis 0.00 0.22 0.31 0.01 0.77 
Renal Stone 0.05 2.01 1.36 5.37 1.73 
Rheumatoid Arthritis 0.02 1.19 0.70 1.28 2.90 
Schizophrenia 0.02 0.84 0.81 0.09 1.96 
Scleroderma 0.00 0.09 0.05 0.03 0.15 
Sjogren’s syndrome 0.00 0.22 0.10 0.13 1.20 
Sleep Problem 0.05 4.55 2.17 6.10 9.36 
Stroke 5.99 13.70 19.18 29.21 23.51 
Systemic Lupus Erythematous 0.00 0.08 0.04 0.07 0.09 
Tuberculosis 0.02 1.01 0.44 0.99 1.42 
Vision Problem 0.04 1.68 1.47 3.07 3.85 
                   CV-  Cardiovascular; MH- Mental Health; MSK- Musculoskeletal; ^only for men 
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Appendix Table 21 Summary statistics of different models across gender in the OA population (n=221k) 
 
Class  log-likelihood BIC SABIC likelihood-ratio AIC Entropy C1 C2 C3 C4 C5 C6 C7 C8 C9 C10 
Men 1 -707711 - 1415835 213962.6 1415521  100          
 2 -683958 1369073 1368752 166457.6 1368118 0.59 35.42 64.58         
 3 -680328 1362397 1361914 159198.1 1360961 0.54 25.62 58.62 15.76        
 4 -678182 1358688 1358043 154904.8 1356770 0.5 24.77 8.48 19.74 47.01       
 5 -677217 1357342 1356535 152975.1 1354942 0.5 2.09 23.85 18.54 47.39 8.13      
 6 -676495 1356482 1355512 151530.5 1353599 0.52 8.22 0.72 23.91 0.64 19.35 47.18     
 7 -675869 1355813 1354682 150278.3 1352449 0.51 20.81 0.72 48.07 6.93 6.47 0.65 16.34    
 8 -675337 1355334 1354041 149215.1 1351488 0.53 16.33 49.09 6.5 0.63 5.14 4.22 0.74 17.36   
 9 -674825 1354894 1353438 148190.8 1350566 0.52 5.46 8.45 0.64 4.09 16.61 0.62 10.38 4.93 48.82  
 10 -674425 1354677 1353060 147390.3 1349867 0.49 5.44 4.12 4.21 15.31 17.24 0.61 8.33 40 4.09 0.66 
                  
Women 1 -1046505 - 2093439 313363.8 2093110  100          
 2 -1016959 2035106 2034785 254272.5 2034120 0.56 61.22 38.78         
 3 -1007064 2015915 2015432 234481.4 2014431 0.57 21.96 21.62 56.42        
 4 -1004124 2010636 2009991 228602.7 2008655 0.53 22.4 7.55 25.05 45       
 5 -1002057 2007100 2006293 224467.4 2004621 0.55 24.01 20.63 2.68 45.96 6.74      
 6 -1000467 2004520 2003550 221287.1 2001543 0.56 45.84 20.65 0.78 6.62 23.51 2.59     
 7 -999195 2002577 2001446 218744.8 1999103 0.55 9.87 20.15 45.84 5.93 15.14 0.76 2.3    
 8 -998348 2001482 2000189 217050.2 1997510 0.53 15.1 5.37 43.62 10.01 4.11 2.32 0.76 18.71   
 9 -997683 2000752 1999296 215720.2 1996282 0.5 0.74 5.42 30.34 2.18 8.57 23.09 15.8 9.19 4.66  
 10 -996996 1999978 1998360 214346.1 1995010 0.54 4.66 2.16 5.12 31.18 3.41 5.41 15.58 22.76 8.98 0.74 
 







Appendix Table 22  Summary statistics of different models across the age group in the OA population (n=221K) 
 Model log-likelihood BIC SABIC likelihood-ratio AIC Entropy C1 C2 C3 C4 C5 C6 C7 C8 C9 
20-39  1 -84301.8 - 168896.7 30831.18 168697.6  100.00         
 2 -81300.6 163495.5 163193.6 24828.76 162791.1 0.57 43.04 56.96        
 3 -80795.7 162937.6 162483.1 23818.94 161877.3 0.56 52.81 38.80 8.39       
 4 -80474.7 162747.5 162140.5 23176.95 161331.3 0.53 49.67 32.85 10.94 6.52      
 5 -80296.8 162843.5 162084 22821.14 161071.5 0.54 53.18 23.92 15.02 5.56 2.30     
 6 -80122.3 162946.4 162034.4 22472.15 160818.5 0.55 27.61 0.97 1.97 5.80 53.23 10.41    
 7 -80002.6 163158.9 162094.3 22232.75 160675.1 0.53 30.05 5.74 1.91 9.87 8.03 0.96 43.44   
 8 -79888 163381.6 162164.5 22003.59 160542 0.53 46.98 19.73 1.07 3.46 8.85 12.79 1.99 5.13  
 9 -79777.6 163612.8 162243.2 21782.9 160417.3 0.52 8.46 0.39 5.93 1.12 23.75 2.02 4.98 41.31 12.04 
40-59 1 -794856 - 1590100 260018.3 1589806  100.00         
 2 -768549 1538182 1537880 207403.3 1537287 0.61 56.83 43.17        
 3 -762821 1527274 1526820 195947.4 1525927 0.56 38.97 37.19 23.84       
 4 -759436 1521053 1520446 189177.4 1519253 0.55 33.81 28.66 26.32 11.20      
 5 -757514 1517756 1516997 185333.2 1515505 0.56 31.17 27.60 26.29 9.79 5.14     
 6 -755975 1515227 1514314 182255.1 1512523 0.58 34.19 22.58 20.26 10.77 7.40 4.76    
 7 -754631 1513088 1512023 179568.5 1509932 0.56 9.90 35.29 3.79 1.01 22.08 20.60 7.32   
 8 -753657 1511688 1510471 177620.7 1508081 0.55 3.57 5.22 1.00 29.10 10.34 8.94 19.57 22.26  
 9 -753089 1511100 1509731 176484.5 1507040 0.55 4.30 21.66 2.37 20.03 3.70 28.79 1.01 7.39 10.75 
60-79                 
 1 -1112361 - 2225115 466617.9 2224817  100.00         
 2 -1075437 2151969 2151667 392769.3 2151064 0.7 69.49 30.51        
 3 -1066509 2134666 2134211 374912.8 2133304 0.63 26.38 15.78 57.85       
 4 -1062240 2126681 2126074 366374.6 2124862 0.57 33.89 29.35 19.66 17.09      
 5 -1059898 2122551 2121791 361691 2120274 0.56 30.16 27.09 15.72 14.35 12.66     
 6 -1058402 2120113 2119201 358699.7 2117379 0.57 29.70 26.05 14.92 13.77 11.61 3.92    
 7 -1057169 2118199 2117135 356233.2 2115008 0.58 29.41 19.45 13.84 13.28 12.43 6.26 5.30   
 8 -1056061 2116537 2115320 354017.8 2112889 0.57 14.12 3.76 9.32 11.17 8.26 1.06 26.05 26.27  
 9 -1055061 2115091 2113721 352017.9 2110985 0.59 23.02 7.47 13.77 2.38 13.99 5.05 7.28 1.04 26.00 
>=80                 
 1 -206667 - 413636.6 128573.5 413426.4  100.00         
 2 -199829 400565.5 400269.9 114898 399844.9 0.85 18.33 81.67        
 3 -198582 398529.5 398084.6 112403.9 397444.8 0.61 13.97 55.95 30.08       
 4 -197873 397569.3 396975 110985.5 396120.4 0.57 23.82 14.55 29.82 31.81      
 5 -197329 396938.5 396194.9 109896.5 395125.4 0.56 28.44 25.12 17.45 14.96 14.00     
 6 -197082 396903.9 396010.9 109403.8 394726.7 0.57 22.90 20.17 16.07 14.62 13.38 12.84    
 7 -196842 396881.3 395838.9 108923 394339.9 0.57 22.71 20.03 16.15 13.83 12.96 8.77 5.51   
 8 -196632 396918.9 395727.2 108502.5 394013.4 0.56 22.57 13.04 3.36 7.38 15.27 13.71 3.17 21.51  
 9 -196449 397012 395670.9 108137.4 393742.3 0.56 21.01 3.20 14.48 21.81 13.05 3.58 8.37 6.77 7.73 




Appendix Table 23 Summary statistics of different models across the gender in the non-OA population (n=221K)  
 
Model log-likelihood BIC SABIC likelihood-ratio AIC Entropy C1 C2 C3 C4 C5 C6 C7 C8 C9 C10 
Men 1 -586257 - 1172927 160617.3 1172613  100          
 2 -564671 1130498 1130177 117445.9 1129544 0.59 31.95 68.05         
 3 -561526 1124792 1124309 111155.7 1123356 0.54 22.77 63.18 14.04        
 4 -559814 1121953 1121308 107732.4 1120034 0.49 53.04 22.01 6.95 17.99       
 5 -558735 1120378 1119570 105573.3 1117977 0.5 1.77 21.33 17.15 53.14 6.62      
 6 -558035 1119562 1118593 104173.7 1116680 0.51 0.61 17.71 21.35 0.76 6.54 53.03     
 7 -557550 1119176 1118044 103203.4 1115812 0.49 19.64 0.59 53.22 7.85 5.99 0.7 12.02    
 8 -557029 1118718 1117424 102161.4 1114872 0.51 12.72 54.79 7.41 0.71 4.95 4.24 0.58 14.6   
 9 -556645 1118533 1117078 101393 1114205 0.49 4.62 7.57 0.59 3.52 14.83 0.72 14.88 3.76 49.51  
 10 -556330 1118488 1116870 100763.9 1113678 0.49 0.72 49.94 3.41 3.27 2.16 0.59 4.52 14.55 6.92 13.94 
 
                 
 
                 
Women 1 -850709 - 1701847 224654.9 1701518  100          
 2 -824269 1649726 1649405 171775.6 1648740 0.55 67 33         
 3 -816692 1635171 1634688 156620.9 1633688 0.56 62.8 17.79 19.42        
 4 -814589 1631566 1630921 152416.2 1629585 0.51 5.72 20.64 20.23 53.41       
 5 -812760 1628506 1627699 148756.4 1626027 0.52 4.1 18 18.72 54.09 5.09      
 6 -811217 1626021 1625052 145671.5 1623044 0.54 19.02 0.69 18.24 4.98 54.45 2.62     
 7 -810405 1624997 1623865 144047.7 1621522 0.54 5.09 17.74 2.77 0.72 19.63 1.28 52.77    
 8 -809761 1624307 1623014 142758.7 1620335 0.52 0.71 4.16 0.86 3.55 21.75 48.03 18 2.94   
 9 -809125 1623637 1622181 141488.2 1619167 0.5 2.32 47.41 3.77 18.83 4.62 6.25 0.71 0.9 15.2  
 10 -808547 1623078 1621461 140330.3 1618111 0.49 2.98 5.51 45.68 18.85 15.54 2.6 0.48 3.36 0.7 4.3 
 






Appendix Table 24 Summary statistics of different models across the age groups in the non-OA population (n=221K) 
 Model log-likelihood BIC SABIC likelihood-ratio AIC Entropy C1 C2 C3 C4 C5 C6 C7 C8 C9 
20-39                 
 1 -71006.1 - 142308.2 19871.23 142106.3           
 2 -68852.6 138605.2 138303.3 15564.17 137895.2 0.51 60.9 39.1        
 3 -68462.9 138280.6 137826.1 14784.77 137211.8 0.49 59.6 29.7 10.6       
 4 -68213.2 138236 137629 14285.45 136808.5 0.51 59.4 28.3 11.3 0.97      
 5 -67960.8 138185.9 137426.4 13780.6 136399.6 0.55 58.4 30.0 7.30 3.24 0.95     
 6 -67798.6 138316.2 137404.2 13456.15 136171.2 0.5 1.0 40.6 6.3 2.5 7.1 42.5    
 7 -67702.2 138578.2 137513.6 13263.33 136074.4 0.52 1.0 6.0 2.2 1.0 48.1 34.8 6.9   
 8 -67617.7 138864.1 137646.9 13094.47 136001.5 0.51 7.2 39.3 2.1 0.8 7.4 37.2 5.0 1.0  
 9 -67554.6 139192.6 137822.9 12968.25 135971.3 0.53 18.7 0.8 0.5 42.6 9.9 2.0 4.4 14.5 6.6 
40-59                 
 1 -679652 - 1359692 184619 1359398           
 2 -659274 1319633 1319331 143862.3 1318738 0.56 49.5 50.5        
 3 -654441 1310515 1310061 134196.4 1309168 0.54 21.9 47.9 30.2       
 4 -652322 1306826 1306219 129959.6 1305027 0.51 34.5 34.2 22.9 8.40      
 5 -650611 1303951 1303191 126535.9 1301699 0.54 36.0 31.6 22.2 6.98 3.18     
 6 -649160 1301598 1300686 123634.4 1298894 0.55 36.2 32.9 31.0 22.8 5.79 0.93    
 7 -648293 1300412 1299348 121900.7 1297256 0.55 33.4 0.9 2.2 3.4 6.0 34.1 19.9   
 8 -647768 1299911 1298694 120851.2 1296302 0.52 8.6 28.2 1.9 18.5 33.4 3.2 0.9 5.2  
 9 -647269 1299461 1298092 119853.4 1295401 0.52 3.9 1.3 27.1 0.9 3.5 3.1 9.8 20.0 30.4 
60-79                 
 1 -994852 - 1990095 368056.2 1989797           
 2 -962423 1925940 1925638 303199.1 1925036 0.66 63.4 36.6        
 3 -956037 1913721 1913266 290427 1912360 0.60 56.5 19.3 24.2       
 4 -951818 1905835 1905228 281988.2 1904017 0.56 30.9 30.7 21.6 16.8      
 5 -949594 1901940 1901180 277540.1 1899665 0.55 29.8 26.5 19.7 14.1 9.93     
 6 -948146 1899596 1898684 274644.1 1896865 0.58 30.2 24.9 18.1 12.9 8.5 5.3    
 7 -946885 1897628 1896563 272122.5 1894440 0.57 29.4 19.4 13.8 13.3 12.4 6.3 5.3   
 8 -946059 1896529 1895311 270470.9 1892884 0.54 9.4 13.9 23.7 8.5 1.0 19.1 3.0 21.3  
 9 -945487 1895938 1894568 269327.1 1891836 0.54 3.5 8.1 2.9 21.2 22.6 0.9 13.6 19.0 8.3 
>=80                 
 1 -194509 - 389326.3 111852.9 389111.3           
 2 -188296 377518.8 377216.9 99428.05 376782.5 0.78 22.8 77.2        
 3 -187228 375851.3 375396.8 97292.49 374742.9 0.6 54.7 15.5 29.8       
 4 -186429 374721.1 374114.1 95694.28 373240.7 0.57 32.1 28.1 23.3 16.5      
 5 -186044 374419.1 373659.5 94924.19 372566.6 0.54 28.0 22.0 19.2 15.6 15.1     
 6 -185749 374296.8 373384.7 94333.87 372072.3 0.56 27.3 19.9 17.8 15.1 14.3 5.5    
 7 -185477 374221.3 373156.7 93790.41 371624.8 0.57 27.8 20.8 16.9 15.0 13.4 5.1 0.96   
 8 -185320 374374.1 373157 93475.17 371405.6 0.56 4.1 13.1 26.6 12.6 0.8 15.9 12.0 14.9  
 9 -185173 374548.9 373179.2 93181.91 371208.3 0.55 9.0 12.3 21.3 0.8 16.7 3.6 11.2 15.0 10.0 













Osteoarthritis     
 
Class 1 9087641 8956381 -2613941 36 
100 
Class 2 8585302 8403212 -2803813 102 
0.66 
Class 3 8083211 7983918 -3092181 167 
0.65 
Class 4 7478432 7410985 -3287312 233 
0.64 
Class 5 6877108 6880180 -3438256 298 
0.69 
Class 6 6889342 6890183 -3421843 365 
0.64 
Class 7 7456932 7450932 -3302814 431 
0.64 
Class 8 7985400 7984513 -3039471 497 
0.61 
Class 9 8487212 8510393 -2735715 562 
0.59 




    
 
Class 1 7011091 7012094 -3421392 36 
100 
Class 2 6796783 6795883 -3382123 102 
0.61 
Class 3 6703452 6707631 -3348726 167 
0.63 
Class 4 6632157 6634559 -3315846 233 
0.63 
Class 5 6561408 6564480 -3280406 298 
0.67 
Class 6 6505843 6509606 -3252557 365 
0.65 
Class 7 6561601 6564502 -3281201 431 
0.61 
Class 8 6622315 6645408 -3334653 497 
0.57 
Class 9 6762432 6695720 -3340032 562 
0.55 
Class 10 6973465 7063701 -3350016 628 
0.55 

















Anaemia 1.07 13.23 3.33 8.61 3.56 
Ankylosing Spondylitis 0.11 3.38 0.13 8.66 0.07 
Asthma 5.50 15.80 10.63 20.84 14.24 
Back pain 27.16 64.42 25.59 77.73 33.05 
Benign Prostatic Hypertrophy^ 1.01 12.66 7.79 3.46 2.51 
Cataract 3.91 25.83 8.87 2.85 3.13 
Chronic Heart Disease 0.01 41.26 15.59 2.70 5.01 
Hypercholesterolemia  0.99 42.66 23.50 13.76 11.56 
Arterial and venous 0.00 4.36 0.92 0.21 0.18 
Chronic Kidney Disease 0.01 28.96 9.63 2.31 3.17 
COPD 1.56 19.35 6.90 11.98 5.84 
Gout 0.89 13.78 8.51 1.64 3.02 
Dementia 0.13 4.04 1.09 0.29 0.95 
Depression 0.01 46.76 0.01 43.86 95.70 
Diabetes 0.27 32.48 15.97 4.33 7.53 
Epilepsy 0.78 2.40 1.14 2.41 2.06 
Fatigue 0.17 3.01 0.46 4.93 1.11 
Fibromyalgia 0.06 1.70 0.07 6.27 1.18 
Gastritis 1.27 21.00 5.17 17.46 4.02 
Gall stones 1.16 16.17 5.64 13.50 4.30 
Gastrointestinal bleed 0.11 5.06 0.93 3.20 0.79 
Hearing Problem 3.66 28.67 14.35 14.73 9.81 
Heart Failure 0.00 9.68 1.89 0.03 0.28 
HIV/AIDS 0.01 0.02 0.01 0.00 0.02 
Hypertension 0.04 72.75 60.76 18.02 25.95 
Hyperthyroid  0.00 4.25 1.54 2.96 1.33 
Hypothyroid  1.20 17.70 7.40 11.50 7.27 
Inflammatory Bowel Disease 1.36 12.00 2.88 15.65 3.29 
Irritable Bowel Syndrome 4.91 11.80 2.10 28.39 6.15 
Liver Disease 0.12 1.37 0.56 0.96 0.86 
Migraine  2.24 9.09 3.10 26.87 6.98 
Multiple sclerosis 0.12 0.29 0.18 0.54 0.44 
Osteoporosis 0.74 12.18 3.36 7.02 2.30 
Parkinson Disease 0.10 1.30 0.55 0.23 0.58 
Polymyalgia  0.03 4.38 1.85 1.19 0.59 
Psoriasis   1.67 5.14 3.69 4.61 3.84 
Psychosis  0.00 0.52 0.00 0.00 1.64 
Peripheral Vascular Disease 0.43 12.31 3.13 3.43 1.75 
Rheumatoid Arthritis 0.58 1.98 1.13 3.22 1.37 
Renal Stone 0.38 3.26 1.70 1.64 0.81 
Schizophrenia  0.00 1.65 0.00 0.25 4.74 
Scleroderma  0.00 0.13 0.05 0.08 0.02 
Sjogren’s syndrome 0.04 0.62 0.09 0.55 0.08 
Systemic Lupus Erythematous 0.02 0.21 0.03 0.22 0.04 
Sleep Problem 0.36 8.15 2.20 5.01 3.73 
Stroke  7.61 22.48 9.54 4.03 6.20 
Tuberculosis  0.21 1.59 0.73 1.16 0.46 
Vision problem  0.01 3.55 0.90 0.48 0.41 
















Anaemia 0.87 10.12 11.1 0.68 4.71 
Ankylosing spondylitis 0 3.62 0.31 0.01 3.37 
Arterial/Venous 0 3.88 0.37 0.78 0.07 
Asthma 4.65 11.65 12.3 7.77 13.66 
Back pain 16.03 52.7 21.97 16.2 40.91 
Benign Prostatic Hypertrophy 0.91 13.62 0.79 6.72 2.35 
Cancer (any) 1.83 12.46 10.54 6.42 4.23 
Cataract 3.9 24.06 15.02 7.27 1.41 
Chronic Kidney Disease 0.01 26.84 11.91 10.37 1.08 
COPD 1.55 17.86 4.42 5.02 7.27 
Coronary Heart Disease 0.01 36.99 6.41 15.47 1.46 
Dementia 0.13 3.68 2.41 0.66 0.41 
Depression 0.07 34.96 15.16 3.24 54.24 
Diabetes 0.13 26.45 10.64 16.41 2.6 
Epilepsy 0.53 2.22 1.71 0.75 1.81 
Fatigue 0.04 2.47 1.49 0.15 2.71 
Fibromyalgia 0 1 0.24 0 1.97 
Gall stones 0.96 13.15 6.46 3.51 6.39 
Gastritis 0.24 19.53 2.42 2.73 10.38 
Gastrointestinal bleed 0.01 4.87 0.44 0.32 1.78 
Gout 0.17 9.9 1.55 7.18 0.9 
Hearing impairment 3.75 28.89 15.77 11.28 9.88 
Heart Failure 0 6.81 0.95 1.23 0.01 
HIV/AIDS 0 0 0 0.01 0.01 
Hypocholesteraemia 0.51 39.41 15.81 25.53 8.04 
Hypertension 0 67.72 41.79 66.22 12.57 
Hyperthyroidism 0 1.47 13.78 0 0.17 
Hypothyroidism 0.01 9.76 49.55 0 3.27 
Inflammatory Bowel Disease 0.66 10.4 3.13 1.88 9.25 
Irritable Bowel Syndrome 2.38 11.09 3.73 0.44 15.85 
Liver Disease 0.1 0.97 0.53 0.3 0.78 
Migraine 0.25 8.65 5.35 1.69 17.23 
Multiple Sclerosis 0.12 0.3 0.86 0 0.7 
Osteoporosis 0.53 9.79 15.66 0.26 3.07 
Parkinson's Disease 0.08 1.09 0.67 0.26 0.3 
Peripheral Vascular Disease 0.29 10.55 2.12 2.4 1.77 
Polymyalgia 0.07 2.93 4.66 0.19 0.24 
Psoriasis 1.31 4.46 2.9 3.08 3.74 
Psychosis 0 0.58 0.01 0 1.01 
Renal Stone 0.28 3.16 0.33 1.82 1.13 
Rheumatoid Arthritis 0.14 1.02 2.55 0.09 0.67 
Schizophrenia 0 1.75 0.25 0 2.92 
Scleroderma 0.01 0.12 0.24 0 0.02 
Sjogren’s disease 0 0.36 0.54 0 0.15 
Sleep problem 0.32 7.69 3.74 1.22 3.28 
Stroke 6.79 20.97 8.45 8.83 4.5 
Systemic Lupus Erythematous 0.01 0.14 0.18 0 0.09 
Tuberculosis 0.25 1.55 2.08 0.13 0.81 
Vision problem 0.02 3.33 3.58 0 0.11 
                   CV-  Cardiovascular; MH- Mental Health; MSK- Musculoskeletal; ^only for men 
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Appendix Table 28 Transition probabilities across clusters in OA  
 





Transition at year 5 
 
CV-MSK 100.0 0.0 0.0 0.0 0.0 
CV 11.6 88.4 0.0 0.0 0.0 
MSK 5.2 0.0 94.8 0.0 0.0 
Relative Healthy 0.0 12.6 1.4 81.7 4.3 
MH 3.3 0.0 0.0 0.0 96.7 
Year 5 
 
Transition at year 10 
  
CV-MSK 100.0 0.0 0.0 0.0 0.0 
CV 15.5 84.1 0.0 0.0 0.4 
MSK 11.7 0.0 88.2 0.0 0.0 
Relative Healthy 0.0 14.1 2.5 80.7 2.7 
MH 7.9 0.1 0.4 0.0 91.7 
Year 10 
 
Transition at year 15 
  
CV-MSK 82.0 9.3 2.4 3.2 3.1 
CV 22.5 70.5 2.8 2.4 1.8 
MSK 6.0 2.0 85.1 2.6 4.4 
Relative Healthy 0.5 14.5 7.0 72.2 5.9 
MH 22.5 3.4 2.7 1.9 69.5 
CV-Cardiovascular; MH- Mental Health; MSK- Musculoskeletal 
Shaded cell is the cases remaining in the same LTA class on successive years.  
The transition is to be read from row to column. For example, at year 5; 100% cases moved 












Appendix Table 29 Transition probabilities across clusters in non-OA 
 Metabolic Cardiovascular Relative healthy CV-MSK Mental Health 
Index date 
 
Transition at year 5 
 
Metabolic 99.8 0 0 0.2 0 
Cardiovascular 0.0 91.3 0 8.7 0 
Relative Healthy 3.1 10.4 85.8 0 0.8 
CV-MSK 0 0 0 100 0 
Mental Health 0 0 0 6.0 93.9 
Year 5 
 
Transition at year 10 
  
Metabolic 98.5 0.0 0 1.5 0 
Cardiovascular 1.4 83.9 0 14.7 0 
Relative Healthy 3.8 11.8 81.1 0.0 3.3 
CV-MSK 0.0 0 0 100.0 0 
Mental Health 0.0 0 0 12.3 87.7 
Year 10 
 
Transition at year 15 
  
Metabolic 87.6 0.2 1.7 8.8 1.6 
Cardiovascular 7.3 72.2 0.4 19.1 1.0 
Relative Healthy 3.9 9.5 80.6 0.7 5.4 
CV-MSK 0.3 2.8 2.1 93.3 1.5 
Mental Health 2.5 1.2 1.0 11.7 83.6 
















Appendix Table 30 Transition pattern with more than 1% of total in OA 
 At index Year 0 Year 5 Year 10 Year 15 














Path 2 MH MH MH MH MH 20.1 
Path 3 CV CV CV CV CV 12.2 
Path 4 CV-MSK CV-MSK CV-MSK CV-MSK CV-MSK 8.1 
Path 5 MSK MSK MSK MSK CV-MSK 6.3 
Path 6 MSK MSK MSK MSK MSK 4.9 




CV CV CV CV 1.6 
Path 9 MSK CV-MSK CV-MSK CV-MSK CV-MSK 1.6 
Path 10 CV CV CV CV CV-MSK 1.3 
Path 11 MSK MSK CV-MSK CV-MSK CV-MSK 1.1 
Path 12 CV CV-MSK CV-MSK CV-MSK CV-MSK 1.0 
Names in each cell at each time point represent the leading conditions in the cluster. 










Appendix Table 31 Statistical parameters for each class IN RMLCA in people with OA 
 Model log-likelihood BIC SABIC likelihood-ratio AIC Entropy npar C1 C2 C3 C4 C5 C6 C7 C8 C9 
At year 5 1 -36607 - 73526.43 8174.411 73308.04 47 NA 100         
 2 -34666.4 70266.08 69964.18 4293.128 69522.76 0.546 95 85.97 14.03        
 3 -34504.9 70414.71 69960.26 3970.182 69295.81 0.498 143 6.66 83.59 9.75       
 4 -34438 70752.42 70145.43 3836.317 69257.95 0.501 191 7.66 8.21 0.56 83.57      
 5 -34388.7 71125.49 70365.96 3737.82 69255.45 0.504 239 0.87 83.45 6.3 8.68 0.71     
 6 -34338 71495.62 70583.55 3636.379 69250.01 0.498 287 82.33 1.03 5.53 10 0.45 0.65    
 7 -34307.7 71906.56 70841.95 3575.745 69285.37 0.513 335 0.13 1.26 82.51 0.29 0.79 5.09 9.95   
 8 -34276.9 72316.6 71099.44 3514.205 69319.83 0.461 383 5.48 0.26 1.15 12 2.24 1.82 0.52 76.52  
 9 -34242.6 72719.57 71349.87 3445.602 69347.23 0.459 431 0.26 0.28 1.09 2.59 11.91 76.11 1.73 1.49 4.54 
At year 10 1 -34330.8 - 68956.59 13877.73 68759.59 49 NA 100         
 2 -31449.5 63809.67 63495.06 8115.187 63097.05 0.716 99 76.86 23.14        
 3 -31209.5 63789.54 63316.04 7635.152 62717.02 0.651 149 13.77 74.19 12.04       
 4 -31099.9 64030.17 63397.78 7415.868 62597.73 0.621 199 4.47 12.31 10.29 72.93      
 5 -31034.3 64358.86 63567.57 7284.651 62566.52 0.62 249 10.46 72.93 1.08 12.15 3.39     
 6 -30981.8 64713.77 63763.59 7179.654 62561.52 0.63 299 71.53 1.89 12.8 2 1.7 10.08    
 7 -30941.3 65092.69 63983.62 7098.665 62580.53 0.545 349 1.21 66.28 4.69 1.85 10.19 13.53 2.25   
 8 -30901.2 65472.41 64204.45 7018.477 62600.34 0.637 399 0.9 1.18 12.19 10.79 1.12 1.27 71.96 0.58  
 9 -30857.8 65845.65 64418.79 6931.806 62613.67 0.583 449 4.05 8.33 14.05 0.69 2.25 67.3 1.36 1.48 0.49 
                  
At year 15 1 -16252.6 - 32732.54 9454.857 32597.19 46 NA 100         
 2 -14583.1 29921.4 29625.89 6115.909 29352.24 0.812 93 31.42 68.58        
 3 -14457 30050.84 29606 5863.712 29194.04 0.715 140 67.5 16.82 15.68       
 4 -14389.2 30296.93 29702.75 5728.161 29152.49 0.711 187 18.43 12.44 67.04 2.09      
 5 -14337.4 30574.87 29831.35 5624.464 29142.79 0.698 234 6.81 14.36 66.99 2.92 8.92     
 6 -14298.1 30877.86 29985 5545.816 29158.15 0.684 281 9.95 6.13 1.26 65.83 7.06 9.77    
 7 -14268.9 31201.08 30158.87 5487.387 29193.72 0.353 328 65.29 0.22 2.17 13.68 6.11 7.14 5.39   
 8 -14232.8 31510.68 30319.13 5415.348 29215.68 0.706 375 8.97 1.67 0.67 66.55 1.66 12.53 2.64 5.32  
 9 -14213.2 31853.05 30512.16 5376.079 29270.41 0.744 422 1.05 11.98 1.96 0.68 4.14 65.76 1.05 10.72 2.66 
 








Appendix Table 32 Statistical parameters for each class IN RMLCA in people with non-OA 
 Model log-likelihood BIC SABIC likelihood-ratio AIC Entropy npar C1  C2 C3 C4 C5 C6 C7 C8 C9 
At year 5 1 -32360.3 - 65038.7 5982.273 64814.69 47 NA 100         
 2 -30977.5 62899.74 62597.83 3216.642 62145.06 0.493 95 10.23 89.77        
 3 -30821 63063.89 62609.44 2903.483 61927.9 0.413 143 4.16 83.23 12.61       
 4 -30750.3 63399.8 62792.81 2762.085 61882.51 0.43 191 83.01 3.87 1.24 11.88      
 5 -30714.2 63804.94 63045.41 2689.915 61906.34 0.394 239 3.08 81.28 1.01 0.83 13.8     
 6 -30673.2 64200.35 63288.27 2608.012 61920.43 0.435 287 0.45 81.56 0.33 1.82 4.89 10.95    
 7 -30645.1 64621.33 63556.72 2551.686 61960.11 0.407 335 4.13 0.79 0.26 10.93 0.44 80.31 3.14   
 8 -30609.8 65028.13 63810.98 2481.178 61985.6 0.234 383 3.87 3.17 0.44 43.35 0.28 4.47 0.19 44.23  
 9 -30570.7 65427.26 64057.56 2402.998 62003.42 0.425 431 0.45 0.64 1.18 2.84 2.66 78.55 13.39 0.02 0.27 
At year 10  1 -35804.0 - 71915.58 11510.43 71706.01 49 NA 100         
 2 -33329.3 67594.59 67279.98 6560.98 66856.57 0.642 99 19.25 80.75        
 3 -33100.6 67610.05 67136.54 6103.701 66499.29 0.57 149 76.76 15.58 7.66       
 4 -33016.8 67915.17 67282.77 5936.082 66431.67 0.592 199 1.16 13.9 77.37 7.57      
 5 -32942.2 68238.6 67447.31 5786.78 66382.37 0.57 249 2.43 76.13 13.27 6.67 1.51     
 6 -32888.1 68603.09 67652.9 5678.529 66374.11 0.563 299 0.55 14.46 6.65 1.34 1.94 75.06    
 7 -32863.1 69025.98 67916.9 5628.682 66424.27 0.343 349 1.38 30.8 0.56 6.92 1.44 48.82 10.08   
 8 -32798.4 69369.16 68101.18 5499.118 66394.7 0.574 399 5.02 1.53 1.44 14.47 0.44 1.09 3.56 72.45  
 9 -32773.3 69791.71 68364.83 5448.925 66444.51 0.552 449 8.42 5.07 6.87 3.25 1.08 72.42 0.76 0.86 1.28 
At  year 15 1 -19936.8 - 40127.72 9838.909 39969.64 48 NA 100         
 2 -18193.4 37208.52 36900.29 6352.092 36580.82 0.748 97 72.29 27.71        
 3 -18013.8 37264.47 36800.54 5992.959 36319.69 0.673 146 12.7 69.21 18.09       
 4 -17935.2 37522.2 36902.56 5835.599 36260.32 0.662 195 17.52 68.15 4.64 9.69      
 5 -17872.5 37812.04 37036.69 5710.35 36233.08 0.67 244 9.32 1.32 68.22 4.12 17.01     
 6 -17828.3 38138.59 37207.54 5621.816 36242.54 0.671 293 2.43 3.39 8.09 16.86 67.75 1.48    
 7 -17785.3 38467.72 37380.97 5535.858 36254.58 0.701 342 1.94 2.5 2.4 0.92 67.43 17.11 7.72   
 8 -17750.0 38812.21 37569.76 5465.266 36281.99 0.644 391 2.61 0.52 9.61 1.51 7.69 10.51 1.3 66.25  
 9 -17725.6 39178.6 37780.44 5416.566 36331.29 0.673 440 2.89 1.72 1.04 1.07 66.57 12.16 7 5.46 2.08 
BIC- Bayesian information criteria; AIC- Akaike information criteria; SABIC- Sample size adjusted BIC 
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Anaemia 0 2 3 
Ankylosing Spondylitis 0 0 1 
Arterial and venous diseases 0 0 0 
Asthma 0 4 4 
Backpain 1 27 43 
Benign Prostatic Hypertrophy^ 0 3 3 
Cancer 0 5 1 
Cataract 6 6 1 
Cerebral stroke 3 4 2 
Chronic Kidney Disease 0 7 0 
COPD 0 2 2 
Coronary Heart Disease 0 9 1 
Dementia 0 1 0 
Depression 0 10 18 
Diabetes 0 13 0 
Epilepsy 0 1 1 
Fatigue 0 0 1 
Fibromyalgia 0 0 1 
Gall stones 0 2 2 
Gastritis 0 3 2 
Gastrointestinal bleed 0 1 0 
Gout 0 3 1 
Hearing problem 0 7 4 
Heart failure 0 1 0 
Hypercholesteremia 0 18 3 
Hypertension 1 41 5 
Hyperthyroidism 0 1 0 
Hypothyroidism 0 6 1 
Inflammatory Bowel Disease 0 2 2 
Irritable Bowel Syndrome 7 3 8 
Liver disease 0 0 0 
Migraine 0 0 4 
Multiple Sclerosis 0 0 0 
Osteoporosis 0 3 1 
Parkinson Disease 0 0 0 
Peripheral Vascular Disease 0 2 1 
Polymyalgia 0 1 0 
Psoriasis 0 1 1 
Psychosis 0 0 0 
Renal stone 0 0 0 
Rheumatoid arthritis 0 1 1 
Schizophrenia 0 1 0 
Sjogren’s syndrome 0 0 0 
Sleep problem 0 2 1 
Systemic Lupus Erythematous 0 0 0 
Tuberculosis 0 0 0 
Vision problem 0 1 0 
^only for men 
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Anaemia 0 3 4 
Ankylosing Spondylitis 0 2 0 
Arterial and venous diseases 0 0 1 
Asthma 0 5 7 
Backpain 1 58 42 
Benign Prostatic Hypertrophy^ 0 2 7 
Cancer 0 3 8 
Cataract 9 0 13 
Cerebral stroke 7 2 9 
Chronic Kidney Disease 0 2 15 
COPD 0 2 4 
Coronary Heart Disease 0 1 12 
Dementia 0 0 3 
Depression 0 26 13 
Diabetes 0 2 20 
Epilepsy 0 0 1 
Fatigue 0 2 1 
Fibromyalgia 0 2 0 
Gall stones 0 3 3 
Gastritis 0 4 5 
Gout 0 2 7 
Gastrointestinal bleed 0 1 1 
Hearing problem 1 8 12 
Heart failure 0 0 2 
HIV/AIDS 0 0 0 
Hypercholesteremia 0 7 22 
Hypertension 1 8 54 
Hyperthyroidism 0 0 2 
Hypothyroidism 0 3 7 
Inflammatory Bowel Disease 0 5 3 
Irritable Bowel Syndrome 8 9 4 
Liver disease 0 1 1 
Migraine 0 6 2 
Multiple Sclerosis 0 0 0 
Osteoporosis 0 3 6 
Parkinson Disease 0 0 0 
Peripheral Vascular Disease 0 2 4 
Polymyalgia 0 0 1 
Psoriasis 0 2 2 
Psychosis 0 0 1 
Renal stone 0 0 1 
Rheumatoid arthritis 0 1 2 
Schizophrenia 0 0 1 
Scleroderma 0 0 0 
Sjogren’s syndrome 0 0 0 
Sleep problem 0 3 3 
Systemic Lupus Erythematous 0 0 0 
Tuberculosis 0 0 0 
Vision problem 0 0 1 

















Anaemia 0 8 4 4 7 
Ankylosing Spondylitis 0 2 5 0 0 
Arterial and venous diseases 0 9 1 0 0 
Asthma 0 18 9 5 11 
Backpain 2 63 70 44 67 
Benign Prostatic 
Hypertrophy^ 0 14 14 7 0 
Cancer 1 16 9 9 4 
Cataract 11 31 6 6 0 
Cerebral stroke 11 14 6 8 0 
Chronic Kidney Disease 0 42 0 12 5 
COPD 0 9 2 4 6 
Coronary Heart Disease 0 34 0 10 3 
Dementia 0 11 3 0 0 
Depression 1 25 16 11 48 
Diabetes 0 25 0 26 6 
Epilepsy 0 3 1 0 1 
Fatigue 0 6 0 0 6 
Fibromyalgia 0 3 0 0 5 
Gall stones 0 10 3 2 9 
Gastritis 0 9 8 4 6 
Gout 0 15 10 10 0 
Gastrointestinal bleed 0 2 0 1 0 
Hearing problem 0 31 20 13 8 
Heart failure 0 11 0 0 0 
Hypercholesteremia 0 26 13 29 10 
Hypertension 1 64 7 59 24 
Hyperthyroidism 0 8 0 0 0 
Hypothyroidism 0 20 0 6 9 
Inflammatory Bowel Disease 0 5 6 2 6 
Irritable Bowel Syndrome 9 2 7 3 16 
Liver disease 0 1 3 1 0 
Migraine 0 0 5 2 11 
Multiple Sclerosis 0 0 0 0 1 
Osteoporosis 0 14 11 4 3 
Parkinson Disease 0 3 2 0 0 
Peripheral Vascular Disease 0 12 5 2 3 
Polymyalgia 0 5 2 1 0 
Psoriasis 0 5 5 1 5 
Psychosis 0 0 0 0 0 
Renal stone 0 1 3 1 1 
Rheumatoid arthritis 0 0 0 3 3 
Schizophrenia 0 0 2 0 0 
Scleroderma 0 0 1 0 0 
Sjogren’s syndrome 0 0 0 0 1 
Sleep problem 0 7 5 2 3 
Vision problem 0 4 0 0 0 















Anaemia 0 8 0 1 
Ankylosing Spondylitis 0 0 0 0 
Arterial and venous diseases 0 0 1 0 
Asthma 0 2 3 4 
Backpain 0 21 17 27 
Benign Prostatic Hypertrophy^ 0 3 2 1 
Cancer 0 7 2 2 
Cataract 7 13 4 0 
Cerebral stroke 3 12 5 0 
Chronic Kidney Disease 0 13 4 0 
COPD 0 6 1 1 
Coronary Heart Disease 0 16 7 1 
Dementia 0 3 0 0 
Depression 0 6 8 9 
Diabetes 0 7 11 1 
Epilepsy 0 1 0 0 
Fatigue 0 3 0 1 
Fibromyalgia 0 1 0 0 
Gall stones 0 8 0 1 
Gastritis 0 8 0 1 
Gout 0 4 3 1 
Gastrointestinal bleed 0 1 0 0 
Hearing problem 0 12 3 4 
Heart failure 0 5 0 0 
Hypercholesteremia 0 8 19 3 
Hypertension 1 31 56 0 
Hyperthyroidism 0 4 0 0 
Hypothyroidism 0 17 1 2 
Inflammatory Bowel Disease 0 6 0 3 
Irritable Bowel Syndrome 5 8 1 4 
Liver disease 0 0 0 0 
Migraine 0 0 1 2 
Multiple Sclerosis 0 0 0 0 
Osteoporosis 0 1 1 1 
Parkinson Disease 0 1 0 0 
Peripheral Vascular Disease 0 5 1 0 
Polymyalgia 0 1 0 0 
Psoriasis 0 1 1 1 
Psychosis 0 0 0 0 
Renal stone 0 0 1 0 
Rheumatoid arthritis 0 1 0 0 
Schizophrenia 0 0 0 0 
Scleroderma 0 0 0 0 
Sjogren’s syndrome 0 0 0 0 
Sleep problem 0 0 2 0 
Tuberculosis 0 0 1 0 
Vision problem 0 2 0 0 
















Anaemia 0 5 2 3 2 
Ankylosing Spondylitis 0 0 1 0 0 
Arterial and venous diseases 0 1 0 1 0 
Asthma 0 8 6 3 2 
Backpain 1 48 45 22 17 
Benign Prostatic Hypertrophy^ 0 7 2 5 4 
Cancer 0 9 4 7 5 
Cataract 9 21 0 8 0 
Cerebral stroke 7 15 1 9 1 
Chronic Kidney Disease 0 18 0 18 5 
COPD 0 9 2 4 0 
Coronary Heart Disease 0 24 2 6 0 
Dementia 0 5 0 1 0 
Depression 0 15 16 5 22 
Diabetes 0 12 3 16 6 
Epilepsy 0 1 0 0 1 
Fatigue 0 3 1 0 3 
Fibromyalgia 0 1 0 0 1 
Gall stones 0 11 2 0 3 
Gastritis 0 11 2 2 0 
Gout 0 4 1 6 0 
Gastrointestinal bleed 0 0 0 0 0 
Hearing problem 0 27 7 6 0 
Heart failure 0 5 0 0 0 
HIV/AIDS 0 0 0 0 1 
Hypercholesteremia 0 17 6 24 4 
Hypertension 1 42 10 58 11 
Hyperthyroidism 0 1 0 0 13 
Hypothyroidism 0 11 0 3 50 
Inflammatory Bowel Disease 0 10 4 0 1 
Irritable Bowel Syndrome 6 9 5 1 3 
Liver disease 0 0 0 1 0 
Migraine 0 0 3 2 4 
Multiple Sclerosis 0 0 0 0 2 
Osteoporosis 0 6 2 3 1 
Parkinson Disease 0 1 0 0 3 
Peripheral Vascular Disease 0 7 0 3 0 
Polymyalgia 0 1 0 1 0 
Psoriasis 0 4 2 0 3 
Psychosis 0 0 0 0 2 
Renal stone 0 0 1 2 1 
Rheumatoid arthritis 0 0 1 0 1 
Schizophrenia 0 1 0 0 5 
Scleroderma 0 0 0 0 0 
Sjogren’s syndrome 0 0 0 0 1 
Sleep problem 0 4 2 0 0 
Systemic Lupus Erythematous 0 0 0 0 0 
Tuberculosis 0 0 0 1 0 
Vision problem 0 1 0 0 0 


















Anaemia 0 12 3 0 10 
Ankylosing Spondylitis 0 0 1 0 0 
Arterial and venous  0 3 0 1 2 
Asthma 0 11 7 5 5 
Backpain 1 68 54 32 43 
Benign Prostatic Hypertrophy^ 0 10 3 5 0 
Cancer 0 10 6 10 1 
Cataract 11 31 1 10 0 
Cerebral stroke 10 28 1 9 0 
Chronic Kidney Disease 0 20 1 26 0 
COPD 0 12 5 3 0 
Coronary Heart Disease 0 22 4 10 0 
Dementia 0 8 1 2 0 
Depression 1 22 21 5 24 
Diabetes 0 27 0 19 12 
Epilepsy 0 2 1 0 4 
Fatigue 0 5 1 0 5 
Fibromyalgia 0 1 0 0 0 
Gall stones 0 4 3 6 6 
Gastritis 0 12 3 3 0 
Gout 0 0 2 9 0 
Gastrointestinal bleed 0 2 1 0 0 
Hearing problem 1 30 10 12 0 
Heart failure 0 3 0 2 0 
HIV/AIDS 0 0 0 0 0 
Hypercholesteremia 0 27 9 30 9 
Hypertension 1 50 16 68 14 
Hyperthyroidism 0 1 0 0 31 
Hypothyroidism 0 10 1 4 75 
Inflammatory Bowel Disease 0 9 6 0 3 
Irritable Bowel Syndrome 5 8 7 2 6 
Liver disease 0 0 0 1 0 
Migraine 0 2 6 1 5 
Multiple Sclerosis 0 0 0 0 2 
Osteoporosis 0 5 4 7 2 
Parkinson Disease 0 1 0 0 0 
Peripheral Vascular Disease 0 11 1 3 0 
Polymyalgia 0 0 1 2 0 
Psoriasis 0 3 2 3 4 
Psychosis 0 1 0 0 0 
Renal stone 0 1 2 2 0 
Rheumatoid arthritis 0 0 1 0 2 
Schizophrenia 0 2 1 0 0 
Sjogren’s syndrome 0 0 0 0 5 
Sleep problem 0 8 3 0 3 
Systemic Lupus Erythematous 0 0 0 0 0 
Tuberculosis 0 2 0 0 0 
Vision problem 0 3 0 0 0 




Appendix Table 39 Checklist for Latent class growth analysis 
GRoLTS checklist item Yes/No Comments  
1. Is the metric of time used in the statistical 
model reported?  
Yes Time metrics is years 
2. Is information presented about the mean and 
variance of time within a wave?  
NA Exact time of the measurement is used in 
the analysis, so time-structured data is not 
relevant in this study. 
3a. Is the missing data mechanism reported? Yes  
3b. Is a description provided of what variables 
are related to attrition/missing data? 
Yes Described in the model specification in the 
manuscript.  
3c. Is a description provided of how missing data 
in the analyses were dealt with? 
Yes  
4. Is information about the distribution of the 
observed variables included? 
Yes  
5. Is the software mentioned?  Yes R with ‘lcmm’ package 
6a. Are alternative specifications of within-class 
heterogeneity considered (e.g., LGCA vs. 
LGMM) and clearly documented? If not, was 
sufficient justification provided as to eliminate 
certain specifications from consideration?  
Yes  
6b. Are alternative specifications of the between-
class differences in variance–covariance matrix 
structure considered and clearly documented? If 
not, was sufficient justification provided as to 
eliminate certain specifications from 
consideration?  
Yes   
7. Are alternative shape/functional forms of the 
trajectories described?  
Yes Linear, cubic, and quadratic functions were 
explored 
8. If covariates have been used, can analyses 
still be replicated?  
No   
9. Is information reported about the number of 
random start values and final iterations 
included?  
Yes   
10. Are the model comparison (and selection) 
tools described from a statistical perspective?  
Yes  BIC and AIC were used 
11. Are the total number of fitted models 
reported, including a one-class solution?  
Yes  
12. Are the number of cases per class reported 
for each model (absolute sample size, or 
proportion)?  
Yes  
13. If classification of cases in a trajectory is the 
goal, is entropy reported?  
Yes  
14a. Is a plot included with the estimated mean 
trajectories of the final solution?  
Yes  
14b. Are plots included with the estimated mean 
trajectories for each model?  
Yes  
14c. Is a plot included of the combination of 
estimated means of the final model and the 
observed individual trajectories split out for each 
latent class?  
No.  Only observed trajectories are reported. 
15. Are characteristics of the final class solution 
numerically described (i.e., means, SD/SE, n, 
CI, etc.)?  
Yes Proportion and different SES 
16. Are the syntax files available (either in the 
appendix, supplementary materials, or from the 
authors)?  
Yes Available on request from the authors. 
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Appendix Table 40 Disability weights for UK and Europe 
Conditions  Disability weight Severity/Type 
Anaemia 0.118 Severe 
Ankylosing Spondylitis   
Arterial/Venous 0.647  
Asthma 0.045 Partly controlled 
Back pain 0.365 Severe without leg pain 
Benign Prostate Hypertrophy 0.067  
Cancer 0.451 Metastatic 
Cancer  0.288 Non metastatic  
Cataract 0.17  
Chronic Kidney Disease 0.104 Stage 4 
COPD 0.225 Moderate 
Coronary Heart Disease 0.432 MI 
Dementia  0.377 Moderate 
Depression 0.396 Moderate 
Diabetes Mellitus  0.015  
Epilepsy 0.552 Severe 
Fatigue   
Fibromyalgia   
Gall stones 0.448  
Gastritis  0.003  
Gastrointestinal bleed 0.325  
Gout 0.295 Acute 
Hearing problem 0.158 Severe 
Heart failure 0.179 Severe 
High Cholesterol 0.304  
Hypertension 0.502  
Hyperthyroid  0.145  
Hypothyroidism  0.019  
Inflammatory Bowel Disease 0.231  
Irritable Bowel Syndrome 0.062  
Liver Disease 0.178  
Migraine 0.441  
Multiple sclerosis 0.719 Severe 
Osteoporosis    
Parkinson Disease 0.575 Severe 
Peripheral Vascular Disease 0.43  
Polymyalgia    
Psoriasis  0.235  
Psychosis    
Renal stone 0.294  
Rheumatoid Arthritis 0.199  
Schizophrenia 0.778 Acute 
Scleroderma    
Sjogren’s syndrome   
Sleep Disorder 0.1  
Stroke  0.316 Long with cognition 
Systemic Lupus Erythematous 0.594  
Tuberculosis 0.333 Without HIV 
Vision Problem 0.011 Presbyopia 
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Congestive heart failure 9 7 1 7 
Cardiac arrhythmias 0 5  5 
Valvular disease 0 -1  -1 
Pulmonary circulation disorders 6 4  4 
Peripheral vascular disorders 3 2 1 2 
Hypertension (combined 
uncomplicated and complicated) -1 0  0 
Paralysis 5 7 1 7 
Other neurological disorders 5 6 1 6 
Chronic pulmonary disease 3 3 1 3 
Diabetes, uncomplicated 0 0 1 0 
Diabetes, complicated -3 0 2 0 
Hypothyroidism 0 0  0 
Renal failure 6 5 2 5 
Liver disease 4 11 1 11 
Peptic ulcer disease, excluding 
bleeding 0 0 1 0 
AIDS/HIV 0 0 6 0 
Lymphoma 6 9 2 8 
Metastatic cancer 14 12 6 8 
Solid tumour without metastasis 7 4 2 8 
Rheumatoid arthritis/collagen 
vascular diseases 0 0 1 0 
Coagulopathy 11 3   
Obesity -5 -4   
Weight loss 9 6   
Fluid and electrolyte disorders 11 5   
Blood loss anaemia -3 -2  -2 
Deficiency anaemia -2 -2  -2 
Alcohol abuse -1 0   
Drug abuse -7 -7   
Psychoses -5 0  0 
Depression -5 -3  -3 
Dementia   1  
Leukaemia   2  








Appendix Method 1 False Discovery Rate (FDR) test methods 
Controlling the false discovery rate: Benjamini–Hochberg procedure 
An approach to manage multiple testing problem is false discovery rate. This is the 
proportion of "discoveries" (significant results) that are false positives.  
One good technique for controlling the false discovery rate was briefly mentioned by 
Simes (1986) and developed in detail by Benjamini and Hochberg (1995).  
 
Steps of FDR:  
1. Put the individual P values in order, from smallest to largest.  
2. The smallest P value has a rank of i=1, then next smallest has i=2, etc.  
3. Compare each individual P value to its  
Benjamini-Hochberg adjusted P value = (i/m)Q,  
where i is the rank, 
m is the total number of tests, and  
Q is the study p value.  
4. The adjusted p value less than the alpha error is considered as significant. 
 








Appendix Method 2 Model statistics for different methods for cluster analysis 
 1000 random samples 2000 random samples 
 HCL LCA K-Mode HCL LCA K-Mode 
Calinski 
Harabasz 
60.46 65.39 40.89 23.97 25.04 20.59 
Tau 0.498 0.371 0.499 0.53 0.50 0.40 
Silhouette 0.009 0.023 0.009 0.001 0.09 0.049 
 
 
HCL -Hierarchical clustering analysis 
LCA- Latent class analysis 
Calinski Harabasz (1) 
This is also known as the Variance Ratio Criterion. The score is defined as the 
ratio between the within-cluster dispersion and the between-cluster dispersion. 
The higher the score the better is the cluster. 
Tau Index (2) 
Silhouette Index (3) 
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Comorbidities in Osteoarthritis: A Systematic Review and Meta-
Analysis of Observational Studies 
Subhashisa Swain,1   Aliya Sarmanova,1   Carol Coupland,2 Michael Doherty,1 and Weiya Zhang1 
 
Objective. Osteoarthritis (OA) is a common chronic condition in older individuals, but its association with other 
chronic conditions is largely unknown. This study aimed to systematically review the literature on comorbidities in 
individuals with OA compared to those without. 
Methods. We searched 4 databases for observational studies on comorbidities in individuals with OA. Studies of 
OA only or in comparison with non-OA controls were included. The risk of bias and study quality were assessed using 
the Newcastle-Ottawa Scale. The prevalence of comorbidities in the OA group and the prevalence ratio (PR) and 95% 
confidence interval (95% CI) between OA and non-OA groups were calculated. 
Results. In all, 42 studies from 16 countries (27 case-only and 15 comparative studies) met the inclusion criteria. 
The mean age of participants varied from 51 to 76 years. The pooled prevalence of any comorbidity was 67%    (95% 
CI 57–74) in individuals with OA versus 56% (95% CI 44–68) in individuals without OA. The pooled PR for any 
comorbidity was 1.21 (95% CI 1.02–1.45). The PR increased from 0.73 (95% CI 0.43–1.25) for 1 comorbidity to 1.58 
(95% CI 1.03–2.42) for 2, and to 1.94 (95% CI 1.45–2.59) for ≥3 comorbidities. The key comorbidities associated with 
OA were stroke (PR 2.61 [95% CI 2.13–3.21]), peptic ulcer (PR 2.36 [95% CI 1.71–3.27]), and metabolic syndrome 
(PR 1.94 [95% CI 1.21–3.12]). 
Conclusion. Individuals with OA are more likely to have other chronic conditions. The association is dose- 
dependent in terms of the number of comorbidities, suggesting multimorbidities. Further studies on the causality of 




Osteoarthritis (OA) is by far the most common form of arthritis 
and is a major cause of pain and disability in older individuals (1). 
It is a common, complex disorder with multiple genetic, constitu- 
tional, and environmental risk factors (2). The presence of multiple 
chronic conditions in a single individual causes higher mortality, 
increased hospitalization, impaired physical and mental health, 
worse disease outcome, and poorer quality of life (3,4). The coex- 
istence of chronic conditions with OA is also very common, espe- 
cially in the later decades of life (5,6). For example, according to 
the Centers for Disease Control and Prevention, >30% of individ- 
uals with diabetes mellitus and heart disease have OA (7). 
Most literature on OA comorbidity was published in the last 
3 years. The review articles focused on the distribution and 
impact of individual chronic conditions such as cardiovascular 
diseases, diabetes mellitus, and depression in OA (8–11). Even 
though comorbidity was discussed as a concept in the 1960s, 
only in 1996 was a distinct definition first suggested to differen- 
tiate comorbidity (implying an index disease with mechanistically 
linked additional conditions) and multimorbidity (implying any 
co-occurrence of medical conditions) within an individual (12). 
Comorbidity research in OA is still at a preliminary stage, and the 
evidence is yet to be accumulated. 
A systematic review on OA reported worsening of pain and a 
decline in functional activities among individuals due to the pres- 
ence of other chronic conditions (13). Clinically, comorbidities in 
OA create greater challenges for management. The number and 
pattern of different comorbid conditions determine the severity 
and burden in patients with multimorbidities (14,15). However, 
except for shared risk factors such as aging and obesity, little is 
known about biologic plausibility to explain the concurrence of OA 
and associated comorbidities (16,17). According to the European 
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